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SSCP Single strand conformation polymorphism 
STK Smokeless Tobacco Keratosis 
STM Specimen transport medium 
STWS Scott’s Tap Water Solution 
TAE Tris-Acetate-EDTA 
TBE Tris-Borate-EDTA 
TGFb Tumour growth factor 
TILs Tumour-infiltrating lymphocytes 
TNM T, tumour size; N, node involvement; M, distant metastasis 
TSGs Tumour suppressor genes 
UICC Internationale Contre le Cancer 
URR Upstream regulatory region 
UV Ultra violet 
VAIN Vaginal intraepithelial neoplasia 
VC Verracous carcinoma 
VIN Vulval intraepithelial neoplasia 
WHO World Health Organisation 
XRE Xenobiotic response element 
  
xxiii 
  
 
Summary 
 
There is some evidence to suggest that human papilloma virus (HPV) may play a causal 
role in head and neck carcinoma (HNSCC). The aim of this study was to investigate the 
prevalence of HPV DNA in HNSCC and to determine whether any correlation exists 
with p16 or survival.  
  
An initial pilot study of sixty formalin-fixed HNSCC was carried out in order to 
optimise the methodology for the PCR and immunohistochemistry.  A further 84 benign 
lesions, 12 dysplasias and additional 80 HNSCC were also included.   
 
In the pilot study the prevalence of all HPV types was 67% of which 18% were high 
risk-HPV (HR-HPV) and for the combined carcinoma sample it was 59% of which 25% 
were HR-HPV. The overall HPV prevalence was 51% and 42% for benign lesions and 
dysplasias with HR-HPV accounting for 14% and 8% respectively.  A total of four 
alpha HPV types were identified and eleven beta HPV types. Multiple HPV types co-
existed in the same tissue and in some cases both alpha and beta HPV. The results may 
suggest that HR-HPV may play a role in a small subset of HNSCC. An association was 
found between HPV status and gender, age group, survival, nodal metastasis and T3 
tumour size and smoking. HPV16 was predominantly present in female patients and 
was associated with an improved overall survival and recurrence free survival.  
 
p16 positivity varied from 76-78% in carcinomas, 51% in benign lesions and 66% in 
dysplasias.  p16 status was not associated with disease recurrence or nodal metastasis.  
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Positive p16 staining and high staining intensity was associated with a poorer overall 
survival and the male gender, an older age group, anatomic site, and T2 tumour size.  
 
Overall HPV status was not correlated with p16 expression but a correlation found 
between p16 and HPV16 may suggest that p16 could potentially act as a surrogate 
marker of HPV16. However, the lack of concordance would suggest that in isolation 
p16 may not be a reliable marker for HR-HPV and should not be relied upon in 
isolation. Our findings could suggest that HPV16 and p16 status may be independent 
predictors for prognosis and disease recurrence.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 ORAL CARCINOGENESIS 
 
1.1.1 What is cancer? 
 
Cancer is one of the five major causes of mortality across all society. Generally, cancer 
is a manifestation of a malignant neoplasm or tumour, which is an unusual mass of 
tissues (except for leukaemias and other cancer types) generated as a result of 
uncoordinated growth of that tissue. It is distinctively different from a benign neoplasm 
which is localised and can normally be removed from the affected part of the body. So, 
cancer is a malignant neoplasm which has the capability to invade neighbouring tissues 
(invasion) and spread to other parts of the body (metastasise). 
 
 Cancer is essentially a chronic disease, usually being classified according to the 
tissue of origin. To date, more than 150 different types of human cancers have been 
recognised.  
 
1.1.2 Head and neck cancer 
 
Head and neck cancer encompasses epithelial malignancies that arise in the paranasal 
sinuses, nasal cavity, oral cavity (including the buccal mucosa, upper and lower alveolar 
ridges, retromolar trigone, floor of the mouth, hard and soft palate and anterior two-
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thirds of the tongue), oropharynx, nasopharynx, hypopharynx, pharynx, and larynx 
(Marur and Forastiere, 2008). The incidence and mortality of head and neck cancer 
varies throughout the world. Globally, it is the sixth most common cancer type, 
accounting for 6 % of all cases, and responsible for 650 000 new cancer cases annually 
with a mortality of 350 000 cases annually worldwide (Argiris et al., 2008).  
 
 Gender and racial differences in head and neck cancer incidence and mortality 
appear to reflect differences in risk factor exposure. As with most cancers, age itself 
may be a risk factor for the development of head and neck cancer. The epidemiology of 
head and neck squamous cell carcinoma has changed considerably in this century. Risk 
factors appear to explain most of the geographic, racial and gender variations seen, as 
well as incidence changes over time (Davidson, 2001). The history of previous head and 
neck cancer is one of the best predictors of cancer risk. Previously treated head and neck 
squamous cell carcinomas patients have a risk of developing second cancers of the head 
and neck, esophagus and lung (Braakhuis et al., 2003; Ha and Califano, 2003).  
 
 The risk of second cancers appears to relate to tobacco and alcohol exposure as 
was previously believed and described by the concept of field cancerisation (Lydiatt et 
al., 1998; Mignogna et al., 2007). The progress of this concept will be discussed further 
in the later part of this chapter in relation to the development of multiple primary 
lesions. There are variations in risk related to tobacco types and delivery methods and 
also alcohol consumption. Accurately measuring these risk exposures is complex. Other 
factors may act in concert with tobacco and alcohol exposure to contribute to the 
epidemiology of this disease. 
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1.1.3 Oral cancer 
 
As a subset of head and neck malignancy, oral cancer is specifically found in the oral 
cavity (sites as mentioned in 1.1.2), including the lips, salivary glands and oropharynx 
(Marur and Forastiere, 2008). The latest version of the International Classification of 
Diseases (ICD version 10) coding system of the World Health Organization (WHO) 
categorised these cancer sites as: the lip (ICD-10, C00); base of tongue (ICD-10, C01); 
other and unspecified parts of tongue (ICD-10, C02); gum (ICD-10, C03); floor of the 
mouth (ICD-10, C04); palate (ICD-10, C05); other and unspecified parts of the mouth 
(ICD-10, C06); parotid gland (ICD-10, C07); other and unspecified parts of major 
glands (ICD-10, C08); oropharynx (ICD-10, C10); nasopharynx (ICD-10, C11); 
pyriform sinus (ICD-10, C12); hypopharynx (ICD-10, C13); other and ill-defined sites 
in the lip, oral cavity and pharynx (ICD-10, C14)   (Johnson, 2003).  
 
1.1.4 Classification of oral cancer 
 
Oral cancer is categorised by specific location and the cell-type of origin. There are two 
types of oral cancer clearly recognised according to location, i.e. oral cavity and 
oropharyngeal cancer. Oral cavity cancer includes the tongue, the floor of the mouth, 
the hard palate, upper and lower jaw, gums and teeth, the cheeks and salivary glands. 
Oropharyngeal cancer on the other hand, includes the base of the tongue, uvula and soft 
palate (Morrow, 2007). 
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 Ninety percent of all diagnosed oral cancers are squamous cell carcinoma. The 
second commonest type is minor salivary gland cancer and, therefore, glandular in 
origin (Morrow, 2007). 
 
1.1.5 Epidemiology of oral cancer 
 
Despite increased understanding of oral cancer carcinogenesis, fully supported by the 
most recent technology including combined treatment modalities of oral cancer 
management, diagnosis has not improved significantly with regard to the 5 year overall 
survival rates for the disease over the past three decades especially in the United 
Kingdom (UK) (Rapidis et al., 2009; Warnakulasuriya, 2009).  
 
 Based on global incidence, the group of oral and pharyngeal cancers rank sixth 
among human cancers (Warnakulasuriya, 2009). Geographic variations in oral cancer 
incidence are greatly influenced by factors such as genetic, habits and lifestyle (Moore 
et al., 2000). High-risk countries for oral cancer are India, Pakistan, Sri Lanka and 
Bangladesh. Although, Scotland shows higher rates for oral cancer in both genders 
within the UK, oral cancer incidence in the UK region as a whole shows relatively 
lower rates (5325 new cases in 2006) compared to other European Union (EU) countries 
(Warnakulasuriya, 2009). In the UK, 1851 deaths were caused by oral cancer in 2007 
and with Scotland showing higher death rates for both sexes (6.4 and 3.3 per 100,000 
population for male and female, respectively) than the rest of the UK (Cancer Research 
UK 2006, Mortality: http://info.cancerresearchuk.org/cancerstats/ types/oral/mortality/). 
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 About 95% of all oral cancer cases occur in people over the age of 50 and twice as 
frequently in men as in women. Nowadays, a new trend of oral cancer in young people 
before the age of 40 is emerging and the male:female ratio has been changing 
significantly, from 5:1 to 2:1, over the last five decades (Cancer Research UK 2006, 
Incidence: http://info.cancerresearchuk.org/cancerstats/types/oral/incidence/).  
 
 In Asian populations, the buccal mucosa is the most common intraoral site for 
mouth cancer, whereas tongue is the commonest among European and US cases 
(Warnakulasuriya, 2009).    
 
1.1.6 Aetiology of oral cancer 
 
The exact causes of oral cancer remain unknown due to the multifactorial nature of 
carcinogenesis (Scully et al., 2005). Studies on inherited genes thus far only explain a 
proportion of all cancers. A genetic predisposition for oral cancer is at best small but 
does not preclude it being important in a minority of cases. However, the effects are 
swamped by environmental factors on a population basis (Scully and Boyle, 2005; Shah 
and Gil, 2009). Nevertheless, determination of the reality and nature of these genetic 
factors would have enormous benefit, not only to ‘at-risk’ family members, who would 
thus take particular care to avoid these risks, but also in unravelling the molecular 
mechanisms of oral carcinogenesis, opening the way to better prevention and treatment 
(Rapidis et al., 2009; Scully and Bagán, 2009 and Petersen, 2009). 
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1.1.7 Risk factors for oral cancer  
 
It is widely considered that the major risk factors for oral cancer are tobacco smoke 
(IARC, 1988; IARC, 2004), alcoholic beverage drinking (IARC, 1988) or synergy 
between the former and later factors (IARC, 2007).  
 
1.1.7.1 Tobacco smoking 
 
More than 300 carcinogens are present in either tobacco smoke or its water-soluble 
components in heavy smokers’ saliva (IARC, 2004). The first 69 carcinogens were 
previously reported and categorised into eleven groups as follows: polynuclear aromatic 
hydrocarbons (PAHs), heterocyclic hydrocarbons, volatile hydrocarbons, 
nitrohydrocarbons, aromatic amines, N-heterocyclic amines, N-nitrosamines, aldehydes, 
miscellaneous organic compounds, inorganic compounds and phenolic compounds 
(Hoffmann et al., 2001). It was observed that dose-related tobacco smoking practice 
(i.e. the frequency of cigarettes smoking and duration of smoking) is strongly associated 
with oral cancer (Rodu and Jansson, 2004; IARC, 2006; Warnakulasuriya et al., 2007 
and Weitkunat et al, 2007). 
 
 An increase in metabolism of PAH, which is caused by the up-regulation of the 
CYP1A1 and CYP1B1 (cytochrome P450 related enzymes) and finally leading to the 
release of diolepoxides (biologically reactive intermediates), can result in DNA damage 
(Figure 1.1, Penning and Lerman, 2008). In this respect diolepoxides, which are the 
product of monoxygenation of PAH by both enzymes, form covalent bulky adducts with 
DNA that may lead to mutation. 
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Figure 1.1: Gene alteration results of tobacco smoking.  
Reprinted with permission from Penning and Lerman (Penning and Lerman, 2008) 
AhR, aryl hydrocarbon receptor; AKR, aldo-keto reductase; ALDH, aldehyde 
dehydrogenase; ARE, antioxidant response element; CYP, cytochrome P450 related 
enzyme; PAH, polynuclear aromatic hydrocarbons; ROS, reactive oxygen species; Nrf, 
nuclear respiratory factor2; XRE, xenobiotic response element. 
 
1.1.7.2 Smokeless tobacco 
 
Smokeless tobacco (ST) is an alternative way of consuming tobacco, whereby 
combustion is not required. Nevertheless, nasal snuff in various forms (loose or small 
packet), and chewing tobacco (in block or flakes) still keeps mucous membranes in 
contact with the carcinogenic agent(s). It is commonly practiced in America or Europe, 
and carries at most a minor increase risk of oral cancer (Rodu and Godshall, 2006). 
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 Rodu and Jansson summarised that cancer-inhibiting agents exist in tobacco leaf 
(which has cancer protection characteristics) in their review involving case-controlled 
studies, restricted mainly to the United States and Sweden (Rodu and Jansson, 2004). 
Carotenoids and phenolic compounds are present in tobacco leaf and have antioxidant 
properties. Smokeless tobacco use is believed to reduce oral cancer risk. Rodu and 
Godshall stated that smokeless tobacco use had been associated with oral cancer and 
contradicts previous epidemiological studies (Rodu and Godshall, 2006). Moreover, 
elevated cancer risks in specific populations or from specific products cannot be 
excluded (Weitkunat et al., 2007). Several issues were addressed by Boffetta and 
colleagues on smokeless tobacco practice including oral use in several regions. 
Nevertheless this practice could not minimise cancer risks to this group than non-users 
of any form of tobacco use (Boffetta et al., 2008). 
                                                                                                                                                                                                                                                                                                                                                                                                      
1.1.7.3 Alcohol 
 
The conversion of ethanol to acetaldehyde is catalysed by alcohol dehydrogenases 
(ADH), and the formation of acetic acid from acetaldehyde is catalysed by aldehyde 
dehydrogenases (ALDH). Most alcohol and aldehyde metabolism occurs in the liver, 
but metabolism by ADH, the cytochrome P450–related enzyme CYP2E1, and ALDH is 
carried out in the upper aerodigestive tract (UADT) (include the oral cavity, pharynx, 
larynx, and esophagus) (Pöschl and Seitz, 2004). A few studies focused on isoenzymes 
related to ethanol metabolism, such as ADH (Peters et al., 2005), CYP2E1 (Figaro Gattá 
et al., 2006) and ALDH with expectation that such enzymes might be found as a 
convincing risk factor for OSCC (Hashibe et al., 2007; Ho et al., 2007).  
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 It is well known that the active substance in alcoholic beverages is ethanol and 
regular consumption is directly associated with increased oral cancer risk in a dose-
dependent relationship (Petti, 2009). The mutagenic effect of acetyldehyde, a product of 
ethanol metabolism, in oral cancer is well established in animal research although there 
is hitherto insufficient evidence to support this in humans (Figuiero-Ruiz et al., 2004). 
The source of this mutagen is not only alcohol metabolism but also from oral microflora 
activity, particularly Streptococci species (Kurkivuori et al., 2007).  
 
 Tables 1.1 and 1.2 show selected investigations on alcohol as a risk factor in oral 
cancer (with findings) and a compilation of supporting evidence on either alcohol as an 
independent risk factor or in combination with other risk factors in oral cancer (in 
descending order of year of publication), respectively.   
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Table 1.1: Selected findings on alcohol with other risk factors in oral cancer 
 
 
Study (first author, year) 
 
 
Conclusions 
 
Bagán and Scully, 2009 
 
It was noted that the frequency and duration of tobacco 
chewing and alcohol drinking and duration of bidi smoking 
were the manifestation of dose–response relationships. 
 
Hennessey, 2009 Sexual history is more relevant than tobacco or alcohol as the 
major risk factors for HPV-positive HNSCC, but this is not 
the case for HPV-negative HNSCC. 
 
Hooper et al., 2009 A recent study has shown that alcohol consumption may also 
change microflora level in the oral cavity such as 
Streptococcus anginosus. It was reported that this microbes 
were significantly higher in alcoholics compared with non-
alcoholic patients. 
 
Lucenteforte, 2009 It was reported that heavy alcohol drinkers tend to have a 
limited intake of other more beneficial foods especially 
essential nutrients. 
 
Petersen, 2009 Although heavy intake of alcoholic beverages is related to 
nutrient deficiency, study results have shown that both act 
independently in oral carcinogenesis. 
 
Petti, 2009 Globally, 7-19% of oral cancers are associated with alcohol 
intake. 
 
Scully and Bagán, 2009 
 
Current trends have demonstrated that there has been a slight 
increase in alcohol and tobacco use in women. 
 
Shah and Gil, 2009 
 
Even though tobacco and alcohol consumption remain the 
major etiologic factors, recent findings have shown that HPV 
has been implicated in oral cancer. 
 
Marichalar-Mendia, 2010 The actual role of alcohol in oral carcinogenesis remains 
unknown, but regular alcohol consumption might be a risk 
factor in oral tumorigenesis based on epidemiological studies. 
It is thought that almost 20% of oral cancer cases are 
associated with heavy alcohol intake. 
 
 
  
11 
Table 1.2: Reported evidence for alcohol with others risk factors in oral cancer 
 
 
Alcohol only (28 studies) 
 
 
Alcohol-Smoking (36 studies) 
 
Alcohol-Others (21 studies) 
 
Cancela et al., 2009 
Massarrat, 2008 
Salehi et al., 2008 
Rodu & Phillips, 2007 
Farshadpour et al., 2007 
Kruk and Aboul-Enein, 2006 
Petti & Scully, 2005 
Ogden, 2005 
Figuero Ruiz et al., 2004 
Pöschl and Seitz, 2004 
Salaspuro et al., 2003 
Das et al., 2003 
Huang et al., 2003 
Yokoyama & Omori, 2003 
Zavras et al., 2002 
Mignogna et al., 2001 
Schwartz et al., 2001 
Holmes-McNary, 2001 
Teschke et al., 2001 
Cortese et al., 2000 
Franceschi et al., 2000 
Hindle et al., 2000 
Maier et al., 1999 
Ogden & Wight, 1998 
Wight & Ogden, 1998 
Harty et al., 1997 
Harris, 1997 
Palmer, 1985 
 
 
Mayne et al., 2009 
Varshney et al., 2003 
Adewole, 2002 
Girja et al., 2002 
Chen et al., 2001 
Zavras et al., 2001 
Hindle et al., 2000 
Khan et al., 2000 
Moreno-Lopez et al., 2000 
Castellsagué et al., 1999 
Franceschi et al., 1999 
Hayes et al., 1999 
Katoh et al., 1999 
Kerawala, 1999 
Kurumatani et al., 1999 
Warnakulasuriya & Johnson, 1999 
Talamini et al., 1998 
Canto et al., 1998 
Schildt et al., 1998 
de Boer et al., 1997 
Sanderson et al., 1997 
Szabo et al., 1997 
Fabian et al., 1996 
Bundgaard et al., 1995 
Bundgaard et al., 1994 (NSND) 
Llewelyn & Mitchell, 1994 
Day et al., 1994 
Mashberg et al., 1993 
Choi & Kahyo, 1991 
Herschfus, 1991 (synergy) 
Talamini et al., 1990 (NS/ND) 
Wey et al., 1987 (NSND) 
Kune & McLaughlin, 1983 
Kuschnir, 1980 
Johnston & Ballantyne, 1977  
Vincent & Marchetta, 1963 
 
 
Muwonge et al., 2008 
Ide et al., 2008 
Ho et al., 2007 
Güneri et al., 2005 
Shui & Chen, 2004 
Liao et al., 2003 
Lissowska et al., 2003 
Znaori et al., 2003 
Vora, 2000 
Rao & Desai, 1998 
Takezaki et al., 1996 
Ying-Chin et al., 1995 
Macfarlane et al., 1995 
Kabat et al., 1994 
Rao et al., 1994 
Day et al., 1993 
Kune et al., 1993 
Marshall et al., 1992 
Zheng et al., 1990 
Elwood et al., 1984 
Graham et al., 1977 
Abbreviation:- NSND – non-smoking and non-drinking; NS/ND – either non-smoking or non-drinking 
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1.1.7.4 Synergy between smoking and alcohol 
 
Taking both risk factors together, the total proportional impact of tobacco and alcohol 
on upper aero-digestive tract (UADT) cancer is around 80%, and yet only a small 
percentage of affected individuals with these carcinogens in their background develop 
neoplastic lesions (Canova et al., 2009) (Table 1.2, middle column). In his review on the 
influence of lifestyles on oral cancer prevalence, Petti provided evidence that the 
synergistic effect of both factors is more prominent than the other risk factors (Petti, 
2009). Despite agreement on the conjoint impact of both factors, looking at them 
separately for an effect was unlikely to be meaningful in view of their tendency towards 
confounding characteristics in patient populations (Smith et al., 2007). There is no 
doubt on the effect of both tobacco smoking and alcohol drinking as evidence by an 
excessive frequency of second primary cancers (SPCs) observed in HNSCC (Chuang et 
al., 2008). The prevalence of second primary tumours (SPTs) observed in non-smokers 
and non-drinkers (NSND) were statistically comparable in both smokers and drinkers, 
even though their distinctiveness in clinicopathological properties has been established 
(Farshadpour, 2007). 
  
1.1.7.5 Betel-quid or areca nut (Areca cathecu) chewing 
 
Thomas and co-workers have shown that betel quid chewing and smoking are 
independent risk factors for oral cancer in a large case-control study in Papua New 
Guinea where betel quid does not contain tobacco (Thomas et al., 2007). Nair and 
colleagues (1999) revealed that habitual betel quid/tobacco chewers of Indian ethnicity 
are at risk of developing oral leukoplakia, a potentially malignant lesion. 
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1.1.7.6 Nutritional status and iron deficiency 
 
It was reported in one study that deficiencies in iron, vitamins A, C and E, zinc and 
selenium may be implicated in the aetiology of oral cancer. Low intake of fruit and 
vegetables has been associated with cancer of the mouth, larynx and oesophagus. It was 
believed that the active anti-oxidant substances that exist in fruit and vegetables act as 
suppressor agents to control cell growth. Active ingredients mentioned include indoles, 
flavonoids, isothiocyanates, terpenes, rutin and phenolic antioxidants (Lucenteforte et 
al., 2009). The fibre content in vegetables was also found to be associated with a 
reduction in oral cancer risk. A few studies provided evidence that vitamin A deficiency 
correlated with oral precancerous lesions and subsequent cancer (Zain, 2001; 
Lucenteforte et al., 2009); Even though beta-carotene (a precursor to vitamin A and a 
potent antioxidant as well) could be found in some fruits and vegetables, it has not been 
shown to control premalignant or cancerous oral lesions developing. 
 
1.1.7.7 Bacteria and other microbial infections  
 
There are a large number of studies investigating the possible relationship between 
microorganisms and oral carcinomas. Numerous mechanisms by which bacteria and 
yeast may initiate or promote carcinogenesis have been proposed (Hooper et al., 2009). 
However, conclusive evidence has yet not getting emerged to show such microbes being 
involved directly or indirectly in oral cancer. 
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1.1.7.8 Viruses 
 
More recently, another focus has been the small proportion of patients who develop oral 
cancer without exposure to one or both of the risk factors (tobacco smoking and/or 
alcohol consumption) (Farshadpour et al., 2007; Dahlstrom et al., 2008). The aetiology 
of these unusual and rare cases remains unknown. Therefore, it is possible that other 
factors are operating such as heredity and other environmental factors such as viral 
infections and/or nutritional deficiencies. Furniss and colleagues conducted a case-
control study involving 1034 pharyngeal cancer patients testing for antibodies to 
common HPV types. They concluded that the increased risk of HPV6 expression was 
no direct association with smoking and alcohol consumption in head and neck 
squamous cell carcinoma (Furniss et al., 2009).  
 
 It was noted by Kreimer that approximately 25 percent of all cancer types may be 
aetiologically connected with viruses (Kreimer et al., 2005). Human papillomaviruses 
(HPVs) have been proven to be important agents in promoting a diverse set of the head 
and neck cancers. To date, direct involvement of viruses in oral carcinomas is not 
strongly supported by the data but it is known that the role of HPVs in some part of the 
carcinogenesis processes in some human neoplasms is around 23.5% (Shillitoe, 2009). 
The involvement of HPVs in oral carcinogenesis will be discussed further in a 
subsequent chapter. There are other types of human viruses such as hepatitis C virus, 
retroviruses (enveloped viruses) and DNA tumour viruses that could also be involved in 
cancer (Bellon and Nicot, 2008).  
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 Human papillomavirus (Papovaviridae group: icosahedral, non-enveloped 
particles, 45-55 nm in diameter, containing double-stranded circular DNA) is among the 
candidates of DNA tumour viruses that include other viruses such as Simian Virus 40, 
polyomavirus, human adenoviruses, Epstein-Barr virus (EBV), Hepatitis B virus and 
Human herpesvirus 8 (HHV8). 
 
 DNA viruses downregulate the activity of tumour suppressors such as p53 and 
retinoblastoma (Rb) protein. Many viruses contain genes that block apoptosis or inhibit 
immune recognition of the infected host cell, which favour cell survival. 
 
1.1.8 Clinical and Histopathological Aspects 
 
The term ‘oral cancer’ is almost synonymous with the term squamous cell carcinoma 
(SCC) because of the great numerical dominance of SCCs in mouth cancer. Oral cancer 
is often difficult to identify at its early stages due to its often asymptomatic nature. In 
addition, the disease usually does not lead to early symptoms or complaints which 
would force the patient to seek professional advice.  
 
 Three main parameters are usually used for comparing and assessing the different 
forms of treatment outcomes for oral cancer patients. This includes anatomical 
description accuracy of the lesion site, the record of the treatment regimen instituted and 
a reliable system used for pre-therapeutic clinical staging of the lesion. The TNM (T, 
tumor size; N, node involvement; M, presence of distant metastasis) staging system for 
head and neck cancers (HNCs) is now in its Seventh Edition (AJCC Cancer Staging 
Handbook, 2010). It is a vital tool for comparing and reporting therapy outcomes and 
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for inclusion in clinical trials by improving patient stratification. This system is the most 
widely used for the clinical staging of tumours of the oral cavity. This system was 
developed by the American Joint Committee on Cancer (AJCC) and the Union 
Internationale Contre le Cancer (UICC) to identify clinically the stage of primary 
tumors of the oral cavity. As shown in Table 1.3, Stage IV has been revised in the sixth 
edition by defining subcategories to reflect therapeutic strategies: Stage IVA is assigned 
to tumours that are locally advanced but surgically resectable; Stage IVB consists of 
tumours that are locally advanced and surgically unresectable but potentially treatable 
with chemoradio-therapy; and Stage IVC includes patients with distant metastatic 
disease that is incurable and therefore only suitable for palliative treatment (Patel and 
Shah, 2005). 
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Table 1.3: TNM stage grouping for oral cancer 
Stage of tumour Primary tumoura Regional lymph 
nodesb 
Distant metastasesa 
Stage 0 
 
 
Stage I 
Stage II 
Stage III 
 
 
 
Stage IVA 
 
 
Stage IVB 
Stage IVC 
Tx 
T0 
Tis 
T1 
T2 
T3 
T1 
T2 
T3 
T4 
T4 
Any T 
Any T 
Any T 
Nx 
 
N0 
N0 
N0 
N0 
N1 
N1 
N1 
No 
N1 
N2 
N3 
Any N 
Mx 
 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M0 
M1 
Adapted from AJCC Cancer Staging Handbook, Seventh Edition (2010), AJCC 
 
Descriptions: 
 
a determination done via clinical examination and radiography 
b determination done via clinical examination only 
 
 Tx 
T0 
Tis 
T1 
T2 
T3 
T4a  
 
 
 
 
T4b 
Primary tumour cannot be assessed 
no evidence of primary tumour 
preinvasive carcinoma (carcinoma in situ) 
≤ 2 cm tumour in its greatest dimension 
2 cm ≤ tumour size < 4 cm in its greatest dimension 
≥ 4 cm tumour in its greatest dimension 
Lip: tumour invades through cortical bone, inferior alveolar nerve, floor of mouth 
or skin of face (i.e. chin or nose) 
Oral cavity: tumour invades through cortical bone, into deep (extrinsic) muscle of 
tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary 
sinus, or skin of face 
Tumour involves masticator space, pterygoid plates, or skull base and.or encases 
internal carotid artery 
According to 2002 AJCC/UICC staging system for cervical lymph node metastasis 
 Nx the minimum requirements to access the regional lymph nodes cannot be met 
 N0 no regional lymph node metastasis 
 N1 movable ipsilateral lymph nodes present ≤ 3 cm 
 N2A movable single ipsilateral lymph nodes (3 cm < metastasis < 6 cm) in its greatest 
dimension or multiple ipsilateral or bilateral or contralateral lymph nodes present 
≤ 6 cm 
 N2B multiple ipsilateral lymph nodes, none > 6 cm 
 N2C Metastasis in bilateral or contralateral lymph nodes, none > 6 cm 
 N3 any palpable lymph nodes > 6 cm in its greatest dimension 
 Mx 
 
the minimum requirements to access the present of distant metastases cannot be 
met 
 M0 no evidence of distant metastases 
 M1 evidence of distant metastases (blood borne) 
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1.1.9 Field Cancerisation versus Clonal Spread/Monoclonal Origin 
 
This multi-step process of carcinogenesis was first suggested by Slaughter et al. (1953), 
and focused on multiple lesions arising as result of exposure of the oral epithelium to a 
carcinogen. This concept has been challenged by the clonal spread theory, based on 
findings that second primary tumours may be found distant from the original one 
(monoclonal origin model) and supported by genetic analysis (Califano et al., 1996; 
Bedi et al., 1996 and Partridge et al., 1997; 1998). There have been a number of studies 
supporting either or both concepts as represented in Table 1.4.  
 
Table 1.4: Polyclonal origin versus Monoclonal origin 
Independent abnormalities 
Field Canserisation-Slaughter’s 
(Polyclonal Origin) 
 
Support both concepts 
 
Clonal Spread 
(Monoclonal Origin) 
 
Leedham et al., 2009 
 
Klinge and Fiebeler, 2009 
 
Ostby et al., 2006 
Parsons, 2008 Abou-Elhamd and Habib, 
2007 
Pateromichelakis et al., 2005 
Partridge et al., 2001 
Gonzáles-Moles et al., 2008 Scholes et al, 1998 Braakhuis et al., 2002; 2003; 2005 
Mignogna et al., 2007 Worsham et al., 1995 Brieger et al., 2003 
Raimondi et al., 2005 Hays et al., 1995 Nagai et al., 2003 
Almadori et al., 2004  Vriesema et al., 2001 
Bagán et al., 2004  Tabor et al., 2001 
Thomas et al., 2003  Cloos et al., 2000 
Thomson et al., 2002  Califano et al., 1996; 1999; 2000; 
2003 
Nagler, 2002  Garcia et al., 1999 
Jang et al., 2001  Bedi et al., 1996 
Van Rees et al., 2000   
Martins, 2000   
Bloching et al., 2000   
Van Oijen et al., 1999;  
Van Oijen and Slootweg, 2000 
  
Lydiatt et al., 1998   
Mitsudomi et al., 1997   
Ogden et al., 1997   
Copper et al., 1993   
   
*Details of 42 studies supporting either or both concepts are given in the references 
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 The risk of developing second cancers of the head and neck, oesophagus, and 
lung is approximately 4 percent per year when treated patients are followed over time 
(Benner et al., 1994). Long term exposure to tobacco and alcohol appears to place large 
areas of the aerodigestive tract mucosa at increased risk of carcinogenesis (Schwart et 
al., 1994). 
 
1.1.10 Prognostic Factors 
 
Prognosis (comes from the Latin word, prognōsis and from Greek, progignōskein, to 
foreknow: pro-, before; gignōskein, gnō-, to know) is defined as a prediction of the 
probable outcome of a disease, based on the individual's condition and the usual course 
of the disease as seen in similar situations and a second definition is patient’s chance of 
recovery from a disease (Bailey, 1998).  
 
 Prognosis on its own is a dynamic process and influenced by multiple factors 
such as time, the disease itself and the planned intervention. The framework for 
explaining prognostic factors in cancer was proposed and included subject-based 
classification and clinical-relevance classification (Gospodarowicz and Sullivan, 2001; 
Gospodarowicz et al., 2001). Three broad and distinct categories were proposed 
according to subject-based classification and for clinical-relevance classification. The 
former classification relates those prognostic factors to tumour, patients and to the 
environment. The latter classification grouped those factors into essential (basic 
requirement for making treatment decision of cancer type defined by histology of 
molecular tumour characteristics), additional (required to define the outcome more 
precisely but not to lead general treatment decision) and new and promising factors 
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(mainly refers to molecular factors) (Gospodarowicz et al., 2006). Therefore the 
combination of both classifications can be simplified as the prognostic factors for oral 
cancer and is affected by the choice of the planned intervention and the outcome of the 
interest (Figure 1.2). 
 
Figure 1.2: Prognostic factors interaction leading to appropriate prognosis 
(Modified from Gospodarowicz et al., 2006) 
 
 Over the years, surgical pathologists and clinicians have sought reproducible and 
reliable histopathologic factors with possible prognostic implications in oral cancer. The 
histopathologic factors with potential prognostic significance such as tumour depth, 
tumour thickness, lymphatic or vascular invasion, perineural invasion, margin of 
surgical excision, angiogenesis density score, histopathologic scoring and grading 
system and histopathologic classification of the carcinoma. 
 
 Studies on molecular biological markers for predicting malignant transformation 
of oral pre-malignant lesions have not demonstrated methods that are readily applicable 
for routine diagnostic work. In future studies, it may be important to evaluate the 
Prognostic factors 
Patient Environment 
Oral tumour 
PROGNOSIS 
Intervention Relevant 
outcome(s) 
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combined significance of several markers and/or clinical and histological variables for 
their prognostic value (Reibel, 2003). Recently, the DNA image cytometry approach in 
evaluating prognosis for tumour cell ploidy is a promising to supplement to clinical and 
histopathological parameters and could facilitate malignant and premalignant lesions in 
HNSCC evaluation (Abou-Elhamd and Habib, 2009). 
 
1.1.10.1 Tumour site 
 
The hard palate, buccal mucosa, gingiva, and tongue were the well known sites for 
squamous cell carcinoma development. For alcohol drinkers and tobacco smokers, 
among the site specific intraoral regions to be considered as high-risk were the anterior 
floor of the mouth and oral tongue (Mashberg and Samit, 1995). Alcohol and other 
dissolved carcinogens in saliva may remain in prolonged contact with mucosa which 
most predisposed to develop squamous cell carcinoma. The lower lip is the most 
common site for oral cancer (Woolgar and Hall, 2009). The anterior two-third of the 
tongue accounts for 40 percent of oral cancer and is the most frequent site for primary 
lesions (Woolgar and Hall, 2009). Tongue cancer may spread along the mucosal surface 
to involve the floor of the mouth and mandible, oropharynx, or deep invasion between 
muscle fascicles. 
 
 In contrast, Shaw and colleagues (2009) concluded that site had less effect on 
prognosis when comparing 485 consecutive patients with buccal tumours with those of 
another oral site with reference to prognostic variables. This was supported by another 
study indicating that site effect was found less certain and might not be considered a 
significant independent factor within oral cavity (Rogers et al., 2009). 
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1.1.10.2 Tumour thickness and invasion depth 
 
The thickness of a tumour means a direct micrometer measurement of the vertical bulk 
of the tumour regardless of the histologic structure of an ulcerative or exophytic form of 
tumour’s growth (Breslow, 1970). Depth of invasion, on the other hand, is the extent of 
growth into tissues beneath an epithelial surface; where epithelium is destroyed. A few 
studies have identified tumour thickness as an important prognostic indicator in upper 
aerodigestive neoplasms, especially as a predictor of regional metastasis (Spiro et al., 
1986). However, another study found that the risk of lymph nodes metastasis was not 
influenced by tumour thickness and depth (Amaral et al., 2004). It was suggested that 
regional node involvement in OSCC patients could be estimated by tumour thickness as 
a reliable histopathological parameter for prognosis (Pentenero et al., 2005).  
  
 The tumour thickness is among the factors in clinical oncology with greater 
consensual influence on disease outcome (Massano et al., 2006). Early tongue cancers 
demonstrate occult spread to the cervical lymph nodes in 20 to 30 percent of cases. A 
depth of invasion by tongue cancer of greater than 5 mm is associated with an increased 
incidence of occult metastasis (Woolgar and Hall, 2009). Depth is the most significant 
predictor of cervical node metastasis in early squamous carcinomas of the oral cavity. 
Patients with a tumour depth of more than or equal to 5 mm are at an increased risk of 
harbouring node metastasis, hence should have elective node dissection (Kane et al., 
2006). Tumour depth greater than 2 mm is correlated with significantly lower survival 
and control of disease in the neck. Chen and colleagues believed that invasion depth of 
more than 3 mm at the time of presentation may be responsible for an increased 
incidence of neck nodal metastasis (Chen et al., 2008). 
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1.1.10.3 Tumour staging 
 
Costa et al. (2005) reported the convincing relationship between clinical and 
histological staging and malignancy scores based on estimation of keratinization degree, 
nuclear pleomorphism and lymphoplasmocytic infiltrate in OSCC. Therefore, it was 
suggested that TNM clinical staging might be suitable as a prognostic indicator for 
OSCC. Other supporting opinion was based on data from a retrospective study that was 
carried out in 128 patients with SCC of the tongue and floor of the mouth. It was 
concluded that the conventional histopathological grading system has more prognostic 
value in oral cancer compared to available biological markers thus far (Weijers et al., 
2009). Current studies have suggested the introduction of other parameters to improve 
existing TNM staging and to enhance more comprehensive dynamic prognosis 
estimates especially involving disease recurrence and metastasis in head and neck 
patients (Van der Schroeff and Jong, 2009). 
 
1.1.10.4 Extracapsular spread (ECS) 
 
ECS is defined as extranodal extension of metastatic deposits outside the lymph node 
capsule it is a noticeably important prognostic factor, associated with higher 
locoregional recurrence rates, distant metastases, and lower survival rates (Woolgar et 
al., 2003). Woolgar et al. (2006) found that the 3-year survival probability was similar 
in those with macroscopic or microscopic ECS (33% and 36%, respectively) and much 
worse than the rate of 72% for those with strict intranodal metastases. Additionally, it 
has been found that patients with multiple metastatic nodes have poorer prognosis, and 
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individuals with multiple nodes with ECS show an extremely short median time interval 
until disease recurrence as well as higher mortality rates. 
 
1.1.10.5 Perineural invasion 
 
Perineural invasion by squamous cell carcinoma is considered an ominous prognostic 
sign and had been shown to correlate with an increased incidence of local recurrence, 
regional lymph node metastasis and a decreased survival (Carter et al., 1985). Rodolico 
and colleagues demonstrated the association between perineural invasion with the risk 
of nodal metastasis (Rodolico et al., 2004). Nevertheless, the status of perineural 
invasion as an independent prognosticator is unclear. A previous study was supported 
by an observation in tongue cancer that positive perineural invasion was not the only 
factor to influence the increase of incidence in head and neck metastasis but clearly 
other related histopathological and clinical parameters at the time of presentation (Chen  
et al., 2008). Similarly, Jones et al. 2009 suggested that perineural invasion role was not 
conclusive based on published data to date, but their study demonstrated 
lymphovascular invasion instead as the potential determining factor in oral cancer 
patients’ survival. 
 
1.1.10.6 Pattern of infiltration 
 
It was noted that the interaction of stromal and cancer cells particularly at the invasive 
tumour front (ITF) is significantly involved in tumour progression (Bànkfalvi and 
Piffkò, 2000). The evaluation of ITF as the tumour marker (especially the interaction 
with intratumoral dendrite cells of squamous cell carcinomas) would be more 
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meaningful if they could be assessed histopathologically (ITF grading) to indicate 
survival (Schliephake, 2003). Further reviews have supported that the pattern of 
infiltration as a result of tumour-infiltrating lymphocytes (TILs) interaction with antigen 
presenting cells (dendrite) could be of good prognostic value (Bettendorf et al., 2004). 
A study conducted on tongue cancer demonstrated that infiltration that extended to 
muscular layer had a higher chance of occult metastasis (Amaral et al., 2004). A review 
of the clinicopathologic data of 73 patients diagnosed with Stage I–II squamous cell 
carcinoma of the tongue suggested that depth of infiltration could be beneficial in occult 
metastasis prediction (Keski-Santti et al., 2007). Despite being sensitive enough to 
assist in clinical decision-making, its value was hampered by poor specificity. 
  
1.1.10.7 Excision margins 
 
The margin of uninvolved tissue around the excised neoplasm is one of the putative 
indicators of completeness of surgical removal. The effect of the closeness to a margin 
and of severe dysplasia at the margin on recurrences and prognosis has not been 
systematically evaluated. Sieczka et al. (2001) concluded that based on the increase in 
local recurrence in buccal mucosa cancers that negative margins were not a sufficient 
estimator of local control. Close surgical margin (the region within 5-mm circumference 
in OSCC without any evidence tumour at the margin) as an aggressive disease indicator 
has been considered (Sutton et al., 2003). It was later found that a 5-mm standard 
practice margin would not be adequate if there was evidence of an infiltrative pattern of 
spread (Huang et al., 2007) but should include histological assessment especially once 
the high-risk score observed for the purpose of adjuvant radiation therapy (Brandwein-
Gensler et al., 2005). The surgical margins in OSCC resections, involving deep margins 
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were found as high as 45% to 33% in tumours of the maxillary alveolus, retromolar 
region, oropharynx and buccal mucosa (Woolgar and Triantafyllou, 2005). It was stated 
that considering the histological status of resection margin which were disease free has 
a great influence on prognosis (Massano et al., 2006; Woolgar, 2006).  
 
 In addition, the close margin needs to be defined systematically by referring to 
the width of the margin on outcome to give the best estimate of both local recurrence 
and survival (Binahmed et al., 2007). Haque et al. (2006) suggested that positive 
surgical margin after adjustments of related clinical parameters was suitable to indicate 
higher in mortality. A later study claimed that involved and close margins could be used 
for mortality predictors (Rogers et al., 2009).  Liao et al. (2008) revealed that two 
independent prognostic factors (pathological margin within 7 mm, pathological tumour 
for at least 10 mm) were highly associated with disease-specific survival (DSS) and 
overall survival (OS) for local tumour control. Therefore it was suggested to measure 
the distance of tumour to nearest deep and mucosal resection margins. It should also be 
based on the macroscopic and microscopic assessment when assessing the size of an 
OSCC which usually no obvious invasive front (Woolgar & Triantafyllou, 2009). 
Proposed classification system for depth of tumor invasion helped to determine the 
optimal level of surgical resection (to include the buccinator in the clinical 
classification) and as an important predictor of buccal mucosa SCC prognosis (Ota et 
al., 2009). 
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1.1.11 Oral precancer role 
 
Conventional clinical and histopathological characteristics are still relevant for the 
prediction of malignant transformation in oral pre-malignant lesions in routine 
diagnostic oral pathology (Reibel, 2003). Although premalignant mucosal changes do 
not always precede oral cancers, such changes warn of risk and present a chance for 
preventive measures. 
 
1.1.11.1 Dysplasia 
 
Dysplastic lesions can present clinically as white patches (leukoplakias), red patches 
(erythroplakias), a combination of white and red patches (speckled leukoplakias), 
erosions or ulcers. The gold standard for a definitive diagnosis of an oral lesion is to 
perform a biopsy to obtain a histopathological diagnosis due to variable presentation of 
potentially malignant disorders. The terminology of dysplasia (preneoplastic changes) is 
a diagnosis defined by the presence of certain histological and cytological atypia 
(variations in the size and shape of the keratinocytes) but no evidence of invasion 
(Warnakulasuriya et al., 2008). Generally, the epithelium of precursor lesions may be 
thick but in the mouth are usually atrophic.  
 
 Dysplasia has three grades based on the severity of the architectural disturbance 
of the epithelium as shown in Figure 1.3. The first grade is mild dysplasia, if the 
disturbance limiting to the lower third of the epithelium with minimal cytological 
atypia. In addition, the mildly atypical features of the lesions present in the middle third 
of the epithelium might fall into this group either. In moderate dysplasia, on the other 
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hand, the lesions extend to the middle third of epithelium with a degree of cytological 
atypia. The third grade, severe dysplasia, is when the architectural disorder exists with 
cytological atypia and starts with greater than two-thirds of the epithelium. The 
presence of marked atypical even the lesions are not extending into the upper third of 
the epithelium might also categorise into the last grade (Woolgar and Triantafyllou, 
2009). 
 
 Significant variation among pathologists based on individual criteria hampered 
the reliable histopathological diagnosis of oral epithelial dysplasias (Scully et al., 2003). 
Even though fundamentally accepted two important criteria, architectural features and 
cytological assessment for grading epithelial dysplasia, unacceptable disagreement of 
inter- and intra-examiners’ interpretation putting patients management with such lesion 
in dilemma (Warnakulasuriya et al., 2008). The understanding of malignant 
transformation from dysplastic lesions to oral cancer probably depends on prospective 
molecular markers (Scully et al., 2003; Arduino et al., 2009; Eversole, 2009; Matta et 
al., 2009; Ralhan et al., 2009; Torres-Rendon et al., 2009; Tsui et al., 2009) and in 
combination the former with histopathological data (Pitiyage et al., 2009) as the risk 
predictors. 
 
 The concept of carcinoma in situ explains the occurrence of malignant 
transformation (at viable cellular layer as nearly full thickness architectural 
abnormalities together with significant cytological atypia) but the absence of invasion 
(Warnakulasuriya et al., 2008).     
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1.1.12 T he clinical pr esentation of potentially malignant lesions 
 
Clinically, leukoplakia is defined as a raised white patch or plaque of oral mucosa 
measuring 5-mm or more in diameter, which cannot be scraped off and which cannot be 
attributed to any other diagnosable disease (Batsakis, 2003). Histologically, 
hyperkeratosis, acanthosis, and subepithelial and perivascular infiltrate may be seen. 
 
 Erythroplakia can be described as a bright red, velvety plaque which cannot be 
characterised clinically or pathologically as being due to any other condition (Kramer et 
al., 1978). Histologically, most of these lesions tend to show squamous cell carcinomas 
or severe dysplasias (Shafer and Waldron, 1975).   
 
1.1.13 Potential malignant conditions  
 
Oral lichen planus (OLP) is a benign lesion with a characteristic white, lacy, reticular 
pattern that classically presents on the buccal mucosa. Papular, atrophic or erosive 
lesions constitute the major subtypes of OLP, and present infrequently. Erosive lesions, 
in particular, may be quite painful and result in multiple complications, such as 
secondary infections (predominantly Candida species), as well as poor nutrition and 
dehydration because of pain (Katta, 2000). Oral lichen planus lesions are suspected of 
possessing some cancer potential. It is strongly associated with tobacco use (Bhonsle et 
al., 1979, Gupta et al., 1980); however, malignant transformation rates (Murti et al., 
1986) and the relative risk were not significant enough to confirm malignant potential. 
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 Oral submucous fibrosis (OSF) is a unique chronic disease seen almost 
exclusively in adult patients from south Asia, where its occurrence has a significant 
association with areca nut use, principally in betel quid (combined areca nut, betel leaf, 
tobacco and slaked lime) chewing (Sinor et al, 1990; Dave et al, 1992; Jeng et al, 2001). 
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1.2 HUMAN PAPILLOMAVIRUS 
 
1.2.1 General information of HPV 
 
HPVs are non-enveloped DNA viruses about 55 nm in diameter, containing a single 
molecule of circular double-stranded DNA (Muñoz et al., 2006). Their genome size 
ranges from 7600 to nearly 8000 base pairs in length in the nucleohistone core with 
eight early genes (E1 to E8) and two late genes (L1 and L2) encoded (Letian and 
Tianyu, 2010). These genes are previously transcribed as polycistronic mRNAs (Hebner 
and Laimins, 2006).  An upstream regulatory region (URR) or a non-coding regulatory 
region called the long control region (LCR), is estimated 0.4-0.7 kb in length, contains 
the origin of replication, promoters, binding sites for core transcription factors, enhancer 
and repressor proteins (Chow et al., 2010) (Figure 1.3). The functions of the various 
HPV proteins are as shown in Table 1.5. 
 
1.2.2 Types of HPV 
 
Currently, more than 120 different HPV types have been isolated and identified by 
various molecular techniques and can be classified according to similarity in DNA 
sequences or based on risk (Chow et al., 2010). When a comparison of genomic DNA 
sequence and the biology of these viruses is made, if the sequence homology with 
respect to existing types is <90%, the HPV is classified as a new type; if the homology 
is 90-98% it is classified as a sub-type; if homology is > 98% it is classified as a variant 
(Doorbar, 2005).  
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Figure 1.3: Genome map of HPV16 
Reprinted with permission from Villa (Villa, 2006). 
 
 
Table 1.5: The main role of HPV proteins 
 
 
 
Protein 
 
 
Roles 
 
Reference 
 
E1 
 
Directs initiation of DNA replication 
Episomal maintenance 
 
Ustav et al., 1991; 
Sarver et al., 1984  
E2 A transcription activator that has auxiliary role in 
replication 
Controlling DNA replication and transcription 
(ORFs E6-E7)  
Ham et al., 1991 
 
McBride et al., 1991 
 
E3 Remains unknown/Not still clear  
E4 Disrupts cytokeratins and is important for viral 
release 
Disrupting the cytoskeleton   
Doorbar et al., 1991 
 
Roberts et al., 1993 
E5 A cellular membrane protein that interacts with 
growth factor receptors 
Interacting with cellular proteins (EGFR) 
Petti et al., 1991; 1994 
E6 A transforming protein that targets p53 for 
degradation by the ubiquitin pathway 
Ciechanover, 1994; 
Hochstrasser, 1995 
E7 A transforming protein that binds to Rb1, p107, 
p130 and cyclin AICDK2 proteins 
Ciccolini et al., 1994;  
Davies et al., 1993;  
Tommasino et al., 1993; 
McIntyre et al., 1996 
E8 Remains unknown/Not still clear  
L1 Major capsid (viral coat protein) 
 
Baker et al., 1991;  
Hagensee et al., 1994 
L2 Minor capsid that associates with genomic DNA 
(viral coat protein) 
 
Baker et al., 1991 
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Table 1.6: Human HPV supergroups and selected candidates 
 
 
 
HPV supergroup 
 
 
HPV types 
 
Origin of cloned genome (or comments) 
A  
(Alpha papillomaviruses) 
 
HPV2, 26, 27 and 29 
HPV3, 10 and 28 
HPV6 and 54 
HPV7 
HPV11 
HPV13 and 32 
HPV16, 18, 33, 35 
and 66 
HPV30 
HPV34 
HPV39 and 40 
HPV42 and 70 
HPV43 
HPV44 
HPV45, 51, 52, 58 
and 69 
HPV53 
HPV55 
HPV56 
HPV57 
HPV59 and 68 
HPV61, 62, 64, 67 
and 71 
HPV72 and 73 
HPV74 
HPV77 
HPV78, 94 
 
HPV81, 83, 84, 86, 
87, 89, candHPV85 
and candHPV90 
HPV82 
candHPV91 
 
Verruca vulgaris 
Verruca plana 
Condyloma acuminatum  
Butcher’s warts 
Laryngeal papilloma 
Focal epithelia hyperplasia 
Cervical carcinoma 
 
Laryngeal carcinoma 
Bowen’s disease 
Penile intraepithelial neoplasia (PIN) 
Vulval papilloma 
Vulval hyperplasia 
Vulval condyloma 
Cervical intraepithelial neoplasia (CIN) 
 
Normal cervical mucosa 
Bowenoid papulosis 
CIN, cervical carcinoma 
Inverted papilloma of the maxillary sinus 
Vulvar intraepithelial neoplasia (VIN) 
Vaginal intraepithelial neoplasia (VAIN) 
 
Oral lesion 
Cervical lesion 
Skin wart 
More frequently cause cutaneous than 
mucosal lesions 
Mucosal lesions 
 
 
Mucosal lesions, also in benign lesion 
Mucosal and cutaneous lesions 
B 
(Beta papillomaviruses) 
 
HPV5, 8, 9, 12, 14, 
15, 17, 19, 20, 21, 22, 
23, 24, 25 and  47 
HPV36 
HPV37  
HPV38 
HPV49 
HPV75 and 76 
HPV80 and 93 
candHPV92 and 
candHPV96 
  
Epidermodysplasia verruciformis (EV) 
lesion 
 
Actinic keratosis 
Keratoacanthoma 
Malignant melanoma 
Verruca plana 
Skin wart 
Cutaneous lesions 
Pre- and malignant cutaneous lesions 
G 
(Gamma 
papillomaviruses) 
 
HPV4 
HPV48, 88 and 95 
HPV50 
HPV60 
HPV65 
 
Verruca vulgaris 
Cutaneous squamous cell carcinoma 
EV lesion 
Epidermoid cyst 
Pigmented wart 
  
M 
(Mu papillomaviruses) 
 
HPV1 
HPV63 
 
Verrucas plantaris 
Myrmecia  
N 
(Nu papillomaviruses) 
 
HPV41 
 
 
Disseminated warts 
 
 Modified from Syrjänen and Syrjänen, 1999 and IACR, 2007  
  
34 
 Three major groups are identified as supergroup A (Alpha papillomavirus), 
supergroup B (Beta papillomavirus) and the remaining group of HPVs are members of 
supergroup E (Mu and Nu-papillomaviruses) (Syrjänen and Syrjänen, 2005). Table 1.6 
illustrates the selected human HPV types for each major supergroup and their infection 
sites in the body.  The alpha papillomavirus group, mucosotropic HPVs are further 
divided into two classes according to their risk to humans i.e. HR-HPV types 
(potentially oncogenic) and “low risk”-HPV types (non-oncogenic) (Chow et al., 2010) 
as shown in Table 1.7. 
 
Table 1.7: Epidemiologic classification of HPV types in alpha HPV supergroup 
 
 
 
Risk (candidates) 
 
 
HPV types 
 
High (24) 
 
 
Low (30) 
  
 
HPV16, 18, 26, 30, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 
70, 73, 82 and candHPV85 
 
HPV2, 3, 6, 7, 10, 11, 13, 28, 29, 32, 40, 42, 43, 44, 54, 61, candHPV62, 71, 
72, 74, 78, 81, 83, 84, candHPV86, candHPV87, candHPV89, candHPV90 
candHPV91 and 94 
  
Undetermined 
(6) 
 
HPV2a, 27, 55, 57, 62 and 77 
 
 Modified from Muñoz et al., 2006; Campisi et al., 2007, IACR, 2007 and Chow et al., 2010 
     
1.2.3 HPV oncoproteins 
 
The E6 and E7 are the critical molecules in viral replication and both are the major 
mediators of carcinogenesis for high risk types. The E6 and E7 ORF encode small 
proteins of approximately 150 and 100 amino acids, respectively. Both proteins contain 
C-x-x-C motifs (four for the former and two for the latter) which cause transcription 
activation, transformation, immortalisation and the association with cellular proteins. 
The E6 COOH-terminal region contains a post synaptic density protein (PSD95), 
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drosophila disc large tumor suppressor (DlgA), and zonula occludens-1 protein (zo-1) 
(PDZ) domain for interaction with several PDZ domain-containing proteins. The E7 
proteins incorporate three conserved regions, CR1 (NH2-terminal), CR2 region and CR3 
(COOH-terminal). The CR2 region contains LxCxE (for pRB binding) and a casein 
kinase II phosphorylation site (CKII) (Hebner and Laimins, 2006). E5 ORF encodes 7.0 
kDa small proteins of approximately 44 amino acids which function as a 
transmembrane domain, with a hydrophobic (30 amino acid) N-terminal and a 
hydrophilic (14 amino acid) C-terminal (Sparkowski et al., 1996).  
 
1.2.4 Pathogenesis of HPV infection 
 
It has been established that HPVs are exclusively epitheliotropic, meaning that their 
infection is specifically localised in epithelial cells of the host. In order to complete their 
life cycle, they rely on epithelial differentiation (Doorbar, 2005). HPV infection 
involves highly complex mechanisms which are still poorly understood. For simplicity, 
the sequences of the commonly shared stages of general viral pathogenesis are adopted 
here. The chronological events of the HPV life cycle, regardless of genotype could be 
divided into five distinct phases: infection and uncoating, genome maintenance, the 
proliferative-phase, genome amplification and virus synthesis. 
 
 It is currently believed that the basal keratinocytes of the squamous epithelium 
become the prime target for HPV infectious particles as this region has a link to the 
external environment (Syrjänen and Syrjänen, 2005). In respect to anatomic site, skin, 
oral cavity, upper gastrointestinal tract, larynx, conjunctiva of the eye, genital tract and 
anal canal could be the viral portals to permit an initiation of HPV infection into the 
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host which is composed of adsorption, penetration and uncoating of the viral genome. 
To ensure the successful of initial infection, a break in the stratified epithelium is a 
prerequisite since HPV is unlikely to enter into an intact squamous epithelium (Egawa, 
2003; Syrjänen and Syrjänen, 2005). Thus, it was suggested that either micro trauma 
had been established prior to infection or targeting of immature squamous epithelium 
(prone to infection of high-risk mucosal HPV 16) (Doorbar, 2005; Syrjänen and 
Syrjänen, 2005). In cutaneous skin, on the other hand, hair follicles seem a ‘special and 
important route’ for the B1 supergroup of HPV entry (Boxman et al., 2001). 
 
 To date, the nature of cell surface receptors to establish initial viral attachment for 
the HPV-host cell interaction remains controversial and needs to be elucidated. Two 
putative cellular receptors, the α4β6 heterodimer of integrin and/or the syndecan-1 of 
heparan sulphate proteoglycans (HSPGs) were suggested to play a crucial role in the 
binding of HPVs to the cell surface (Letian and Tianyu, 2010). It was believed that 
endocytosis of clathrin coated vesicles was commonly used by viruses to penetrate the 
plasma membrane (Culp and Christensen, 2004; Syrjänen and Syrjänen, 2005). Thus 
far, the release of viral particles from endosomes and their content into the cytoplasm is 
called uncoating, but is poorly understood. Two other putative alternative uptake 
pathways have been proposed, caveolar endocytosis and a clathrin- and caveolae-
independent pathway, but they remain to be validated by convincing experimental 
evidence (Letian and Tianyu, 2010). In principle, the mechanism involves capsid 
transportation, DNA virus release and disintegration of the empty shell in the nucleus 
which was adopted from picornaviruses (Cann, 1997).  
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 As previously stated the initial replication of HPVs occurs within the basal (and 
suprabasal) cells of the squamous epithelium. Upon uncoating viral E1 and E2 proteins 
are expressed to permit an episomal form of the viral genome to be maintained (Wilson 
et al., 2002) and also as a low copy number in the basal cells of the epithelium 
(Doorbar, 2005). At this point, normal terminal differentiation is retarded in which 
suprabasal cell layers are supposed to exit the cell cycle by the action of both E6 and E7 
proteins. During productive infection, E7 stimulates cell proliferation by associating 
with pRB and its normal induction effect towards apoptosis in response to unscheduled 
S-phase entry is thought to be prevented by E6 action (Doorbar, 2005). Therefore 
epithelium infected with HPV 16 undergoes cell cycle progression (Sherman et al., 
1997; Stacey et al., 2000). The E5 protein, which has hydrophobic properties, could 
play a vital role in inhibiting death receptor signalling and to overcome the elimination 
of infected cells during the early stages of HPV infection (Garnett and Duerksen-
Hughes, 2006).  
 
 Papillomavirus genome amplification occurs in the mid or upper epithelial layers 
prior to packaging the DNA into infectious particles (Doorbar, 2005).  Promoter P3, 
which resides within the E7 gene, was thought to be up-regulated leading to the 
increased expression of E1, E2, E4 and E5 proteins which are responsible for DNA 
replication (Doorbar, 2005, Chow et al., 2010).  
 
 The final phase of HPV infection involves the undistinguishable steps: assembly, 
maturation and release (Cann, 1997). The expression of two structural proteins, L2 (a 
minor coat protein) first followed by L1 (a major capsid protein) permits assembly in 
the upper layers of the infected tissue (Florin et al., 2002). As HPV are non-lytic, it was 
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believed that by limiting its epitopes/antigen presentation strategy this may prevent it 
from being detected by the host immune machinery until the cell reaches the uppermost 
epithelial layers (Matthews et al., 2003). 
 
1.2.5 Detection and identification of HPVs 
 
One of the historical dates in HPV research was 1983, when Syrjänen et al. (1983) first 
proposed HPV’s involvement in head and neck carcinogenesis (Syrjänen et al., 1983). 
Since then, we have seen the rapid development of various detection methods with the 
vast majority of them focusing on HPV’s prime target, keratinocytes. A few 
controversial issues still exist in the details of the mechanism involved in HPV-host 
interaction. There is no doubt that the holistic understanding of the significance of the 
role of HPV in oral carcinogenesis might be exploited for diagnostic, prognostic and 
treatment purposes.  
 
 Clearly, keratinocytes infected with HPV exhibit structural and functional changes 
in comparison to normal cells (Syrjänen and Syrjänen, 2005). Two distinct types of 
infections can be outlined, a productive infection and a transforming infection. The 
former could result in benign epithelial proliferation and normally are detected via 
microscopic observation of the presence of koilocytosis (Zur Hausen, 1996). The latter 
could end up with the progression of cancer precursors and invasive cancer. The 
detection method for this type of infection seems not to be straight forward due to the 
fact that the cytopathic changes of transformed cells commonly disappear with the 
progression of cancer. DNA detection techniques could be suggested as an alternative, 
since morphological means for demonstrating the presence of HPV are generally 
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unreliable (Syrjänen and Syrjänen, 2005). The percentage of HPV detected in various 
types of tissue is shown in Table 1.8. (normal), Table 1.9 (benign), Table 1.10 
(dysplasia) and Table 1.11 (carcinoma). 
   
1.2.5.1 HPV in cervical specimens 
 
A large number of studies have successfully detected the presence of HPV in cervical 
tissues. Unfortunately, the reported detection rate (percentage) amongst them and 
identified HPV genotypes vary due to differences in the HPV detection and genotyping 
methods. In addition, great variation exists in the sample size of each study. Table 1.12 
compares those thirty-five studies from 2007 to 2009, focusing on the sensitivity and 
the specificity of the detection methods mainly in identifying HR-HPV in the 
specimens. Out of them, sixteen studies applied two or more different HPV 
identification methods purposely to review the degree of concordance between or 
among techniques utilised. It was found the percentage of agreement varied from 33% 
to 100%.      
  
1.2.5.2 HPV in head and neck clinical samples including oral sites 
 
A Scopus database search for publications from 2000 to 2010 was carried out by using 
preset keywords: head and neck cancer, oral cancer, HPV identification, HPV 
genotyping and molecular biology techniques. This ended up with eight relevant studies 
based on the restricted criteria given above. Similarly, Table 1.13 shows a comparison 
of parameters as in 1.2.5 (a) among those findings in head and neck clinical samples. 
 
  
40 
 
Table 1.8: HPV prevalence among studies (2000–2010) in normal individuals 
 
 
No. 
 
Investigators 
 
N 
 
Type of tissue 
 
HPV (%) 
 
HPV types 
      
1. Bouda et al., 2000 16 Oral 0 - 
2. Patiman et al., 2001 7 Oral 1/7 (14) HPV16 
3. Jimenez et al., 2001 20 Oral 2/20 (10) HPV6, HPV16 
4. Fukui et al., 2001 14 Head and neck 0 - 
5. Sugiyama et al., 2003 44 Oral 16/44 (36) HPV16 
6. Kansky et al., 2003 66 Oral 4/61 (6.6) HPV11, HPV16, 
HPV31, HPV68 
7. ÓFlatharta et al., 2003 20 Oral 0 HPV16 
8. Chang et al., 2003 30 Oral 6/30 (20) 17% ‘high risk’ HPVs 
9. Zhang et al., 2004 44 Oral 22/44 (55) HPV16, HPV18 
10. Kurose et al ., 2004  662 Oral 4/662 (0.6) HPV16, HPV53, 
HPV71, HPV12 
11. Koppikar et al., 2005 102 Head and neck 5/102 (5) n/a 
12. Hormia et al., 2005 31 Gingival 8/31 (26) High-risk HPV 
13. Giovannelli et al., 2006 17 Oral 7/17 (41) HPV18, HPV16, 
HPV6,  HPV33, 
HPV53 
14. Marais et al., 2006 116 Oral 4/116 (3.5) HPV13, HPV32 
15. Kansky et al., 2006 45 Oral 3/45 (7) HPV6, HPV11, HPV31 
16. Luo et al., 2007 90 Oral 8/90 (9) High-risk HPV 
17. Gonzalez et al., 2007 60 Oral 0 - 
18. González-Losa et al., 
2008 
77 Oral 1/77(1.2) High-risk HPV 
19. Llamas-Martínez et al., 
2008 
30 Oral 7/30 (23) n/a 
20. Lohavanichbutr et al., 
2009 
35 Oropharyngeal 2/35 (5.7) n/a 
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Table 1.9: HPV prevalence among studies (2000–2010) in individuals with oral benign 
 
 
No. 
 
Investigators 
 
N 
 
Type of tissue 
 
HPV (%) 
 
HPV types 
      
1. Jimenez et al., 2001 40 Oral 22/40 (55) HPV6, HPV13, 
HPV32, HPV16 
2. ÓFlatharta et al., 2003 38 Oral lichen planus 10/38 (26) HPV16 
3. Gonzalez et al., 2007 11 Oral 10/11 (91) 30% ‘high risk’ HPVs 
4. Llamas-Martínez et al., 
2008 
35 Oral 16/35 (46) 40% HPV16 
 
Table 1.10: HPV prevalence among studies (2000–2010) in individuals with oral dysplastic 
 
 
No. 
 
Investigators 
 
N 
 
Type of tissue 
 
HPV (%) 
 
HPV types 
      
1. Patiman et al., 2001 30 Oral 20/30 (67) HPV16 
2. Sugiyama et al., 2003 51 Oral 31/51 (61) HPV16 
 
Table 1.11: HPV prevalence among studies (2000–2010) in individuals with carcinoma  
 
 
No. 
 
Investigators 
 
N 
 
Type of tissue 
 
HPV (%) 
 
HPV types 
      
1. Cao et al., 2000 40 Oral 29/40 (73) HPV16, HPV18 
2. Patiman et al., 2001 38 Oral 35/38 (92) HPV16 
3. Fukui et al., 2001  Head and neck 25/98 (26) HPV16 
4. Sugiyama et al., 2003 86 Oral 30/86 (35) HPV16, HPV18 
5. Kansky et al., 2003 59 Oral 5/59 (8) HPV16, HPV33, 
HPV58 
6. Chang et al., 2003 103 Oral 51/103 (50) 42% ‘high risk’ HPVs 
7. Zhang et al., 2004 73  54/73 (74) HPV16, HPV18 
8. Koppikar et al., 2005 102 Head and neck 32/102 (31) 6%  HPV16, HPV18 
9. Giovannelli et al., 2006 17 Oral 6/17 (35)  
10. Kansky et al., 2006 44 Oral 4/44 (9) HPV6, HPV16 
11. Luo et al., 2007 51 Oral 11/51 (22) High-risk HPV 
12. Gonzalez et al., 2007 25 Oral 15/25 (60) 86% ‘high risk’ HPVs 
13. Llamas-Martínez et al., 
2008 
33 Oral 13/33 (39) 33% HPV16 
14. Lohavanichbutr et al., 
2009 
119 Oropharyngeal 41/119 (35) n/a 
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Table 1.12: Comparison among various studies for HPV detection in cervical specimens 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
1 
 
Chacón et al., 2007 
 
272 
 
 
PCR 
HybridCapture 
Microarray 
 
 
33% HPV 16/18 in 212 patients 
25% with mixed infection 
 
HPV 16/18 were detected in 55.73% of the 61 patients with H-SIL and cancer, whereas these 
genotypes were detected in only 7.9% and 22% of women with ASCUS and L-SIL 
Genotypes 16 and or 18 were detected in most patients with a diagnosis of H-SIL. Other high-
risk-HPV genotypes were much less prevalent. Hybrid capture testing is a useful screening test. 
PCR was effective for identifying genotypes 16 and 18. Histological and cytological findings in 
cervical samples should be interpreted together with high-risk HPV detection. 
 
2 He et al., 2007 120 cervical swabs Multi-fluorescent 
quantitative PCR 
HybridCapture2   
 
52.5% (63/120) positive for HPV The multi-fluorescent quantitative PCR assay is a simple, quick, sensitive and specific method 
for genotyping and quantization of HPV infections, it provides strong and detailed data for 
clinical screening on cervical specimens, virus-load on level of infection and objective mediod 
on result of HPV infection therapy. 
 
4 Lee et al., 2007 2358 HPV DNA chip 
analysis 
hr HPV in 23.5% of 1650 normal 
samples 
81.8% of 708 samples with CIN 
and carcinoma 
 
The major prevalent high-risk HPV genotypes in 381 samples of CIN II/III were HPV-16, -58, -
33, and -31, in order of prevalence rate (average overall, 78.0%), and HPV-16, -18, -58, and -33 
(average overall, 81.2%) in 133 samples of squamous cell carcinoma (SCC). HPV DNA chip 
analysis may be a reliable diagnostic tool for the detection of cervical neoplasia and that there 
are geographic differences in the distribution of high-risk HPV genotypes.  
 
5 Lin et al., 2007 8900 and 
7 extrinsic controls  
 
EasyChip® HPV 
blot 
 
1–50 copies of HPV genome 
equivalent (overall) 
There was no cross-reactivity with amplicons of other HPV genotypes. The intra-batch and 
inter-batch reproducibility was 98 and 97%, respectively. The EasyChip® HPV blot is a highly 
sensitive, reliable and reproducible tool for detection and identification of HPV genotypes. 
 
6 Park et al., 2007 60 (LSIL (30) and 
LSIL-MA (30)) 
 
SPF10 PCR and 
line probe assay 
n/a H-SIL on follow-up was significantly more common in patients with LSIL-MA (36%) than in 
patients with LSIL (7%), and negative follow-up was significantly more common in patients 
with LSIL (50%) than LSIL-MA (23%).  
 
7 Campos et al., 2008 57 
 
 
PCR; Roche 
Linear Array 
HybridCapture2 
 
56/57 (98%) HPV detected In that study, concordance between the two detection techniques was good and the authors 
concluded that the medium adequately preserves HPV DNA. The present study adds further 
knowledge on the compatibility of conventional DNA extraction with the automated Linear 
Array amplification procedure. 
 
8 Castle et al., 2008 5659 
(1427 for LA) 
 
SPF10 LiPA 
Linear Array 
HybridCapture2 
 
83.3% (overall agreement) and 
86.9% (agreement among 
specimens) for HPV positive by 
both methods. 
Both HPV genotyping methods showed excellent agreement for common HPV genotypes 
detected in baseline cervical specimens. The use of both methods will provide an accurate 
estimate for the main outcomes in HPV vaccine trials, and both will be useful in studies of the 
natural history of HPV. 
 
Abbreviations:  CIN-cervical intraepithelial neoplasia; ASCUS-atypical squamous cells of undetermined significance (ASCUS); L-SIL and H-SIL-lowgrade and high-grade squamous intraepithelial lesion; MA-marked cytological atypia  
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Table 1.12: (continued) 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
9 
 
Jeronimo et al., 2008 
 
1745 
 
Roche Linear 
Array 
 
1018/1745 (58.3%) positive for 
HPVs 
 
Standardization of HPV typing is worth the effort because it forms the basis for HPV research 
and might play a central role because of its role in defining the persistence of HPV, in clinical 
decision making for patient management, and even in treatment. 
 
10 LaMere et al., 2008 572 (143 x 4) frozen 
cervical specimens 
PCR, multiplex 
hybridisation by 
Luminex® xMAP® 
Tested: no HPV (6%), one HPV 
(62%), > 2 HPVs (32%) genotypes  
Controls: no HPV (8%), one HPV 
(63%), > 2 HPVs (29%) genotypes 
 
There was no difference by group. HPV viral DNA was resilient for up to 6-months of frozen 
storage in the typical alkaline conditions employed for denaturing DNA for hc2 testing. Hybrid 
Capture 2-tested specimens stored under these conditions can be HPV genotyped using this 
PCR-based genotyping method. 
11 Lin et al., 2008 433 cervical swabs EasyChip® HPV 
blot (modified) 
vs L1-type specific 
419/433 (96.8%) - HPV positivity; 
394/433 (91.0%) - type-specific 
HPV 
 
The modified MY11/GP6+ PCR-based HPV Blot assay is generally satisfactory for clinical 
HPV genotyping in cervical swab samples. 
12 Mo et al., 2008 470 Hybrid Capture-II® 
vs AMPLICOR®, 
INNO-LiPA  
241/470 (51.3%) both positive; For 
HR HPV, both similar in sensitivity 
(96.4%) and specificity (100%). 
Both AMPLICOR® HPV Test and HCII® serve as excellent systems with similar efficacy for 
the detection of HR-HPV DNA. The AMPLICOR® HPV Test is efficient, sensitive and can be 
used routinely to evaluate HPV status, especially in women with an ASC-US diagnosis. 
 
13 Nazarenko et al., 
2008 
122 cervical samples; 
603 (450 +HC2 & 153 
-HC2) STM samples  
PCR, Hybrid 
Capture2, 
Luminex® XMAP® 
115/122 (94.3%); 434/450 (96.4%) 
+HC2/+PCR; 143/153 (93.5%) -
HC2/-PCR 
 
This new sequence-specific Hybrid Capture® sample preparation is fast, efficient and allows 
direct HPV genotyping by PCR and slightly better detection of multiple HPV infections. 
14 Nielsen et al., 2008 10,544: aged 20-29;  
1443: aged 40-50; 
women 
Hybrid Capture2, 
SPF10-LiPA 
HR HPV prevalence was  
17.9% (aged 20-29 years) and  
4.4% (aged 40-50 years) 
HR HPV infection was common among younger women, with HPV16 as the predominant type. 
Sexual activity is important for the risk of HR HPV infection and the role of sexual behaviour 
for the risk of having multiple HR HPV types. 
 
15 Nobre et al., 2008 27: HPV positive 
patient samples 
30: cervical samples 
In silico analysis 
PCR-RFLP 
 
HPV DNA positive in 16/30 (53%) 
(3 normal, 3 low grade-, 5 high 
grade-lesions and 5 carcinoma) 
 
This approach offers significant advantages over the PCR-RFLP techniques, and other currently 
available HPV typing assays. It particularly suited for routine HPV detection and identification 
in settings of poor financial resources, like cervical screening programs in developing countries. 
 
16 Sabol et al., 2008 153 (126 HSILs, 
27 LSILs) samples 
 
 
Linear Array  
vs INNO-LiPA 
vs non-commercial 
(GP-RLB) assay   
 
HPV types were detected by LA, 
LiPA, GP-RLB, and BS-RLB 
assays,  in 94.1%, 92.8%, 88.2% 
and 94.1%.  
By LA, LiPA, GP-RLB, and BS-RLB assays, the multiple infections were detected: 55.6%, 
37.3%, 43.1%, and 52.9% samples, respectively. The majority of double infections: 58.8%, 
54.4%, 66.7%, and 60.5% by the LA, LiPA, GP-RLB and the BS-RLB assay, respectively. A 
large variability in the ability of a particular assay to detect different HPV types. The LA and 
BS-RLB assays found larger numbers of cases positive for multiple types than the two other 
assays did. The lowest capability of detecting multiple infections was observed for LiPA. The 
interassay agreement was moderate for single infections and poor for multiple infections. 
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Abbreviations:  STM-specimen transport medium; n/a-not available 
Table 1.12: (continued) 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
17 
 
de Antonio et al., 
2008 
 
218 
 
HybridCaptureII® 
Linear Arrays 
 
For HR HPV detection, 
+HC2/+LA: 94/218 (43.1%); 
 -HC2/-LA: 105/218 (48.1%) 
 
 
The two tests used in this study for the detection of HPV in cervical samples – hybrid capture 
and linear array – useful and reliable tests to detect the presence of HPV cervical infection. 
18 Baleriola et al., 2008 834 HGS High-Risk 
HPV detection kit; 
HybridCaptureII® 
Specificity: HGS and HCII tests 
were 90.6% and 84.6%, 
Sensitivity: HGS and HCII tests 
were 63.1% and 64.7% 
 
HGS test is simpler, less sample volume, less time and does not require as much specialized 
equipment (e.g. Luminometer) viable and more accurate alternative to the Hybrid Capture II 
Assay. 
19 
 
Schmitt et al., 2008 1085 PCR and 
hybridisation by 
Luminex 
1085 samples and 27 HPV types 
analysed (total=29295),  
639 (2.2%)  +ve concordant, 
28,378 (96.9%) -ve concordant 
 and 278 (0.9%) discordant 
 
BSGP5+/6+ multiplexed with β-globin PCR provides an improvement in type-specific 
amplification sensitivity and homogeneity compared to GP5+/6+ and offers simultaneous 
internal control of DNA quality. BSGP5+/6+-MPG, therefore, is suitable for epidemiologic and 
also diagnostic applications. 
20 Stevens et al., 2008 142 cervical brush BeeBlot vs 
Linear Array 
100/142 (70.4%) HPV detected. 
The HPV genotyping profiles 
obtained were identical using either 
the manual or automated procedure 
(concordance of 100%) 
The BeeBlot automated platform, as a supplementary tool with the LA-HPV test, has a capacity 
equal in sensitivity to the current recommended detection protocol for typing single and 
multiple HPV infections. The BeeBlot automated hybridisation and detection system could 
quite effectively be utilized for processing LA-HPV strips upon appropriate internal laboratory 
validation. 
 
21 Brandao et al., 2009 147 (51 were pregnant 
and HIV +ve, 51 HIV 
+ve and not pregnant  
and 45 pregnant and 
HIV-ve) 
PCR 
HybridCapture 
HPV positive was 122/143 
(85.3%). Among HIV-positive 
pregnant women: HPV prevalence 
of 48/50 (96%), of whom 29/48 
(60.4%) were high-risk. 
 
A high prevalence of HPV infection was identified, especially with the high-risk types 16, 58, 
18 and 66. This study identified high-risk HPV types in all three groups examined (HIV-
positive pregnant women, HIV-negative pregnant women and HIV-positive not pregnant), 
characterising its distribution in this setting. 
 
22 
 
Brebi et al., 2009 41 cervical biopsies of 
adenocarcinoma 
PCR and  
Reverse Line Blot 
HPV positive was (29/41) 71%; 
HPV 16 (61%); HPV 18 (19.5%) 
 
Eighty seven percent of biopsies had a single HPV infection. Three patients had a multiple HPV 
infection. A high prevelence of HPV 16 and a low prevalence of HPV 18, which historically 
has been related to adenocarcinoma. Technique. 
 
23 
 
Brismar et al., 2009 84 CIN with cone 
biopsies; ectocervix 
PCR and Roche 
Linear Array HPV 
genotyping 
HPV was detected in 65/84 (77%) 
cone specimens. The most common 
high-risk types in the cones were 
HPV 16, 18, 31, 33, 51, and 52  
(> 5% of the cases). 
 
Fifty-five (85%) of the 65 hrHPV positive cone specimens contained a single hrHPV infection, 
9 (14%) had a double hrHPV infection, and 1 cone contained 4 hrHPV types. 
Testing for HR HPV identified all recurrent/residual high-grade CIN. Focusing on women with 
persistent HPV types through genotyping substantially increased positive predictive value but at 
a loss in sensitivity. 
 
Abbreviations:  HGS-human genetic signatures; BS- additional eight upstream and two downstream primers to GP5+/6+; MPG-multiplexed HPV genotyping; CIN-cervical intraepithelial neoplasia 
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Table 1.12: (continued) 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
24 
 
Castle et al., 2009 
 
531 
 
Linear Array® and 
cobas 4800 HPV 
(c4800) 
 
 
162/531 (30.5%) both positive; 
209/531 (39.4%) both negative; 
142/531 (24.9%) HR HPV detected 
 
 
A very good agreement between the well-validated Linear Array HPV genotyping assay and the 
new prototype clinical assay, the c4800 test, which offers partial HPV genotyping for HPV16 
and HPV18. The reproducibility and reliability of the c4800 test should be established before it 
can be widely used for cervical cancer screening 
 
25 
 
Dalstein et al., 2009 135 cervical samples 
positive with HC2 
PCR, Hybrid 
Capture 2; Linear 
Array®  HPV 
genotyping vs 
PapilloCheck test 
 
91/135 (67.4%) +ve concordant  
34/135 (25.1%) –ve concordant 
10/135 (7.4%) discordant 
58/110 (52.7%) multiple infections 
 
The PapilloCheck test and the Linear Array test give comparable results for detecting HPV in 
cervical specimens. However, these results also suggest that there is a need to standardize the 
type-specific sensitivity of genotyping methods and to evaluate their accuracy to detect multiple 
HPV infections. 
 
26 Erali et al., 2009 197 Real-time PCR 
DNA sequencing 
HPV-QUAD vs 
Hybrid Capture 2 
 
91% concordant (180/197)   
9% discordant (17/197) 
Single infection: 48.6%  (53/109) 
Multiple infections:16.5% (18/109) 
 
The automation conferred with the INFINITI automated system provides a reliable and 
convenient platform for walkaway analysis in the clinical laboratory. The HPV-QUAD assay 
chemistry is robust and provides reproducible HPV genotyping results. 
 
27 Galan-Sanchez and 
Rodriguez-Iglesias, 
2009 
83 Hybrid Capture 
INNO-LiPA vs 
Linear Array vs 
Clinical Array 
 
39.7% concordant (31 samples) 
56.4% compatible (44 samples) 
3.8% discordant (3 samples) 
Single infection: 77.4%  (24/31) 
Multiple infections: 22.6% (7/31) 
 
All genotyping methods tested are highly comparable and suitable for clinical and 
epidemiological studies. The major challenges to HPV typing are to find international standards 
to evaluate the typing techniques and to make available these technical improvements to 
developing countries, where the necessity for such tests is a prime concern. 
28 García-Sierra et al., 
2009 
 
408 Clinical Array vs 
Hybrid Capture II 
Papanicolau smear 
90% concordant (367/408) 
246/408 (60.2%) HPV positive 
206/246 (83.7%) HR HPV 
Multiple infections: 50% (123/246)  
 
Screening with Papanicolau smear and HC-II tests, followed by HPV detection and genotyping, 
provided an optimal identification of women at risk for the development of cervical cancer. The 
array method also made allowed us to determine the possible contribution of the available 
vaccines. 
29 Hong et al., 2009 258 Hybrid Capture 2 
CM-LA vs  
DM-LA 
83.1% concordant (207/249) 
147/249 (59%) HPV positive 
 
 
Digene media to be interchangeable with Cytyc media when performing the Roche linear array 
genotyping test. Clinically, we could perform the Roche linear array genotyping test with the 
same Digene media among women, positive for HC2 assay. 
 
30 
 
Iftner et al., 2009 11000 Hybrid Capture II 
Real-time Multi-
plex PCR 
INNO-LiPA v2 
 
Overall concordant: INNO-LiPA 
v2/multiplex PCR, with SurePath, 
normal (85.7%), ASCUS /LSIL-1 
(87.5%), ASCUS/LSIL-2 (92.2%), 
and HSIL (94.9%) 
 
Analyses of DNA genotype testing compared to cytology results demonstrated a significant 
discordance between cytology-negative (normal) and HPV DNA-positive results. This 
demonstrates the challenges of cytological diagnosis and the possibility that a significant 
number of HPV-infected cells may appear cytologically normal. 
 
Abbreviations:  CM-LA - Cytyc media-based linear array HPV test; DM-LA - Digene media-based linear array HPV test 
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Table 1.12: (continued) 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
31 
 
Jamison et al., 2009 
 
175 
 
PCR 
Roche Linear 
Array 
 
82.9% (145/175) HPV-positive 
17.1% (30/175) HPV-negative 
37% (10/27) HPV-positive in 
normal cytological samples  
 
The assay was able to detect multiple HPV infection with a wide range of genotypes in LBC 
samples sent for routine cytological analysis. It would be suitable for use in a cytopathology 
laboratory. 
 
32 
 
Lee et al., 2009 
 
3222 
 
Nested PCR 
DNA sequencing 
 
11% (352/3222) HPV-positive 
92% (324/352) single infection 
8% (28/352) multiple infections 
 
 
 
Direct automated DNA sequencing is a reliable means for validation of HPV genotyping in a 
routine clinical microbiology laboratory. However, PCR amplification, the identification of the 
signature sequence for different genotypes by DNA sequence alignment for genotyping are 
some of the challenging issues that the laboratory staff must become familiar with. 
 
33 Meftah el khair et al., 
2009 
 
89 PCR 
Southern Blot 
92% (82/89) HPV-positive 
56.1% (46/82) single infection 
44.9% (36/82) multiple infections 
 
HPV-16 and persistent infections with other high-risk HPV types are more likely to progress 
toward cervical neoplasia, but the present study suggests that infections with multiple types 
might contribute additional prognostic value. 
34 Schenk et al., 2009 123 (101 gyneco-
logical, 8 genital 
warts,7 otorhino-
laryngeal lesions, 5 
skin warts, 2 
orolabial) 
 
Biochip vs 
CE marked PCR 
RH (GenID-PCR) 
87.8% concordant (101/115) 
24.3% (30/123) HR HPV 
16.2% (20/123) LR HPV 
The Biochip showed better performance in the detection of multiple infections of high-risk 
genotype. Due to the different probe configurations used in the two assays, GenID-PCR 
achieves only group-specific detection of many HPV genotypes, whereas Biochip allows for 
specific identification. Overall, the newly developed HPV chip system (Biochip) proved to be a 
suitable tool for HPV detection and genotyping; it also proved to be superior for establishing 
HPV genotyping methods. 
 
35 Seme et al., 2009 70 DG RH Test 
RUO vs 
IG E CE 
 
60% concordant (42/70) 
40% compatible (28/70) 
88% HR HPV detected (37/42) 
7% LR HPV detected (3/42) 
5% no HPV detected (2/42) 
 
A novel Digene test is suitable for the detection of hr-HPV genotypes in clinical samples and it 
provides comparable results to the well established INNO-LiPA assay. Although INNO-LiPA 
identified significantly more samples with multiple HPV genotypes than the Digene test, the 
clinical benefit of such a difference is at present unclear. 
 
      
Abbreviations: LBC-liquid-based cytology; DG – Digene HPV Genotyping;; IG E CE-INNO-LiPA HPV Genotyping Extra CE assay; RH-reverse hybridisation; 
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Table 1.13: Comparison among various methods for HPV detection and genotyping in the head and neck 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
1 
 
Schwartz et al., 2001 
 
254 tissues from 
OSCC patients 
 
 
PCR and 
sequencial 
hybridisation 
 
15.1% mucosal HPV 16 detected 
 
The presence of HPV type 16 DNA is independently associated with a favorable prognosis in 
patients with oral squamous cell carcinoma. 
HPV genotyping may provide important prognostic information. 
 
2 Klaassen et al., 2004 30 FFPETs 
100 liquid-based 
cytology samples 
PCR 
High-density 
microarray 
DNA sequencing  
 
53/130 (41%) mucosal HPVs A total of 45 HPV types were identified by a single type-specific probe, whereas the remaining 
8 mucosal HPV types could be identified by a specific combination of probes. The simple assay 
format allows usage of this assay without expensive equipment, making it accessible to all 
diagnostic laboratories with PCR facilities. 
 
3 Gonzalez et al., 2007 77 oral lesions (cases) 
60 normal oral 
mucosa (control) 
PCR-RFLP-dot 
blot 
91.0% of HPV- benign lesions 
14.3% of non-HPV-benign lesions 
51.5% of preneoplasias 
60.0% of cancers. 
No control sample tested HPV positive. In benign HPV- associated lesions, 30.0% of HPV 
positive samples harbored high-risk types, while in preneoplastic lesions the value rose to 
59.9%. In cancer lesions, HPV detection in verrucous carcinoma was 88.9% and in squamous 
cell carcinoma 43.8%, with high-risk type rates of 75.5% and 85.6%, respectively.  
 
4 Mitra et al., 2007 92 head & neck and 
28 leukoplakia lesions 
PCR 
Southern 
hybridisation 
DNA sequencing 
HPV positivity was 69%. (59) 
27 were HPV negative (31%) 
21% to harbour p53 mutations in 
the coding region of the gene. 
HPV status was identified in 86 samples. HPV status for six samples was not determined 
because of the unavailability of the DNA samples. It was proposed that genetic and epigenetic 
alteration of p53 and HPV mediated p53 inactivation possibly follow distinct pathways during 
the development of HNSCC from normal epithelium via dysplasia.  
 
5 Schlecht et al., 2007 42 fresh frozen 
tumour samples  
 
PCR and RT-PCR 
cDNA microarray 
HPV 16 was detected in 29% 
(12/42) of HNSCC tumours by 
both type specific PCR and RT-
PCR. HPV prevalence was highest 
in pharyngeal tumours (45%) 
A total of 13 tumours were positive for HPV16-specific L1, or for the HPV16-E6 gene and 
URR. Most were positive for HPV16 alone (11/13). Strong RNA expression for HPV16-E6 was 
observed in all but four HPV16-positive specimens, and three demonstrated moderate levels for 
the E6*splice variant. An additional three tumours exhibited strong HPV16-E6 activity despite 
being DNA-negative, and six displayed moderate expression for the E6*splice variant. 
 
6 Acay et al., 2008 paraffin-embedded 
specimens 
50 oral lesions 
50 (controls) 
 
CSA-ISH 24% HPV infection markedly 
higher than controls. 
The overall prevalence in these premalignant and malignant lesions was markedly higher than 
in the control group, and that high-risk types were the most frequently found within HPV-
positive cases, strongly suggests that HPV is likely to play a role in oral carcinogenesis. 
 
7 Fujita et al., 2008 paraffin-embedded 
specimens 
23 verrucous 
carcinomas (VCs) 
10 (controls) 
 
ISH-PCR-IHC 11 (48%) had HPV-DNA (by PCR) 
6 (26%) had intranuclear HPV in 
the upper portion of the squamous 
epithelium (by ISH). 
Nine of the 11 PCR-positive specimens showed multiple infections with low- and high-risk 
HPVs. No HPV could be found in control specimens by ISH.  
Multiple infections with low- and high-risk HPVs and their rapid replication during 
hyperkeratinization may participate in the histogenesis of oral VC. Oral VC tumorigenesis may 
involve the inactivation of p53, which is associated with HPV infection. 
Abbreviations:  FFPETs - formalin-fixed paraffin-embedded tissues; URR – upstream regulatory region; CSA-ISH – In situ hybridisation with signal amplification; IHC – immunohistochemistry; RFLP – random fragment length polymorphism  
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Table 1.13: (continued) 
 
 
No. 
 
Reference 
(First author, year) 
N 
(actual sample size) 
Method Specificity/Sensitivity 
(especially high-risk HPVs) 
Findings/Conclusions 
 
8 
 
Lohavanichbutr et al., 
2009 
 
119 patients with 
primary OSCC 
35 patients without 
cancer (controls) 
 
PCR 
Roche LINEAR 
ARRAY HPV 
Genotyping Test 
 
41/119 tumours (34.5%) HPV 
positive. 2/35 normal tissue 
samples (5.7%) HPV positive;  
39/43 (91%) HPV specimens were 
HPV type 16. 
 
 
A higher prevalence of HPV DNA was found in oropharyngeal cancer (23 of 31) than in oral 
cavity cancer (18 of 88). The differences in the biology of HPV-positive and HPV-negative 
oropharyngeal cancer may have implications for the management of patients with these 
different tumors.  
 
Abbreviations:  FFPETs - formalin-fixed paraffin-embedded tissues; URR – upstream regulatory region; ISH – in situ hybridisation; IHC – immunohistochemistry; RFLP – random fragment length polymorphism 
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1.2.6 Meta-analysis of HPV involvement in specified cancer types 
 
1.2.6.1 HPV in head and neck cancer 
 
A compilation of 94 case reports and a clinical series over the past 18 years were 
included in this comprehensive meta-analysis involving diverse HPV detection systems 
and types of samples used and comparing their efficiency in discriminating amongst 
normal oral mucosa, potentially malignant lesions and carcinomas. They made the very 
conservative generalisation that regardless of the chosen HPV detection systems, and 
sample types analysed, the likelihood of detecting HPV was 2-3 times higher in 
precancerous oral mucosa and 4.7 times more in oral carcinoma relatively compared to 
normal oral mucosa (Miller and Johnstone, 2001). A meta-analysis was carried out 
targeting any association that may exist between oral carcinogenesis and HPV infection 
in a Chinese ethnic group following inclusive criteria, case-control studies (from 1990 
to 2003) and PCR techniques finalised 10 studies at the end. Overall HPVs (regardless 
HPV types) were more likely to be detected at 8.89 times higher in OSCC compared in 
normal oral mucosa. On the other hand, HPV16 was positively identified at 6.81 times 
higher in OSCC compared in normal oral mucosa specimens (Wang et al., 2004).  
 
 Hobbs et al. (2006) systematically selected seventeen studies (unmatched case-
control and matched analysis) to compare HPV16 exposure among site-specific head 
and neck cancer. They successfully outlined the magnitude of the association between 
HPV16 infection and anatomical sites in descending order as follows: tonsil (the 
strongest), oropharynx (intermediate), and the weakest for oral and larynx. In meta-
analysis involving 37 studies, patients with HPV-positive HNSCC was associated with 
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an improved overall survival (OS) (Hazard ratio, HR: 0.85) and disease-free survival 
(DFS) (HR: 0.62) than HPV-negative HNSCC patients. In oropharyngeal cases, patients 
with HPV-positive was associated with an improved OS (HR: 0.72) than HPV-negative 
patients. In non-oropharyngeal cases, patients with HPV-positive and HPV-negative 
seem to be comparable in OS (Ragin and Taioli, 2007).   
 
1.2.7 Reviews of head and neck cancer and the role of HPV in oral cancer 
 
Syrjänen (2003) suggested that the two most prominent candidates of HPV types in 
potentially malignant and malignant lesions were HPV 16 and HPV 18. Whilst HPV 6 
and HPV 11 could be connected with benign papillomatous lesions of the oral mucosa 
(Syrjänen, 2003). It was noted that strong and convincing experimental data are required 
to support the proposed “hit and run” theory and to unravel HPV mechanism of 
infection in oral carcinoma (Syrjänen, 2003). Despite the establishment of HPVs as an 
independent risk factor for oral cancer, its involvement in laryngeal cases is still 
unresolved and controversy still exists (Syrjänen, 2005).        
 
 Nowadays, HNSCC are being treated via combined treatment modalities but still 
there are confounding issues i.e. suitable dose, reagent sequences and to precisely set 
the usage of biologically active agents (Mao et al., 2004). More than 90% head and neck 
cancers are SCCs and alcohol and smoking are the major risk factors and have an 
additive effect. Multi-modality treatment with surgery or radiotherapy is limited to 
early-stage tumours and concurrent chemoradiation to locally advanced unresectable 
tumours (Marur and Forastiere, 2008). Generalisation could be made about a new trend 
of HPV-positive prevalence towards younger individuals, male patients who either do 
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not smoke or smoke less and have a low alcohol intake (Fakhry and Gillison, 2006; 
Adelstein and Rodriguez, 2010; Lajer and Buchwald, 2010).  
    
1.2.8 Novel studies or reviews on HPVs involvement in various sites 
 
1.2.8.1 HPVs in cutaneous squamous cell carcinomas 
 
Purdie et al. (1993) established the presence of episomal HPV in cultured keratinocytes 
from cutaneous lesions of renal allograft patients. The nature of viral episomic loss 
observed from this study could be overcome by maintaining serial passages of cultures 
until senescence (William et al., 1994). Utilising the newly developed combination of 
degenerate primer PCR, we are able to identify multiple HPV infections from mucosal 
and cutaneous biopsies (Surentheran et al., 1998). Harwood et al. (1999) successfully 
improved HPV detection in wart samples using degenerate and nested PCR approaches 
and the incidence ranges from 27-84%. Another study provided further support for the 
role of Epidermodysplasia verruciformis (EV)-type HPV in cutaneous lesions (Purdie et 
al., 2005). Despite facing a great challenge in identifying multiple HPV infections that 
exist in a single sample (either from eyebrow hairs or paraffin-embedded skin biopsies), 
a newly applied method by combining broad-spectrum PCR (PM-PCR) and reverse 
hybridisation assay (RHA) promises the detection of 25-beta HPV types in a single 
reaction (de Koning et al., 2006). A 6-month period of beta papillomaviruses 
persistence in the skin of healthy individuals might be set as baseline guidance to 
understand the mechanism of malignant transformation to be elucidated by future 
studies (de Koning et al., 2007).  
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 Casabonne et al. (2007) in their prospective case-control study involving 39 
cutaneous SCC cases (selected from the actual population size of 65,429 recruited 
people and another fresh blood samples provided by 19,500 candidates) were unable to 
demonstrate a strong link with HPV presence but did not exclude the possibility of 
HPV-UV interaction causing cell immortalisation, as suggested from a previous study. 
The low prevalence of cutaneous HPV types observed in another case-control study still 
unravelled cutaneous HPV’s role in the aetiology of ocular surface squamous neoplasia 
(de Koning et al., 2008). In their review, Feltkamp and co-workers (2008) suggested 
that epidemiological studies involving UV exposure at multiple latitudes might provide 
a true indication of its association with HPV prevalence, which were mainly beta types, 
in carcinogenesis of the skin (Feltkamp et al., 2008).  
 
1.2.8.2 HPVs in cervical squamous cell carcinomas 
 
The novel Short PCR Fragments (SPF) system was claimed amongst the most efficient 
approaches in identifying, at minimum, simultaneously 43 different HPV genotypes in a 
single reaction in cervical specimens (Kleter et al., 1998). There was no doubt that by 
combining previously reported methods with RHA, improved the detection rate and was 
less laborious and might be an option for routine HPV screening of cervical scrapes 
(Melchers et al., 1999; Kleter et al., 1999; Fey and Beal, 2004; Khan et al., 2005). In 
addition, this approach appeared more sensitive relatively than PCR-DNA sequencing 
techniques in handling cases related to multiple infections of HPV in a single sample 
(Kleter et al., 1999; Van Doorn et al., 2006; Castle et al., 2008). By exploiting Tm 
differential in real-time PCR, the distinction between multiple high-risk HPV infections 
could be made, specifically between HPV 16 and HPV 18 infections and/or with other 
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non-oncogenic HPV types and this is truly beneficial in mass screening of cervical 
specimens for HPV (Cubie et al., 2001).  
 
 Wentzensen and colleagues in their systematic review revealed that random 
integration of HPV occurred within the host genome but its effect on the functionality 
of crucial cellular genes was not observed in anogenital tract specimens (Wentzensen et 
al., 2004). There are advantages with repeated HPV genotyping especially for type 
specific identification of persistent HPV infections, but related cost-benefit analysis on 
a larger scale are required before being taken into routine practice (Cuschieri et al., 
2005).  
 
1.2.8.3 HPV in oesophageal squamous cell carcinomas 
 
Si et al. (2005) demonstrated that the integration of high-risk HPV, particularly HPV 
16, into the host genome was frequently present in oesophageal squamous carcinoma 
(ESCC) as it was previously reported in cervical cancer. The existence of cutaneous 
EV-HPV type 5 together with mucosal HPV 16 in oesophageal cancer has been reported 
but the actual role of the former is still disputed (Saravanan et al., 2006).      
 
1.2.8.4 Cancer of the oropharynx  
 
HPV DNA was consistently detected in a substantial fraction of cancers of the 
oropharynx with an estimated average prevalence of 35%. HPV16 DNA was detected in 
approximately 80% of HPV-positive cases. Several studies that compared tumours with 
normal tissue revealed large differences in HPV DNA detection, particularly that of 
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HPV16 in cancer of the tonsil. Seroepidemiological case–control studies and one 
prospective study showed marked increases in risk associated with serological markers 
of expression of HPV. These associations were much stronger than those observed for 
cancer of the oral cavity.  
 
1.2.8.5 Cancer of the larynx 
 
HPV DNA was detected in a variable fraction of cancers of the larynx. Limited and 
contradictory data resulted from comparisons of tumours and normal tissue. Some 
cross-sectional and prospective seroepidemiological data suggested a modest 
association with HPV16 and 18. In patients with recurrent papillomatosis, some well 
documented reports pointed to an involvement of HPV6 and 11. 
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1.3 p16INK4a, A TUMOUR SUPPRESSOR GENE 
 
1.3.1 Genetic background 
 
The G1/S cell cycle checkpoint controls the passage of eukaryotic cells from the first 
'gap' phase (G1) into the DNA synthesis phase (S). Two cell cycle cyclin-dependent 
kinases, CDK 4/CDK 6, cyclin D and the transcription complex that includes 
retinoblastoma protein (Rb) and E2F are pivotal in controlling this checkpoint (Rocco 
and Sidransky, 2001). During G1 phase, hypophosporylated RB (pRB) binds to the E2F 
transcription factors, inhibiting the downstream transcription (Doeberitz, 2002). The 
complexes formed between the former to cyclin-D, CDK 4 and/or CDK 6 trigger 
phosphorylation of pRB. At this stage, pRB releases E2F, permitting transcription of S-
phase genes encoding for proteins that amplify the G1 to S phase switch and that are 
required for DNA replication (Schafer, 1998; Nagpal and Das, 2003) (Figure 1.4).  
 
 The Human Genome Organisation nomenclature committee assigned the 
designation CDKN2A (for cyclin dependent kinase inhibitor 2A) for p16INK4a. This gene 
is located on chromosome 9p21 and lies on three exons (Foulkes et al., 1997). CDKN2A 
encodes a 156 amino acid with Mr 16, 569 cell cycle inhibitor protein (Ruas and Peter, 
1998). In normal cells, it binds to the non-catalytic side of CDK 4 and/or CDK 6 
(Figure 1.4). The tumour suppressive action of p16 inhibits the catalytic activity of 
CDK4-6/cyclin D1 enzyme complex, required for hypophosphorylated retinoblastoma 
protein (pRB) and cell cycle progression. Thus, it blocks abnormal cellular division and 
proliferation (Serrano et al., 1993). Ultimately, the cell cycle at the G1 phase is halted 
due to the enzyme activity that has been inhibited (Giordano et al., 2008).  
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Figure 1.4: p16 roles in cell cycle regulation  
Reprinted with permission from Liggett and Sidransky (Liggett and Sidransky, 1998). 
  
 Free cyclin D1 is degraded by a ubiquitin-dependent proteosome pathway if there 
are increased levels of p16. In addition, p16 also has a dual role by inhibiting E2F-DB 
active transcriptional complex formation and at the same time promoting Rb-E2F 
repressive transcriptional complex formation. The consequence is that p16 restricts the 
progress of cell division at the G1/S checkpoint by preventing E2F-dependent 
transcription (Rocco and Sidransky, 2001). Many different stimuli exert checkpoint 
control including TGFb, DNA damage, contact inhibition, replicative senescence, and 
growth factor withdrawal. The first four act by inducing members of the INK4 or 
Kip/Cip families of cell cycle kinase inhibitors (Schwart and Shah, 2005).  
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1.3.2 p16 and oral cancer 
 
Results from an in vitro study suggested that early genetic alterations involving the 
functional loss of tumour suppressor genes i.e. p16 and p53 (lies on locus 9p21 and 
17p13, respectively) were associated with oral cancer progression (Prime et al., 1997). 
In addition, Partridge and colleagues found deletions located centromeric and telomeric 
to the p16 gene at 9p21 in OSCC (Partridge et al., 1999). In contrast with another study, 
no p16 genetic alterations were observed in HPV-positive cases associated with betel 
chewing practices (Heinzel et al., 1996) or tobacco smoking exposure of oral cancer 
patients (Lazarus et al., 1998). Nevertheless, inactivation of p16 expression due to 
alteration of the α transcript was commonly observed in OSCC and was consistent with 
previous findings (Akanuma et al., 1999).  
 
 The postulated sequence of malignant transformation events in oral 
carcinogenesis is based on the occurrence of aberrations in descending order, 9p21 
(encodes for p16) and 3p (encodes for several tumour suppressor genes, TSGs) and 
17p13 (encodes for p53) (Scully et al., 2000). Despite no association having been found 
between the p16 gene alterations with cancer stage and cancer site, an association was 
found between p16 and cancer metastasis to regional neck nodes (Tsai et al., 2001). 
Therefore, screening for both cyclin D1 and p16 aberrations in OSCCs may be useful 
for identifying aggressive tumours, disease recurrence and in patients with a poor 
prognosis (Uzawa et al., 2007). The expression of p16INK4a was associated with OSCCs 
(Suzuki et. al., 2006; Muirhead et al., 2006). Similarly, Greer Jr. et al., (2008) found that 
p16INK4a expression was strong in all 45 OSCC samples tested. Commonly, p16 is 
inactivated by deletions, mutations or promoter methylation in the absence of HPV in 
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HNSCC (Shintani et al., 2001). Table 1.14 shows the proportion of p16 expression 
among selected studies. 
 
Table 1.14: The percentage of p16 expression among studies 
 
No. 
 
 
Investigator 
 
N 
 
Type of sample 
 
p16 expression (%) 
 
Remark 
      
1. Sathyan et 
al., 2006 
241 147 buccal carcinoma 
94 tongue carcinoma 
28% of buccal 
47% of tongue 
p16 expression could 
support conventional 
prognostic markers in 
buccal mucosa 
 
2. Muirhead et 
al., 2006 
45 OSCC 13% p16 expression was 
associated with the status 
of keratinisation and 
differentiation 
 
3. Suzuki et 
al., 2006 
66 OSCC 21% without lymph 
node metastasis 
6% with metastasis 
 
p16INK4a is a suitable 
marker for OSCC 
4. Greer Jr. et 
al., 2008 
140 81 STK 
29 SCC 
30 benign alveolar ridge 
keratoses (ARK) 
35% grade I STK 
44% grade II STK 
43% grade III STK 
52% SCC 
20% ARK 
0% normal 
 
p16 is suitable for 
assessing SCC and 
dysplasia but not for STK 
lesions 
5. Buajeeb et 
al., 2009 
56 16 OSCC,  
15 OL (with/without 
dysplasia) and normal  
18.75% OSCC 
26.7% OL 
p16 is not reliable as a 
marker  
      
N – number of samples; STK-smokeless tobacco keratosis 
 
1.3.3 p16 promoter hypermethylation  
 
Alteration of p16 mRNA expression as a result of methylation of the p16 gene promoter 
region was observed in oral rinses from leukoplakia patients (Lopez et al., 2003) and in 
primary OSCCs (Akanuma et al., 1999; Shintani et al., 2001; Nakahara et al., 2001; 
Yakushiji et al., 2003; Lee et al., 2004 and Ohta et al., 2009). However, Nakashini et al, 
(1997), did not observe p16 hypermethylation in OSCCs. Inactivation of the p16 gene 
by CpG methylation was most unlikely to occur in normal human oral keratinocytes 
(Cody et al., 1999). Nevertheless, CpG methylation was associated with malignant 
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transformation in mild or moderate epithelial dysplasia (Cao et al., 2009). 
Hypermethylation of p16 due to pathogenesis of potentially malignant oral lesions was 
associated with betel-quid (Lin et al., 2000; Tran et al., 2005; Takeshima et al., 2008; 
Yoshihiro et al., 2008), chewing tobacco (Kulkarni and Saranath, 2004) and tobacco 
smoking (Hasegawa et al., 2002; Saatci et al., 2009).  
 
 Ishida and colleagues found that concurrent promoter hypermethylation of p16 
and p14 were significant and directly associated with clinical parameters of OSCC 
(Ishida et al., 2005). In contrast, p16 and p14 both exhibited opposing clinical effects of 
gene methylation in oral carcinoma (Sailasree et al., 2008). In addition, p16 methylation 
was found to be independent from tumour stage and specific location in the oral cavity 
(Viswanathan et al., 2003). Hasegawa et al. 2002, on the other hand, noted that p16 
hypermethylation was directly associated with tumour size but that did not exhibit 
lymph node metastasis. Guo 2007, revealed that promoter hypermethylation results in 
inactivation of p16 tumour suppressor gene in mucoepidermoid carcinoma (MEC), 
human salivary glands (Guo et al., 2007). A similar scenario was observed in saliva 
DNA where abnormal p16 promoter methylation occurred and at a higher percentage 
especially near to the oral cavity (Rosas et al., 2001). Kresty et al. (2002) found that the 
highest p16 hypermethylation presented at the tongue and the floor of the mouth of 
patients with severe epithelial dysplasia.  
 
 CpG site methylation was found in the p16 gene promoter in carcinoma specimens 
and this was highly tumour specific (Shaw et al., 2006; Shaw et al., 2007). It was 
believed that p16 promoter hypermethylation would cause its inactivation and that it 
occurred at the early stage of OSCC carcinogenesis (Von Ziedler et al., 2004; Kato et 
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al., 2006; Ruesga et al., 2007 and Šupić et al., 2009). Table 1.15 shows the proportion 
of p16 promoter hypermethylation observed among 30 studies and the specific method 
used for assessment. It was noted that the occurance of this event in OSCC cases varied 
among studies from 0-90% depending on the method of detection. No p16 
hypermethylation was observed in normal oral specimens (controls) in appropriate 
studies. 
 
 The loss of p16 expression as a result of promoter hypermethylation is an early 
event in oral carcinoma and a useful biomarker for predicting local recurrence in 
carcinoma of the tongue (Sinha et al., 2009). Nakahara et al., (2006) reported that p16 
hypermethylation could also be observed in the serum of recurrent OSCC by using a 
methylation specific-PCR (MS-PCR) technique. However, the role of p16 
hypermethylation as a predictive risk factor for OSCC or disease recurrence remains 
unclear and contradictory (Ruesga et al., 2007). In addition, p16 methylation did not 
associate with HPV-induced tumours (pathogenic mechanism) and affect protein 
expression in cervical carcinoma but was more related to genetics and epigenetic 
instability (Nehls et al., 2008). 
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Table 1.15:  The prevalence of p16 promoter hypermethylation among studies 
 
No. 
 
 
Investigator 
 
Region 
 
Method 
 
N 
 
% of PH1 
      
1 Nakashini et al., 1997 Japan n/a 50 0% 
2 Akanuma et al., 1999 Japan MS-PCR2 14 28.6% 
3 Lin et al., 2000 Taiwan RFMA3 110 54% tongue 
22% other sites 
4 Nakahara et al., 2001 Japan MS-PCR 32 50% 
5 Shintani et al., 2001 Japan MS-PCR 32 50% 
6 Rosas et al., 2001 Brazil MS-PCR 30 47% 
7 Kresty et al., 2002 USA MS-PCR 28 57.7%* 
severe oral dysplasia  
8 Hasegawa et al., 2002 USA MS-PCR 80 32.5% HNSCC 
9 Viswanathan et al., 2003 India MS-PCR 99 23% 
10 Lopez et al., 2003 Spain MS-PCR 34 44% 
Leukoplakia 
11 Yakushiji et al., 2003 Japan n/a 25 48% 
12 Kulkarni and Saranath, 2004 India MS-PCR 60 66.7% 
13 Von Zeidler et al., 2004 Brazil MS-PCR 258 9.7% 
normal posterior 
tongue border 
14 Ishida et al., 2005 Japan MS-PCR 49 34.7% 
15 Tran et al., 2005 Japan MS-PCR 27 63% 
16 Kato et al., 2006 Japan MS-PCR 55 50.9% 
mixed OSCC, VC and 
Cis 
17 Nakahara et al., 2006 Japan MS-PCR 17 64.7% 
18 Shaw et al., 2006 UK Pyrosequencing 79 28% 
19 Guo et al., 2007 China MS-PCR 38 34.2% 
MEC salivary glands 
20 Ruesga et al., 2007 Spain MS-PCR 145 20% 
21 Shaw et al., 2007 UK Pyrosequencing 20 90% 
22 Guerrero et al., 2008 Spain MS-PCR 24 38% 
penile SCC 
22 Nehls et al., 2008 Germany MS-PCR 70 25.7% 
cervical carcinomas 
23 Sailasree et al., 2008 India MS-PCR 116 29% 
24 Takeshima et al., 2008 Sri Lanka MS-PCR 64 73% 
mild/severe dysplasia 
25 Hall et al., 2008 UK Pyrosequencing 284 1-26% 
epithelial dysplasia 
26 Šupić et al., 2009 Serbia MS-PCR 77 58.4% 
27 Cao et al., 2009 China MS-PCR 78 41% 
epithelial dysplasia 
28 Ohta et al., 2009 USA MS-PCR 44 63.6% 
29 Saacti et al., 2009 Turkey MS-PCR 42 31.8% MP users 
25% tobacco users 
30 Sinha et al., 2009 India MS-PCR 38 86.8% 
      
1% of promoter hypermethylation (PH) in OSCC unless stated;  2MS-PCR – Methylation specific-PCR; 3 RFMP – Restriction 
Fragment Methylation Analysis; VC – verracous carcinoma; Cis – Carcinoma in situ; MEC – Mucoepidermoid carcinoma; MP – 
maras powder ; N – number of samples  
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1.3.4 Was there a link between p16 expression and HPV infection? 
 
Fregonesi et al. (2003) suggested that p16 over-expression occurred as a result of either 
the failure of this tumour suppressor protein or due to high-risk HPV integration into the 
host genome. The phenomenon of p16 over-expression found in the nucleus and 
cytoplasm was highly associated with HPV positivity and was speculated to be unique 
for HPV positive oropharyngeal carcinoma (Hafkamp et al., 2003; Li et al., 2003). As 
p16 over-expression is very rarely seen in HPV negative HNSCC and that functional 
inactivation of Rb by E7 induces p16 upregulation, it is considered a surrogate marker 
for HPV infection in OPSCC. Figure 1.5 depicts a putative mechanism on the over-
expression of p16 in response to the present of HPV particularly HR-HPV.  
 
 
Figure 1.5: The postulated mechanism on upregulation of p16 in HPV infection. 
(Mulvany et al., 2008)  
 
 It was later concluded that p16 was a potential biomarker to indicate the presence 
of high-risk HPV infection in oral cancer. Other studies clearly observed over-
expression of p16INK4a on HPV-induced high-grade oral squamous dysplasia or 
carcinoma (Cunningham et al., 2006), penile sarcomatoid carcinoma (Poblet et al., 
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2008), uterine cervical lesions (Yoshida et al., 2008) and cervical carcinoma (Fujii et al., 
2008; Ozgul et al., 2008). A study that was carried out on tonsillar squamous cell 
carcinomas strongly supported the relationship between HPV16 integration with p16 
over-expression (Charfi et al., 2008; Hafkamp et al., 2008; Kuo et al., 2008; Klussmann 
et al., 2003, 2009).  
 
 It was demonstrated that p16INK4a was a sensitive predictor in vulval carcinomas 
positive for mucosal HPV (de Koning et al., 2008) and especially high risk-HPV 
(Hoevenaars et al., 2008). p16 over-expression has a significant correlation with HR 
HPV especially involving HPV16 infections in oropharyngeal cancer (Preuss et al., 
2008; Nichols et al., 2009). Moreover, p16INK4a was an indirect marker candidate for 
cell cycle dysregulation due to its association with high risk-HPV infections in cervical 
dysplasia and carcinomas (Mulvany et al., 2008). Nevertheless, in laryngeal cases, it 
was suggested that other factors may take precedence (Laco et al., 2008) because the 
association was not as strong as in cervical neoplastic lesions (Duncan et al., 2008). A 
recent study to assess HPV presence found that the combination of a strong HPV signal 
by pyrosequencing approach and strong p16INKa positive staining gave the best 
interpretation for relapse and survival in HNSCC (Kong et al., 2009). 
 
 However, contradictory findings have shown that over-expression of p16INK4a 
proteins in OSCC did not correlate with HR-HPV types (Nemes et al., 2006). In 
addition, very high p16 expression observed not only in HPV positive groups but also in 
other groups in the absence of HPVs. Therefore, it revealed unconvincing support for 
previous claims on the HPV-p16 relationship (Smeets et al., 2007; Aulmann et al., 
2008; Bohn et al., 2008 and Samama et al., 2008). Another study demonstrated that p16 
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expression might not be a good predictor of HPV status but a fairly reliable determinant 
for epithelial atypia severity (Braganca et al., 2008). Carcinogenesis of HPV did not 
show convincing association with over-expression of p16 in oral smokeless tobacco 
keratosis (STK), non-neoplastic lesions (Greer Jr. et al., 2008) and female genital tract 
neoplasm (Giordano et al., 2008). Smith et al. (2008) were unable to get conclusive 
evidence of this association for survival and disease recurrence for head and neck 
cancer due to the combined HPV/p16 biomarkers data differ if both were assessed 
separately. Nowadays, the role of p16 in human cancer is more complex and it related to 
loss-of-function mutations as cancer progression to advance stage (Rocco and 
Sidransky, 2001).  
 
1.3.5 Is p16 a surrogate marker for high risk-HPV in oral cancer? 
 
Despite the current advancement in molecular technology, the future diagnostic role of 
p16 was still hampered by a few vital elements that urgently needed to be resolved. As 
many published articles leave behind very constructive take home messages that could 
be generalised and quoted as follows: Interpretation variability observed in staining 
results, sampling convenience and defective gold standard amongst studies. The above 
question should be answered with caution in order to justify with various sources of 
evidence to support very convincing and conclusive findings (Table 1.16 and 1.17). 
Throughout the proposed study, we will try to unravel this mystery by exploiting our 
recent knowledge and persistent belief in this area and to explore its maximum potential 
for the benefit of human oral cancer prognosis. 
   
 
  
65 
 
Table 1.16: An association observed between p16 (IHC) and HPV (HR) expression among studies 
 
 
 
No 
 
 
Investigator 
 
Sample origin 
 
HPV/p16 detection 
 
HPV types 
     
1 Singhi and Westra, 2010 Head and neck ISH/IHC HPV16 
2 Al-Swiahb et al., 2010 Oropharyngeal PCR/IHC HPV 
3 Smith et al., 2010 Head and neck PCR/IHC HR-HPV 
4 Laksmi et al., 2009 Cervical ISH/IHC HR-HPV 
5 Kumar et al., 2008 Oropharyngeal PCR/IHC HPV16 
6 Smith et al., 2008 Head and neck PCR/IHC HR-HPV 
7 Hafkamp et al., 2008 Tonsillar FISH/IHC HPV16 
8 König et al., 2007 Head and neck ISH/IHC HPV16, HPV18 
9 Lambert et al., 2006 Cervical PCR/IHC HPV16/18/31/33 
10 Cunningham et al., 2006 Oral dysplasia PCR/IHC HPV16 
11 Tsai et al., 2005 Cervical ISH/IHC HPV16, HPV18 
12 Wittekindt et al., 2005 Tonsillar - /IHC HR-HPV 
13 Begum et al., 2005 Tonsillar ISH/IHC  HPV16 
14 Fregonesi et al., 2003 OSCC ISH/IHC HPV16, HPV18 
15 Li et al., 2004 Tonsillar PCR/IHC HPV 
16 Lu et al., 2003 Anorectal BS-HPV/IHC HPV16 
17 Klussmann et al., 2003 Tonsillar PCR/IHC HPV16, HPV18 
18 Sano et al., 2002 Cervical/dysplasia ISH/IHC HPV 
19 Sano et al., 1998 Cervical ISH/IHC HPV16, HPV18 
     
Abbreviation: ISH – in situ hybridisation; IHC – immunohistochemistry; BS-HPV – Broad spectrum-HPV  
 
 
Table 1.17: No association observed between p16 (IHC) and HPV (HR) expression among studies 
 
 
 
No 
 
 
Investigator 
 
Sample origin 
 
HPV/p16 detection 
 
HPV types 
     
1 Klingenberg et al., 2010 Tonsillar PCR/IHC HPV16, 18 
2 Friedrich et al., 2010 OSCC PCR/IHC HPV6, 11, 16 
3 Cao et al., 2010 Head and neck ISH/IHC HPV16 
4 Greer Jr. et al., 2008 Oral dysplasia PCR/IHC HPV 
5 Galmiche et al., 2006 Cervical dysplasia - /IHC HR-HPV 
6 Nemes et al., 2006 OSCC ISH/IHC HPV 
7 Samama et al., 2006 Anogenital ISH/IHC HR-HPV 
8 Hashi et al., 2006 Endocervical PCR/IHC HPV 
9 Munirajan et al., 1998 Uterine cervix PCR-SSCP/RE HPV16, HPV18 
     
  Abbreviation: SSCP – single strand conformation polymorphism; RE – restriction enzyme 
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1.3.6 p16 immunohistochemistry and its semi-quantitative assessment  
 
Numerous studies have made an effort to utilise immunohistochemistry to assess the 
expression of p16 in diverse types of specimens. Generally, we have to admit at this 
point that there was no consensus agreement amongst investigators in relation to scoring 
criteria for p16 positivity either via quantitative or qualitative assessments. Table 1.18 
shows the summary of selected studies using semi-quantitative assessment and the 
parameters. 
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Table 1.18: Comparison of p16 IHC semi-quantitative scoring amongst studies 
 
Reference Sample types (oral) IHC Kit IHC scoring method 
 
Fischer et al., 2010 
 
 
 
 
 
Buajeeb et al., 2009 
 
5-µm section FFPET;  
365 blocks of OPSCC 
punched biopsies 
 
 
56 samples including 
OSCC, OL with or without 
dysplasia and normal oral  
mucosa 
 
Hematoxylin p16INK4a   
(ABC-Elite, Vector Laboratories, 
Burlingame, CA)  
 
 
 
Hematoxylin p16INK4a  
(DakoCytomation) 1:25 
DakoCytomation Target Retrieval 
Solution in steamer 
 
 
Positive: 
The percentage of nuclear staining of the tumour over total number of tumour cells (nuclei) 
> 5% immunoreactivity in tumour cells. 
The score between two independent observers were averaged 
No staining intensity was assessed  
 
Positive: 
When nuclear and/or cytoplasmic staining was compatible with that of positive control. 
Five or more stained cells. All positive cells and all cells in the specimens were counted, calculated – 
percentage of positive cells. 
The staining intensity:  
Weak, moderate or strong when compared with the positive control. 
10 Random areas were counted. At least 500 cells were counted in each case. 
 
Greer Jr. et al., 2008 
 
 
 
 
 
 
 
 
 
 
 
 
Angiero et al., 2008 
 
140 tissues; 81 STK cases, 
29 SCC and 30 cases of 
benign alveolar ridge 
keratoses (ARK) 
Negative control: 
1 mg/ml of subclass 
matched IgG 1k 
 
 
 
 
 
 
5-µm section FFPET; 
54 oral cavity biopsies 
 
DAKO autostainer 
Indirect avidin-biotin 
immunoperoxidase 
Normal horse serum 
p16INK4a Ab-4 antibody (16PO4) 
 
 
 
 
 
 
 
 
p16 (clone E6H12, dilution 1:40; 
Novocastra, Newcastle, UK 
 
Positive: 
Brown nuclear and cytoplasmic staining. The proportion of positively staining and the strength of 
staining to produce a semi-quantitative scoring standard. 
0 – staining was similar to background 
1+ - just slightly darker than the background 
2+ - clearly darker than the background and there was relatively strong staining of cytoplasmic and 
nuclei 
3+ - intense staining sections (dark brown staining) 
To quantify the proportion of cells with positive result 
1+ - 5-35% 
2+ - 36-75% 
3+ > 75% 
 
Positive: 
The relative number of nuclei stained and their localisation (upper 2/3 of the epithelium) ; The areas 
of infiltration for invasive carcinoma 
> 10% of nuclei were stained 
 
Muirhead et al., 2006 
 
 
5-µm section FFPETs; 
45 oral cavity squamous 
carcinomas 
 
 
Hematoxylin 
p16INK4a  (DakoCytomation) 1:25 
DakoCytomation Target Retrieval 
Solution in steamer 
 
 
p16 was not observed in normal mucosa 
The amount of staining 
0 – no staining 
1 – staining up to 24% of tumour cell of nuclei 
2 – 25-49% of nuclei 
3 – 50-74% of nuclei 
4 – staining of > 75% of nuclei 
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Table 1.18: (continued) 
 
 
Reference 
 
 
Sample types (non-oral) 
 
IHC Kit 
 
IHC scoring method 
 
Kok et.al., 2010 
 
 
 
5-µm section FFPETs; 35 
hysterectomy specimens; 
14 endocervical 
adenocarcinomas (ECAs) 
and 21 endometrial 
adenocarcinomas (EMAs) 
Positive control: 
Tissues of SCC from 
uterine cervix 
Negative control: 
Excluding primary 
antibody 
 
 
p16INK4a  (F12, sc-1661, Santa Cruz) 
1:200 
pre-treatment: microwave with citrate 
buffer (pH 6.0) 
Streptavidin peroxidase method  
 
Independent cytoplasmic stain alone, irrespective of the nuclear stain, and vice versa 
German semi-quantitative scoring system (staining intensity and staining extent): 
Staining intensity 
0 – no stain 
1 – weak stain 
2 – moderate stain 
3 – strong stain 
Staining extent 
0 – 0% 
1 – 1-10% 
2 – 11-50% 
3 – 51-80% 
4 – 81-100% 
Final immunoreactive score – by multiplying the three-tier intensity score with the four-tier extent of 
positive staining score in the tumour (min 0, max 12). 
 
Tsoumpou et al., 2009 
REVIEW PAPER 
 
61 studies; 27 cervical 
cytological specimens (6 
studies the biomarkers in 
histological specimens), 
34 staining only in 
histological samples 
 
 
 
Classification proposed by Klaes and colleagues: 
Negative - <1% of the cells were positive 
Sporadic - <5%, isolated cells were positive 
Focal - <25% of the cells were positive, small clusters 
Diffuse - >25% of the cells were stained positive 
Positive cut-off for p16 – the diffuse stain that includes both basal and parabasal cell layers and 
indicates hr-HPV-induced transformation 
 
Bradley et al., 2006 
 
4-µm section FFPETs; 119 
biopsies 
Positive control: 
Vaginal squamous cell 
carcinoma sections 
Negative control: 
1o antibody replaced by 
buffer 
 
H & E 
Heat-induced (electric pressure cooker) 
antigen retrieval 
1:40 mouse monoclonal antibody, clone 
16P04 
Horseradish peroxidase (HRP)-labeled 
polymer conjugated with secondary 
antibodies 
 
 
Positive: 
Five or more squamous epithelial cells with staining of the nucleus, cytoplasm, or both. 
Positive cases were divided into two semi-quantitative groups: 
Basal layer staining, in which staining was confined to the basal cells with no staining or very rare 
staining of more superficial cells; 
Basal and suprabasal layer staining, defined as positivity of cells in both the basal and suprabasal 
layers. 
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1.4 HYPOTHESIS AND AIMS 
 
Hypothesis 
 
There is some evidence to suggest that HPV may play a role in the development of 
various cancers and in some cases HPV positivity has a favourable impact on survival.  
HPV may have a role to play in HNSCC, and more specifically oral carcinoma, and 
may be of prognostic use.  In addition the presence of HPV may identify those 
dysplastic lesions with a greater potential to progress to OSCC. p16INK 4a has been used 
as a surrogate marker of HPV due to its correlation with HPV DNA but is this justified? 
 
Aims 
The aims of this study are: 
• to investigate the incidence of HPV DNA in oral mucosal lesions by polymerase 
chain reaction 
• to compare the incidence of HPV DNA in benign oral lesions; dysplasias; and 
carcinomas to determine whether there is an association with disease 
progression  
• to utilise a novel sensitive technique to investigate the genotypes of HPV, both 
alpha and beta HPV, in a subset of oral cancer 
•  to investigate whether HPV is of prognostic use in oral cancer 
• to investigate the expression of p16 in oral tissues 
• to investigate the use of p16 as a surrogate marker of HPV DNA in oral tissues 
• to investigate the prognostic use of p16 in oral cancer 
Figure 1.6 shows the overall strategies to achieve the aims of this study.
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Figure 1.6: The overall strategies of the study. 
The above approaches will be described further in the appropriate chapter. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 THE ROLE OF HPVs IN ORAL CANCER 
 
2.1.1 Introduction 
 
The involvement of certain types of HPV in lesions is clearly understood. The HPVs 
that have been termed as ‘low-risk’ (HPV types 6, 11, 13 and 32) are associated with 
benign lesions of the oral mucosa (Snijders et al., 1996). In contrast, ‘high risk’ HPV 
types including HPVs 16, 18, 31, 35 and 39 are associated with premalignant lesions 
and squamous cell carcinomas (Zur Hausen, 1991; Snijders et al., 1996; Androphy, 
1994). PCR-based approaches are now widely used in human papillomavirus (HPV) 
studies. These highly sensitive approaches are capable of amplifying as low as 10–100 
copies of the HPV genome and may give an advantage over other approaches. In 
addition, only a small amount of specimen is required, and sample preparation prior to 
amplification is simpler, especially if automation is utilised.  
 
Using this approach, several universal primer sets such as MY11/MY09 (Manos et 
al., 1989), MY11/GP6 (Manos et al., 1989; Snijners et al., 1990) and GP5+/GP6+ (de 
Roda Husman et al., 1995) are widely used for routine diagnosis of HPV infection. A 
novel type-specific six PCR primers designated as Short PCR Fragment (SPF), was 
developed targeting a 65 bp of HPV L1 region. This SPF system is highly sensitive and 
capable of detecting at least 43 different HPV genotypes by using a mixture of nine 
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probes in a microtiter hybridisation format, DNA enzyme immunoassay (DEIA) (Kleter 
et al., 1998). Recently, a rapid and broad-spectrum PCR amplification was developed 
utilising 10 SPF primers denoted as SPF10 (six novel type specific primer sets and four 
universal primer sets, MY11/MY09 and GP5+/GP6+).  SPF amplimers were detected 
via reverse hybridisation technique in strip format utilising a 28 line probes assay 
(LiPA). The combination of the former approach in generating broad-spectrum PCR 
amplimers and later detection assay, designated as SPF10-LiPA simultaneously 
identified 25 HPV genotypes (Quint et al., 1999). 
 
Another novel one-step PCR (PM-PCR) plus RHA was developed for detection of 
beta-HPV (PM-PCR RHA) focusing on the E1 region. It was concluded the approach 
was highly sensitive, reproducible and reliable in dealing with either fresh or FFPETs 
(de Koning et al., 2006). 
 
2.1.2 Aim 
 
The aim of this study was to investigate the expression of human papillomavirus (HPV) 
in 60 FFPET oral squamous cell carcinomas.  
 
This involved: 
• Optimising the DNA extraction from FFPET by a comparison of two different 
techniques (Promega and Qiagen) using DNA purity and yield as the criteria for 
assessment. 
• Investigating the effect of volume of FFPET on DNA extraction with both 
methods. 
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• Using the result of the above to extract DNA from 60 oral cancer samples for 
analysis by PCR for mucosal alpha HPV L1 gene. 
• Using the SPF-DEIA and SPF10-LiPA methods [Mucosal (alpha) HPV prototype 
research assay; DDL, The Netherlands] to identify alpha HPV in the same 60 
FFPETs.  
• Using the PM-PCR RHA method [Skin (beta) HPV prototype research assay; 
Diassay BV, The Netherlands] to identify beta HPV in the same 60 FFPETs. 
 
2.1.3 General Equipment 
 
Photographs of selected major instruments used are as shown in Figure 2.1 
An automated microtome, Shandon Citadel 2000, Microm HM335E 
A microtome blades MB 34o/80cm (Cat. no. 0022403), Shandon Scientific 
Limited, Runcorn, Cheshire, England 
Forceps or tweezers 
Gilson micropipettes (2, 10, 200 and 1000 µl) and filtered (aerosol resistant) 
micropipette tips (10, 200 and 1000 µl), Rainein Instrument Co. Inc. UK. 
Sub Aqua 26 water bath with lid, Grant Instruments (Cambridge) Ltd.  
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Figure 2.1: General instruments 
 
 
 
 
 
 
  
Automated microtome 
Whirlimixer 
WPA UV1101 Spectrophotometer Class I Microbiological 
Safety Cabinet 
Sub Aqua 26 water bath Benchtop autoclave 
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WPA UV 1101 UV Photometer (80-3000-74), Biochrom Ltd., Cambridge, UK   
 Quartz cuvettes (80-3000-81), Biochrom Ltd., Cambridge, UK  
 Class I Microbiological Safety Cabinet, Howorth Air Engineering, Faraworth, 
Bolton, England 
 Mettler PM200 topload balance (American Instrument Exchange, Inc.) 
 Progene thermocycler, 20-sample for PCR (Techne, Gmbh, Germany) 
 TC-412 thermocycler, 96-well format for PCR (Techne, Gmbh, Germany) 
 
2.1.4 Specimens 
 
2.1.4.1 Positive controls (n=2+3) 
 
Five positive controls were provided for PCR and HPV genotyping (Appendix 2), 3T3 
embryonic mouse fibroblasts (from EACC, Sigma-Aldrich), human salivary glands 
containing HPV18 DNA and plasmid DNAs containing HPV genes (HPV6, HPV8 and 
HPV16). The first two (3T3 and HPV18) were positive controls for DNA extraction. 
The second three positive controls (HPV6, HPV8 and HPV16 DNA) were diluted at the 
concentration of 10 ηg/µl prior PCR and HPV genotyping. 
 
2.1.4.2 Negative controls (n=2) 
 
Two negative controls, tissue free paraffin sections and RNase free water were utilised 
for PCR and HPV genotyping. 
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2.1.4.3 Pilot study 
 
Eleven oral FFPET blocks [Appendix 7, samples C1-C6; Appendix 8 and 9, samples 
D1-D5] were randomly selected for DNA extraction, were obtained from the archives of 
the Oral Pathology Department, University of Dundee. This was part of the optimisation 
and the DNA extraction kit comparison. The next sixty oral FFPET blocks were strictly 
selected based on histopathological and microscopic observations made by pathologists 
via a double-blind method. The details of the samples used and the patient clinical data 
in each experiment are given in the appropriate chapter. 
 
2.1.4.4 The role of HPVs in oral disease progression (n=183) 
 
In total one hundred and ninety four FFPETs were used in the experiments. 183 oral 
FFPETs used in the experiments were obtained from Oral Pathology Department, 
University of Dundee archives. The details of the samples used and the patient clinical 
data in each experiment are given in the appropriate chapter.  
 
2.1.5 Materials for MagneSil Genomic, Fixed Tissue System, Cat. No. MD1490 
(Promega Corporation, USA) 
Kit contents 
MD1170: MagneSil Genomic, Fixed Tissue Processing Module 
Incubation Buffer, 35 ml 
Proteinase K, 2x 10 mg 
1M DDT, 1.125 ml 
MD1180: MagneSil Genomic, Fixed Tissue Purification Module 
  
77 
Resin, 0.9 ml 
Lysis Buffer, 40 ml 
2X Wash Buffer, 30 ml 
Elution Buffer, 15 ml 
MagneSphere Technology Magnetic Separation Stand (two-position) 
(Cat.#Z5332) 
 
Equipments and reagents to be supplied by the user 
95-100% ethanol 
Isopropyl alcohol (P/7490/17), Mackay and Lynn (DD) Ltd, Dundee UK 
Oven, 56oC 
Water bath, 65oC 
Whirlimixer, Fisons Scientific Apparatus, Leicestershire 
Microcentrifuge tubes, 1.5 ml (Cat. #V1231) 
 Aerosol-resistant micropipette tips 
 
2.1.6 Materials for QIAamp DNA FFPE Tissue Kit, Catalog no. 56404 
(QIAGEN GmbH, Hilden, Germany) 
Kit Contents 
QIAamp MinElute® Columns 
Collection tubes (2 ml) 
Buffer ATL 
Buffer AL (contains guanidine hydrochloride) 
Buffer AW1 (concentrate, contains guanidine hydrochloride) 
Buffer AW2 (concentrate, contains sodium azide as preservative) 
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Buffer ATE (contains sodium azide as a preservative) 
Proteinase K 
Equipment and Reagents to be supplied by the user 
Xylene, VWR International Ltd, Lutterworth, UK 
Ethanol (96-100%), Chemistry Store, University of Dundee 
1.5 ml or 2 ml microcentrifuge tubes (for lysis steps) 
1.5 ml microcentrifuge tubes (for elution steps) from Brinkmann (Safe-Lock, 
cat. no. 022363204) 
Micropipettes, 10 µl, 20 µl, 200 µl and 1000 µl (BioRad) 
Pipette tips, 10 µl, 250 µl and 1000 µl (with aerosol to avoid cross-
contamination) 
Oven, 56oC 
Water bath, 90oC 
Floater 
Whirlimixer, Fisons Scientific Apparatus, Leicestershire 
Eppendorf centrifuge 5417C, VWR LabShop, Batavia IL 
 
2.1.7 Reagents for Polymerase Chain Reaction (PCR) 
 
Photographs of selected major instruments used for this method are as shown in Figure 
2.2. The preparation for each reagent is illustrated in Appendix 1 and the components of 
the PCR as shown in Table 2.1 and 2.2 (except for SPF-DEIA). The final PCR reaction 
volume for SPF-DEIA was performed at 100 µl. The PCR reaction mixture including 10 
µl of 10 ηg/µl of the isolated DNA, PCR buffer [which consists of 10 mmol/L TrisHCl, 
pH 9.0, 50 mmol/L KCl, 0.1% Triton X-100 and 0.01% (w/v) gelatin], 2.5 mmol/L 
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MgCl2, 200 mmol/L each deoxynucleoside triphosphate, 20 pmol of  six biotinylated 
PCR primers, of which the mixture of type-specific PCR primers for HPV genotypes 
(four SPF1 and two SPF2), and 0.25 U of SuperTaq (Sphaero Q, Cambridge, UK) 
(Kleter et al., 1998). Finally, the PCR conditions for SPF-DEIA are as shown in Table 
2.3. 
 
2.1.8 Materials for gel electrophoresis 
 
Photographs of selected instruments used for this method are as shown in Figure 
2.3 
Agarose, For Routine Use (Cat. no. A9539-250G), Sigma-AldrichTM Inc., USA 
Agarose, low melting point (Cat. no.A9414-100G), Sigma-AldrichTM Inc., USA 
10X TAE (Tris-acetate/EDTA - ethylenediaminetetraacetic acid) 
Loading Dye, Research Biolab Ltd. 
100 bp DNA marker, Research Biolab Ltd. 
Gel Staining solution Fast Blast DNA Stain (Cat. no. 166-0420EDU), Bio-Rad 
Laboratories, Inc., USA 
Staining container 
500 ml conical flask 
Weighing boats 
Spatula 
Parafilm 50mm wide (SE165-15), Mackay and Lynn (DD) Ltd, Dundee UK 
EV243 Electrophoresis power supply (286-026 EV243U), Jencons (Scientific) 
Ltd., England 
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Midi horizontal electrophoresis unit (286-312 J-HU13), Jencons (Scientific) Ltd., 
England 
Gel cast and combs (20-well, 16-well and 10-well) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Instruments for PCR and RHA 
8-strip PCR tube with 
improvised holder 
  
TC-412 thermocycler Progene thermocycler 
 
 
Peltier thermal cycler 
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Table 2.1: Oligonucleotide primers used for HPV detection 
 
 
 
Human 
genome 
  
ORF 
 
Primer 
 
Sequence (5’-3’) 
 
Annealing site 
 
Size (bp) 
 
Degeneracy 
 
Remark 
 Bases 
 
β-globin 
  
 
 
GH20 
PC04 
 
GAAGAGCCAAGGACAGGTAC1 
CAACTTCATCCACGTTCACC1 
 
 
 
70400-70419 
70648-70669 
 
268 
  
Human genomic 
DNA quality 
 
HPV class 
 
 
HPV group 
(type) detected 
 
ORF 
 
Primer 
 
Sequence (5’-3’) 
 
Annealing site 
 
Size (bp) 
 
Degeneracy 
 
Remark 
HPV Bases 
 
Mucosal 
 
 
Mucosal 
 
 
Mucosal 
 
 
Mucosal 
 
 
 
 
 
 
 
Cutaneous 
 
 
 
 
 
General 
mucosal 
 
Semi-nested 
 
 
Nested 
 
 
43 Alpha-HPV 
 
 
 
 
 
 
 
25 Beta-HPV 
 
 
 
 
 
L1 
 
 
L1 
 
 
L1 
 
 
L1 
 
 
 
 
 
 
 
E1 
 
 
 
 
 
MY11 
MY09 
 
MY11 
GP6 
 
GP5+ 
GP6+ 
 
SPF1/2 
primer 
mix5 
 
 
 
 
 
PM 
Primer 
mix6 
 
 
GCMCAGGGWCATAAYAATGG2 
CGTCCMARRGGAWACTGATC2 
 
GCMCAGGGWCATAAYAATGG2 
GAAAAATAAACTGTAAATCA4 
 
TTTGTTACTGTGGTAGATACTAC3 
GAAAAATAAACTGTAAATCATATTC3 
 
Commercially unavailable 
 
 
 
 
 
 
 
Commercially unavailable 
 
6 
 
 
6 
 
 
6 
 
 
6,11,13,16,18,26,30, 
31,33,34,35,39,40, 
42,43,44,45,51,52, 
53,54,55,56,58,59, 
61,62,64,66,67,68, 
69,70,72,73,74, 
MM4,MM7,MM8 
 
5,8,9,12,14,15,17, 
19,20,21,22,23,24, 
25,36,37,38,47,49, 
75,76,80,92,93,96 
 
 
6722-6742 
7150-7170 
 
6722-6742 
6882-6903 
 
6765-6784 
6876-6903 
 
6582-6646 
 
 
 
 
 
 
 
2644-2760 
 
450 
 
 
190 
 
 
140 
 
 
65 
 
 
 
 
 
 
 
117 
 
16 
16 
 
16 
0 
 
Mucosal HPV 
 
 
Mucosal HPV 
 
 
Detection for 
uncommon HPV  
 
Mucosal HPV 
SPF10-LiPA5 
[Mucosal (alpha) 
HPV] 
 
 
 
 
Cutaneous HPV 
PM-PCR RHA6 
[Skin (beta) HPV] 
 
 
Notes:  1 Bauer et al., (1991); JAMA 265(4): 472-2   
 2 Manos et al., (1989); Cancer Cells 7: 209-214 
 3 de Roda Husman et al., (1995); J Gen Virol 76: 1057-62 
 4 Snijders et al., (1990); J Gen Virol 71: 173-181 
 5 Van Doorn et al., (2006); J Clin Microbiol 44(9): 3292-3298 
 6 de Koning et al., (2006); J Clin Microbiol 44(5): 1792-1800 
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Table 2.2:  Reagents and their composition for each PCR amplification 
 
 
 
 
 
PCR amplification 
 
PCR mastermix 
 
                                                                                     
Template 
DNA,  
10 ng/ul 
 
 
 
TOTAL 
 
Buffer II 
10x 
 
MgCl2  
(25 mM) 
 
dNTPs 
(2.5 mM) 
 
Primers 
 
Amplitaq Gold 
(5U/µl) 
 
Distilled 
water 
Total 
master
mix                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
(µl) (µl) mMa (µl) µMa Primer name (µl) ρmole (µl) Unit (µl) (µl) (µl) (µl) 
β-globin gene detection 5.0 3.0 1.5 4.0 200 PC04 (6 ρmole/µl) 2.0 12 0.2 1.0 23.8 40.0 10.0 50.0 
     GH20 (6 ρmole/µl) 2.0 12 
 
      
General PCR for L1 gene of mucosal HPV 
detection (First round) 
5.0 3.0 1.5 4.0 200 MY11 (50 ρmole/µl) 1.0 50 0.2 1.0 25.8 40.0 10.0 50.0 
     MY09 (50 ρmole/µl) 1.0 50 
 
      
Semi-nested PCR for L1 gene of mucosal HPV 
detection (Second round) 
5.0 3.0 1.5 4.0 200 MY11 (50 ρmole/µl) 1.0 50 0.2 1.0 32.8 47.0 3.0b 50.0 
     GP6 (50 ρmole/µl) 1.0 50 
 
      
Nested PCR for L1 gene of mucosal HPV 
detection (Second round) 
5.0 7.0 3.5 4.0 200 GP5+ (50 ρmole/µl) 1.0 50 0.2 1.0 32.8 47.0 3.0 b 50.0 
     GP6+ (50 ρmole/µl) 1.0 50 
 
      
SPF10-LiPA method [Mucosal (alpha) HPV] 
prototype research assay 
5.0 c 5.0 2.5 4.0 200 Type-specific SPF1/2  
and universal primer 
mix  (15 ρmole/µl) d 
1.0 15 0.3 1.5 24.7 40.0 10.0 50.0 
              
PM-PCR RHA method [Skin (beta) HPV; 
Diassay BV] prototype research assay 
5.0 5.0 2.5 4.0 200 PM Primer mix e 10.0  0.3 1.5 15.7 40.0 10.0 50.0 
     (in RHA kit) 
 
        
 
Notes: 
 
a  Final concentration;  b  Initial concentration of template DNA used will depend on the PCR product from the first amplification 
c  10 mmol/L TrisHCl, pH 9.0, 50 mmol/L KCl, Triton X-100, 0.01% gelatin;  d & e   Biotinylated PCR primers  
3T3 cells DNA (details preparation be given in Appendix 3) - Positive control for β-globin gene detection 
Human Salivary Gland DNA (details preparation be given in Appendix 3) – Positive control for L1 gene of mucosal HPV detection via semi-nested, nested and each independent PCR 
HPV type 6 DNA – Positive control for L1 gene of mucosal HPV detection via semi-nested or nested or independent PCR 
HPV type 16 DNA - Positive control for L1 gene of mucosal HPV detection via semi-nested or nested PCR, SPF-DEIA and SPF10-LiPA method 
HPV type 8 DNA - Positive control for PM-PCR RHA method 
Negative control 1 – distilled water 
Negative control 2 – paraffin alone, which tissue free from FFPET (paraffin to replace tissue during DNA extraction) 
Negative control 3 – reagents control   
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Table 2.3: PCR condition for each amplification method 
 
 
  
Initial Denaturation 
 
 
 
 
 
Number of cycles 
 
Final extension 
 
Incubation 
 
β-globin gene detection 
 
 
94oC for 7 min 
 
Denaturation: 94oC for 1 min 
Primer annealing: 55oC for 1 min 
Elongation: 72oC for 1 min 
 
 
 
40 
 
72oC for 7 min 
 
4oC 
PCR for L1 gene of general mucosal HPV detection 
(First Round) 
 
95oC for 10 min Denaturation: 95oC for 1 min 
Primer annealing: 55oC for 1 min 
Elongation: 72oC for 1 min 
 
 
30 
72oC for 5 min 4oC 
Semi-nested PCR for L1 gene of mucosal HPV detection 
(Second Round) 
 
95oC for 10 min Denaturation: 95oC for 1 min 
Primer annealing: 50oC for 1.5 min 
Elongation: 72oC for 2 min 
 
 
30 
72oC for 5 min 4oC 
Nested PCR for L1 gene of mucosal HPV detection 
(Second Round) 
 
94oC for 4 min Denaturation: 94oC for 1 min 
Primer annealing: 48oC for 2 min 
Elongation: 72oC for 1.5 min 
 
 
40 
72oC for 4 min 4oC 
SPF-DEIA [Mucosal (alpha) HPV] prototype research 
assaya 
 
94oC for 1 min Denaturation: 94oC for 1 min 
Primer annealing: 45oC for 1 min 
Elongation: 72oC for 1 min 
 
 
40 
72oC for 5 min 4oC 
SPF10-LiPA [Mucosal (alpha) HPV] prototype research 
assayb 
 
94oC for 9 min Denaturation: 94oC for 30 sec 
Primer annealing: 52oC for 45 sec 
Elongation: 72oC for 45 sec 
 
 
40 
72oC for 5 min 4oC 
PM-PCR RHA method [Skin (beta) HPV; Diassay BV] 
prototype research assayc 
 
94oC for 9 min Denaturation: 94oC for 30 sec 
Primer annealing: 52oC for 45 sec 
Elongation: 72oC for 45 sec 
 
 
35 
72oC for 5 min 4oC 
 
 
Notes: 
 
a  Kleter et al., (1998); Am J Pathol 153(6):  1731-1  
 b  Kleter et al., (1999); J Clin Microbiol 37(8): 2508-2517 
 c  de Koning et al., (2006); J Clin Microbiol 44(5): 1792-1800
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Figure 2.3: Instruments for gel electrophoresis 
 
 
 
Horizontal gel electrophoresis set 
and power pack 
 
 
Gene Flash, Syngene bioimager 
Sony gel image printer 
 
3D Rocking platform 
Microwave 
 
Digital camera Nikon D70 
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A microwave, Technolec T250t: 750 Watts 
A 3D Rocking platform, Stuart Scientific STR9 
Gene Flash, Syngene Bioimager (Beacon House, Nuffield Road, Cambridge) 
Sony Video Graphic Printer, UP-895MD, Tokyo, Japan 
 
2.1.9 Materials for PCR Purification Kits 
 
QIAquick PCR Purification Kits (Cat. no. 28104) 
QIAquick Spin Columns 
Buffer PBI – contains chaotropic salt 
Buffer PE (concentrate) 
Buffer EB 
Collection tubes (2 ml) 
Loading dye 
QIAquick Gel Extraction Kits (Cat. no. 28704) 
Similar contents as Cat. no. 28104 except Buffer QG to replace Buffer PBI  
For all protocols 
Ethanol (96-100%) 
Microcentrifuge 
1.5 or 2 ml microcentrifuge tubes 
3M sodium acetate, pH 5.0 
Distilled water or TE buffer (10 mM Tris-Cl 1 mM EDTA, pH 8) (optional) 
Gel extraction protocol 
Isopropanol (100%) 
 Water bath 
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2.1.10 Materials for automated PCR products sequencing 
 
Photographs of selected instruments used for this method are as shown in Figure 
2.4 
Kit Contents 
The BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, PN 
4337455) 
Ready Reaction Mix 
BigDye® Terminator v3.1 Sequencing Buffer (5X) 
pGEM® -3Zf(+) plasmid, double-stranded DNA Control Template 
-21 M13 forward primer (Control) 
Materials supplied by the user 
For cycle sequencing:  
 GeneAmp® PCR System 9700 (Applied Biosystems) 
 MicroAmp® 96-Well Reaction Plate (Applied Biosystems, PN N801-0560) 
 ABI PRISM® Optical Adhesive Cover (Applied Biosystems, PN 4311971) 
 Sorvall® Legend RT, DJB Labcare Ltd., England 
 Eppendorf MixMate PCR 96, (Cat. no. EF7505A), Daigger & Company Inc. 
For purifying extension products (Ethanol/EDTA precipitation): 
 Ethanol (EtOH), 200 proof, Molecular Biology grade 
EDTA, 125 mM 
 Sealing tape 
For electrophoresis: 
 ABI PRISM 3730 DNA Analyser with Data Collection v2.0 
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Figure 2.4: Instruments for automated DNA sequencing 
 
 
 
 
 
 
3730 DNA Analyser equipped with 48-capillary  
 
Sorvall microtiter plate centrifuge  
PCR system 9700  
 
Vortex mixer for 
microtiter plate 
  
 
Cycle sequencing reaction 
in microtiter plate format  
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Hi-DiTM Formamide, 25-mL bottle (Applied Biosystems, PN 4311320) 
3730 BigDye® Terminator v3.1 Sequencing Standard (Applied Biosystems, PN 
4336943) 
 3700 BigDye Terminator v3.1 Matrix Standard for Spectral Calibration and Dye 
Set H (Applied Biosystems, PN 4336975) 
 
2.1.11 Materials for SPF-DEIA 
 
Reagents for PCR amplification (as was previously described in section 2.1.7) 
Materials for Reverse Hybridisation  
Hybridisation buffer (150 mmol/L NaCl, 15 mmol/L sodium citrate, pH 7.0, 
0.1% Tween 20) 
Microtiter plate streptavidin coated 
Denaturation solution (100 mmol/L NaOH) 
Digoxigenin (DIG)-labeled HPV-specific probes solution 
Anti-DIG alkaline phosphatase conjugate 
Substrate solution (5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium) 
Stopping solution (0.5 mmol/L sulphuric acid) 
 Microtiter plate reader 
 
2.1.12 Materials for SPF10-LiPA25 (version 1) 
 
Reagents for PCR amplification (as stated in Table 2.2) 
Materials for Reverse Hybridisation  
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Denaturation solution (NaOH) 
Hybridisation buffer (3X SSC [1X SSC is 15 mM Na-citrate and 150 mM 
NaCl], 0.1% sodium dodecyl sulfate) 
Immobilised 28-parallel-line probes on nitrocellulose membrane strips 
Fixed 25-trough on tray 
Forcep and pencil 
Alkaline phosphatase-streptavidin conjugate 
Rinse solution 
Substrate buffer 
Substrate solution (5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium) 
Stopping solution (distilled water) 
 Auto-LiPA 
 
2.1.13 Materials for Reverse Hybridisation Assay (RHA) 
 
Photographs of selected instruments used for this method are as shown in Figure 
2.2 
Reagents for PCR amplification (as stated in Table 2.1) 
Materials for Reverse Hybridisation 
Thin wall with dome shaped PCR microcentrifuge tubes (200 µl) 
Removable 8-trough on tray 
Immobilised 27-parallel-line probes on nitrocellulose membrane strips 
Denaturation solution 
3B Buffer 
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Hybridisation Buffer (3X SSC [1X SSC is 15 mM Na citrate and 150 mM 
NaCl], 0.1% sodium dodecyl sulphate) 
Stringent Wash solution 
Alkaline phosphatase-streptavidin conjugate solution (100X concentration) 
Conjugate diluent  
Rinse solution (5X concentration) 
Substrate Buffer 
Substrate solution (5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium)  (100X concentration) 
 
2.1.14 α and β-HPV typing algorithm for pilot studies 
 
Overall strategies through the pilot studies are summarised in Figure 2.5. Details of each 
approach will be explained further in the later part of this chapter. All selected FFPET 
samples were previously mentioned in section 2.1.4. DNA was extracted from the 
FFPET and quantified prior to testing the quality of the DNA by amplification for β-
globin gene.  
 
 Three major independent approaches, but inter-related amongst them in HPV 
genotyping routes were as follows, PCR (semi-nested, nested, and independent), α-HPV 
detection (via SPF-DEIA and SPF10-LiPA) and β-HPV detection utilising RHA method. 
Finally, confirmation of the HPV types could be made using DNA sequence analysis 
using BLAST (Basic Local Alignment Systematic Tools) from the Genebank. 
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Figure 2.5: α-HPV and β-HPV detection and genotyping algorithm
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(OSCC) 
Repeat 
α-HPV detection 
Broad spectrum SPF10 PCR 
Repeat 
First round PCR 
MY11/MY09  
(450 bp) 
DNA quantification 
(spectrophotometry) 
DNA extraction FFPET excision 
PM-PCR RHA 
HPV 
genotype(s) 
+ 
+ 
+ 
Borderline (75-100%) 
α-HPV typing  
SPF10-LiPA v.1 
Sequence analysis of HPV-positive 
LiPA-negative samples 
- 
- 
Repeat 
Laser Captured 
Microdissection (LCM) 
HPV DEIA 
Sequence analysis  
+ + 
- + - 
Repeat 
Repeat if 
+ 
β-HPV detection 
Broad spectrum PM-PCR 
Sequence alignment  
(HPV databases) 
Competition Testing 
Specimen 
(FFPET) 
Amplimers purification 
OR 
Independent 
PCR 
Unidentified Mixed HPV typing 
Semi-nested PCR 
MY11/GP6  
(190 bp) 
Nested PCR 
GP5+/GP6+  
(140 bp) 
DNA  
qualification  
β-globin  
PCR 
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2.1.15 Tissue specimen preparation 
 
In order to investigate the effect of tissue volume on DNA yield and purity three 
volumes of FFPET were studied. The effect of three, five and ten 5 µm sections was 
studied in triplicate. A spectrophotometer was used to determine the yield and purity of 
the DNA. The method of DNA quantification and qualification will be described in the 
appropriate section. The results of this then guided the technique used on the pilot study 
(n= 60) and oral disease progression study (n=183). The DNA extraction for the pilot 
study was carried out in duplicate. In contrast, the DNA extraction for 183 FFPET 
specimens were carried out once for each sample. The positive and negative controls are 
as described in 2.1.4.  
 
A microtome was utilised to excise 5 µm sections from each FFPET block for 
each DNA extraction kit. The first 2-3 sections were discarded to avoid any 
contamination from air. Tweezers or forceps were used to collect the sections which 
were immediately placed in a clean 1.5 ml eppendorf tubes. The cutting area on the 
microtome, especially where the blade was placed and the platform, was carefully 
wiped with alcohol inbetween tissue blocks. A brand new blade and forceps was also 
used for the tissue from the subsequent FFPET block to get rid of any DNA 
contamination from the previous specimen. 
 
2.1.16 Isolating DNA from cells and tissues 
 
The key protocols of DNA extraction and purification from cells and tissues are sample 
lysis and separation of nucleic acid from contaminants. Initially, detergents are used to 
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solubilise the cell membranes during lysis step. The most common detergents are 
sodium dodecyl sulphate (SDS), Triton-X and hexadecyltrimethyl ammonium bromide 
(CTAB). In addition, the combination of a gentle enzyme such as proteinase K and SDS 
are often used to lyse the cells. This is then followed by treatment with potassium 
acetate, a cosmotrope to decrease the solubility of protein, SDS and lipid. A white 
precipitate is usually formed which can be removed via centrifugation retaining the 
nucleic acid in solution.  
 
Another approach to isolate nucleic acid is to use the combination of chaotropic 
guanidinium salts and reducing agents (β-mercaptoethanol, dithiothreitol). A chaotrope 
increases the solubility of molecules and the reducing agent to protect the nucleic acid 
from oxidative damage. Lysis buffer composition is the major difference when using 
commercial products and protocols for nucleic acid isolation. The nucleic acid 
purification is carried out by creating hydrophobic adsorption to silica resin (a solid, 
predispensed matrix in spin column format) in the presence of chaotropic substances.  
This can be followed by low salt/ethanol wash to eliminate excess chaotrope and any 
impurities that present in nucleic acid-resin binding matrix. Finally, nucleic acids are 
eluted from the silica resin in Tris-EDTA buffer or deionised distilled water and are 
ready for DNA quantification and use. 
 
2.1.17 Human Genomic DNA Extraction from FFPET using a Promega kit 
 
The oven must first be set at 56oC before the sample is incubated overnight. Prior to 
genomic DNA extraction one should ensure that all buffers in the extraction kit are 
equilibrated to ambient temperature. The water bath must be set at 65oC for DNA 
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elution step. Lysis Buffer ATL needs to be pre-warmed to 37-60oC to dissolve any 
precipitate, if present. The reagents need to be freshly prepared according to 
manufacturer’s instructions.  
 
100 µl of freshly prepared incubation buffer/proteinase K solution was added to 
the sections and incubated at 56oC overnight in the oven to deparaffinise the tissues. 
The tube was removed and 2 volumes of Lysis Buffer added. 7 µl of resin slurry was 
later added and the mixtures were vortexed for 3 sec at top speed and incubated for 5 
min at ambient temperature. 
 
The tube was vortexed for 2 sec at top speed and was placed in the Magnetic 
Stand for instant separation to occur. The solution in the tube was removed by pipetting 
taking care not to interrupt the Resin on the other side of the tube. 100 µl Lysis Buffer 
was added and the tube was removed from the Magnetic Stand and was vortexed for 2 
sec at top speed. The tube was returned to the Magnetic Stand and all Lysis Buffer was 
discarded by pipetting.  
 
100 µl of prepared 1X Wash Buffer was added and the tube was removed from 
the Magnetic Stand and was vortexed for 2 sec at room temperature. The tube was 
returned to the Magnetic Stand and all Wash Buffer was carefully discarded by 
pipetting. The washing steps were repeated at least three times with the prepared 1X 
Wash Buffer and all of the solution was completely removed for each wash. 
 
The tube was returned to the Magnetic Stand and the lid was kept open to air-dry 
the Resin for 5 min at ambient temperature. The lid was closed after 25 µl of Elution 
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Buffer was added and the tube was vortexed for 2 sec at high speed. The tube was 
incubated in the preheated water bath at 65oC for 5 min. The tube was removed and was 
vortexed for 2 sec at high speed. The DNA-containing solution was transferred to 
polypropylene containers to reduce the amount of DNA that binds to the sides. 
 
2.1.18 Human Genomic DNA Extraction from FFPET using Qiagen kit 
 
Prior to genomic DNA extraction, all buffers in the extraction kit were equilibrated to 
ambient temperature. The water bath was set at 56oC. Buffer AL or Buffer ATL was 
heated to 70oC to dissolve any precipitate, if present. The addition of ethanol to Buffer 
AW1 and Buffer AW2 was made following manufacturer’s instructions prior to being 
used. 
 
1 ml xylene was added to the sections, the lid was closed and microcentrifuge 
tube was vortexed vigorously for 10 sec to homogenise the solution. Later 
centrifugation at full speed (20,000 x g or 14,000 rpm) was carried out for 2 min at 
room temperature. Supernatant was carefully discarded by pipetting using a fine pipette 
tips, leaving the pellet untouched at the bottom of the tube.  
 
1 ml ethanol [96-100% (v/v)] was added to the pellet and mixed by vortexing. A 
similar procedure was followed for centrifugation, removal of any residual ethanol from 
the specimen. The microcentrifuge tube was opened for 10-minute incubation at room 
temperature (15-25oC) or up to 37oC until ethanol had completely evaporated. The 
pellet was resuspended in 180 µl Buffer ATL and 20 µl proteinase K and homogenised 
by vortexing. The microcentrifuge tube was incubated at 56oC for 1 hour in the water 
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bath followed by incubation at 90oC for 1 hour in the incubator to completely lyse the 
specimen. Subsequently, the 1.5 ml tube was briefly centrifuged to eliminate drops from 
the internal lid. 
 
A premixed solution containing 200 µl Buffer AL and 200 µl ethanol [96-100% 
(v/v)] was added to the specimen. Each tube was vortexed to obtain a homogeneous 
solution and briefly centrifuged to remove drops from the inside of the lid. The entire 
lysate was carefully transferred to the QIAamp MinElute column (in a 2 ml collection 
tube) without wetting the rim, the lid was closed and centrifuged at 6000 x g (8000 rpm) 
for 1 min. QIAamp MinElute column was then placed in a clean 2 ml collection tube 
and the collection tube containing the flow-through was discarded. 
 
500 µl Buffer AW1 was carefully added to the QIAamp MinElute column without 
wetting the rim, the lid was closed and centrifuged at 6000 x g (8000 rpm) for 1 min. 
QIAamp MinElute column was then placed in a clean 2 ml collection tube and the 
collection tube containing the flow-through was discarded. 500 µl Buffer AW2 was 
carefully added to the QIAamp MinElute column without wetting the rim, the lid was 
closed and centrifuged at 6000 x g (8000 rpm) for 1 min. QIAamp MinElute column 
was later placed in a clean 2 ml collection tube and the collection tube containing the 
flow-through was discarded. 
 
Each tube was centrifuged at full speed (20,000 x g or 14,000 rpm) for 3 min to 
completely dry the membrane. QIAamp MinElute column was then placed in a clean 2 
ml collection tube and the collection tube containing the flow-through was discarded. 50 
µl of Buffer ATE was carefully applied to the centre of the membrane of the column 
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without wetting the rim, the lid was closed and incubated at room temperature (15-
25oC) for 5 min and centrifuged at full speed (20,000 x g or 14,000 rpm) for 1 min. 
 
2.1.19 Quantification and Qualification of Extracted DNA 
 
The spectrophotometer, WU 1101 or NanoVue (GE Healthcare UK Ltd.) was first set 
for measuring nucleic acids and selected for DNA and default settings were 
recommended for routine measurements. DNA parameters such as pathlength 
(automatically adjusted either 0.2 or 0.5 mm), to turn off background subtraction and 
dilution factor with the unit of DNA concentration been given as µg/µl. The filters 
provided in the instrument automatically read the absorbance at wavelengths (230, 260, 
280 and 320 nm) together with the absorbance ratio of 260/280. The ratio range from 
1.6 and 2.2 gave an indication the purity of DNA samples.  
 
 2 µl of reference solution (DNA elution buffer, Tris-EDTA buffer) was pipetted 
into the indicated well and the sample head was lowered. The spectrophotometer was 
zeroed by pressing the reference button to read. Once the measurement was complete, 
the sample head was raised and the top and bottom plates were cleaned with a lint-free 
tissue. Similarly, 2 µl of reference solution was pipetted and the reading was repeated. 
The plates were cleaned and later multiple samples were measured once the reference 
information was stored. 2 µl of sample was used for testing. The measurement was 
performed in triplicate and the average for each parameter was recorded without 
removing the sample.  
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All the details of these measurements are listed below and will be discussed in the 
appropriate chapter.   
a. The quality and quantity of the positive controls (n=2+3) (human salivary 
glands, 3T3 embryonic mouse fibroblast cells, HPV16/6/8). 
b. Repeated measurements variation within and between DNA samples extracted 
from FFPETs (n=6). 
c. The effect of DNA volume to the DNA extraction (n=5) in triplicate. 
d. DNA extraction methods comparison (Qiagen kit versus Promega kit) (n=5) in 
triplicate. 
e. Extracted DNA for pilot study using Qiagen kit (n=60) in duplicate. 
f. Extracted DNA for HPVs role in oral disease progression study using Qiagen kit 
(n=183). 
 
2.1.20 Agarose gel electrophoresis 
 
2.1.20.1 Agarose gel preparation 
 
0.2 g of standard agarose was weighed and was poured into 250 ml conical flask. 100 
ml of Tris-Acetate EDTA (1X TAE) (gel buffer) and was added and mixed evenly. The 
flask was microwaved until the agarose was fully melted. Periodically the flask was 
removed from the microwave and gently swirled to homogenise the agarose without 
making bubbles and ripples. The agarose was left on the bench until its temperature was 
approximately 50oC.     
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2.1.20.2 Gel Casting 
 
The rubber gaskets were inserted into the groove at both edges of the gel tray. This was 
to give a good contact between the open edges of the gel tray to the sides of the pouring 
box and to avoid any leakage prior the agarose being poured into it. The gel tray was 
pushed down into the pouring box. Alternatively, transparent rubbers were securely 
attached to both open edges of the gel cast. It was left on an even surface at room 
temperature. 
  
A comb of appropriate width, size and number was placed into the niche at the 
end of the tray. The agarose solution was poured evenly into the tray and left for about 
15 min to solidify and completely set for another 15 min. The gel tray was lifted and 
both rubber gaskets were removed. The comb was removed by lifting it straight up. The 
gel tray was rotated 90o to ensure the ends of the gel were exposed to the ends of the gel 
box. The well was positioned at the cathode. 400 ml of 1X TAE buffer (electrophoresis 
buffer) was added to fill both the gel tanks and gel was ensured to be completely 
immersed.            
 
2.1.20.3 DNA sample loading 
 
Gel loading dye, Blue (6X) is a premixed tracking dye with loading buffer for agarose 
gel electrophoresis. It contains SDS (to obtain sharper DNA bands), EDTA (to chelate 
magnesium for stopping enzymatic reaction if present) and bromophenol blue (a 
universal tracking dye for electrophoresis). On a standard agarose gel 1% TBE, it 
migrates at approximately 300 bp. 
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1 µl of loading dye was gently mixed with 5 µl of DNA sample by pipetting up 
and down on parafilm (working concentration of loading dye is 1X). The homogenous 
mixture of DNA sample and loading dye was gently loaded by pipetting out into the 
second well of the agarose gel. The first well was reserved for the DNA marker either 
100 bp DNA ladder or 1 Kb DNA ladder. 
 
2.1.20.4 Gel electrophoresis 
 
The cover lid of electrophoresis set was closed. The power supply was set for 
electrophoresis running time of 1 hour at constant voltage of 120V. The power supply 
was started and the progress of the migrated DNA was monitored regularly by 
migration of the loading dye. Once the electrophoresis was complete, the power supply 
was switched off and the agarose gel was removed for staining.   
 
2.1.20.5 Gel staining using Fast Blast DNA Stain 
 
Fast Blast DNA stain is a non-toxic and non-carcinogenic option to ethidium bromide in 
the agarose gel after electrophoresis to detect the DNA present. The thiazin family of 
dyes (cationic substance – positively charged) is one of its components. Negatively 
charged phosphate groups on the DNA molecules are attracted to the dye molecules. 
The staining procedure generally takes longer than conventional fluorescent DNA stains 
like ethidium bromide due to the fact that Fast Blast is a non-fluorescent observable 
stain. The minimum quantity of DNA that can be visualised in an agarose gel either as a 
quick or an overnight staining using this method is 50 ηg of DNA. The quick staining 
usually takes around 15-30 min to complete. It was recommended to use 60 ml of 100X 
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Fast Blast to stain 7 x 7 cm or 7 x 10 cm agarose gel and the stain can be reused at least 
7 times. The DNA bands of the stained gel may emerge blurred initially but turned into 
sharper bands gradually within 5-15 min after the second wash. The preparation of 
reagents for quick or overnight staining is illustrated in Appendix 34. 
 
The agarose gel was placed in the staining tray after electrophoresis. 100X Fast 
Blast DNA stain was poured into the tray and the gel was stained for 2-3 min. Used 
staining solution was poured back into a storage bottle by using a funnel for future use. 
The gel was transferred into a vessel containing 500-700 ml of warm (40-55oC) clean 
tap water. The gel was gently shaken on a rocking platform for 5 min for washing. The 
washing procedure was repeated twice. 
 
2.1.20.6 Gel image capturing 
 
The agarose gel was placed on the platform inside the Syngene imager. The gel image 
(black and white) was captured and printed using an integrated Sony printer. 
Alternatively, a coloured gel image was generated by using a digital camera, Nikon 
D70.   
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2.1.21 Optimisation of Polymerase Chain Reaction (PCR) 
 
2.1.21.1 PCR for detection of human β-globin gene 
 
A preliminary effort to optimise the PCR amplification was carried out using the 
positive and negative controls in triplicate.  As a gold standard for quality checking of 
the extracted DNA from human samples and cells, detection of β-globin gene 
expression was used. The DNA sequence of human β-globin gene (Appendix 4) and the 
location of both primer pairs flanking the target region are shown in Figure 2.6.  Two 
positive controls carrying human DNA were tested as mentioned in 2.1.15 and 
described further in Appendix 3. The initial PCR amplifications as shown in Table 3 
and preparation of each reagent is illustrated in Appendix 2. 10 µl of extracted DNA at 
10 ηg/µl concentration was added to 40 µl of mastermix as shown in Table 2. 50 µl of 
reaction mixture for each specimen underwent PCR amplification according to 
condition shown in Table 2.3. 
 
 
LOCUS       NG_000007             81706 bp    DNA     linear   PRI 25-JAN-2009 
DEFINITION  Homo sapiens beta globin region (HBB@); and hemoglobin, beta (HBB); 
            and hemoglobin, delta (HBD); and hemoglobin, epsilon 1 (HBE1); and 
            hemoglobin, gamma A (HBG1); and hemoglobin, gamma G (HBG2), on 
            chromosome 11. 
ACCESSION   NG_000007 
VERSION     NG_000007.3  GI:28380636 
KEYWORDS    RefSeqGene. 
SOURCE      Homo sapiens (human)  
 
    ...... 
             GH20 
    70381 aactcctaag ccagtgccag aagagccaag gacaggtacg gctgtcatca cttagacctc 
    70441 accctgtgga gccacaccct agggttggcc aatctactcc caggagcagg gagggcagga 
    70501 gccagggctg ggcataaaag tcagggcaga gccatctatt gcttacattt gcttctgaca 
    70561 caactgtgtt cactagcaac ctcaaacaga caccatggtg catctgactc ctgaggagaa 
    70621 gtctgccgtt actgccctgt ggggcaaggt gaacgtggat gaagttggtg gtgaggccct 
        PC04 
    ...... 
 
 
Figure 2.6: GH20 and PC04 primer annealing sites in human beta globin gene 
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2.1.21.2 PCR for detection of protein L1 of mucosal HPV 
 
An initial effort to optimise the PCR amplification and conditions was carried out using 
a single positive control (a plasmid containing insert of HPV 6 L1 gene) and several 
negative controls.  The strategies and algorithm for detection of the alpha HPV L1 gene 
expression was carried out either via PCR-gel electrophoresis, SPF-DEIA or SPF10-
LiPA. The last two approaches will be explained further in section 2.1.25.1 and 
2.1.25.2, respectively. Figure 2.7 shows the DNA sequence of HPV 6 L1 protein gene, 
the location of three universal primer pairs (MY11/MY09, MY11/GP6 and 
GP5+/GP6+), type-specific SPF primer sets and designed HPV detection probes 
(shaded DNA sequences) flanking the target region. Each primer set, MY11/MY09, 
MY11/GP6, GP5+/GP6+ and SPF1/SPF2 was expected to generate approximately 450 
bp, 190 bp, 140 bp and 65 bp amplimers, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
  
104 
 
LOCUS       AF092932                8012 bp    DNA     linear   VRL 14-NOV-2001 
DEFINITION  Human papillomavirus type 6, complete genome. 
ACCESSION   AF092932 
VERSION     AF092932.1  GI:6002612 
KEYWORDS    . 
SOURCE      Human papillomavirus type 6 
  ORGANISM  Human papillomavirus type 6 
            Viruses; dsDNA viruses, no RNA stage; Papillomaviridae; 
            Alphapapillomavirus. 
 
    ...... 
    ...... 
                                                       SPF1 
     6541 tgtttgccag acattttttt aacagggctg gcgaggtggg ggaacctgtg cctgatactc 
     6601 ttataattaa gggtagtgga aatcgaacgt ctgtagggag tagtatatat gttaacaccc      
                                                        SPF2 
     6661 caagcggctc tttggtgtcc tctgaggcac aattgtttaa taagccatat tggctacaaa 
           MY11                                           GP5+ 
     6721 aagcccaggg acataacaat ggtatttgtt ggggtaatca actgtttgtt actgtggtag 
     6781 ataccacacg cagtaccaac atgacattat gtgcatccgt aactacatct tccacataca 
     6841 ccaattctga ttataaagag tacatgcgtc atgtggaaga gtatgattta caatttattt 
                                                GP6+   GP6 
     6901 ttcaattatg tagcattaca ttgtctgctg aagtaatggc ctatattcac acaatgaatc 
     6961 cctctgtttt ggaagactgg aactttgggt tatcgcctcc cccaaatggt acattagaag 
     7021 atacctatag gtatgtgcag tcacaggcca ttacctgtca aaagcccact cctgaaaagg 
     7081 aaaagccaga tccctataag aaccttagtt tttgggaggt taatttaaaa gaaaagtttt 
     7141 ctagtgaatt ggatcagtat cctttgggac gcaagttttt gttacaaagt ggatataggg 
                                      MY09 
     7201 gacggtcctc tattcgtacc ggtgttaagc gccctgctgt ttccaaagcc tctgctgccc 
     7261 ctaaacgtaa gcgcgccaaa accaaaaggt aatatatgtg tatatgtact gttatatata 
 
    ...... 
    ...... 
 
Figure 2.7: Primer annealing sites for universal primer sets and type- 
specific SPF primer sets and probes in HPV 6 L1 protein 
 
2.1.22 PCR using extracted genomic DNA 
 
2.1.22.1 The detection of β-globin gene (268 bp) 
 
The amplification of a 268 bp β-globin gene demonstrated that the extracted human 
genome DNA from FFPET was of sufficient quality for further PCR amplifications as 
shown in Table 2.1. Preparation of each reagent is illustrated in Appendix 2. 10 µl of 
extracted DNA at 10 ηg/µl concentration was added to 40 µl of mastermix as shown in 
Table 2.2. 50 µl of reaction mixture for each specimen was undergone PCR 
amplification according to condition as stated in Table 2.3. 
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 For the pilot study, DNA from 60 FFPET specimens was analysed for quality as 
mentioned above, in triplicate. Similarly, for larger samples consisting of 183 extracted 
DNA from three different pathological groups (benign, dysplasia and carcinoma) were 
to be positively confirmed prior L1 gene HPV detection. Each sample was considered 
positive for the β-globin gene if it exhibited very clear and convincing data for at least 
one repetition. Only doubtful positive or negative results were re-analysed either by 
PCR or the DNA was re-extracted to ensure potentially positive results were never 
missed. Finally, those samples positively identified at this stage qualified for the next 
stage which was HPV gene detection and the rest of the samples were identified as 
negative. 
 
2.1.22.2 Semi-nested PCR for detection of L1 gene of mucosal HPV 
 
The positive samples from 2.1.22.1 were qualified for HPV detection. DNAs from 
FFPET were suitable for first round PCR amplification of approximately 450 bp 
expected product size, in triplicate, using MY11/MY09 primer pair as shown in Table 
2.1. The related positive and negative controls for PCR were also included. 10 µl of 
extracted DNA at 10 ηg/µl concentration was added to 40 µl of mastermix as shown in 
Table 2.2. 50 µl of reaction mixture for each specimen was used for PCR amplification 
according to conditions stated in Table 2.3. All PCR products from the first round PCR 
amplification were used for the second round PCR amplification to obtain a 190 bp 
product using MY11/GP6 primer pair as shown in Table 2.1. 3 µl of product from the 
first round of PCR was added to 47 µl of mastermix as shown in Table 2.2. 50 µl of 
reaction mixture for each specimen was amplified by PCR according to conditions 
stated in Table 2.3. 
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2.1.22.3 Nested PCR for detection of L1 gene of general mucosal HPV 
 
All PCR products of 450 bp in size from the first round PCR amplifications were used 
for the second round PCR amplification in triplicate to obtain 140 bp using GP+/GP6+ 
primer pair as shown in Table 2.1. Positive and negative controls were also included to 
estimate the performance of PCR and to detect unnecessary DNA contaminants that 
might be present in the reaction. 10 µl of extracted DNA at 10 ηg/µl concentration was 
added to 40 µl of mastermix as shown in Table 2.2. 50 µl of reaction mixture for each 
specimen amplified by PCR according to the conditions stated in Table 2.3. 
 
2.1.22.4 Independent PCR for detection of L1 gene of mucosal HPV using two 
separate primer pairs 
 
The rational for this direct approach is an alternative route for those DNA samples 
which failed to produce a 450 bp amplimer from the first PCR amplification. Since 
dealing with extracted DNA from FFPETs, it is a big challenge to amplify bigger 
products and this relies upon the moderate quality of the DNA sources. 
 
Independent PCR amplifications were carried out using MY11/GP6 and 
GP5+/GP6+ primer pairs and fresh DNA template. These were in done in separate 
reactions to increase the chances of obtaining positive results due to the expected size of 
both amplimers being relatively small, 190 bp and 140 bp. 
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2.1.23 Purification of PCR products 
 
The QIAquick system was designed for fast DNA purification which includes: 
 
• QIAquick PCR Purification Kit 
This kit is mainly used for robust analysis of PCR products involving double- or 
single-stranded PCR products within the size range of 100 bp – 10 Kb. 
• QIAquick Gel Extraction Kit 
These kits were used to improve DNA recovery and to extract DNA fragments 
around the size range of 70 bp – 10 Kb from either standard agarose or low-melt 
agarose gels in TAE (Tris-acetate/EDTA) or TBE (Tris-borate/EDTA) buffer.   
 
2.1.23.1 QIAquick PCR Purification Kit 
 
5 volumes of Buffer PBI were added to 1 volume of the PCR sample and were mixed by 
pipetting. The colour of the mixture should be yellow (to indicate pH ~ 7.5 which is 
optimal for DNA binding) after the gel slice has completely dissolved. 10 µl of 3M 
sodium acetate, pH 5.0 was added to the mixture (if the colour is orange or violet after 
the incubation) to turn the colour to yellow. 
 
A QIAquick spin column was placed in a 2 ml collection tube. The sample was 
applied to the column and was centrifuged at 17,900 x g (13,000 rpm) for 30–60 sec. 
The flow-through was discarded and the column was returned to the same tube. 750 µl 
of Buffer PE was added to the QIAquick column and was centrifuged at 17,900 x g 
(13,000 rpm) for 30–60 sec. The flow-through was discarded and the QIAquick column 
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was returned to the same collection tube and was centrifuged for an additional 1 min at 
17,900 x g (13,000 rpm). 
 
The QIAquick column was placed into a clean 1.5 ml microcentrifuge tube. 50 µl 
of Buffer EB (10 mM Tris-Cl, pH 8.5) or water (pH 7.0-8.5) was added to the centre of 
the QIAquick membrane and the column was centrifuged for 1 min. 1 volume of 
Loading Dye was added to 5 volumes of purified DNA and was mixed by pipetting if 
the DNA is to be analysed on a gel. 
 
2.1.23.2 QIAquick Gel Extraction Kit 
 
The DNA fragment was excised from the agarose gel with a clean and sharp scalpel. 
The size of the gel slice was reduced by removing extra agarose. The gel slice was 
weighed in a colourless tube and 3 volumes of Buffer QG were added to 1 volume of 
gel (100 mg~100 µl). 6 volumes of Buffer QG were added for 2% (w/v) agarose gel and 
the maximum amount of gel slice per QIAquick column is 400 mg. 
 
The tube was incubated at 50oC for 10 min or until the gel had completely 
dissolved. The colour of the mixture should be yellow (to indicate pH ~ 7.5 which is 
optimal for DNA binding) after the gel slice has completely dissolved. 10 µl of 3M 
sodium acetate, pH 5.0 was added to the mixture (if the colour is orange or violet after 
the incubation) to turn the colour to yellow. 1 gel volume of isopropanol was added to 
the sample which was then homogenised by inverting the tube 3-5 times. 
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The QIAquick spin column was placed in a 2 ml collection tube. The sample was 
applied to the QIAquick column and was centrifuged at 17,900 x g (13,000 rpm) for 1 
min. The maximum quantity of the column reservoir was 800 µl. The flow-through was 
discarded and the QIAquick column was returned to the same collection tube. 500 µl of 
Buffer QG was added to QIAquick column and was centrifuged at 17,900 x g (13,000 
rpm) for 1 min. 
 
The flow-through was discarded and the QIAquick column was returned in the 
same collection tube. 750 µl of Buffer PE was added to QIAquick column and was 
centrifuged at 17,900 x g (13,000 rpm) for 1 min. The flow-through was discarded and 
the QIAquick column was returned in the same collection tube and was centrifuged for 
an additional 1 min at 17,900 x g (13,000 rpm). 
 
 The QIAquick column was placed into a clean 1.5 ml microcentrifuge tube. 50 µl 
of Buffer EB (10 mM Tris-Cl, pH 8.5) or water (pH 7.0-8.5) was added to the centre of 
the QIAquick membrane and the column was centrifuged for 1 min to elute the DNA. 1 
volume of Loading Dye was added to 5 volumes of purified DNA which was mixed by 
pipetting if the DNA is to be analysed on a gel. 
 
2.1.23.3 Quantification and Qualification of the purified PCR products 
 
PCR products purified by using either the former or the latter method were assessed 
quantitatively and qualitatively by spectrophotometry as described in the section 2.1.19. 
Statistical analyses were carried out in the appropriate chapter as stated for comparison 
of their means. The measurements include: 
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a. All amplicons from pilot study (n = 67; all carcinoma); CHAPTER 3 
b. All amplicons from oral disease progression study (n = 142; which include 
carcinoma, n = 67); CHAPTER 4 
c. Carcinoma, n = 134 (combination from data a and b, n = 67 + 67); 
CHAPTER 5 
    
2.1.24 Automated DNA Sequencing of the PCR products 
 
In principle, the purified DNA fragments amplified by PCR are denatured to single 
strands and one of the strands is hybridised to a primer. Heat-resistant Taq polymerase 
and a pool of deoxyribonucleotide triphosphates (dNTPs) allow the synthesis of new 
DNA strands from the terminal of primer sequence. This is similar to the PCR method 
except a single primer is required (either forward or reverse primer) in each reaction and 
one of four chain-terminating and fluorescent-labelled nucleotides, ddNTPs. For 
instance, if ddGTP is used, the resulting synthesis of nested DNA fragments in variable 
sizes and each fragment ends at one of the Gs in the sequence through the replacement 
of a fluorescent-labeled ddGTP. Similarly, a set of fragments is created for each of the 
other three bases and is labelled according to ddNTPs being used. 
  
Electrophoresis in a capillary for each sample separates a mixture of all labelled 
DNA fragments by size. The presence of each of the four labels is determined by 
scanning the ladder of fragments and a computer programme then analyses the probable 
order of the peaks and predicts the DNA sequence. 
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2.1.24.1 Cycle Sequencing 
 
The automated DNA sequencing of amplimers was performed by an experienced 
technician. The reaction mixtures to be added for each PCR products are as shown in 
Table 2.4. This preparation was made for MicroAmp® 96-Well Reaction Plate. An ABI 
PRISM® Optical Adhesive Cover was used to seal the plate to avoid environmental 
contamination. All the cycle sequencing mixtures in the plate were well mixed using 
Eppendorf MixMate PCR 96. 
 
Table 2.4: Reagents for cycle sequencing of PCR products 
 
 
Reagent 
 
Quantity 
Terminator Ready Reaction 
Mix 
Ready Reaction Premix, 2.5X 
and BigDye® Terminator v3.1 
Sequencing Buffer, 5X 
 
4 µl         5 µl of the mixture 
+             was used for each reaction 
2 µl 
Template DNA1 (PCR product) 1-3 ηg (140 bp and 190 bp amplicons) 
3-10 ηg (450 bp amplicons) 
Primer2 
   Forward or reverse 
 
5 ρmol 
Deionised water Top up to the final volume 
 
Final volume 
 
20 µl 
 
Notes: 
1 pGEM®- 3Zf(+) plasmid was used as a control for cycle sequencing 
2 -21 M13 forward primer for control template  
 
Later, the plate was placed in the GeneAmp® PCR System 9700 thermal cycler 
and the amplification was carried out according to the conditions in Table 2.5. Each 
extended products were held at 4oC in thermo cycler until ready for purification. 
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Table 2.5: Cycle sequencing condition of each sample 
 
Initial Denaturation 96oC for 1 min  - Rapid termal ramp to 96oC 
Denaturation   
Primer annealing 
Extension  
96oC for 10 sec 
50oC for 5 sec 
60oC for 4 min 
      - 25 cycles and 
      rapid termal ramp to each 
      setting temperature 
Incubation 4oC - Rapid termal ramp to 4oC and 
was held until ready for extension 
products purification 
 
 
2.1.24.2 Purification of the extension products via ethanol/EDTA precipitation method 
 
The 96-well reaction plate was removed from the thermal cycler and was briefly spun 
down using a Sorvall® Legend RT centrifuge. 5 µl of 125 mM EDTA was added to each 
well and to ensure the EDTA was completely mixed with the extension products. It was 
followed by the addition of 60 µl of 100% ethanol to each well. Later, the plate was 
sealed with optical adhesive cover and the content of each well was mixed by inverting 
4 times.  
 
The plate was incubated at room temperature for 15 min and subsequently was 
spun at the maximum speed of 1400-2000 x g for 45 min using Sorvall® Legend RT 
centrifuge which was set at 4oC. The plate was inverted and was spun up to 185 x g, and 
then was removed from the centrifuge. 60 µl of 70% (v/v) ethanol was added to each 
well and the plate was centrifuge at 4oC for 15 min at 1650 x g. The plate was inverted 
and was later spun up to 185 x g, and was then removed from the centrifuge. 
 
2.1.24.3 Sample electrophoresis 
 
The samples and standards were resuspended in injection solution, Hi-Di formamide 
(PN 4311320). The volume of the sample in the reaction plate wells for precise delivery 
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of samples to the capillary array tips (48-capillary with 36-cm array length for 3730 
DNA Analyzer) is illustrated in Table 2.6. The plate was immediately covered by 3100 
Genetic Analyzer Plate Septa (PN 4315933) or Optical Heat-Seal Film (PN 4337570) to 
avoid sample degradation. 
 
Table 2.6: Resuspension volumes for reaction plates 
 
Reaction 
plate 
Minimum volume (ul) Maximum volume (ul) Recommended 
volume (ul) Film Septa Film Septa 
96-well 10 10 200 150 10-30 
 
The reaction plate was centrifuged at 2000 x g for 1 min to bring down the 
samples to the bottom of the wells and later the reaction plate was carefully examined 
the position of the samples. The reaction plate was later placed in the integrated plate 
stacker of 3730 DNA Analyzer (which can accommodate 16 sample plates – 96-well 
format).  The electrokinetic injection, EKI (V-Sec/cm) has to be optimised following 
parameters: injection time (seconds), injection voltage (Volts/cm) and the concentration 
of DNA fragments in the sample according to the strength of the signal and the quality 
of the resolution. The default Standard Run Module was set which was suitable to detect 
maximum 850 bases. The first 20 min was programmed to run the protocol using POP-
7™ polymer and Dye Set H following parameters: the separation voltage was 8.5kV and 
electrophoresis temperature was 60oC. It was followed by data collection 
(approximately 20 to 30 min for 450 bases) which started after DNA fragments 
travelling through a 36-cm capillary array and being scanned by fluorescence detector. 
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2.1.24.4 DNA sequencing outputs 
 
Sequence Analysis software provided with the 3730 DNA Analyzer system gave the 
results in the form of basecaller/s (further details in Appendix 5). The raw DNA 
sequence data in which three different and integrated files was created for each sample, 
chromatogram, SCF chromatogram and SEQ-sequence files. Viewing and final editing 
of the uncertain or ambiguous bases from the chromatogram file can be made using 
Chromas Lite 2.0 software (Technelysium Pty Ltd). Manually edited sequences need to 
be saved and exported into SCF chromatogram and SEQ-sequence files (in FASTA 
format). Contig for each sample (overlapping and non-overlapping sequence) will be 
generated by combining forward and reverse primer results (SCF chromatogram files 
were used) using DNA Baser (http://www.dnabaser.com/, Heracle Software, Germany) 
or DNA for Windows Ver. 2.2.1 (http://www.dna-software.co.uk/, University of 
Durham) softwares. The contig tells us the actual size of PCR products being sequenced 
in base pairs. Subsequently, the generated contig was used to search for HPV DNA 
sequence similarity using BLAST from the Genebank. Pair-wise and multiple sequence 
alignments of the contigs can be performed by using stand-alone programme such as 
ClustalW2 (http://www.ebi.ac.uk/Information/ebi_bac/, European Molecular Biology 
Laboratory). The former for comparing two sequences and the later for more than two 
sequences simultaneously.     
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2.1.25 SPF-DEIA and SPF10-LiPA25 (version 1) for alpha-HPV genotypes 
 
2.1.25.1 SPF-DEIA 
 
Initial PCR amplifications were as described in section 2.1.7 and preparation of each 
reagent is illustrated in Appendix 2. 10 µl of extracted DNA at 10 ηg/µl concentration 
was added to 90 µl of mastermix. 100 µl of reaction mixture for each specimen was 
undergone PCR amplification with positive, borderline positive and several negative 
controls according to condition as stated in Table 3. 
 
PCR products, generated by six biotinylated primers were detected via reverse 
hybridisation in a microtiter plate utilising a composition of nine designed probes based 
on DNA sequences of 39 HPV genotypes at L1 open reading frame region (Kleter et al., 
1998). 100 µl of hybridisation buffer was mixed with 10 µl of amplimer in a 
streptavidin coated microtiter plate well and incubated at 42oC for 30 min. Unbound 
substances were discarded by three washing steps with hybridisation buffer. 100 µl of 
denaturation solution was added to the captured amplimers and the plate was incubated 
at ambient temperature for 5 min. Again, it was followed with three washes with 
hybridisation buffer. 
 
Digoxigenin (DIG)-labeled HPV-specific probes solution was freshly diluted with 
hybridisation buffer, added to each well and incubated for 45 min at 42oC. Anti-DIG 
alkaline phosphatase conjugate was added to each well and was incubated for 45 min at 
42oC following three washing steps. Subsequently, substrate was added and followed by 
incubation at room temperature for 5 min. After, each well was washed for five times. 
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Finally, the addition of 100 µl of 0.5 mmol/L of sulphuric acid stopped the reaction. A 
microtiter plate reader was used to measure an optical density (OD) of the content of 
each well at 450 nm. Positives were identified if the recorded OD450 was 2.5 times 
higher than the negative PCR control. PCR amplification and followed by DEIA 
detection were repeated if the reading within borderline value (75 to 100% of the cut off 
value) (Van Doorn et al., 2006).      
 
2.1.25.2 SPF10-LiPA25 (version 1) 
 
PCR amplifications mentioned in section 2.1.25.1 were performed by using reagents 
and as shown in Table 2.2 and preparation of each reagent is illustrated in Appendix 2. 
10 µl of extracted DNA at 10 ηg/µl concentration was added to 40 µl of mastermix as 
shown in Table 2.2. 50 µl of reaction mixture for each specimen was amplified by PCR 
with positive, borderline positive and several negative controls according to conditions 
stated in Table 2.3. 
 
PCR products, generated by ten biotinylated primers were detected via reverse 
hybridisation in nitrocellulose membrane strips format and simultaneously identified 25 
HPV genotypes. It was denoted as line probe assay (LiPA) utilising a composition of 
twenty eight designed specific probes based on DNA sequences of 39 HPV genotypes at 
L1 open reading frame region (Kleter et al., 1999). 
 
 Hybridisation solution and Stringent Wash solution must be prewarmed at 37oC 
and all crystals should be dissolved by mixing prior being used. The LiPA strip was 
removed from the tube using forceps and was labelled in pencil according to sample 
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identification number above the line of the strip. Care had to be taken not to touch 
below the line of the strip with a bare hand to avoid any contamination. 
 
 10 µl biotinylated amplimer was pipetted into the upper corner of each labelled 
trough. Then, 10 µl of NaOH was added and the solutions carefully mixed by pipetting. 
The denaturation process was performed at room temperature for 10 min. The labelled 
strip was immediately placed in the labelled test trough (one strip per trough and a total 
of twenty five troughs per tray). The strips should be facing up as the label at the top.  
 
 Thereafter, all incubations and washings were automatically done in Auto-LiPA 
with pre-set programmes. 2 ml of prewarmed hybridisation buffer was automatically 
added to each trough and incubated for an hour at 50 + 0.5oC. The removal of the 
solution was done and followed by stringent wash at 50oC with 2 ml of hybridisation 
solution to each strip, twice for 30 sec and once for 30 min. 
 
Later, the strip was incubated for 30 min at ambient temperature with 2 ml of 
alkaline phosphatase-streptavidin conjugate. It was followed by washing steps, twice 
with 2 ml of rinse solution and once with 2 ml of substrate buffer. Subsequently, the 
strips were incubated in 2 ml of substrate (5-bromo-4-chloro-3-indolylphosphate and 
nitroblue tetrazolium) for 30 min at room temperature. The aspiration of the substrate 
solution followed by addition of 2 ml of distilled water will stop the reaction. Following 
the drying step, the strips results were interpreted visually according to the provided 
interpretation sheets.      
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2.1.26 RHA for the Identification of beta HPV genotypes 
 
2.1.26.1 PCR amplification 
 
All 60 extracted human genome DNA from FFPET was suitable for PCR amplification 
for RHA-beta (skin) HPV using primer mix (in RHA kit) as shown in Table 2.2. 10 µl 
of extracted DNA at 10 ηg/µl concentration was added to 40 µl of mastermix as shown 
in Table 2.2. 50 µl of reaction mixture for each specimen was amplified by PCR 
according to conditions stated in Table 2.3. Figure 2.8 showing the PM primer mix 
(commercially unavailable) target region (shaded DNA sequences) in E1 protein gene 
of HPV 8 as one of the candidate for beta HPV genotyping (117 bp amplimer was 
generated). 
 
LOCUS       PPH8CG                  7654 bp    DNA     circular VRL 15-JUL-1998 
DEFINITION  Human papillomavirus type 8, complete genome. 
ACCESSION   M12737 
VERSION     M12737.1  GI:333074 
KEYWORDS    . 
SOURCE      Human papillomavirus type 8 
  ORGANISM  Human papillomavirus type 8 
            Viruses; dsDNA viruses, no RNA stage; Papillomaviridae; 
            Betapapillomavirus. 
 
    ...... 
    ...... 
 
     2581 atccttttcc aatgaaacca gacaatacac ctgaatttga attaactgac caaagctgga 
     2641 aatctttttt tgcaaggctt tggacacaat tagagctgag tgatcaagaa gacgagggcg 
     2701 aacatggaga atctcagcga gcgtttcaat gttctgcaag atcagctaat gaacatttat 
     2761 gaagctgcag aacaaacact tgaggcacag attgcgcatt ggctgctttt gcgaaaagaa 
     
    ...... 
    ......   
 
Figure 2.8: The target region in E1 protein gene for beta HPV genotyping 
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2.1.26.2 HPV Genotyping 
 
A shaking water bath was heated to exactly 50oC and a calibrated thermometer was 
utilised to counter check the temperature. Distilled water was used and the water level 
adjusted to between 1/3 - 1/2 of the trough height. Hybridisation solution and Stringent 
Wash solution must be prewarmed at 37oC – 50oC and all crystals should be dissolved 
by mixing prior being used.  
 
The test strip was removed from the tube using forceps and labelled using a pencil 
according to sample identification number above the line of the strip. Care should be 
taken not to touch below the line of the strip with bare hand to avoid any contamination. 
10 µl of denaturation solution was pipetted into the upper corner of each labelled trough 
followed by 10 µl 3B-Buffer using sterile aerosol pipette tips. Then, 10 µl amplified 
biotinylated PCR product was added and the solutions were carefully mixed by 
pipetting. The denaturation process was allowed to proceed for 5 min at ambient 
temperature.  
 
The prewarmed Hybridisation Solution was shaken and gently 2 ml was added 
into each trough and was mixed by gentle shaking. Care should also be taken not to 
contaminate the adjacent troughs during pipetting. The labelled strip was immediately 
placed in the labelled test trough (one strip per trough and in total eight troughs per 
tray). The strips should be facing up as the label at the top and completely submerged in 
the solution. Splashing water from the water bath into the trough should be avoided. 
The tray is placed in the 50oC shaking water bath and the lid was closed and incubated 
at 80 rpm agitation for 60 min. 
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The tray was removed from the water bath after incubation in hybridisation 
solution. The tray was held at a low angle and the mixture was aspirated from the trough 
using a pipette. 2 ml pre-warmed Stringent Wash solution was added and the tray was 
gently shaken for 10 to 20 sec at ambient temperature for rinsing. The solution was 
aspirated from each trough. This washing step was repeated once. Finally, each strip 
was incubated in 2 ml pre-warmed Stringent Wash solution in the shaking water bath at 
50oC for 30 min and the lid of the water bath was closed. The tray was removed from 
the water bath after stringent wash incubation. The mixture was aspirated from each 
trough and each strip was washed twice for 1 min using 2 ml of Rinse Solution. The 
solution was pipetted out and 2 ml of Conjugate Solution was added to each trough and 
was incubated for 30 min on the shaker at ambient temperature (20 to 25oC). 
 
The tray was removed from the shaker after the conjugate incubation, and each 
strip was washed twice for 1 min using 2 ml diluted Rinse Solution. It was followed 
with a washing step using 2 ml Substrate Buffer and the mixture was aspirated. 2 ml 
Substrate Solution (already kept in the dark) was added to each trough and the tray was 
kept in a container wrapped with foil (to maintain dark environment). The covered 
container was incubated for 30 min on the shaker at 80 rpm agitation at room 
temperature. 
 
 The container was removed from the shaker after the colour development 
incubation and the solution was aspirated. The developing colour was stopped by 
washing twice with 2 ml distilled water while gentle shaking for at least 3 min. The 
strips were removed from the troughs using forceps and were placed in between tissue 
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towel to allow them to dry completely. Each strip was stuck to the interpretation sheet 
by aligning the conjugate control line. 
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2.2 THE ROLE OF p16 IN ORAL DISEASE PROGRESSION 
 
2.2.1 Introduction 
 
Immunohistochemistry is a technique for identifying cellular or tissue constituents 
(antigens) by means of antigen-antibody interactions. One of the biggest problems with 
immunohistochemistry has been how to maintain good morphology and also the 
immunoreactivity of antigens in paraffin embedded tissue sections. The antigen-
masking effects of formaldehyde fixation are reversible to varying degrees by a process 
known as antigen retrieval. Antigen retrieval involves exposing the tissue sections to 
heat or proteolytic enzyme digestion before commencing immunochemical staining. 
The mechanisms of antigen retrieval are poorly understood but this method is believed 
to break the methylene bridge cross-links formed between proteins during formaldehyde 
fixation, thus allowing the proteins to take on a more tertiary-like structure and allowing 
antibodies access to the epitope. The schematic representation of the immunochemical 
staining technique after antigen retrieval is shown in Figure 2.9. 
 
Figure 2.9: ABC immunochemical staining procedure 
 (Haines and Chelak, 1991) 
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Therefore, antigen retrieval by pre-treatment during optimisation is the vital stage 
in the technique prior to incubation with the optimal dilution of the antibody. The 
optimum dilution for an antibody is the highest at which specific immunoglobulin 
saturates the available antigen, leaving some unbound antibody in the solution to ensure 
continued binding. 
    
2.2.2 Aim 
 
Numerous studies have revealed that the development of oral cancer is associated with 
high-risk human papillomavirus (HR-HPV) types. The HPV E7 oncoprotein inactivates 
the pRB tumour suppressor protein and increases the expression of p16INK4a, a cyclin-
dependent kinase inhibitor, by the loss of negative feedback control.  
 
 The aim of this study was to investigate the expression of p16 in 60 FFPETs oral 
squamous cell carcinomas. From the pilot study results, we could correlate the positivity 
of p16 expression with HPV status and will be discussed in chapter 3. In addition, we 
increased the sample size to 176 (which consisted of  benign, dysplasia and carcinoma 
specimens) to assist us with a better understanding of oral disease progression involving 
those two biomarkers and this will be further discussed in chapter 4, 5 and 6. 
 
2.2.3 General Equipment 
 
Photographs of selected major instruments used are as shown in Figure 2.10. 
• An automated microtome, Shandon Citadel 2000, Micron HM335E 
• A microwave, Tecnolec, T250t: 750 Watts 
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• A 3D rocking platform, Stuart Scientific STR9 
• A microscope, Leica Microscopy Systems Ltd (020-519.502) 
• A microscope mounted digital camera, Leica DC100 
• A microscope, Motic BA400 Biological Microscope, Motic Instruments Inc. 
Canada 
• Episcopic-Fluorescence Attachment EF-UPR-III for BA400, Motic 
Instruments Inc. Canada 
• A computer installed with Motic Image Plus 2.0 ML (Motic China Group 
Co., Ltd.) 
 
 
Figure 2.10: Motic BA400 Biological Microscope 
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2.2.4 Specimens for p16 immunohistochemistry staining 
 
2.2.4.1 Optimisation of p16 immunohistochemistry. 
 
Initially, eight paraffin blocks were randomly selected which consisted of normal oral 
mucosa (n=1), kidney (n=1), skin (n=1), papilloma (n=1), oral squamous carcinoma 
(n=4), to optimise p16 expression. Nine paraffin blocks were randomly selected for 
comparing two primary antibodies. The first two were carcinoma of the oral and human 
salivary gland specimens. The second four samples were positively identified 
containing HPV DNA by PCR and HPV genotyping. The third three samples were 
negative for HPV DNA. 
 
2.2.4.2 Pilot study: Oral squamous cell carcinoma specimens for p16 IHC staining 
(n=60) 
 
Sixty paraffin blocks of squamous cell carcinoma previously selected for HPV 
investigation were used for p16 expression based on the optimal condition achieved 
(Appendix 13). A negative control for p16 IHC (n=1) was selected for each run of 24 
FFPET specimens. 
 
2.2.4.3 The role of p16 in disease progression 
 
A hundred and seventy six paraffin blocks of mixed pathological specimens previously 
selected for HPV investigation were used for p16 expression based on the optimal 
conditions achieved. The mixed pathological specimens were (n=176; benign, n=84; 
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dysplasia, n=12; carcinoma, n=80). We utilised another seven normal tissue blocks for 
comparison of p16 expression. A negative control for p16 IHC (n=1) was selected for 
each run of 24 FFPET specimens.. 
 
2.2.5 Materials for immunohistochemistry staining 
 
• PolysineTM glass slides, VWR International (Cat. no. 631-0107) 
• Coverslip autoslip coverglass, (Cat. no. 67761323) 
• ImmEdge pen, (Cat. no. H-4000), Vector Laboratories Ltd., Peterborough, 
UK. 
• DePeX (Distrene, plasticizer, xylene/dibutyl phthalate xylene) mounting 
medium for microscopy, (Lot. 840316160), BDH Chemicals Ltd. , Poole, 
England 
• Xylene, VWR Ltd, Lutterworth, Leicestershire, UK 
• 95% and 100% alcohol, Chemistry Store, University of Dundee 
• 30% (v/v) Hydrogen peroxide, (Cat. no. 285194H), VWR Ltd, Lutterworth, 
Leicestershire, UK. 
• Phosphate buffered saline, pH 7.5 (PBS), (Cat. no. P4417), Sigma-Aldrich 
Ltd, Poole, UK. 
• Citrate buffer (2.1g of anhydrous citric acid dissolved in 1 litre of distilled 
water) (pH=6.0 with 1M of NaOH) (Cat. no. 44445), BDH Laboratory 
supplies, Poole, UK. 
• Retrievagen A (pH6) (Cat. no. 550524), BD Pharmingen, BD Biosciences, 
Inc. USA.  
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• Normal Goat Serum (NGS) (Cat. no. S-1000, Lot. No. T0504), Vector 
Laboratories Ltd., Peterborough, UK. 
• Normal Mouse IgG1, Dako, X0931 (Lot. 00044506) (Negative Control) 
• Protease type XXIV: Bacterial (P24), (Cat. no. P8038, Lot. 85H1192), Sigma, 
UK. 
• Mouse Anti-Human p16 (JC8) (Cat. no. sc-56330), Primary antibody, Santa 
Cruz Biotechnology, Inc. (USA). 
• Purified Mouse Anti-Human p16 (INK4) (Cat. no. 550834), BD Pharmingen, 
Primary antibody, BD Biosciences, Inc. USA. 
• Mouse ABC Staining Systems (Cat. no. sc-2017), Santa Cruz Biotechnology, 
Inc. (USA). 
• Vectastain ABC Kit, Standard Elite (PK6100), Vector Laboratories Ltd., 
Peterborough, UK. 
• Goat Anti- MouseIgG/Biotinylated, (Cat. no. BA-9200, Lot no. T0206), 
Secondary antibody, Vector Laboratories Ltd., Peterborough, UK. 
• Scott’s tap Water Solution (STWS) blueing agent, (Cat. no. PS138/D), Bios-
Europe, Lancashire, UK. 
• DAB (3,3’ diaminobenzidine) solution, (Cat. no. D5637), Sigma-Aldrich 
Ltd., Poole, UK. 
• Mayer’s Haematoxylin, (Cat. no. PS50/C), Bios-Europe, Lancashire, UK. 
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2.2.6 The tissue specimens preparation 
 
A microtome was used to cut 5 µm sections from FFPET blocks. Later, the multiple 
sections were gently placed into a water filled Electrothermal Paraffin Section 
Mounting Bath (already prewarmed at 55oC) to avoid the formation of folding artifacts. 
 
An individual section was mounted onto the Polysine slide by placing it in the 
water bath at an acute angle beneath the floating section and attaching it to 
approximately the middle of the slide by adhesion. All mounted slides were placed in a 
metal rack and kept in the oven at 65oC for at least 2 hours to remove excess paraffin 
and to prevent the section floating off during processing. Next, all slides were labelled 
in pencil according to antibody, dilution, no pre-treatment, pre-treatment and date. 
Finally, all slides were stored into a metal or plastic slide rack for future staining steps. 
 
2.2.7 p16 immunohistochemistry staining protocol 
 
It was important to perform the pre-treatment of the paraffin sections to unmask tissue 
antigens as was mentioned earlier in 2.2.1. Therefore, several pre-treatments were 
undertaken to determine which was the most suitable for the p16 antibody: primary 
antibody dilution, protease XXIV (P24), microwave and autoclave. Two primary 
antibodies were tested throughout p16 IHC optimisation, p16 (JC8), Santa Cruz (Cat. 
no. sc-56330) and p16 (INK4): BD Pharmingen, (Cat. no. 550834). The overall 
optimisation strategy for p16 expression is illustrated in Figure 2.11. 
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2.2.7.1 General protocol – Day 1 
 
• All slides were grouped according to primary antibody used at 1:10, 1:25, 1:50 
and 1:100 dilutions and each with sub-groups (no pre-treatment, enzymatic, 
microwave and autoclave pre-treatments) (Figure 2.11). 
• For optimisation purposes an initial dilution of 1:10 dilution of primary antibody 
was used. The optimum condition achieved through semi-quantitative assessments 
would assist for the selection of suitable dilution.   
• The microwave pre-treatment slides were placed in water for 2 min. 
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Figure 2.11: Key optimisation steps for p16 expression 
 
• All slides (including microwave pre-treatment slides) were deparaffinised in 
xylene for 5 min. 
• The slides were rehydrated in graded alcohol (absolute alcohol, 95% alcohol, and 
70% alcohol) for 5 min each. 
• Later, the slides were rinsed for 5 min under tap water. 
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P24 at 
0.1% 
P24 at 
0.1% 
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Incubation with Biotinylated Anti-
Mouse IgG (H+L) (2o antibody)  
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• 1% (v/v) hydrogen peroxide (H2O2) in PBS was prepared [8 ml of 30% (v/v) H2O2 
in 240 ml of PBS]. 
• The slides were placed in 1% (v/v) H2O2 in PBS for 20 min to block endogenous 
peroxidase activity. 
• The slides were washed with two changes of 1X PBS (approximately 300 ml of 
1X PBS required for each wash).  
o All washing steps in PBS were carried out with agitation on top of gyro-
rocker for 5 min each. 
• The section for each slide was outlined with PAP pen to prevent spillage of 
solutions. 
• All slides with pre-treatments were undertaken to section 2.2.7.2 whereas for none 
pre-treated slides to section 2.2.7.3. 
 
2.2.7.2 Pre-treatments – Day 1 
 
a. Enzymatic treatment, Protease XXIV (P24) 
 
• 0.1% (v/v) and 0.01% (v/v) P24 were prepared [1% (w/v) P24 stock diluted with 
1X PBS]. 
• 100 µl of 0.1% (v/v) or 0.01% (v/v) P24 was added to the assigned slides at the 
staining tray. 
• The slides were transferred into a staining box containing damp tissues and were 
incubated at 37oC for 20 min. 
• The slides were returned to the rack and washed with two changes of PBS. 
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b. Microwave treatment (with citric acid) 
 
• The slides were placed in a plastic holder in a plastic box. 
• The citric acid buffer was added until the slides were submerged. 
• The plastic box was covered with cling film and was placed in the microwave. 
• The microwave was set at full power for 5 min. 
• More buffer was added if the slides were not submerged and microwaved for a 
further 5 min. 
• The slides were allowed to cool down for 10 min and were rinsed in deionised 
water. 
• The slides were returned to the rack and washed with two changes of PBS. 
 
c. Autoclave treatment (with Retrievagen A, pH 6.0)  
 
• The slides were placed in the plastic coplin jar. 
• A working solution of Retrievagen A was prepared by adding 18 ml of 
Retrievagen A solution 1 and 82 ml of Retrievagen A solution 2 and was brought 
the final volume to 1 liter in distilled water. 
• The working solution of Retrievagen A, pH 6.0 was added until the slides were 
submerged. 
• The slides in the plastic coplin jar were autoclaved for 10 min. 
• The coplin jar with the slides was removed and the jar was covered tightly.  
• The solution was allowed to cool down for 20 min at room temperature and the 
slides were rinsed in three changes of PBS, 5 min each. 
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2.2.7.3 General protocol 
Day 1 (after section 2.2.7.2 for slides with pre-treatments)  
 
• All slides were placed in the staining tray containing damp tissues to maintain 
humidity. 
• NGS in PBS at 1:5 dilutions was prepared and applied to each slide at room 
temperature for 20 min to block non-specific staining. 
• Excess NGS/PBS (1:5) was removed before adding the diluted primary antibody. 
• Specific dilution of primary antibody was made up with diluted NGS/PBS (1:5). 
• 100 µl of diluted primary antibody was added to completely cover each section. 
• The staining tray was covered with a lid to avoid evaporation. 
• All slides were incubated at 4oC in the fridge overnight (or at room temperature 
for 30 min).  
 
Day 2 (next morning): 
 
• The primary antibody was rinsed off in a stream of PBS. 
• All slides were washed with two changes of PBS and finally excess PBS was 
removed. 
• The sections were incubated with NGS/PBS (1:5) for 10 min at room temperature 
and excess fluid was removed. 
• Biotinylated secondary antibody (6 µl of anti-mouse IgG in 1 ml NGS/PBS (1:5) 
dilution) was prepared.  
• Each slide was incubated in 100 µl of diluted secondary antibody for 30 min at 
room temperature. 
  
134 
• Meanwhile, ABC staining system was prepared 30 min before it was required by 
mixing 12 µl of reagent A (Avidin) and 12 µl of reagent B (Biotin) in 1 ml of PBS 
and was kept at room temperature until needed. 
• The slides were rinsed in a stream of PBS and were washed with two changes of 
PBS. 
• Excess fluid was removed and 100 µl of ABC was added to completely cover 
each section and then incubated at ambient temperature for 30 min. 
• The slides were rinsed in a stream of PBS and were washed with two changes of 
PBS. 
• The slides were immersed in a solution made up of 1600 µl DAB, 400 µl H2O2 in 
400 ml PBS. 
o DAB was completely thawed without any suspension left at the bottom of 
the vial (heated with water) before mixing the solution. 
o The DAB-containing solution (from staining box) was tested by mixing 
together with excess ABC and the solution should turn to dark brown. 
o Used DAB-containing solution was removed into the designated disposal 
bottle whereas tips and the vials were removed into the designated yellow 
bin. 
• Later, the slides were washed for 2 min under tap water. 
• The slides were counter-stained with Mayer’s Haematoxylin for 1 min. 
• The specimens were rinsed for 1 min under tap water until the water ran clear. 
• The specimens were placed in STWS blueing agent for 1 min and were rinsed in 
running water for 1 min. 
• The slides were placed and dehydrated successively in 70% alcohol, 95% alcohol 
and 100% alcohol for 2 min each. 
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• Finally, the slides were immersed in xylene for 2 min and were mounted with 
DePeX. 
 
2.2.8 Optimisation of p16 expression 
 
Two ABC Staining Systems were tried throughout the optimisation procedures. The 
first was ABC Staining Systems from Santa Cruz Biotechnology, Inc. Reagents 
supplied in the kits (sufficient for 200 slides) include 1.0 ml normal blocking serum, 
250 mg biotinylated secondary antibody, 0.5 ml each avidin and biotinylated 
horseradish peroxidase (AB reagents), 1.0 ml 50x peroxidase substrate, 1.0 ml 50x 
DAB chromogen and 3.0 ml 10x substrate buffer. The second was Vectastain ABC 
Staining Systems from Vector Laboratories, Petersborough.  
 
2.2.8.1 Trial 1: Optimisation of p16 immunohistochemistry. 
 
Eight paraffin blocks were randomly selected as mentioned in 2.2.7 to optimise p16 
expression using only p16 primary antibody and mouse ABC Staining Systems from 
Santa Cruz. 
 
2.2.8.2 Trial 2: Comparing p16 primary antibody from two different suppliers. 
 
Nine paraffin blocks were randomly selected as mentioned in 2.2.7. The primary 
antibody from a different supplier was used i.e. p16 (JC8), Santa Cruz (Cat. no. sc-
56330) and p16 (INK4): BD Pharmingen, (Cat. no. 550834). Vectastain ABC Staining 
Systems from Vector Laboratories, Petersborough was utilised in this section. 
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2.2.9 Pilot study (n=60) 
 
Sixty paraffin blocks, similar FFPETs used for HPVs study as mentioned in 2.1.4. 
Selected primary antibody, best ABC Staining System and optimum pre-treatment from 
2.2.8 was utilised in this section. 
 
2.2.10 Oral disease progression study (n=176) 
 
A hundred and seventy six paraffin blocks, similar FFPETs used for HPVs study as 
mentioned in 2.1.4. Similarly, selected primary antibody, best ABC Staining System 
and optimum pre-treatment from 2.2.8 was utilised in this section. 
 
2.2.11 Semi-quantitative scoring for p16 immunohistochemistry staining 
 
A microscope (Motic BA400) with an eyepiece grid (Mertz) containing 100 points (the 
total size of the grid surface area is 0.476 mm2) was used to assess the sections. 
Scanning the sections at low power (X100, 10x eyepiece and 10x objective lens power) 
to identify the area of positive p16 stained to identify the ‘hot spot’ across the length of 
the epithelium without overlapping. The mean of randomly selected 10 ‘hot spot’ fields 
were assessed at X400 magnification (10x eyepiece and 40x objective lens power) for 
intensity and percentage of staining taken as an estimate (10% cut-off point for p16 
positivity) (Angiero et al., 2008; Tanaka et al., 2005). Strong nuclear and cytoplasmic 
staining defined a positive reaction. The p16 positive staining was limited to the tumour 
cells, occasionally including a few multinucleate giant cells which stained strongly 
positive, and less than 5% epithelium had focal positive stain. The p16 positive 
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distribution was scored on a semi-quantitative scale at first and then converted to 
positive and negative scores before statistical analyses. All p16 slides were examined 
and scored by two observers and 10% were re-reviewed by a third observer. A positive 
reaction by non-tumour cells, such as multinucleated giants cells and epithelia, were not 
included as positive. 
 
2.3 STATISTICAL ANALYSIS 
 
Data was entered into an Excel 2007 spreadsheet (Microsoft Corp., USA) and imported 
into a software package, Statistical Package for Social Sciences (SPSS, version 16, Inc. 
Chicago, Illinois, USA). The Kolmogorov-Smirnov Z statistic with Lilliefors 
significance level was performed to test normality of the data. If the significance level is 
greater than 0.05, then the normality is assumed. The Shapiro-Wilks statistic is also 
calculated if the sample size is less than fifty. The data was later analysed depending on 
the distribution, parametric analysis if normally distributed or non-parametric analysis if 
not normally distributed. Wilcoxon matched-pairs test for two related parameters and 
Friedman’s repeated measures two-way analysis of variance (ANOVA) for multiple 
related parameters was utilised to examine the variation which exist inter-observer. A 
Spearman’s Rank Order Correlation (rho) test was used to correlate the strength of the 
relationship between two variables. Comparisons between tissues were carried out using 
Mann-Whitney U test with a 95% confidence interval. Kaplan-Meier (product 
estimates) and log rank tests were used for survival analysis for each of the variables 
and clinical factors. Cox regression analysis was performed to identify whether any of 
these factors were of independent prognostic significance if p value was less than 0.05 
for the differences. 
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CHAPTER 3 
 
RESULTS OF PILOT STUDIES 
 
3.1 OVERVIEWS 
 
Overviews of aims of this chapter are two fold.  The first is to optimise the 
methodology specifically to answer the following questions: 
• The quality and quantity of the extracted DNA using positive controls 
• The quality and quantity of the extracted DNA from FFPETs 
• The effect of DNA volume on the DNA extraction 
• A comparison of DNA extraction methods (Qiagen versus Promega kit) 
• Optimisation of Polymerase Chain Reaction 
o β-globin detection by PCR for DNA quality determination 
o PCR optimisation for L1 HPV detection 
The second and major aim of this pilot study was: 
o To extract DNA from 60 cancers (FFPETs) 
o PCR amplification for L1 HPV detection 
o Purification and DNA sequencing of the PCR products 
o Alpha and beta (β-HPV) Genotyping 
o HPV prevalence and clinicopathological parameters 
o Correlation among demographic and clinical parameters associated with HPVs 
The third aim is to investigate: 
o The potential role of p16 in the same 60 cancers as above 
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o Possible correlations among demographic and clinical parameters associated 
with p16 
o Correlation between HPVs and p16 expression 
o Potential association with survival for HPV and p16 
 
3.2 OPTIMISATION OF DNA EXTRACTION 
 
3.2.1 The quality and quantity of the extracted DNA of positive controls 
 
3.2.1.1  Repeated measurements within positive controls (HSGs) 
 
The raw data for qualitative and quantitative DNA extracted from human salivary 
glands (A1 and A2) was given in Appendix 6, Table A. Mann-Whitney U and Wilcoxon 
W tests were performed to investigate the variation which could exist from the 
duplication of the same sample. Kruskal Wallis test on the other hand, was performed 
for repeated measurements effect. The result of statistical analysis is shown in Table 
3.1a and 3.1b.  
 
Table 3.1a: The effect of duplication 
Test Statisticsb 
 
A260 A280 
DNA 
purity DNA yield 
Mann-Whitney U 11.000 9.000 14.000 14.500 
Wilcoxon W 32.000 30.000 35.000 35.500 
Z -1.131 -1.444 -0.642 -0.562 
Asymp. Sig. (2-tailed) 0.258 0.149 0.521 0.574 
Exact Sig. [2*(1-tailed Sig.)] 0.310a 0.180a 0.589a 0.589a 
a. Not corrected for ties.    
b. Grouping Variable: HSG (A1 & A2)    
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Table 3.1b: The effect of replication 
Test Statisticsa,b 
 
A260 A280 
DNA 
purity DNA yield 
Chi-Square 0.480 0.203 1.341 0.358 
df 2 2 2 2 
Asymp. Sig. 0.787 0.904 0.511 0.836 
a. Kruskal Wallis Test    
b. Grouping Variable: Replication   
 
 
3.2.1.2 Comparison between two positive controls (cells) 
 
The raw data for qualitative and quantitative DNA extracted from human salivary 
glands (A1 and A2) and 3T3 embryonic mouse fibroblasts (B1 and B2) was given in 
Appendix 6, Table B. Mann-Whitney U, Wilcoxon W and Kruskal Wallis tests were 
performed as in section 3.2.1.1 to investigate the variation which could exist from 
similar sample type (cells). The result of statistical analysis is shown in Table 3.2a and 
3.2b. 
 
Table 3.2a: Comparison between two positive controls  
Test Statisticsb 
 A260 A280 DNA purity DNA yield 
Mann-Whitney U 10.500 16.000 17.000 9.000 
Wilcoxon W 31.500 37.000 38.000 30.000 
Z -1.205 -0.323 -0.160 -1.444 
Asymp. Sig. (2-tailed) 0.228 0.747 0.873 0.149 
Exact Sig. [2*(1-tailed Sig.)] 0.240a 0.818a 0.937a 0.180a 
a. Not corrected for ties.    
b. Grouping Variable: HSG & 3T3     
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Table 3.2b: The effect of replication 
Test Statisticsa,b 
 
A260 A280 
DNA 
purity DNA yield 
Chi-Square 0.203 0.468 0.731 0.261 
df 2 2 2 2 
Asymp. Sig. 0.903 0.791 0.694 0.878 
a. Kruskal Wallis Test    
b. Grouping Variable: Replication   
 
3.2.1.3  Preliminary conclusions 
 
From 3.2.1.1, all parameters assessed in the duplication of the same sample and the 
repeated measurements taken for quality and quantity of the extracted DNA were not 
statistically significant different (p>0.05). Similarly, it was demonstrated in 3.2.1.2 that 
the variation in similar type of sample (cells) and repeated readings were not 
statistically significant. Therefore, it was sufficient to take only a single measurement 
for each sample for DNA quality and quantity comparison purposes. 
 
3.2.2 The quality and quantity of the extracted DNA from FFPETs 
 
3.2.2.1 Repeated measurements within FFPETs 
 
The raw data for qualitative and quantitative DNA extracted from FFPETs (C1 and C2) 
was given in Appendix 7, Table A. Mann-Whitney U and Wilcoxon W tests were 
performed to investigate the variation which could exist from the duplication of the 
same sample. Kruskal Wallis test on the other hand, was performed for repeated 
measurements effect. The result of statistical analysis is shown in Table 3.3a and 3.3b. 
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Table 3.3a: The effect of duplication 
Test Statisticsb 
 
A260 A280 
DNA 
purity DNA yield 
Mann-Whitney U 18.000 18.000 3.000 18.000 
Wilcoxon W 39.000 39.000 24.000 39.000 
Z 0.000 0.000 -2.406 0.000 
Asymp. Sig. (2-tailed) 1.000 1.000 0.016 1.000 
Exact Sig. [2*(1-tailed Sig.)] 1.000a 1.000a 0.015a 1.000a 
a. Not corrected for ties.    
b. Grouping Variable: FFPETs (C1 & C2)    
 
Table 3.3b: The effect of replication 
Test Statisticsa,b 
 
A260 A280 
DNA 
purity DNA yield 
Chi-Square 0.155 0.155 1.245 0.010 
df 2 2 2 2 
Asymp. Sig. 0.925 0.925 0.537 0.995 
a. Kruskal Wallis Test    
b. Grouping Variable: Replication   
 
3.2.2.2 Comparison amongst FFPETs 
 
The raw data for qualifying and quantifying DNA extracted from randomly selected 
FFPETs (C1 to C6) was given in Appendix 7, Table B. Kruskal Wallis test was 
performed similar to section 3.2.1.1 to investigate the variation which could exist from 
similar sample type (FFPETs). The result of statistical analysis is shown in Table 3.4a 
and 3.4b. 
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Table 3.4a: Comparison amongst randomly selected six FFPETs 
Test Statisticsa,b 
 
A260 A280 
DNA 
purity DNA yield 
Chi-Square 16.103 15.862 8.251 15.971 
df 5 5 5 5 
Asymp. Sig. 0.007 0.007 0.143 0.007 
a. Kruskal Wallis Test    
b. Grouping Variable: FFPETs (C1-C6)   
 
Table 3.4b: The effect of replication 
 
Test Statisticsa,b 
 
A260 A280 
DNA 
purity DNA yield 
Chi-Square 0.038 0.073 0.667 0.152 
df 2 2 2 2 
Asymp. Sig. 0.981 0.964 0.717 0.927 
a. Kruskal Wallis Test    
b. Grouping Variable: Replication   
 
3.2.2.3 Preliminary conclusions 
 
From 3.2.2.1, the difference was not statistically significant in all parameters in the 
duplication of the same sample and the repeated measurements taken for quality and 
quantity of the extracted DNA except for DNA purity (p<0.05). Similarly, it was 
demonstrated in 3.2.2.2 that repeated readings were not statistically significantly 
different. In contrast, the variation of DNA yield in similar type of sample (FFPETs) 
were statistically significant (p<0.01). Therefore, from now onwards we would consider 
an average of the measurements for each sample for DNA quality and quantity 
comparison purposes. 
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3.2.3 The effect of DNA volume to the DNA extraction 
 
3.2.3.1 DNA volume effect using Qiagen kit 
 
The raw data for qualifying and quantifying DNA extracted from three different 
volumes (3, 5 and 10 coupes) using Qiagen kit was given in Appendix 8 and 9. One-
Way ANOVA analysis was performed and later with Post Hoc Tests if the overall F 
significant. If the Levene test (Test of Homogeneity of Variance) was significant, 
Games-Howell test was performed or the Tukey HSD (honestly significant differences) 
test, if Levene test was not significant.  It was revealed that DNA quantity was not 
significantly different in the three DNA volumes. Meanwhile, DNA purity of 10 coupes 
was significant higher (p<0.05) than 3 coupes. In addition, DNA purity of either 5 
coupes to 3 coupes or 5 coupes to 10 coupes was comparable statistically.    
 
3.2.3.2 DNA volume effect using Promega kit 
 
The raw data for qualitative and quantitative DNA extracted from three different 
volumes (3, 5 and 10 coupes) using Promega kit was given in Appendix 10 and 11. 
One-Way ANOVA analysis was performed and will proceed with appropriate Post Hoc 
Tests. The result of statistical analysis demonstrated that the DNA quality and quantity 
were statistically comparable amongst the three DNA volumes using Promega kit. Since 
overall F was not significant, Post Hoc tests was not required.  
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3.2.3.3 Preliminary conclusions 
 
From 3.2.3.1 and 3.2.3.2, it can be concluded that DNA yield was comparable amongst 
three different DNA volumes using both kits separately. Similarly, DNA purity seems 
not significantly different in the three DNA volumes utilising Promega kit. 
Nevertheless, by using the Qiagen kit, 10 coupes demonstrated significantly better DNA 
purity than 3 coupes. Certainly, we could utilise the Qiagen kit and extracting 10 coupes 
to meet the highest DNA quality and quantity. Up to this point, no conclusion could be 
made regarding which DNA extraction kit was better for DNA purity and DNA yield 
for the very minimum DNA volume used.     
 
3.2.4 DNA extraction methods comparison (Qiagen kit versus Promega kit) 
 
An average of DNA purity and DNA yield in each DNA volume using two DNA 
extraction methods, Qiagen kit and Promega kit are summarised in Appendix 12. The 
Mann-Whitney U, Wilcoxon W and Two-sample Kolmogorov-Smirnov Z Tests were 
carried out to compare both DNA extraction kits in separate DNA volumes. 
 
3.2.4.1 Comparison using extracted DNA from 3 coupes of FFPET 
 
Table 3.5 shows the result of statistical analysis comparison between extraction kits 
using a DNA volume of 3 coupes. The Promega kit was significantly better than the 
Qiagen kit for DNA purity. In contrast for DNA yield, Qiagen kit performed 
significantly better than Promega kit. 
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Table 3.5: Mean comparison between two kits (3 coupes) 
(a) 
Mann-Whitney Test U: Ranks 
 DNA extraction 
kits N Mean Rank Sum of Ranks 
DNA purity Promega kit 15 19.77 296.50 
Qiagen kit 15 11.23 168.50 
Total 30   
DNA yield Promega kit 15 10.10 151.50 
Qiagen kit 15 20.90 313.50 
Total 30   
(b) 
Test Statisticsb 
 DNA purity DNA yield 
Mann-Whitney U 48.500 31.500 
Wilcoxon W 168.500 151.500 
Z -2.658 -3.361 
Asymp. Sig. (2-tailed) 0.008 0.001 
Exact Sig. [2*(1-tailed Sig.)] 0.007a 0.000a 
a. Not corrected for ties.  
b. Grouping Variable: DNA extraction kits 
 
(c) 
Two-sample Kolmogorov-Smirnov Z: Test Statisticsa 
  DNA purity DNA yield 
Most Extreme Differences Absolute 0.533 0.667 
Positive 0.000 0.667 
Negative -0.533 0.000 
Kolmogorov-Smirnov Z 1.461 1.826 
Asymp. Sig. (2-tailed) 0.028 0.003 
a. Grouping Variable: DNA extraction kits   
 
 
3.2.4.2 Comparison using extracted DNA from 5 coupes of FFPET 
 
Table 3.6 shows the result of statistical analysis comparison between extraction kits 
using a DNA volume of 5 coupes. Promega kit and Qiagen kit were comparable for 
DNA purity. Qiagen kit demonstrated significantly higher yields than Promega kit. 
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Table 3.6: Mean comparison between two kits (5 coupes) 
(a) 
Mann-Whitney Test: Ranks 
 DNA extraction 
kits N Mean Rank Sum of Ranks 
DNA purity Promega kit 15 13.43 201.50 
Qiagen kit 15 17.57 263.50 
Total 30   
DNA yield Promega kit 15 10.23 153.50 
Qiagen kit 15 20.77 311.50 
Total 30   
(b) 
Test Statisticsb 
 DNA purity DNA yield 
Mann-Whitney U 81.500 33.500 
Wilcoxon W 201.500 153.500 
Z -1.287 -3.278 
Asymp. Sig. (2-tailed) 0.198 0.001 
Exact Sig. [2*(1-tailed Sig.)] 0.202a 0.001a 
a. Not corrected for ties.  
b. Grouping Variable: DNA extraction kits 
 
(c) 
Two-sample Kolmogorov-Smirnov Z: Test Statisticsa 
  DNA purity DNA yield 
Most Extreme Differences Absolute 0.267 0.600 
Positive 0.267 0.600 
Negative 0.000 0.000 
Kolmogorov-Smirnov Z 0.730 1.643 
Asymp. Sig. (2-tailed) 0.660 0.009 
a. Grouping Variable: DNA extraction kits   
 
3.2.4.3 Comparison using extracted DNA from 10 coupes of FFPET 
 
Table 3.7 shows the result of statistical analysis comparison between extraction kits 
using DNA volume of 10 coupes. Promega kit and Qiagen kit was comparable for DNA 
purity. Qiagen kit showed a significant higher DNA yield in comparison to Promega kit. 
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Table 3.7: Mean comparison between two kits (10 coupes) 
(a) 
Mann-Whitney U Test: Ranks 
 DNA extraction 
kits N Mean Rank Sum of Ranks 
DNA purity Promega kit 15 12.60 189.00 
Qiagen kit 15 18.40 276.00 
Total 30   
DNA yield Promega kit 15 10.50 157.50 
Qiagen kit 15 20.50 307.50 
Total 30   
(b) 
Test Statisticsb 
 DNA purity DNA yield 
Mann-Whitney U 69.000 37.500 
Wilcoxon W 189.000 157.500 
Z -1.808 -3.112 
Asymp. Sig. (2-tailed) 0.071 0.002 
Exact Sig. [2*(1-tailed Sig.)] 0.074a 0.001a 
a. Not corrected for ties.  
b. Grouping Variable: DNA extraction kits 
 
(c) 
Two-sample Kolmogorov-Smirnov Z: Test Statisticsa 
  DNA purity DNA yield 
Most Extreme Differences Absolute 0.267 0.533 
Positive 0.267 0.533 
Negative 0.000 0.000 
Kolmogorov-Smirnov Z 0.730 1.461 
Asymp. Sig. (2-tailed) 0.660 0.028 
a. Grouping Variable: DNA extraction kits   
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3.2.4.4 Preliminary conclusions  
 
The summary of the comparison between extraction kits is shown in Table 3.8. It was 
demonstrated that Qiagen kit performed significantly better than Promega kit for DNA 
yield at all DNA volumes. From the three independent test results above, we concluded 
that the Qiagen kit should be selected for future DNA extraction and 5 coupes of 5 µm 
paraffin embedded tissues is the best option for the DNA purity and DNA yield. 
 
Table 3.8: Summary of the comparison between extraction kits 
 
 
DNA 
volume 
 
DNA extraction 
kit 
Mann-Whitney U Test (sig.) Kolmogorov-Smirnov Z Test 
(sig.) 
DNA purity DNA yield DNA purity DNA yield 
 
3 coupes 
 
Promega 
Qiagen 
 
0.007** 
 
0.000** 
 
0.028* 
 
0.003** 
 
5 coupes 
 
Promega 
Qiagen 
 
0.202 
 
0.001** 
 
0.660 
 
0.009** 
 
10 coupes 
 
Promega 
Qiagen 
 
 
0.074 
 
0.001** 
 
0.660 
 
0.028* 
Note:  ** - the mean different is significant at the 0.01 level, * - the mean different is significant at the 0.05 level 
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3.3 OPTIMISATION OF POLYMERASE CHAIN REACTION 
  
3.3.1 β-globin detection by PCR for DNA quality determination 
 
PCR amplifications were carried out in triplicate for each diluted DNA from 2.1.21 
according to the procedure mentioned in 2.1.22, Materials and Methods. Figure 3.1 
shows the sample of 2% agarose gel electrophoresis of 268 bp amplicons.  
 
 
Figure 3.1: β-globin detection in 2% agarose gel 
electrophoresis. Well 1–10 = selected 268 bp amplicons, M (100 
bp DNA ladder marker). 
 
 
 
 
 
 
 
 
268 bp 
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3.3.2 PCR optimisation for L1 HPV detection 
 
3.3.2.1 First round Semi-nested/Nested PCR – MY11/MY09 primer pair (450 bp 
amplicons) 
 
DNA template concentration effect 
Multiple serial dilution of the initial known DNA template concentration (from 0.01 ng 
to 100 ng) of the positive control (HPV6 DNA) was performed in triplicate to 
investigate the DNA yield effect. It was observed that 0.01 ng of DNA was the 
minimum quantity detected in a 2% agarose gel (Figure 3.2). 
 
 
Figure 3.2: The effect of DNA template concentration in 2% 
agarose gel. Well 1 = Negative control (RNAse Free water as a 
template DNA); Well 2–4 = 0.01 ng; Well 5–7 = 0.1 ng; Well 8–
10 = 1 ng; Well 11–13 = 10 ng; Well 14-16 = 50 ng; Well 17-19 = 
100 ng. M = 100 bp DNA ladder marker. 
 
3.3.2.2 Second round Semi-nested PCR – MY11/GP6 primer pair (190 bp amplicons) 
 
MgCl2 concentration effect 
The effect of MgCl2 concentration using undiluted 450 bp amplicons was tested in 
triplicate (Figure 3.3). It was found that at 2.5 mM MgCl2 concentration (commercial 
premix) produced relatively more specific amplicons than 3.0 mM MgCl2 (minimum 
450 bp 
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concentration). This suggested that 2.5 mM MgCl2 (commercial premix) should be used, 
even though less bands intensity obtained for future optimisation steps. 
 
 
Figure 3.3: MgCl2 effect is visualised in 2% agarose gel. Well 1 = 2.5 
mM MgCl2 (commercial premix); Well 2–4 = 1.5 mM MgCl2; Well 5–7 
= 2.0 mM MgCl2; Well 8–10 = 2.5 mM MgCl2; Well 11–13 = 3.0 mM 
MgCl2; Well 14-16 = 3.5 mM MgCl2; Well 17-19 = 4.0 mM MgCl2. M 
= 100 bp DNA ladder marker. 
 
Dilution effect of the PCR products from the first round amplification (450 bp)  
Subsequently, the effect of DNA template concentration was tested at constant 2.5 mM 
MgCl2 concentration (commercial premix) in triplicate (Figure 3.4). It was found that at 
34 dilution (or 81x dilution) of the 450 bp amplicon was the minimum requirement to 
obtain more specific 190 bp amplicons in the second round of PCR amplification. But at 
35 dilution (or 243x dilution), it was noted that the reaction was completely free from 
non-specific PCR amplicons. Therefore, it was suggested that relative comparison of the 
band intensity (especially 190 bp) between samples tested to the control to determine 
the suitable dilution of the 450 bp amplicons could be made for the next round of PCR 
amplification. 
 
450 bp 
190 bp 
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Figure 3.4: The effect of DNA template concentration in 2% 
agarose gel. Well 1-3 = undiluted 450 bp amplicons; Well 4–6 = 31 
dilution; Well 7–9 = 32 dilution; Well 10–12 = 33 dilution; Well 13–
15 = 34 dilution; Well 16-18 = 35 dilution; Well 19 = 450 bp amplicon 
and M = 100 bp DNA ladder marker. 
 
 Figures 3.5 and 3.6 showed the effect of undiluted and diluted of selected 450 bp 
amplicons (14 different samples). By comparing relative band intensity amongst sample 
to control, approximate dilutions were made and producing specific 190 bp amplicon 
(Figure 3.9).  
 
 
 
 Figure 3.5: The effect of undiluted 450 bp amplicons (as the template 
for second round of semi-nested PCR) in 2% agarose gel. Well 1-14 = 
sample DNAs; Well 15 = positive control; and M = 100 bp DNA ladder 
marker. 
 
450 bp 
190 bp 
450 bp 
190 bp 
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Figure 3.6: Effect of diluted 450 bp amplicons (as the template for second round of 
semi-nested PCR) in 2% agarose gel. Well 1-14 = sample DNAs (similar sample 
sequence as Figure 8); Well 15 = positive control; and M = 100 bp DNA ladder marker. 
 
3.3.2.3 Second round Nested PCR – GP5+/GP6+ primer pair (140 bp amplicons) 
 
Dilution effect of the PCR products from the first round amplification (450 bp) 
An amplicon dilution approach was used as in section 1.6.2 for nested PCR (Figure 
3.7). 
 
Figure 3.7: 2% agarose gel electrophoresis of diluted 450 bp amplicons as the 
template for the second round of nested PCR. Well 1–6 = Undiluted 450 bp 
amplicons; Well 8-13 = Nested PCR using diluted 450 bp from 1-6; Well 7 and 14 = 
Negative control; and M = 100 bp DNA ladder marker. 
 
190 bp 
450 bp 
140 bp 
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3.3.2.4 Independent PCR reaction using GP5+/GP6+ primer pair 
 
PCR reamplification effect without additional PCR reagents 
 
Figure 3.8 shows the effect of PCR reamplification of two selected samples in triplicate. 
It was found that bands intensity relatively doubled after reamplification and would be 
suggested for future amplification. Even though, the actual period of PCR amplification 
would be twice as long fortunately the 140 bp amplicons specificity was not affected.  
  
 
 
Figure 3.8: PCR reamplification effects of 140 bp amplicons 
without removing samples from thermocycler. Well 1-3 = sample 
1; Well 4-6 = reamplified of sample 1; Well 7-9 = sample 2; Well 
10-12 = reamplified of sample 2; and M = 100 bp DNA ladder 
marker. 
 
DNA template concentration effect 
The effect of DNA template concentration was determined in triplicate (Figure 3.9). It 
was found that 140 bp amplicons could still be detected and visualised on 2% agarose 
gel electrophoresis when as little as 10-4 ng of initial DNA template were used in the 
PCR. 
 
140 bp 
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Figure 3.9: The effect of DNA template concentration in 2% 
agarose gel. Well 1 = Negative control (RNAse Free water); Well 2-
4 = 10-4 ng; Well 5-7 = 10-3 ng; Well 8-10 = 10-2 ng; Well 11-13 = 
10-1 ng; Well 14-16 = 1 ng; Well 17-19 = 10 ng; and M = 100 bp 
DNA ladder marker. 
 
3.4. HPVs ROLE IN ORAL CANCER 
 
3.4.1 Clinical Data 
 
A cohort of 60 patients were studied, 56 patients with resected squamous cell 
carcinoma, 2 patients with carcinoma in situ and one patient each with severe 
dysplasia/carcinoma in situ and high grade squamous dysplasia. The male:female ratio 
was 33:27 with the mean age of 66.2 years, ranging from 36-97 years. The average age 
for male was 65.2 and 67.4 for female. Thirty five patients (58.3%) were smokers and 
drinkers as well, fifteen patients (25%) were non-smokers but drinkers, five patients for 
each group (8.3%) were smokers but non-drinkers and non-smokers and non drinkers 
(Table 3.9).  As to the tumour sites, 29 cases were on the tongue; floor of the mouth, 10 
cases; retromolar pad, 9 cases; alveolus, 4 cases; soft palate, 3 cases; and one case each 
for tonsil, lower lip, pharynx, supraglottis and buccal mucosa. The clinicopathological 
parameters recorded in each tumour consist of the primary tumour (T), regional lymph 
node (N), distant metastases and the stage of tumour as shown in Table 3.10. 
140 bp 
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Table 3.9: Clinical details of oral cancer patients 
 
 
Parameters 
 
N 
 
% 
 
 
Total 
 
Gender 
   Female 
   Male 
 
Age groupα (range, 36-97y)  
   36-65y 
   66-97y 
 
Smoking 
   No 
   Yes 
 
Alcohol 
   No 
   Yes 
 
Smoking-Alcohol 
   No smoking-No drinking (NSND) 
   Smoking-No drinking (SND) 
   No smoking-Drinking (NSD) 
   Smoking-Drinking (SD) 
 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
 
Disease status 
   No recurrence 
   Recurrence 
 
Disease outcome 
   Alive 
   Dead 
 
 
60 
 
 
27 
33 
 
 
31 
29 
 
 
20 
40 
 
 
10 
50 
 
 
5 
5 
15 
35 
 
 
1 
10 
4 
3 
1 
1 
9 
1 
29 
1 
 
 
56 
6 
 
 
37 
23 
 
 
 
 
 
45.0 
55.0 
 
 
51.7 
48.3 
 
 
33.3 
66.7 
 
 
16.7 
83.3 
 
 
8.3 
8.3 
25.0 
58.3 
 
 
1.7 
16.7 
6.7 
5.0 
1.7 
1.7 
15.0 
1.7 
48.3 
1.7 
 
 
90.0 
10.0 
 
 
61.7 
38.3 
 
  Abbreviation: N, number of cases ;α  - Age group was based on median age 
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Table 3.10: Clinicopathologic parameters of oral cancer patients 
 
 
 
Parameters 
 
N 
 
% 
 
 
Total 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent structures 
 
Regional lymph nodes 
   Negative 
   N0 
   N1 
   N2 
 
Distant metastasis 
   Negative 
   No distant metastasis 
 
Tumour stage 
   0 
   I 
   II 
   III 
   IV 
 
 
60 
 
 
2 
24 
19 
1 
14 
 
 
4 
28 
10 
18 
 
 
4 
56 
 
 
6 
17 
4 
7 
26 
 
 
 
 
 
3.3 
40.0 
31.7 
1.7 
23.3 
 
 
6.7 
46.7 
16.7 
30.0 
 
 
6.7 
93.3 
 
 
10.0 
28.3 
6.7 
11.7 
43.3 
 
  Abbreviation: N, number of cases 
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3.4.2 DNA extraction of 60 FFPETs 
 
The DNA extraction of 60 FFPETs was carried out using Qiagen kit in duplicate. The 
quantification results of the extracted DNA are shown in Appendix 13 (the duplicate 
was treated as a backup if the actual sample failed). The quality and quantity of the 
extracted DNA in each parameter is shown in Table 3.11. Each extracted DNA was 
further diluted accordingly with sterile distilled water (dH2O) to a final concentration of 
10 ng/µl for further down-stream analyses such as PCR amplification, DNA sequencing 
and HPV genotyping. The t-Test and ANOVA (Table 3.12), Mann-Whitney and 
Kruskal-Wallis (Table 3.13) tests were performed for means comparison. The statistical 
analysis revealed that DNA purity and DNA yield were not significantly different in all 
of the parameters compared including clinicopathological characteristics except for 
DNA purity of the tumour size. T3 was excluded in the analysis due to the fact only a 
single case existed. In post-hoc tests with Tukey HSD, we found that T4 was 
significantly lower in DNA purity compared to the negative (p<0.05). 
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Table 3.11: The purity and yield of the extracted DNA based on parameters 
 
Parameters 
 
N 
Mean + SDα 
DNA purity  
(A260/A280) 
DNA yield  
(ng/µl) 
 
Total 
 
Gender  
   Female 
   Male 
 
Age groupβ  
   36-65y 
   66-97y 
 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
 
Disease outcome 
   Alive 
   Dead 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent structures 
 
Regional lymph nodes 
   Negative 
   N0 
   N1 
   N2 
 
Distant metastasis 
   Negative 
   No distant metastasis 
 
Tumour stage 
   0 
   I 
   II 
   III 
   IV 
 
 
60 
 
 
27 
33 
 
 
31 
29 
 
 
1 
10 
4 
3 
1 
1 
9 
1 
29 
1 
 
 
36 
24 
 
 
2 
24 
19 
1 
14 
 
 
4 
28 
10 
18 
 
 
4 
56 
 
 
6 
17 
4 
7 
26 
 
 
 
 
 
1.250 + 0.504 γ 
1.228 + 0.476 
 
 
1.149 + 0.336 γ 
1.334 + 0.597 
 
 
0.493 
1.323 + 0.372 γ 
0.983 + 0.442 γ 
1.817 + 0.991 
1.246 
0.677 
1.244 + 0.714 
1.056 
1.226 + 0.363 γ 
1.466 
 
 
1.174 + 0.326 
1.334 + 0.652 
 
 
2.005 + 1.352 
1.167 + 0.313 
1.389 + 0.530 
1.466 
1.029 + 0.425 γ 
 
 
1.531 + 0.957 
1.204 + 0.523 
1.234 + 0.452 
1.229 + 0.298 γ 
 
 
1.531 + 0.957 
1.217 + 0.442 
 
 
1.531 + 0.957 
1.217 + 0.372 γ 
1.050 + 0.402 γ 
1.343 + 0.382 
1.201 + 0.524 
 
 
 
 
0.442 + 0.226 γ 
0.490 + 0.235 γ 
 
 
0.470 + 0.244 γ 
0.467 + 0.218 
 
 
0.147 
0.445 + 0.237 
0.372 + 0.235 
0.238 + 0.143 γ 
0.510 
0.520 
0.552 + 0.185 γ 
0.630 
0.495 + 0.246 
0.347 
 
 
0.467 + 0.229 γ 
0.472 + 0.236 γ 
 
 
0.180 + 0.061 
0.514 + 0.232 γ 
0.472 + 0.234 γ 
0.347 
0.437 + 0.225 γ 
 
 
0.423 + 0.321 γ 
0.478 + 0.233 γ 
0.515 + 0.193 γ 
0.439 + 0.238 γ 
 
 
0.423 + 0.321 γ 
0.472 + 0.226 γ 
 
 
0.423 + 0.321 γ 
0.490 + 0.235 γ 
0.446 + 0.229 γ 
0.487 + 0.114 γ 
0.465 + 0.247 γ 
Note: N, number of patients; SD, standard deviation; α No SD value was calculated for single case; β Age grouping 
was based on overall median age;  γ Normal distribution data is assumed 
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Table 3.12: t-Test and ANOVA for means comparison 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Gender 
Age group 
Anatomic sitesγ 
Disease outcome 
Tumour sizeγ 
Regional lymph nodes 
Distant metastasis 
Tumour stage 
 
 
0.765 
0.068 
0.089 
0.034 
0.014 
0.067 
0.019 
0.227 
 
t-Test 
t-Test 
ANOVA 
t-Test 
ANOVA 
ANOVA 
t-Test 
ANOVA 
 
0.862 
0.140 
0.241 
0.212 
0.016* 
0.668 
0.214 
0.659 
 
0.858 
0.218 
0.373 
0.756 
0.487 
0.424 
0.386 
0.227 
 
t-Test 
t-Test 
ANOVA 
t-Test 
ANOVA 
ANOVA 
t-Test 
ANOVA 
 
0.424 
0.966 
0.273 
0.937 
0.234 
0.831 
0.681 
0.984 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
γ - Cases less than two were excluded from analysis of variance (ANOVA) 
* Statistically significant at the 0.05 level 
 
 
Table 3.13: Mann-Whitney and Kruskal Wallis for means comparison 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Gender 
Age group 
Anatomic sitesβ 
Disease outcome 
Tumour sizeβ 
Regional lymph nodes 
Distant metastasis 
Tumour stage 
 
 
Mann-Whitney 
Mann-Whitney 
Kruskal-Wallis 
Mann-Whitney  
Kruskal-Wallis 
Kruskal-Wallis 
Mann-Whitney  
Kruskal-Wallis 
 
0.923 
0.258 
0.318 
0.312 
0.065 
0.675 
0.989 
0.798 
 
Mann-Whitney  
Mann-Whitney  
Kruskal-Wallis 
Mann-Whitney  
Kruskal-Wallis 
Kruskal-Wallis 
Mann-Whitney  
Kruskal-Wallis 
 
0.494 
0.871 
0.136 
0.833 
0.237 
0.877 
0.577 
0.981 
Notes:  
 α - Test for Equality of Means 
β - Cases less than two were excluded from Kruskal-Wallis Test 
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3.4.3 DNA quality determination by PCR for β-globin detection 
 
The first attempt successfully amplified this fragment in 52 out of 60 samples and 
human salivary gland DNA (positive control). Eight samples and 3T3 embryonic mouse 
fibroblasts (positive control), which were negative for β-globin were repeated for PCR 
and DNA extraction if required, as illustrated in Figure 2.5. Finally, all 60 samples were 
positive for β-globin gene and the template DNA were suitable to proceed to the next 
stage, which was PCR optimisation for L1 gene detection of HPV (Appendix 3.14). 
Unfortunately, 3T3 embryonic mouse fibroblasts failed to amplify the 268 bp fragment 
after several attempts and were removed as an alternative positive control. The human 
salivary gland DNA has remained a positive control for future down-stream analysis. 
 
3.4.4 Summary of the PCR amplification of L1 HPV gene detections 
 
The overall results for each sample (positive and negative separately) for L1 HPV gene 
detection was given in Appendix 3.14. The summary of the positive PCR amplification 
for L1 HPV gene is shown in Table 3.14. 
  
Table 3.14: PCR positivity for L1 HPV gene detection by PCR types 
Type of PCR amplification Expected amplicon sizes (% positivity) 
 450 bp 190 bp 140 bp 
Independent PCR 14a (23.3)   6 (10.0)  19 (31.7) 
Semi-nested PCR  14 (23.3)  
Nested PCR    14 (23.3) 
Total sample positive for L1 HPV 14 (23.3) 20 (33.3) 33 (55.0) 
Total sample tested 60 60 60 
 
Note:   
a  - First round PCR amplicons (450 bp) as the template for either semi-nested 
or nested PCR amplifications 
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3.4.5 Purification of the PCR products 
 
All 67 amplicons positive for L1 HPV gene were purified either directly using 
QIAquick PCR purification kit or QIAquick gel extraction kit (Appendix 15) following 
the criteria described in Materials and Methods. Each quantified amplicon was further 
diluted with sterile dH2O to the final concentration of 10 ng/µl (20 µl) prior to 
automated DNA sequencing. Means comparisons with regard to DNA purity and DNA 
yield of the purified PCR products are shown in Table 3.15. Statistical analyses for 
means comparison (Table 3.16 and 3.17), we concluded that DNA purity and DNA 
yield were comparable amongst the three different amplicon size. In addition, for 
QIAquick PCR Purification kit and QIAquick Gel Extraction kit comparison, the former 
was statistically better for DNA yield but the latter was better for DNA purity.      
 
Table 3.15: Means comparison of the purified amplicons and kit used 
 
Parameters 
 
N 
Mean + SD 
DNA purity  
(A260/A280) 
DNA yield  
(ng/µl) 
 
Amplicon size (N = 67) 
   140 bp 
   190 bp 
   450 bp 
 
PCR Purification Kit (N = 67)  
   QIAquick PCR Purification 
   QIAquick Gel Extraction 
 
 
 
33 
20 
14 
 
 
35 
32 
 
 
 
1.305 + 0.271 
1.246 + 0.349 
1.147 + 0.382α 
 
 
1.215 + 0.318α 
1.297 + 0.324 
 
 
79.39 + 44.58α 
98.85 + 49.55α 
57.14 + 30.55 
 
 
103.29 + 37.57α 
55.69 + 40.45 
 
 Note: N, number of amplicons; SD, standard deviation; α Normal distribution data is assumed 
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(A) 
 
 
(B) 
 
Figure 3.10: DNA purity (A) and DNA yield (B) comparisons among PCR products  
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(A) 
 
 
 
 
(B) 
 
 
 
 
Figure 3.11: DNA purity (A) and DNA yield (B) comparisons between purification 
kits 
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Table 3.16: t-Test and ANOVA 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Amplicon size 
DNA Purification Kits 
 
 
0.392 
0.901 
 
ANOVA 
t-Test 
 
 
0.306 
0.302 
 
0.060 
0.540 
 
ANOVA  
t-Test 
 
0.028* 
0.000** 
 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
** Statistically significant at the 0.01 level and * at the 0.05 level;  
DNA yield of 190bp > 450 bp (p<0.05) and  
QIAquick PCR Purification > QIAquick Gel Extraction (p<0.001) 
 
 
Table 3.17: Mann-Whitney and Kruskal-Wallis Test 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Amplicon size 
DNA Purification Kits 
 
 
Kruskal-Wallis 
Mann-Whitney 
 
 
0.149 
0.533 
 
 
Kruskal-Wallis 
Mann-Whitney  
 
0.034* 
0.000** 
 
Notes:  
α - Test for Equality of Means 
Cases less than two were excluded from Kruskal-Wallis Test 
** Statistically significant at the 0.01 level and * at the 0.05 level; 
DNA yield of 190bp > 450 bp (p<0.05) and QIAquick PCR kits > QIAquick Gel kits (p<0.001) 
 
3.4.6 DNA sequencing of the PCR products 
 
The diluted DNA of each amplicon was sequenced using both forward and reverse 
primers in separate sequencing reactions. The sample DNA sequencing results (MY11, 
forward primer and MY09, reverse primer) were visualised using Chromas Lite is 
shown in Figure 3.12. Both arrows show part of the overlapping DNA sequence and 
should be read according to their direction and in complement sequence such as (220 to 
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210; 3’- ACTGTCCATTA – 5’) from MY11 and its complementary sequence (67 to 76; 
5’ – TGACAGGTAA – 3’) from MY09. The complementary sequence of the MY09 
primer could be located at the end of MY11 primer DNA sequencing result and vice 
versa as shown in the schematic representation below (Figure 3.13). The DNA contig 
(the overlapping and non-overlapping DNA sequence including both primer sequences 
at the terminal of the sequence) will be formed according to expected amplicon size 
(bp). The raw data for the automated DNA sequencing of the purified amplicons are 
given in Appendix 16.  The actual size of 56 out of 67 samples (83.6%) were 
successfully generated contigs for the actual size of the amplicons. Only the partial 
DNA sequences obtained in eleven amplicons (16.6%) due to only forward primer 
sequencing reactions were successful, therefore DNA contigs couldn’t be formed. 
Nevertheless, it did not affect further DNA sequences alignment  
 
 
Figure 3.12: Selected automated DNA sequencing results 
 
 
 
 
 
 
Figure 3.13: Schematic representation of DNA contig formation 
 
 
Overlapping DNA sequence Non-overlapping DNA 
 
Non-overlapping DNA 
 
DNA contig (eg. 450 bases) 
MY11 primer MY09 primer 
MY09 sequence MY11 sequence 
5’ 
5’ 3’ 
3’ 
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3.4.7 DNA sequences alignment 
 
The DNA contig obtained from each sample was individually compared with the 
sequences in the databases using Blastn (nr, non-redundant). The sample of DNA 
multiple sequence alignment carried out using known HPV6, 16, and 18 (Appendix 17). 
The results of all DNA sequences for the identification L1 alpha HPV via DNA 
sequences alignment are given in Appendix 18. The summary of the alpha HPV types 
detected is shown in Table 3.18 and Figure 3.14 in which 53.3% LR α-HPV (all HPV6) 
and 3.3% HR α-HPV were detected. 
 
Table 3.18: The summary of alpha HPV types detected via PCR and 
sequencing 
 
 
Type of infection 
 
HPV type 
HPV type 
N (%) 
α-HPV group 
N (%) 
 
Single infection: 
 
Low risk α-HPV 
 
 
 
HPV6 
 
 
 
32 (53.3) 
 
 
 
32 (53.3) 
 
High risk α-HPV 
 
HPV16 
HPV35 
 
1 (1.7) 
1 (1.7) 
 
 
2 (3.3) 
  
Total sample 
 
60 
 
60 
 
     N – number of sample 
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Figure 3.14: LR α-HPV and HR α-HPV detected via PCR and DNA 
sequencing 
 
3.5 α-HPV GENOTYPING 
 
The combination of SPF-DEIA (results shown in Appendix 19) and SPF10-LiPA25 
(version 1) (results shown in Appendix 20) approaches for α-HPV genotyping was 
formally known as SPF10-LiPA25 (version 1). The interpretation sheet for α-HPV 
genotyping is given in Appendix 21. The cut-off point (borderline) for HPV positivity 
utilising SPF-DEIA was 0.531. It was found that 16 samples (26.7%) were positive for 
HPV as the first screening and eligible for the next SPF10-LiPA25 (version 1) for the 
HPV genotyping. The results of SPF10-LiPA25 (version 1), HPV genotyping for all 60 
samples are summarised in Appendix 22. The summary of 16 α-HPV types (26.7%) 
positively detected is shown in Table 3.19. The single infection found for HPV types: 
10.0% LR α-HPV (all HPV6) and 11.7% HR α-HPV were detected. One sample, #51 
(1.7%) exhibited double infection of LR α-HPV and HR α-HPV types. 
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Table 3.19: The summary of alpha HPV types detected by via SPF10-LiPA25 
(version 1) 
 
 
 
Mode of HPV 
infection 
 
HPV type 
HPV type 
N (%) 
α-HPV group 
N (%) 
    
N/I N/I 2 (3.3) 2 (3.3) 
 
Single infection: 
 
Low risk α-HPV 
 
 
 
HPV6 
 
 
 
6 (10.0) 
 
 
 
6 (10.0) 
 
High risk α-HPV 
 
 
Double infection: 
 
    LR/HR α-HPV 
 
HPV16 
HPV18 
HPV35 
 
 
HPV6/HPV16 
 
 
 
5 (8.3) 
1 (1.7) 
1 (1.7) 
 
 
1 (1.7) 
 
7 (11.7) 
 
 
 
 
1 (1.7) 
  
Total sample 
 
60 
 
60 
 
      N – number of sample; N/I – not identified 
 
 
Figure 3.15:  LR α-HPV and HR α-HPV detected via SPF10-LiPA25 (version 1) 
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possibility that more than one HPV types were present in the same sample, therefore we 
combined the results from both methods. The summary of the alpha HPV types detected 
is shown in Table 3.20. The single infection found for HPV types: 41.7% LR α-HPV 
(all HPV6) and 3.3% HR α-HPV were detected (Figure 3.16). Double infection was 
found in 15% of the samples including two unknown HPV types (N/I).  
 
Table 3.20: Alpha HPV types detected via the combination results of two methods  
 
Mode of HPV 
infection 
 
HPV type 
HPV type 
N (%) 
α-HPV group 
N (%) 
 
Single infection: 
 
Low risk α-HPV 
 
 
 
HPV6 
 
 
 
25 ( 41.7) 
 
 
 
25 (41.7) 
 
High risk α-HPV 
 
 
Double infection: 
 
    LR/HR α-HPV 
 
HPV16 
HPV35 
 
 
 
HPV6/HPV16 
HPV6/HPV18 
HPV6/ N/I 
 
 
1 (1.7) 
1 (1.7) 
 
 
 
6 (10.0) 
1 (1.7) 
2 (3.3) 
 
2 (3.3) 
 
 
 
 
9 (15.0) 
 
  
Total sample 
 
60 
 
60 
 
      N – number of sample; N/I – α-HPV untypable 
 
Figure 3.16: LR α-HPV and HR α-HPV detected via both methods 
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3.6 β-HPV GENOTYPING 
 
The raw data of β-HPV genotyping for all 60 samples by using PM-PCR approaches are 
given in Appendix 24 and are summarised in Appendix 26. The interpretation sheet for 
β-HPV genotyping is given in Appendix 25. The summary of the alpha HPV types 
detected is shown in Table 3.21 and Figure 3.17. The single infection found for HPV 
types: 41.7% LR α-HPV (all HPV6) and 3.3% HR α-HPV were detected.  
 
Table 3.21: Beta HPV types detected via PM-PCR and RHA methods  
Mode  of HPV 
infection 
 
HPV type 
HPV type 
N (%) 
β-HPV status 
N (%) 
 
Single infection: 
 
 
 
HPV15 
 
 
1( 1.7) 
 
 
8 (13.3) 
 
 
     
 
 
 
 
 
 
Total (positive) 
 
HPV23 
HPV36 
HPV38 
HPV76 
HPV80 
HPV93 
 
N/I 
 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
2 (3.3) 
 
3 (5.0) 
 
 
 
 
 
 
 
3 (5.0) 
 
11 (18.3) 
  
Total sample 
 
60 
 
60 
 
       N – number of sample; N/I – β-HPV untypable 
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Figure 3.17: The status of β-HPV types detected 
 
3.7 OVERALL HPV DETECTION 
 
Similarly, (as previously described in 3.1.12) we did not exclude the possibility that 
more than one HPV types were present in the same sample, therefore we combined the 
results from α-HPV and β-HPV genotyping methods to obtain the full spectrum of 
infections which possibly existed within all the samples tested (Appendix 27). In total 
40 out of 60 cases (66.7%) were positive for HPV in this cohort regardless of the type 
of HPV and the mode of infection (Figure 3.18 and Table 3.22). Figure 3.19 showing 
the percentage of HPV types distribution in which 11/56 (19.6%) each for HR α-HPV 
and β-HPV and 34/56 (60.7%) for LR α-HPV were detected in all samples by 
considering the mode of HPV infections. The three types of postulated HPV infection 
are illustrated in Figure 3.20, of which 27/40 (67.5%), 10/40 (25.0%) and 3/40 (7.5%), 
single, double and multiple infections, respectively. The breakdown (percentage) of 
each HPV type into HPV infection category is shown in Figure 3.21. 
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Figure 3.18: The total of HPV positively detected in this pilot study 
 
  
 
 
Figure 3.19: The distribution of HPV types detected  
(Note: Multiple HPV types could exist in the same sample)  
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Table 3.22: Overall HPV types detected by using the results of all methods  
Mode of HPV 
infection 
HPV type HPV type 
N (%) 
HPV group 
N (%) 
    
Single infection:    
 
Low risk α-HPV 
 
HPV6 
 
21 (35.0) 
 
21 (35.0) 
High risk α-HPV HPV16 
HPV35 
1 (1.7) 
1 (1.7) 
2 (3.3) 
β-HPV HPV15 
HPV76 
1 (1.7) 
1 (1.7) 
2 (3.3) 
β-HPV untypable  2 (3.3) 
 
2 (3.3) 
 
Total: 27 (45.0) 
 
Double infection: 
 
   
LR/HR α-HPV HPV6/HPV16 
HPV6/HPV18 
5 (8.3) 
1 (3.3) 
6 (10.0) 
LR α-HPV/β-HPV HPV6/HPV36 
HPV6/HPV38 
HPV6/HPV80 
HPV6/HPV93 
1 (3.3) 
1 (3.3) 
1 (3.3) 
1 (3.3) 
 
4 (6.7 ) 
 
 
 
Total: 10 (16.7) 
 
Multiple 
infection: 
 
   
α-HPV/β-HPV HPV6/HPV16/β-HPV untypable 
HPV6/α-HPV untypable/HPV23 
HPV6/α-HPV untypable/HPV93 
1 (3.3) 
1 (3.3) 
1 (3.3) 
 
3 ( 5.0) 
 
 
Total: 3 (5.0) 
    
 Total (positive) 40  
 Percentage 66.7  
 Total sample 60  
    
 N – number of sample; The percentage was calculated based on the total number of samples, 60 
 
Figure 3.20: The postulated mode of HPV infection 
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Figure 3.21: The distribution of HPV types detected 
 
3.7.1 HPV prevalence and clinicopathological parameters 
 
Most statistics books do not provide advice about how to decide whether a variable is at 
least approximately normal. SPSS recommends that we divide the skewness by its 
standard error. If the result is less than 2.5 (which is approximately the p=0.01 level) 
then skewness is not significantly different from normal. The set back of this method is 
that the standard error relies on the sample size and greatly influenced with large 
samples in which most variables would be found to be non normal (Coakes and Steed, 
2001).  
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 Instead of checking the skewness value, we could also compare the mean, median 
and mode values which can be obtained with the Frequencies command. If these values 
are approximately equal, then we can assume that the distribution is approximately 
normal. A simpler guideline is that if the skewness is less than plus or minus one (< +/- 
1.0) the variable is at least approximately normal (Hair et al., 1998; Morgan et al., 
2004). Table 3.23 shows the determination of normally distributed data and the 
recommended statistical analyses for means comparison between/among 
categories/groups in each individual parameter.  
 
Table 3.23: Normally distributed data assumption among parameters 
Parameter N Sn S.E. (-1/+1) Sn/S.E. (<2.5) 
Recommended statistics 
for means comparison 
 
Total number of samples 
in each parameter, N = 60 
       
Gender 2 -0.206 0.309 ND -0.7 t-Test 
Age group 2 0.068 0.309 ND 0.2 t-Test 
Disease outcome 2 0.419 0.309 ND 1.4 t-Test 
Anatomic site 10 1.504 0.309   4.9 Kruskal-Wallis 
Tumour size 4 0.649 0.309 ND 2.1 ANOVA 
Regional Lymph Nodes 3 0.197 0.309 ND 0.6 ANOVA 
Distant Metastasis 2 -3.564 0.309   -11.5 Mann-Whitney 
Tumour stage 4 -0.361 0.314 ND -1.1 ANOVA 
Recurrence 2 2.736 0.309  8.9 Kruskal-Wallis 
Smoking 2 -0.842 0.314 ND -2.7 t-Test 
Alcohol 2 -2.156 0.314   -6.9 Mann-Whitney 
Smoking-Alcohol 4 -1.442 0.314   -4.6 Kruskal-Wallis 
Overall HPV positivity 2 -0.492 0.309 ND -1.6 t-Test 
α-HPV positivity 2 -0.137 0.309 ND -0.4 t-Test 
High risk HPV 2 2.679 0.309   8.7 Mann-Whitney 
Low risk HPV 2 -0.137 0.309 ND -0.4 t-Test 
β-HPV positivity 2 1.679 0.309   5.4 Mann-Whitney 
β-HPV types >2 3.101 0.309   10.0 Kruskal-Wallis 
p16 IHC 2 -1.411 0.309   -4.6 Mann-Whitney 
       
Note: n - number of categories/groups; ND – normally distributed data is assumed; Sn – Skewness, S.E. – 
Skewness Standard Error 
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3.7.2 Correlation among demographic and clinical parameters associated with 
HPVs 
 
Risk factors and demographic characteristics included gender, age group, alcohol and 
smoking exposure, tumour site, tumour stage, nodal involvement and disease 
recurrence. Unadjusted associations between categorical variables were tested with 
either the Pearson chi-square test of Fisher’s exact test for small sample sizes. We also 
tested for possible interactions among risk factors. Tests for interactions were generated 
using both logistic regression and proportional hazard regression methods. Multivariate 
unconditional logistic regression was used to examine the association between 
dichotomous dependent variables and risk factors for oral cancer (gender, age group, 
alcohol and smoking). Odds ratio (OR) and 95% confidence interval (CI) were 
calculated to measure the magnitude of the associations. 
 
Table 3.24: Demographic and risk factors of oral cancer by HPV status 
 
Characteristics N HPV-, N=20 (%) HPV+, N=40 (%) OR (95% CI) p value 
Gender 
   Femaleα  
   Male 
    
 
33 
27 
 
9 (45.0) 
11 (55.0) 
 
18 (45.0) 
22 (55.0) 
 
1.0 
2.0 (0.9 – 4.5) 
 
 
0.090 
 
Age group (range, 36-97y) 
   36-65yα 
   66-97y 
    
 
31 
29 
 
12 (60.0) 
8 (40.0) 
 
19 (47.5) 
21 (52.5) 
 
1.0 
1.6 (0.8 – 3.3) 
 
0.213 
Smoking  
   Noα 
   Yes 
    
 
20 
40 
 
4 (20.0) 
16 (80.0) 
 
16 (40.0) 
24 (60.0) 
 
1.0 
4.0 (1.3 – 12.0) 
 
 
0.013* 
Alcohol  
   Noα 
   Yes 
    
 
10 
50 
 
2 (10.0) 
18 (90.0) 
 
8 (20.0) 
32 (80.0) 
 
1.0 
4.0 (0.8 – 19.0) 
 
0.080 
Smoking-Alcohol 
   NSNDα 
   NSD 
   SND 
   SD  
 
5 
5 
15 
35 
 
1 (5.0) 
1 (5.0) 
3 (15.0) 
15 (75.0) 
 
4 (10.0) 
4 (10.0) 
12 (30.0) 
20 (50.0) 
 
1.0 
4.0 (0.4 – 36.0) 
4.0 (0.4 – 36.0) 
4.0 (1.1 – 14.0) 
0.053 
      
N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level; α  - reference for odds ratio determination 
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Table 3.25: Clinicopathologic characteristics of oral cancer by HPV status 
 
 
Characteristics 
 
 
N 
 
HPV-, N=20 (%) 
 
HPV+, N=40 (%) 
 
OR (95% CI) 
 
p value 
      
Anatomic site 
   Buccal mucosaα 
   Floor of the mouth 
   Alveolus 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
    
 
1 
10 
4 
3 
1 
1 
9 
1 
29 
1 
 
0 (0) 
6 (30.0) 
1 (5.0) 
0 (0) 
0(0) 
0 (0) 
1 (5.0) 
0(0) 
12 (60.0) 
0(0) 
 
1 (2.5) 
4 (10.0) 
3 (7.5) 
3 (7.5) 
1 (2.5) 
1 (2.5) 
8 (20.0) 
1 (2.5) 
17 (42.5) 
1(2.5) 
 
1.0 
- 
0.7 (0.2 – 2.4) 
3.0 (0.3 – 28.8) 
- 
- 
- 
8.0 (1.0 – 64.0) 
- 
1.4 (0.7 – 3.0) 
 
0.740 
 
 
 
 
 
 
 
 
 
Tumour size 
   Negativeα 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) 
    
 
2 
24 
19 
1 
14 
 
0 (0) 
11 (55.0) 
7 (35.0) 
0 (0) 
2 (10.0) 
 
2 (5.0) 
13 (32.5) 
12 (30.0) 
1 (2.5) 
12 (30.0) 
 
1.0 
- 
1.2 (0.5 – 2.6) 
1.7 (0.7 – 4.3) 
- 
 
 
0.835 
Regional lymph nodes  
   Negativeα 
   N0 
   N1 
   N2 
    
 
4 
28 
10 
18 
 
1 (5.0) 
10 (50.0) 
5 (25.0) 
4 (20.0 
 
3 (7.5) 
18 (45.0) 
5 (12.5) 
14 (35.0) 
 
1.0 
3.0 (0.3 – 29.0) 
1.8 (0.8 – 3.9)) 
1.0 (0.3 – 3.5) 
 
 
0.373 
Distant metastasis 
   Negativeα 
   No distant metastasis 
    
 
4 
56 
 
1 (5.0) 
19 (95.0) 
 
3 (7.5) 
37 (92.5) 
 
1.0 
3.0 (0.3 – 28.8) 
 
0.341 
Tumour stage  
   0α 
   I 
   II 
   III 
   IV 
    
 
6 
17 
4 
7 
26 
 
2 (10.0) 
9 (45.0) 
0 (0) 
3 (15.0) 
6 (30.0) 
 
4 (10.0) 
8 (20.0) 
4 (10.0) 
4 (10.0) 
20 (50.0) 
 
1.0 
2.0 (0.4 – 11.0) 
0.9 (0.3 – 2.3) 
- 
1.3 (0.3 – 6.0) 
 
 
0.933 
Disease outcome 
   Alive 
   Deadα 
    
 
24 
36 
 
6 (30.0) 
14 (70.0) 
 
18 (45.0) 
22 (55.0) 
 
3.0 (1.2 – 7.6) 
1.0 
 
0.020* 
Disease status 
   No recurrenceα 
   Recurrence    
 
54 
6 
 
19 (95.0) 
1 (5.0) 
 
35 (87.5) 
5 (12.5) 
 
1.0 
1.8 (1.0 – 3.2) 
 
0.032* 
      
N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level;  α - reference for odds ratio determination 
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Table 3.26: The distribution of HPV types within demographic characteristics 
 
 
 HR α-HPV types (%)  LR α-HPV (%)  β-HPV types (%)  HPV16 HPV18 HPV35 Untypable  HPV6  HPV15 HPV23 HPV36 HPV38 HPV76 HPV80 HPV93 Untypable  
                 
Gender:                 
   Female 4 (57.1) - - 1 (50.0)  17 (50.0)  1 (100.0) - 1 (100.0) 1 (100.0) - 1 (100.0) 2 (100.0) 1 (33.3)  
   Male 3 (42.9) 1 (100.0) 1 (100.0) 1 (50.0)  17 (50.0)  - 1 (100.0) - - 1 (100.0) - -  2 (66.7)  
                 
Age group:                 
   36 – 65y 3 (42.9) 1(100.0) 1 (100.0) 1 (50.0)  16 (47.1)  - 1 (100.0) - 1 (100.0) - - -  1 (33.3)  
   66 – 97y 4 (57.1) - - 1 (50.0)  18 (52.9)  1 (100.0) - 1 (100.0) - 1 (100.0) 1 (100.0) 2 (100.0) 2 (66.7)  
                 
Smoking:                 
   No 3 (42.9) - 1 (100.0) -  15 (44.1)  - - 1 (100.0) 1 (100.0) - - - 1(33.3)  
   Yes 4 (57.1) 1 (100.0) - 2 (100.0)  19 (55.9)  1 (100.0) 1 (100.0) - - 1 (100.0) 1 (100.0) 2 (100.0) 2 (66.7)  
                 
Alcohol:                 
   No 1 (14.3) 1 (100.0) - -  7 (20.6)  - - 1 (100.0) - 1 (100.0) 1 (100.0) - 1 (33.3)  
   Yes 6 (85.7) - 1 (100.0) 2 (100.0)  27 (79.4)  1 (100.0) 1 (100.0) - 1 (100.0) - - 2 (100.0) 2 (66.7)  
                 
Smoking-Alcohol:                 
   NSND 1 (14.3) - - -  4 (11.8)  - - 1 (100.0) - - - - 1 (33.3)  
   NSD 2 (28.6) - 1 (100.0) -  11 (32.4)  - - - 1 (100.0) - - - -  
   SND - 1 (100.0) - -  3 (8.8)  - - - - 1 (100.0) 1 (100.0) - -  
   SD 4 (57.1) - - 2 (100.0)  16 (47.1)  1 (100.0) 1 (100.0) - - - - 2 (100.0) 2 (66.7)  
                 
Disease status:                 
   No recurrence 5 (71.4) 1 (100.0) 1 (100.0) 2 (100.0)  29 (85.3)  1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 2 (100.0) 3 (100.0)  
   Recurrence 2 (28.6) - - -  5 (14.7)  - - - - - - - -  
                 
Disease outcome:                 
   Alive 5 (71.4) 1 (100.0) 1 (100.0) 1 (50.0)  21 (61.8)  - - - - - - 2 (100.0) -  
   Dead 2 (28.6) - - 1 (50.0)  13 (38.2)  1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) - 3 (100.0)  
                 
Subtotal 7 (63.6) 1 (9.1) 1 (9.1) 2 (18.2)  34 (100.0)  1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 2 (18.2) 3 (27.3)   
TOTALα (N = 56) 11 (19.6)  34 (60.7)  11 (19.6)  
 
Note: 
  α - Total number of HPV types by considering the mode of HPV infections 
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Table 3.27: The distribution of HPV types within clinicopathological parameters 
 
 HR α-HPV types (%)  LR α-HPV (%)   β-HPV types (%)  HPV16 HPV18 HPV35 Untypable  HPV6  HPV15 HPV23 HPV36 HPV38 HPV76 HPV80 HPV93 Untypable  
                 
Anatomic sites:                 
   Buccal mucosa - - - -  1 (2.9)  - - - - - - - -  
   Floor of the mouth - - - 1 (50.0)  4 (11.8)  - - - - - - 2 (100.0)  -  
   Alveolus 1 (14.3) - - -  3 (8.8)  - - 1 (100.0) - - - - -  
   Soft palate 1 (14.3) - - -  2 (2.9)  - - - - 1 (100.0) - - -  
   Pharynx - - - -  1 (2.9)  - - - - - - - -  
   Lower lip - - - -  1 (2.9)  - - - - - - - -  
   Retromolar pad 2 (28.6) - - -  7 (20.6)  1 (100.0) - - - - - - 1 (33.3)  
   Supraglottis - - - -  1 (2.9)  - - - - - - - -  
   Tongue 3 (42.9) 1 (50.0) 1 (100.0) 1 (50.0)  15 (44.1)  - 1 (100.0) - 1 (100.0) - 1 (100.0) - 1 (33.3)  
   Tonsil - - - -  -  - - - - - - - 1 (33.3)  
                 
Tumour size:                 
   Negative - - - -  1 (2.9)  - - - - 1 (100.0) - - -  
   T1 4 (57.1) 1 (100.0) - 1 (50.0)  13 (38.2)  - - - 1 (100.0) - - 2 (100.0)  -  
   T2 2 (28.6) - 1 (100.0) -  8 (23.5)  1 (100.0) - - - - - - 2 (66.7)  
   T3 - - - -  -  - - - - - - - 1 (33.3)  
   T4 1 (14.3) - - 1 (50.0)  12 (35.3)  - 1 (100.0) 1 (100.0) - - 1 (100.0) - -  
                 
Regional lymph nodes:                 
   Negative - 1 (100.0) - -  2 (5.9)  - - - - 1 (100.0) - - -  
   N0 5 (71.4) - 1 (100.0) -  15 (44.1)  1 (100.0) - 1 (100.0) - - - -  1 (33.3)  
   N1 - - - 2 (100.0)  4 (11.8)  - 1 (100.0) - - - - 2 (100.0) 1 (33.3)  
   N2 2 (28.6) - - -  13 (38.2)  - - - 1 (100.0) - 1 (100.0) - 1 (33.3)  
                 
Distant metastasis:                 
   Negative - 1 (100.0) - -  2 (5.9)  - - - - 1 (100.0) - - -  
   No distant metastasis 7 (100.0) - 1 (100.0) 2 (100.0)  32 (94.1)  1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) - 1 (100.0) 2 (100.0) 3 (100.0)  
                 
Tumour stage:                 
   0 - 1 (100.0) - -  3 (8.8)  - - - - 1 (100.0) - - -  
   I 2 (28.6) - - -  8 (23.5)  - - - - - - - -  
   II 2 (28.6) - - -  3 (8.8)  - - - - - - - 1 (33.3)  
   III - - - 1 (50.0)  4 (11.8)  - - - - - - 2 (100.0) -  
   IV 3 (42.8) - 1 (100.0) 1 (50.0)  16 (47.1)  1 (100.0) 1 (100.0) 1 (100.0) 1 (100.0) - 1 (100.0) - 2 (66.7)  
                 
Subtotal 7 (63.6) 1 (9.1) 1 (9.1) 2 (18.2)  34 (100.0)  1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 1 (9.1) 2 (18.2) 3 (27.3)   
TOTAL (N = 56) 11 (19.6)  34 (60.7)  11 (19.6)  
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Table 3.28: The correlations between demographic/clinical parameters and HPV 
status 
 
  
 
Parameter 1 
 
Parameter 2 
Pearson Correlation  Spearman’s rho 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Correlation 
coefficient 
Sig.  
(2-tailed) 
 
Within HPV: 
      
 
HPV status 
 
α-HPV status 
 
0.809** 
 
0.000 
  
0.809** 
 
0.000 
 HR-HPV status 
LR-HPV status 
HPV16 status 
β-HPV status 
 
0.335** 
0.809** 
0.257* 
0.335** 
0.009 
0.000 
0.047 
0.009 
 0.335** 
0.809** 
0.257* 
0.335** 
0.009 
0.000 
0.047 
0.009 
 
α-HPV status HR-HPV status 
LR-HPV status 
HPV16 status 
 
0.414** 
0.864** 
0.318* 
 
0.001 
0.000 
0.013 
 0.414** 
0.846** 
0.318* 
 
0.001 
0.000 
0.013 
 
HR-HPV status HPV16 status 0.767** 0.000  0.767** 0.000 
       
 
Between HPV and demographic/clinical parameters:  
 
α-HPV status 
 
Smoking-Alcohol 
 
-0.262* 
 
0.043 
  
0.262* 
 
0.043 
 Smoking -0.333** 0.009  -0.333** 0.009 
       
β-HPV status Disease outcome  
(Dead-Alive) 
-0.404** 0.001  -0.404** 0.001 
       
LR-HPV status Smoking -0.262* 0.043  -0.262* 0.043 
       
Recurrence No association found - -  - - 
       
 
Within demographic and clinical parameters: 
 
Disease outcome 
 
Tumour size 
 
-0.268* 
 
0.038 
  
-0.344** 
 
0.007 
 (Dead-Alive) Tumour stage 
Smoking-Alcohol 
Alcohol 
-0.270* 
0.361** 
0.365** 
0.037 
0.005 
0.004 
 -0.254 
0.288* 
0.365** 
0.051 
0.026 
0.004 
 
Tumour size 
 
Tumour stage 
 
0.666** 
 
0.000 
  
0.676** 
 
0.000 
 Regional lymph 
nodes 
Distant metastasis 
 
0.286* 
0.333** 
0.027 
0.009 
 0.352** 
0.368** 
0.006 
0.004 
Tumour stage Regional lymph 
nodes 
Distant metastasis 
 
0.488** 
0.442** 
0.000 
0.000 
 0.479** 
0.441** 
0.000 
0.000 
Regional lymph 
nodes 
Distant metastasis 0.468** 0.000  0.464** 0.000 
 Anatomic site 
 
0.347** 0.007  0.376** 0.003 
Smoking-Alcohol Alcohol 0.870** 0.000  0.729** 0.000 
 Smoking 
 
0.625** 0.000  0.749** 0.000 
Smoking Age group 0.259* 0.045  0.259* 0.045 
       
Recurrence No association found - -  - - 
       
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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3.7.3 Preliminary conclusions  
 
The demographic, risk factor and clinicopathological characteristics of oral cancer by 
HPV status are given in Table 3.24 and Table 3.25. It was found that HPV status was 
significantly associated with an increase in relative risk compared to the reference 
group, smokers [OR=4.0(1.3–12.0), p<0.05], survived patient [OR=3.0(1.2–7.6), 
p<0.05] and patients with disease recurrence [OR=1.8(1.0–3.2), p<0.05]. 
 
 Table 3.26 and Table 3.27 illustrate the distribution of HPV types across 
demographic and clinical characteristics. Generally, it was observed that the distribution 
of HR-HPV types and LR-HPV types was nearly comparable across gender and age 
group. Both HPV risk groups followed a similar pattern in smokers and drinkers. It was 
found that both groups were identified in smokers compared to non-smokers. Even 
significantly higher number of both HPV risk groups detected among drinkers 
compared to non-drinkers. Similarly, SD and NSD were the two groups which 
demonstrated significantly higher HPV types observed and this was consistent in both 
HPV risk groups This pattern was also true in the number of patients with no disease 
recurrence for both groups. More female and older patients were identified positive for 
β-HPV types. A similar pattern of β-HPV types distribution was observed as was 
previously described for α-HPV groups (HR-HPV and LR-HPV) in smokers, drinkers, 
SD and no disease recurrence groups. More living patients were positive for both α-
HPV groups but this was not the case for β-HPV types. 
 
 Generally, a very heterogeneous distribution of all HPV types was observed and 
again predominantly with HPV6 in most tumour sizes but typically demonstrated that 
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the frequency of HPV16 detected decreases as the tumour size increases. Anatomically, 
none of HR-HPV and β-HPV types were detected in buccal mucosa, pharynx, lower lip 
and supraglottis. None of the HPV types were identified in tonsil except in one case 
with untypable β-HPV. Tongue was the site where most of the different HPV types 
were detected and predominantly HPV6, 15/34 (44.1%). As it was absent in tonsil, 
HPV6 was the only candidate for LR-HPV found in all anatomic sites studied. An 
uneven distribution of HPV16 and other β-HPV types was observed but confined within 
alveolus, soft palate, retromolar pad and tongue. 
 
 The HPV type distribution in regional lymph nodes and tumour size relatively 
exhibited similar pattern particularly for HR-HPV and LR-HPV. Higher percentage of 
both of HPV risk groups were observed at tumour size less than 2-cm and no regional 
lymph nodes metastasis. As was previously described in disease recurrence, an almost 
similar distribution pattern of all HPV types was observed in the absent of distant 
metastasis. Nearly fifty percent of HR-HPV or LR-HPV were detected at very late 
tumour stage (Stage IV) and an even higher proportion of β-HPV types were observed 
in this group.       
 
 Correlation analyses were carried out to search for any existing association in 
HPV positivity, demographic and clinical parameters using Pearson’s correlation and 
Spearman’s correlation, rho in this cohort. A statistically significant association 
observed was grouped into three, within HPV status, between HPV status and 
demographic/clinical parameters and within demographic/clinical parameters (Table 
3.28). Any significant associations (positive or negative) were transformed into 
schematic representation for better visualisation of the correlation as shown in Figure 
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3.22. We have to acknowledge that a more complex association exists involving 
multifactorial causes once dealing with patient disease outcome. We are fully aware of 
all the difficulties and constrains in obtaining full historical data especially related to 
retrospective study. Therefore, we tried our best to make full use of all the accessible 
data to assist in the correct interpretation of the results.   
 
Figure 3.22: Schematic representation of correlation plot amongst 
parameters. Overlapping circle means a correlation exists. All parameters 
compared exhibit positive correlation except for an association between tumour 
size, tumour stage and β-HPV status towards patient disease outcome, LR-HPV 
status with smoking, α-HPV with smoking and smoking-alcohol which are 
negative as shown in Table 3.28. The size of the circle does not indicate the 
strength of the association. 
 
 For patient disease outcome, initially we set code ‘0’ for dead and code ‘1’ for 
alive for data entry in SPSS. Any negative association to another parameter will be 
interpreted as an increasing number of deceased patients. For instance, tumour size and 
tumour stage were negatively associated with patient disease outcome. With an 
increasing number of patients from T0 to T4 and tumour stage from stage 0 to IV, it is 
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more likely that we observe an increasing number of deceased patients as well. Since 
there are no direct associations between regional lymph nodes, distant metastasis and 
anatomic site with patient disease outcome, we presume these were negative, based on 
their positively associated with tumour size and tumour stage. For anatomic site, we 
gave a code in ascending order from ‘0’ for buccal mucosa to ‘9’ for tonsil for data 
entry in SPSS. Thus, we presume that more samples taken from the tongue were 
associated with an increasing number of deceased patients. 
    
 The positive correlation between alcohol and smoking-alcohol (increasing 
number of patient in SD group) with patient disease outcome appeared to be a 
controversial ‘protective effect’ of alcohol and smoking. Since we have not seen any 
association related to disease recurrence, this factor was put as a separate entity. To 
note, the above assumption was based on the preliminary small size of the cohort. 
Patient disease outcome was negatively associated with β-HPV types. In contrast, no 
direct link was observed either HR-HPV or HPV16 and patient disease outcome. Like 
anatomic site, which exhibited single association, more elderly patients were identified 
as the smokers. 
 
3.8 p16 ROLES IN ORAL CANCER  
 
3.8.1 Clinical data 
 
The cohort of 60 patients was previously mentioned in section 3.1.1. The preparation of 
the tissue specimens was as described in section 2.2.6. Eight to ten individual sections 
mounted onto the labelled slides were prepared for each sample.  
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3.8.2 Semi-quantitative scoring for p16 immunohistochemistry 
 
All p16 IHC slides were semi-quantitatively assessed as described in the appropriate 
part of Chapter 2. A representative of the tissue specimens demonstrating negative and 
positive staining with the p16 antibody are as shown in Figure 3.23. The staining 
intensity was included for p16 positivity determination based on a scale of 1+, 2+ and 
3+ as depicted in Figure 3.24. Strong nuclear and/or cytoplasmic staining was 
considered positive. We commonly observed strong cytoplasmic staining compared to 
nuclear staining and this was limited to the tumour cells. Figure 3.24 (A) shows a 
typical pattern of p16 positive staining (only cytoplasmic staining not nuclear staining) 
was predominantly at basal and extending to a suprabasal region of the epithelium cells. 
Focal and basal positive staining appeared more frequent in our samples. Another 
additional feature that was observed i.e. homogenous (Figure 3.24 (C)) or 
heterogeneous stain and in most cases the former tends to be considered as diffuse. The 
latter, on the other hand, was more common at the invading area of SCC. Before 
statistical analysis was performed, the p16 positive distribution was converted to a 
positive and negative score. Although, positive staining of non-tumour cells, for 
instance epithelia and multinucleated giant cells were occasionally visualised, these 
were excluded as positive. 
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Figure 3.23: Photomicrograph of p16 immunohistochemical 
staining.  
(A) Negative control, (B) p16 positive at x100 magnification 
(rectangular) and x400 magnification (circle) 
 
 
 
 
 
 
   
 
Figure 3.24: Photomicrograph of p16 immunohistochemical staining 
intensity.  
(A) 1+, (B) 2+ and (C) 3+ at x400 magnification. 1+ score is the minimum for 
p16 positivity.  
 
A B 
A B C 
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3.8.3 Correlation among demographic and clinical parameters associated with 
p16 
 
A total of 47 of the 60 cases (78.3%) were positive for p16 immunohistochemistry 
based on consensus agreements among three independent blinded observers by semi-
quantitative assessment (Figure 3.25). The demographic, risk factor and 
clinicopathological characteristics of oral cancer by p16 status are given in Table 3.29 
and Table 3.30. Based on odds ratio, p16 status was significantly associated with an 
increase in relative risk compared to the reference group, male [3.5 (1.4 – 8.7), p<0.01], 
patients aged 66-97 [3.4 (1.5 – 8.0), p<0.01], tumour size T3 [3.7 (1.2 – 11.3), p<0.05], 
dead [7.0 (0.1 – 1.7),  p<0.01] and disease recurrence [3.5 (1.8 – 6.6), p<0.01] and 
regional lymph nodes, N2 [9.0 (1.1 – 71.0), p<0.05].  
  
 
Figure 3.25: The total score of p16 IHC in this pilot study. 
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Table 3.29: Demographic and risk factor characteristics of oral cancer by p16 status 
 
 
 
Characteristics 
 
 
N 
 
p16-, N=13 (%) 
 
P16+, N=47 (%) 
 
Odds ratio (95% CI) 
 
p value 
      
Gender 
   Male 
   Femaleα 
    
 
33 
27 
 
7 (53.8) 
6 (46.2) 
 
26 (55.3) 
21 (44.7) 
 
3.5 (1.4 – 8.7) 
1.0 
 
0.007** 
Age group 
   36-65yα 
   66-97y 
    
 
31 
29 
 
7 (53.8) 
6 (46.2) 
 
24 (51.1) 
23 (48.9) 
 
1.0 
3.4 (1.5 – 8.0) 
 
 
0.004** 
Smoking 
   Noα 
   Yes 
    
 
20 
40 
 
6 (46.2) 
7 (53.8) 
 
14 (29.8) 
33 (70.2) 
 
1.0 
2.3 (0.9 - 6.1) 
 
 
0.082 
 
 
Alcohol 
   Noα 
   Yes 
    
 
10 
50 
 
2 (15.4) 
11 (84.6) 
 
8 (17.0) 
39 (83.0) 
 
1.0 
4.0 (0.8 – 18.8) 
 
0.080 
 
Smoking-Alcohol 
   NSNDα 
   SND 
   NSD 
   SD 
       
 
5 
5 
15 
35 
 
1 (7.7) 
1 (7.7) 
5 (38.5) 
6 (46.2) 
 
4 (8.5) 
4 (8.5) 
10 (21.3) 
29 (61.7) 
 
1.0 
4.0 (0.4 – 35.8) 
4.0 (0.4 – 35.8) 
4.0 (0.7 – 5.9) 
 
 
0.197 
 
 
 
N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level; α  - reference for odds ratio determination 
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Table 3.30: Clinicopathologic characteristics of oral cancer by p16 status 
 
 
 
Characteristics 
 
 
N 
 
p16-, N=13 (%) 
 
p16+, N=47 (%) 
 
Odds Ratio (95% CI) 
 
p value 
      
Anatomic site 
   Buccal mucosaα 
   Floor of the mouth 
   Alveolus 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
    
 
1 
10 
4 
3 
1 
1 
9 
1 
29 
1 
 
0 (0) 
3 (23.1) 
2 (15.4) 
0 (0) 
0 (0) 
0 (0) 
3 (23.1) 
0 (0) 
5 (38.5) 
0 (0) 
 
1 (2.1) 
7 (14.9) 
2 (4.3) 
3 (6.4) 
1 (2.1) 
1 (2.1) 
6 (12.8) 
1 (2.1) 
24 (51.1) 
1 (2.1) 
 
1.0 
- 
2.3 (0.6 – 9.0) 
1.0 (0.1 – 7.0) 
- 
- 
- 
2.0 (0.5 – 8.0) 
- 
4.8 (1.8 – 12.6) 
 
 
0.179 
Tumour size 
   Negativeα 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) 
    
 
2 
24 
19 
1 
14 
 
0 (0) 
6 (46.2) 
4 (30.8) 
0 (0) 
3 (23.1) 
 
 
2 (4.3) 
18 (38.3) 
15 (31.9) 
1 (2.1) 
11 (23.4) 
 
1.0 
- 
3.0 (1.2 – 7.5) 
3.7 (1.2 – 11.3) 
- 
 
0.027* 
 
 
 
 
Regional lymph 
nodes  
   Negativeα 
   N0 
   N1 
   N2 
    
 
4 
28 
10 
18 
 
1 (7.7) 
8 (61.5) 
1 (7.7) 
3 (23.1) 
 
3 (6.4) 
28 (46.7) 
10 (16.7) 
18 (30.0) 
 
1.0 
3.0 (0.3 – 28.8) 
2.5 (1.1 – 5.7) 
9.0 (1.1 – 71.0) 
 
0.018* 
Distant metastasis 
   Negativeα 
   No distant 
metastasis 
    
 
4 
56 
 
1 (7.7) 
12 (92.3) 
 
3 (6.4) 
44 (93.6) 
 
1.0 
3.0 (0.3 - 28.8) 
 
0.341 
Tumour stage  
   0α 
   I 
   II 
   III 
   IV 
    
 
6 
17 
4 
7 
26 
 
1 (7.7) 
6 (46.2) 
0 (0) 
2 (15.4) 
4 (30.8) 
 
5 (10.6) 
11 (23.4) 
4 (8.5) 
5 (10.6) 
22 (46.8) 
 
1.0 
5.0 (0.6 – 42.8) 
1.8 (0.7 – 5.0) 
- 
2.5 (0.5 – 12.9) 
 
0.310 
Disease outcome 
   Alive 
   Deadα 
    
 
24 
36 
 
3 (23.1) 
10 (76.9) 
 
21 (44.7) 
26 (55.3) 
 
7.0 (0.1 – 1.7) 
1.0 
 
0.002** 
Disease status 
   No recurrenceα 
   Recurrence    
 
54 
6 
 
12 (92.3) 
1 (7.7) 
 
42 (89.4) 
5 (10.6) 
 
1.0 
3.5 (1.8 – 6.6) 
 
0.000** 
      
N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level; α  - reference for odds ratio determination 
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Table 3.31: The correlations between demographic/clinical parameters and p16 
status  
 
 
Parameter 1 
 
Parameter 2 
Pearson Correlation  Spearman’s rho 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Correlation 
coefficient 
Sig.  
(2-tailed) 
 
Within p16: 
      
       
p16 status p16 staining intensity 0.769** 0.000  0.756** 0.000 
       
 
Between p16 and demographic/clinical parameters:  
 
p16 status 
 
Gender 
 
0.012 
 
0.926 
  
0.012 
 
0.926 
 Age group 0.023 0.862  0.023 0.862 
 Disease outcome -0.182 0.165  -0.182 0.165 
 Anatomic site 0.115 0.380  0.125 0.343 
 Tumour size 0.007 0.956  0.012 0.925 
 Regional lymph nodes 0.129 0.325  0.136 0.302 
 Distant metastasis 0.022 0.870  0.022 0.870 
 Tumour stage 0.120 0.359  0.126 0.337 
 Recurrence 0.040 0.759  0.040 0.759 
 Smoking 0.143 0.276  0.143 0.276 
 Alcohol -0.018 0.891  -0.018 0.891 
 Age group -0.333** 0.009  -0.333** 0.009 
 
Smoking-Alcohol 0.057 0.664  0.099 0.452 
       
p16 staining intensity Gender 0.012 0.928  0.026 0.846 
 Age group 0.049 0.712  0.042 0.751 
 Disease outcome -0.258* 0.047  -0.258* 0.046 
 Anatomic site 0.131 0.319  0.103 0.434 
 Tumour size 0.061 0.643  0.081 0.536 
 Regional lymph nodes 0.085 0.516  0.090 0.495 
 Distant metastasis 0.074 0.575  0.074 0.576 
 Tumour stage 0.131 0.320  0.136 0.301 
 Recurrence 0.039 0.764  0.017 0.897 
 Smoking 0.237 0.068  0.255* 0.049 
 Alcohol -0.035 0.789  -0.025 0.852 
 Smoking-Alcohol 0.091 0.490  0.189 0.148 
       
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 Correlation analyses were carried out to search for any association existing 
between p16 positivity, p16 staining intensity and demographic and clinical parameters 
using Pearson’s correlation and Spearman’s correlation, rho in this cohort (Table 3.31). 
We found a very strong positive association between p16 positivity and p16 staining 
intensity. Unfortunately, neither the demographic nor clinical parameters were 
correlated with p16 status. A negative correlation was observed between p16 staining 
intensity with patient disease outcome (r =-0.258, p<0.05) whereas positively associated 
with smoking (rho = 0.255, p<0.05). 
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3.9 CORRELATION BETWEEN HPVs AND p16 EXPRESSION 
 
When p16 expression is examined in association with HPV status, the symmetric 
measures table shows that Kappa varies from -0.046 to 0.070 (Table 3.32). Even 
though, there are positive Kappa values in three cases, but this is insufficient enough. 
For reliability measures, they should be high (>0.70). The percentage of concordant 
based on positive kappa value ranging from 33% to as high as 55%. HR α-HPV/p16 
and HPV16/p16 status association (shaded area) need to be focused on the future, we 
suggested that there was less specificity of IHC technique compared to PCR and HPV 
genotyping which affected the discordant values (darker shaded area). Therefore, at this 
point we concluded that none of the HPV and p16 status demonstrated remarkably 
convincing agreements and consistency. Statistical significance is not relevant for 
reliability measures. 
Table 3.32: Cross-tabulation of HPV versus p16 status 
 
 
HPV expression 
 
N 
p16 expression Concordancea (%)  
κ 
 
p value p16 - (%) p16 + (%) 
 
      Overall HPV (-)  
      Overall HPV(+)   
    
 
20 
40 
 
4 (6.7) 
9 (15.0) 
 
16 (26.7) 
31 (51.7) 
 
56.7 
 
-0.027 
 
 
0.825 
      α-HPV (-) 
      α-HPV (+) 
      
26 
34 
 
6 (10.0) 
7 (11.7) 
20 (33.3) 
27 (45.0) 
55.0 
 
 
0.026 
 
0.817 
      HR α-HPV (-) 
      HR α-HPV (+) 
      
49 
11 
12 (20.0) 
1 (1.7) 
37 (61.7) 
10 (16.7) 
36.7 
 
 
0.068 
 
0.263 
      HPV16 (-) 
      HPV16 (+) 
      
53 
7 
13 (21.7) 
0 (0) 
40 (66.7) 
7 (11.7) 
33.3 
 
 
0.070 
 
0.139 
      LR α-HPV (-) 
      LR α-HPV (+) 
   
26 
34 
5 (8.3) 
8 (13.3) 
21 (35.0) 
26 (43.3) 
51.7 
 
 
-0.046 
 
0.689 
      β-HPV (-) 
      β-HPV (+) 
   
49 
11 
10 (16.7) 
3 (5.0) 
39 (65.0) 
8 (13.3) 
30.0 
 
 
-0.030 
 
0.617 
a(Concordance positive and concordance negative)x100/total specimens 
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Table 3.33: Chi-square analysis of prevalence of p16 positivity with HPV status 
 
 
 
HPV status 
 
N 
p16 status  
χ2 
 
p value p16 - (N = 13) (%) p16 + (N = 47) (%) 
 
      Overall HPV (-)  
      Overall HPV(+)   
    
 
20 
40 
 
4 (20.0) 
9 (22.5) 
 
16 (80.0) 
31 (77.5) 
 
0.049 
 
 
0.825 
      α-HPV (-) 
      α-HPV (+) 
      
26 
34 
 
6 (23.1) 
7 (20.6) 
20 (76.9) 
27 (79.4) 
0.054 
 
0.817 
      HR α-HPV (-) 
      HR α-HPV (+) 
      
49 
11 
12 (24.5) 
1 (9.1) 
37 (75.5) 
10 (90.9) 
1.255 
 
0.263 
      HPV16 (-) 
      HPV16 (+) 
      
53 
7 
13 (24.5) 
0 (0) 
40 (75.5) 
7 (100.0) 
2.192 
 
0.139 
      LR α-HPV (-) 
      LR α-HPV (+) 
   
26 
34 
5 (19.2) 
8 (23.5) 
21 (80.8) 
26 (76.5) 
0.160 
 
0.689 
      β-HPV (-) 
      β-HPV (+) 
   
49 
11 
10 (20.4) 
3 (27.7) 
39 (79.6) 
8 (72.7) 
0.249 
 
0.617 
 
Table 3.34: Chi-square analysis of prevalence of p16 staining intensity with HPV 
status 
 
 
 
HPV status 
 
N 
p16 staining intensity  
χ2 
 
p value Negative (%) 1+ (%) 2+ (%) 3+ (%) 
 
      Overall HPV (-)  
      Overall HPV(+)   
    
 
20 
40 
 
4 (20.0) 
9 (22.5) 
 
9 (45.0) 
14 (35.0) 
 
7 (35.0) 
14 (35.0) 
 
0 (0) 
3 (7.5) 
 
1.886 
 
 
0.596 
      α-HPV (-) 
      α-HPV (+) 
      
26 
34 
 
6 (23.1) 
7 (20.6) 
10 (38.5) 
13 (38.2) 
10 (38.5) 
11 (32.4) 
0 (0) 
3 (8.8) 
2.494 
 
0.476 
      HR α-HPV (-) 
      HR α-HPV (+) 
      
49 
11 
12 (24.5) 
1 (9.1) 
19 (38.8) 
4 (36.4) 
18 (36.7) 
3 (27.3) 
0 (0) 
3 (27.3) 
14.59** 
 
0.002 
      HPV16 (-) 
      HPV16 (+) 
      
53 
7 
13 (24.5) 
0 (0) 
21 (39.6) 
2 (28.6) 
19 (35.8) 
2 (28.6) 
0 (0) 
3 (42.9) 
24.722** 
 
0.000 
      LR α-HPV (-) 
      LR α-HPV (+) 
   
26 
34 
5 (19.2) 
8 (23.5) 
11 (42.3) 
12 (35.3) 
9 (34.6) 
12 (35.3) 
1 (3.8) 
2 (5.9) 
0.439 
 
0.932 
      β-HPV (-) 
      β-HPV (+) 
   
49 
11 
10 (20.4) 
3 (27.3) 
19 (38.8) 
4 (36.4) 
18 (36.7) 
3 (27.3) 
2 (4.1) 
1 (5.0) 
0.890 
 
0.828 
**. Correlation is significant at the 0.01 level (2-tailed). 
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 Correlation analyses were performed seeking any existing association between 
HPV status and p16 positivity (Table 3.33) and p16 staining intensity by Pearson Chi-
square correlation (Table 3.34). We found that no significant association existed 
between HPV and p16 status. In other words, HPV status was not significantly different 
whether the status of p16 was positive or negative. Positive association was observed 
between p16 staining intensity with HR-HPV status (χ2 = 14.59, df = 3, N = 60, 
p<0.001) and HPV16 status (χ2 = 24.72, df = 3, N = 60, p<0.001). Therefore, we 
concluded that HR-HPV and HPV16 status were significantly associated with p16 
staining intensity. 
 
3.10 SURVIVAL ANALYSIS 
 
Survival was measured in months from the date of diagnosis until death or until the 
patient was last known to be alive. The Kaplan-Meier curve of survival followed by Log 
Rank (Mantel-Cox) test was used to investigate whether there was an association 
between the clinical parameters and patients survival. All survival curves were 
generated in SPSS ver.16. Continuous data were divided by the median and the 
comparison was made using the log-rank test. The Kaplan-Meier is the univariate 
version of survival analysis. Then, by performing Cox regression analysis it will also 
assist the assessment of the actual impact of confounders on the survival of the patient.  
 
 Cox proportional hazard models were used to assess the relationships between 
p16 and HPV and to adjust for factors previously found to be prognostically significant 
in oral cancer. These analyses included age, alcohol, smoking, tumour stage, tumour site 
also were examined in separate models. All variables were assessed for the proportional 
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hazard assumption before inclusion in the models. HPV and p16 status were examined 
separately and then four groups: HPV/p16+ (reference group), HPV/p16-negative, 
HPV-negative/p16+, HPV-negative/p16-negative. The magnitude of the associations 
was assessed with hazard ratios (HRs) calculated from the Cox regression models. 
Statistically significance was based on two-tailed tests and p-values < 0.05. Statistical 
analyses were performed using SPSS 16.0. 
 
3.10.1 Kaplan-Meier Survival Analysis 
 
The results suggested that the overall patient survival was worst in six groups (Table 
3.35): 
1. Pharynx, lower lip, tonsil and buccal mucosa compared with other anatomic 
sites (p<0.01) (Figure 3.26). 
2. Tumour size, T3 compared with T1 (p<0.01) (Figure 3.27). 
3. Tumour stage II compared with stage 0 (p<0.01) (Figure 3.28). 
4. Non-drinkers compared to drinkers, (p<0.01) (Figure 3.29). 
5. Non-smokers and non-drinkers compared to non-smokers but drinkers, 
(p<0.01) (Figure 3.30). 
6. Patients with positive β-HPV type compared to the negative one, (p<0.01) 
(Figure 3.31).  
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Table 3.35: The prognostic significance from overall survival analysis 
Parameter (N=60) Log Rank (Mantel-Cox) 
Chi-Square df Sig. 
    
Gender 0.587 1 0.444 
Age group 2.887 1 0.089 
Anatomic site 33.893 9 0.000** 
Tumour size 15.845 4 0.003** 
Regional Lymph Nodes  4.150 3 0.246 
Distant Metastasis 0.512 1 0.474 
Tumour stage 31.566 4 0.000** 
Recurrence 0.267 1 0.605 
Smoking    1.408 1 0.235 
Alcohol 16.128 1 0.000** 
Smoking-Alcohol    31.205 3 0.000** 
Overall HPV status 1.373 1 0.241 
High risk HPV status    0.658 1 0.417 
HPV16 status      0.201 1 0.654 
Low risk HPV status      0.021 1 0.885 
α-HPV status 0.222 1 0.637 
β-HPV status 10.695 1 0.001** 
HPV’s mode of  infection 2.861 3 0.414 
p16 status   2.293 1 0.130 
HPV/p16 status   3.912 3 0.271 
High risk HPV/p16 status   3.448 3 0.328 
HPV16/p16 status   2.816 3 0.245 
    
      N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
 
 
Figure 3.26: An association amongst anatomic sites and 
overall survival as generated by Kaplan-Meier test. Vertical 
tick marks on curves indicate censored observations. 
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Figure 3.27: An association amongst tumour sizes and 
overall survival as generated by Kaplan-Meier test. 
 
 
 
Figure 3.28: An association amongst tumour stage and 
overall survival as generated by Kaplan-Meier test. 
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Figure 3.29: An association between patients with alcohol 
exposure and overall survival as generated by Kaplan-Meier 
test. 
 
 
 
 
Figure 3.30: An association amongst smoking-alcohol 
exposure and overall survival as generated by Kaplan-Meier 
test. 
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Figure 3.31: An association between patients with positive β-
HPV types and overall survival as generated by Kaplan-
Meier test. 
 
3.10.2 Survival analysis according to the Cox Regression Model 
 
Multifactorial effect on patient survival as analysed by Cox regression model. These 
prognostic factors exhibited independently an agreement with overall survival analysis 
by Kaplan-Meier test except for anatomic site and tumour stage (Table 3.36).    
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  Table 3.36: Patient survival analysis by Cox regression model 
Parameter (N=60) Cox Regression Model 
Wald df Sig. 
    
Gender 0.573 1 0.449 
Age group 2.733 1 0.098 
Anatomic site 13.242 9 0.152 
Tumour size 11.494 4 0.022* 
Regional Lymph Nodes  3.847 3 0.278 
Distant Metastasis 0.484 1 0.487 
Tumour stage 9.364 4 0.053 
Recurrence 0.260 1 0.610 
Smoking    1.360 1 0.243 
Alcohol 13.039 1 0.000** 
Smoking-Alcohol    19.478 3 0.000** 
Overall HPVstatus 1.320 1 0.251 
High risk HPV status    0.635 1 0.425 
HPV16 status      0.103 1 0.748 
Low risk HPVstatus      0.021 1 0.885 
α-HPV status 0.218 1 0.64 
β-HPVstatus 9.175 1 0.002** 
HPV’s mode of  infection 2.694 3 0.441 
p16 status   2.114 1 0.146 
HPV/p16 status   1.459 3 0.692 
High risk HPV/p16 status   2.661 3 0.447 
HPV16/p16 status   2.598 3 0.273 
    
      N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
 
3.11 CONCLUSIONS 
 
Our results thus far from a small cohort in this pilot study could conclude: 
1.A Optimisation of DNA extraction  
• For samples in the form of cell suspension, sample duplication and repeated 
measurements for DNA quality and quantity was not necessary since no 
significance different observed within and between cells (p>0.05). 
• Even though, statistically no significant qualitative and quantitative variations 
observed within FFPETs by repeated readings (p>0.05) variations existed between 
samples (p<0.05). Therefore, it was reliable and a good practice having each 
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sample in duplicate and by taking an average of the measurements for each 
sample for DNA quality and quantity comparison. 
• Based on overall performance comparison, Qiagen kits were selected for future 
DNA extraction method used and 5 coupes of 5 µm paraffin embedded tissues 
was the best option for the DNA purity and DNA yield. 
1.B Optimisation of Polymerase Chain Reaction 
• 0.01 ng of DNA template was the minimum quantity required to be detected in 
2% agarose gel. 
• 2.5 mM MgCl2 concentration (commercial premix) produced relatively more 
specific amplicon than 3.0 mM MgCl2 (manually prepared). Therefore, the former 
will be utilised for future amplification. 
• 35 dilution (or 243x dilution) of the initial 450 bp amplicon as a DNA template 
gave the highest specificity for the nested or semi-nested amplicons, 140bp or 190 
bp. 
• The band intensity of the 140 bp amplicons relatively doubled after 
reamplification (without removing them from the thermocycler) and was free 
from other non-specific PCR products and this would be suggested for future 
amplification for nested PCR. 
2. HPV prevalence in oral squamous cell carcinoma samples 
• 40/60 (66.7%) overall HPV positivity was observed in this cohort. 
• It was postulated that more than single mode of HPV infections existed in the 
same sample. But this needs to be elucidated in a more advanced future study such 
as utilising viral load and laser capture microdissection (LCM) approaches. 
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• Overall, the highest proportion of LR-HPV observed particularly, HPV6 (34/56 or 
60.7%) followed by an equal percentage of HR-HPVs and β-HPVs, 11/56 
(19.6%) 
• The actual roles played by β-HPV (commonly found in cutaneous) in oral 
mucosal specimen remains a mystery. 
• Two α-HPV untypable (both were present in postulated multiple HPV infection) 
and three β-HPV untypable (two were detected in postulated single HPV infection 
and one as multiple HPV infection with α-HPV types) could be the novel HPV 
types. Since conventional PCR, PM-PCR RHA and SFP10-LiPA25 (version 1) 
approaches failed to identify them, other methods should be employed as a follow 
up for further HPV genotyping purposes. 
• Subsites analysis was unreliable due to very low sample size in certain groups. 
• HPV positivity was associated with other demographic and clinical risk factors 
such as smoking and patient disease outcome each with (p<0.05). 
• No direct association observed between HR-HPV or HPV16 with patient disease 
outcome. 
3A. p16 positivity in oral squamous cell carcinoma samples 
• 47/60 (78.3%) p16 positivity observed in this cohort 
• p16 status was significantly associated with an increased relative risk in male, 
older patients, tumour size, T3 , patient with disease recurrence and having 
positive lymph nodes. 
• A positive correlation was observed between p16 staining intensity with p16 
status and smoking, but negatively associated with patient disease outcome. 
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3B. Association between HPVs and p16 
• Chi-square analysis demonstrated that p16 staining intensity is associated with 
HR-HPV and HPV16 status. Nevertheless, no association was observed for 
overall HPV types and p16 status. 
• No direct association between HPVs and p16 expression was observed and the 
main cause was due to the lack of power in analysis. 
3C. Prognostic value of HPVs and p16 
• The overall patients survival were worst in four parameters; tumour size T3, 
non-drinkers, NSND group and patients positive with β-HPV type. These were 
satisfied by Cox regression analysis. 
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CHAPTER 4 
 
HPVs AND ORAL DISEASE PROGRESSION 
 
4.1 OVERVIEWS 
 
Overviews of aims of this chapter are given as follows: 
• To extract DNA from 183 FFPETs which was composed of benign (n=84), 
dysplasia (n=12), squamous cell carcinoma (n=80) and normal tissues (n=7) 
• PCR amplification for L1 HPV detection 
• Purification  and DNA sequencing of the PCR products 
• To establish HPV prevalence, demographic and clinicopathological parameters in 
benign, dysplasia and carcinoma. 
•  To determine whether there is an association with disease progression 
• Potential association with survival for HPV (for carcinoma group only) 
 
4.2 CLINICAL DATA 
 
A total of 183 cases were used with histologically confirmed benign, dysplasia and 
squamous cell carcinoma and normal tissues of various anatomic sites evaluated at the 
Unit of Oral Surgery and Medicine, University of Dundee, between 2005 and 2009. The 
male:female ratio was 56:44 with the mean and standard deviation (SD) age of 57.4 + 
15.4 years, ranging from 16-99 years. An average age for male was 58.8 + 16.9 and 
56.2 + 14.0 for female. As to the tumour loci, 46 cases (25.1%) were on buccal mucosa; 
tongue, 44 cases (24%); floor of the mouth, 23 cases (12.6%); retromolar pad, 5 cases 
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(2.7%); gingivae, 10 cases (5.5%); hard palate, 3 cases (1.6%); soft palate, 39 cases 
(21.3%); upper lip, 2 cases (1.1%), lower lip, 9 cases (4.9%) and one case (0.5%) for 
skin and tonsil. The clinico-pathological parameters recorded in each tumour consist of 
the primary tumour (T), regional lymph node (N). The clinical details of 176 samples 
from those patients of three pathological groups i.e. benign (B), dysplasia (D) and 
carcinoma (C) [Appendix 30 (A)] and are summarized in Table 4.1. The overall median 
(age 57) was used to classify those patients into two age groups. The histopathological 
details of patients with carcinoma were considered in Table 4.2. Another seven samples 
of normal tissues (N) were randomly selected. The clinical details are shown in 
Appendix 30 (B).  
 
4.3 DNA EXTRACTION FROM ORAL DISEASE PROGRESSION STUDY 
 
The raw data for qualitative and quantitative measurements of extracted DNA from 
normal tissues [Appendix 30 (C)] and three pathological groups is given in Appendix 31 
(benign), Appendix 32 (dysplasia) and Appendix 33 (carcinoma). The overall purity and 
yield of extracted DNA from FFPETs is given in Appendix 54.  
 
4.4 β-GLOBIN DETECTION BY PCR FOR DNA QUALITY DETERMINA-
TION 
 
PCR amplication was undertaken in triplicate for each diluted DNA from 2.1.21 
according to the procedure mentioned in 2.1.22, Materials and Methods. The first 
attempt successfully amplified this fragment in 168 out of 183 samples (91.8%). 
Finally, all 183 samples (100%) were positive for β-globin gene and suitable as a 
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template DNA for L1 gene detection of HPV. The PCR results for β-globin detection 
were given separately in normal tissues [Appendix 30 (D)] and each pathological group: 
Appendix 34 (benign), Appendix 35 (dysplasia) and Appendix 36 (carcinoma). 
 
Table 4.1: Clinical details of patients in each pathological group 
 
Characteristic N  
Benign 
N (%) 
Dysplasia 
N (%) 
Carcinoma 
N (%) 
Total 
 
176  84 (47.7) 12 (6.8) 80 (45.5) 
Gender 
   Female 
   Male 
 
 
99 
77 
 
45 (45.5) 
39 (50.6) 
 
5 (5.0) 
7 (9.1) 
 
49 (49.5) 
31 (40.3) 
Age groupα (range, 16-99y) 
   16-57y 
   58-99y 
 
 
92 
84 
 
52 (56.5) 
32 (38.1) 
 
2 (2.2) 
10 (11.9) 
 
38 (41.3) 
42 (50.0) 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
10 
3 
39 
2 
8 
4 
1 
41 
 
 
41 (91.1) 
3 (13.0) 
6 (60.0) 
2 (66.7) 
3 (7.7) 
2 (100.0) 
4 (50.0) 
1 (25.0) 
1 (100.0) 
21 (51.2) 
 
 
1 (2.2) 
8 (34.8) 
0 (0.0) 
1 (33.3) 
2 (5.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
 
3 (6.7) 
12 (52.2) 
4 (40.0) 
0 (0.0) 
34 (87.2) 
0 (0.0) 
4 (50.0) 
3 (75.0) 
0 (0.0) 
20 (48.8) 
 
Disease status  
   No recurrence 
   Recurrence 
 
 
171 
5 
 
84 (49.1) 
0 (0.0) 
 
12 (7.0) 
0 (0.0) 
 
75 (43.9) 
5 (100.0) 
Disease outcome (N=80) 
    Alive 
    Dead 
 
 
45 
35 
 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
 
45 (100.0) 
35 (100.0) 
 Note: N, number of patients, α - Age group was based on median age 
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Table 4.2: Histopathological details of patients with carcinoma 
 
Characteristic 
 
N 
 
% 
Total 
 
80  100 
Tumour size 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent 
structures 
 
 
41 
22 
13 
4 
 
 
51.2 
27.5 
16.2 
5.0  
 
Regional Lymph Nodes 
   N0 
   N1 
   N2 
 
 
67 
7 
6 
 
83.8 
8.8 
7.5 
Histological grade  
   Well differentiated 
   Moderately differentiated 
   Poorly differentiated 
   Basaloid 
 
 
9 
58 
11 
2 
 
 
11.2  
72.5 
13.8 
 2.5 
 
  Note: N, number of patients 
 
 
 
4.5 SUMMARY OF THE PCR AMPLIFICATION OF L1 HPV GENE 
DETECTIONS 
 
Similarly, the details of PCR results for each sample of L1 HPV gene detection were 
given in Appendices 34-36. Figure 4.1 illustrates the overall PCR results for L1 HPV 
detection according to the strategies mentioned in appropriate section in Materials and 
Methods. The overall potentially positive PCR amplification for L1 HPV gene is shown 
in Table 4.3. The actual positive PCR for L1 HPV will be determined later via 
automated DNA sequencing and DNA sequences alignment results. The PCR positivity 
based on three pathological groups is given in Table 4.4. 
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Table 4.3: Overall PCR results for L1 HPV gene detection 
Type of PCR amplification Expected amplicon sizes (%) 
 450 bp 190 bp 140 bp 
    
Independent PCR (positive) 2 (1.1)   
Independent PCR (negative) 174 (98.9)   
Total samples tested 176    
Semi-nested PCR (positive) 2α 2 (1.1)  
Semi-nested PCR (positive) 174β  124 (70.5)  
Semi-nested PCR (negative)  50 (28.4)  
Total samples tested  176  
Nested PCR (positive)  2α 2 (1.1) 
Nested PCR (positive)  124β 117 (66.5) 
Nested PCR (false positive)   7 (4.0) 
Nested PCR (positive)  50β 18 (10.2) 
Nested PCR (negative)   32 (18.2) 
   176 
Presumptive PCR positive for L1 HPV 2 (1.1) 126 (71.6) 137 (77.8) 
PCR negative for L1 HPV 174 (98.9) 50 (28.4) 39 (22.2) 
Total sample tested 176 176 176 
 
Note:   
α  - First round PCR which was positive as the template for either  semi-nested or  nested 
PCR amplifications 
β  - First round PCR which was negative as the template for either semi-nested or nested PCR 
amplifications 
 
Table 4.4: Summary of PCR results of L1 HPV gene detection  
(pathological groups) 
 
 
Type of PCR amplification Number of samples (%) Total 
 Benign Dysplasia Carcinoma  
     
Independent PCR 0 (0.0) 1 (8.3)    1 (12.5)    2 (1.1) 
Semi-nested PCR (Positive) 61 (72.6) 9 (75.0)    56 (70.0)   126 (71.6) 
Nested PCR (false positive) 4 (4.8) 0 (0.0) 3 (37.5) 7 (4.0) 
Nested PCR (Positive) 61 (72.6) 9 (75.0) 67 (83.8) 137 (77.8) 
     
Presumptive PCR positive for L1 HPV 61 (72.6) 9 (75.0) 67 (83.8) 137 (77.8) 
PCR negative for L1 HPV 23 (27.4) 3 (25.0) 13 (16.2) 39 (22.2) 
Total sample tested 84 12 80 176 
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4.6 MULTIPLE DNA SEQUENCES ALIGNMENT VIA BLASTn 
 
In total of three pathological groups, 90 out of 137 amplicons (65.7%) were positively 
identified as HPVs which demonstrated very high expectation value (E) of the 
alignment (Mount, 2001) (Appendix 37-39). In total, forty seven amplicons (34.3%) 
were considered negative for HPVs via multiple DNA sequence alignment. Generally, a 
very low degree of DNA sequence similarity was observed in those sequences and less 
than 10% identity involving 10 base nucleotides or less (data not shown). Those 
amplicons (which were initially positive in PCR for L1 HPV detection) were included 
in DNA sequencing to ensure that we did not exclude any possibility of HPV positivity 
in the samples tested. Therefore, we concluded that 86 of 176 samples (48.9%) were 
negative for HPVs of which 39/86 (45.3%) and 47/86 (54.7%) were identified via PCR 
and DNA sequencing, respectively. In normal tissues, one of five amplicons (20%) was 
positively identified as HPV. We concluded that six out of seven normal tissue samples 
(85.7%) were negative for HPVs of which 2/6 (33.3%) and 4/6 (66.7%) were identified 
via PCR and DNA sequencing respectively.   
 
4.7 A COMPARISON OF HPV DNA EXPRESSION IN DIFFERENT 
SAMPLES 
 
We found that HPV16 was present in one of seven normal tissues (14.3%). It was 
previously reported elsewhere that HPV positivity in normal tissues varied from as low 
as 0% to 100%. Table 4.5 and Figure 4.1 show the positively detected HPV types, 43/84 
(51.2%) in benign, 5/12 (41.7%) in dysplasia and 42/80 (52.5%) in carcinoma samples 
tested. Overall, we found that 54/90 (60.0%) positive for LR α-HPV (only HPV6 
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detected), 26/90 (28.9%) for HR α-HPV and 10/90 (11.1%) for other HPV types. HR α-
HPV types were positively detected, 12/84 (14%) in benign, 13/80 (16%) carcinoma but 
1/12 (8%) was present in dysplasia samples (Figure 4.2). Across the pathological group, 
HPV6 was the most predominantly observed compared to other HPV types, 28/43 
(65.1%) in benign, 2/5 (40%) in dysplasia and 24/42 (57%) in carcinoma. Within HR α-
HPV, the ratio of HPV16:HPV18 was 9:4. The proportion of HPV16 observed across 
pathological group was 7/43 (16.3%) in benign, 1/5 (20%) in dysplasia and 10/42 
(23.8%) in carcinoma. The comparison of HPV prevalence in normal tissues and three 
pathological groups was not statistically significant. Therefore, HPV prevalence 
comparison was carried out among three pathological groups.  
 
 Figure 4.2 and Figure 4.3 show the distribution and the breakdown of each HPV 
type detected in the three pathological groups. HPV16 was predominantly detected 
within HR α-HPV types in all pathological groups, 7/84 (8.3%) in benign and 10/80 
(12.5%) in carcinoma and 1/12 (8.3%) present in dysplasia samples (Table 4.5). The 
ratio of total LR α-HPV:HR α-HPV type was approximately 2:1 observed across the 
pathological groups. In addition, only single HPV type, HPV6 observed in LR α-HPV 
group. HPV33 and HPV113 were found only in benign tumours whereas HPV64, 
HPV103 and HPV109 were detected only in the carcinoma group. HPV100, on the 
other hand, was present in all pathological groups. In the benign group, 23/84 (27.4%) 
true negatives for HPV detection were observed at the pre-DNA sequencing stage and 
false positive results of 18/84 (21.4%) at the post-DNA sequencing stage. Similarly, it 
was noted that false positive PCR, 4/12 (33.3%) and true negative PCR, 3/12 (25.0%) 
results were almost comparable in the dysplasia group. Nevertheless, it seems that both 
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negative results were quite significantly different in the carcinoma group, 13/80 (16.3%) 
and 25/80 (31.3%) for true negative and false positive PCR, respectively.  
 
Table 4.5: Summary of HPV types detected in each pathological group 
HPV types detected Number of samples HPV positive (%) Total 
 Benign Dysplasia Carcinoma  
     
LR α-HPV 
 
 
    
  HPV6 28 (100.0) 2 (100.0)    24 (100.0)   54 
   Total 28 2   24   54 (60.0) 
HR α-HPV      
   HPV16 7 (61.5) 1 (100.0) 10 (76.9) 18 
   HPV18 5 (38.5) - 3 (23.1) 8 
   Total 12 1 13 26 (28.9) 
Other HPV types      
   HPV33 1 (33.3) - - 1 
   HPV64 - - 1 (20.0) 1 
   HPV100 1 (33.3) 2 (100.0) 2 (40.0) 5 
   HPV103 - - 1 (20.0) 1 
   HPV109 - - 1 (20.0) 1 
   HPV113 1 (33.3) - - 1 
   Total 3 2 5 10 (11.1) 
     
     
Presumptive PCR positive for L1 HPV 61 (72.6) 9 (75.0) 67 (83.8) 137  
True positive PCR for L1 HPV 43 (51.2) 5 (41.7) 42 (52.5) 90 
False positive PCR for L1 HPV 18 (21.4) 4 (33.3) 25 (31.25) 47 
True negative PCR for L1 HPV 23 (27.4) 3 (25.0) 13 (16.25) 39 
Total sample tested 84 12 80 176 
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Figure 4.1: HPV types positively detected in each pathological group  
 
 
Figure 4.2: HPV types distribution in each pathological group, N (%). 
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Figure 4.3: The breakdown of specific HPV types (%) identified. 
The percentage given is based on its total number from all the pathological 
groups   
 
 The distribution of HPV types within clinical groups for benign is shown in Table 
4.6, dysplasia (Table 4.7), carcinoma (Table 4.8) and histopathological parameters for 
carcinoma in Table 4.9. It was observed that HPV16 and HPV6 were equally distributed 
between gender in benign and carcinoma. The latter type appeared in nearly similar 
proportions in carcinoma. The high risk HPV and other HPV types were predominantly 
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found in females compared to their counterpart in benign and carcinoma. Even though, 
HPV16 was only identified in male patients with dysplastic lesions but this difference 
relatively was not significant. 
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Table 4.6: The distribution of HPV types within clinical groups in benign (N = 43) 
 
 
Parameters N  HR α-HPV (%)  LR α-HPV (%)  Other HPV types (%)  HPV16 HPV18  HPV6  HPV33 HPV64 HPV100 HPV103 HPV109 HPV113 
              
Gender:              
   Female 45  3 (6.7) 5 (11.1)  14 (31.1)  1 (2.2) - - - - 1 (2.2) 
   Male 39  4 (10.3) -  14 (35.9)  - - 1 (2.6) - - - 
 
Age group:              
   16 – 57y 52  3 (5.8) 2 (3.8)  18 (34.6)  1 (1.9) - 1 (1.9) - - 1 (1.9) 
   58-99y 32  4 (12.5) 3 (8.6)  10 (31.3)  - - - - - - 
 
Anatomic sites:              
   Buccal mucosa 41  3 (7.3) 4 (9.8)  15 (36.6)  - - 1 (2.4) - - - 
   Floor of the mouth 3  - -  1 (33.3)  - - - - - - 
   Gingivae 6  - -  2 (33.3)  - - - - - - 
   Hard palate 2  - -  -  - - - - - - 
   Soft palate 3  - -  2 (66.7)  - - - - - - 
   Upper lip 2  1 (50.0) -  -  - - - - - - 
   Lower lip 4  1 (25.0) 1 (25.0)  -  - - - - - - 
   Retromolar pad 1  - -  1 (100.0)  - - - - - - 
   Skin 1  - -  -  - - - - - - 
   Tongue 21  2 (9.5) -  7 (33.3)  1 (4.8) - - - - 1 (4.8) 
              
Disease status:              
   No recurrence 84  7 (8.3) 5 (6.0)  28 (33.3)  1 (1.2) - 1 (1.2) - - 1 (1.2) 
   Recurrence -  - -  -  - - - - - - 
              
Disease outcome (N=0):              
   Alive -  - -  -  - - - - - - 
   Dead -  - -  -  - - - - - - 
              
Subtotal   7 (58.3) 5 (41.7)  28 (100.0)  1 (33.3) - 1 (33.3) - - 1 (33.3) 
TOTAL (N = 84)   12 (14.3)  28 (33.3)     3 (3.6)   
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Table 4.7: The distribution of HPV types within clinical groups in dysplasia (N = 5) 
 
 
Parameters N  HR α-HPV (%)  LR α-HPV (%)  Other HPV types (%)  HPV16 HPV18  HPV6  HPV33 HPV64 HPV100 HPV103 HPV109 HPV113 
              
Gender:              
   Female 5  - -  -  - - 1 (20.0) - - - 
   Male 7  1 (14.3) -  2 (28.6)  - - 1 (14.3) - - - 
 
Age group:              
   16 – 57y 2  1 (50.0) -  -  - - 1 (50.0) - - - 
   58-99y 10  - -  2 (20.0)  - - 1 (10.0) - - - 
 
Anatomic sites:              
   Buccal mucosa 1  - -  -  - - 1 (100.0) - - - 
   Floor of the mouth 8  1 (12.5) -  1 (12.5)  - - 1 (12.5) - - - 
   Gingivae -  - -  -  - - - - - - 
   Hard palate 1  - -  -  - - - - - - 
   Soft palate 2  - -  1 (50.0)  - - - - - - 
   Upper lip -  - -  -  - - - - - - 
   Lower lip -  - -  -  - - - - - - 
   Retromolar pad -  - -  -  - - - - - - 
   Skin -  - -  -  - - - - - - 
   Tongue -  - -  -  - - - - - - 
              
Disease status:              
   No recurrence 12  1 (8.3) -  2 (16.7)  - - 2 (16.7) - - - 
   Recurrence -  - -  -  - - - - - - 
              
Disease outcome (N=0):              
   Alive -  - -  -  - - - - - - 
   Dead -  - -  -  - - - - - - 
              
Subtotal   1 (100.0) -  2 (100.0)  - - 2 (100.0) - - - 
TOTAL (N = 12)   1 (8.3)  2 (16.7)     2 (16.7)   
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Table 4.8: The distribution of HPV types within clinical groups in carcinoma (N = 42) 
 
 
Parameters N  HR α-HPV (%)  LR α-HPV (%)  Other HPV types (%)  HPV16 HPV18  HPV6  HPV33 HPV64 HPV100 HPV103 HPV109 HPV113 
              
Gender:              
   Female 49  10 (20.4) 1 (2.0)  13 (26.5)  - 1 (2.0) - 1 (2.0) 1 (2.0) - 
   Male 31  - 2 (6.5)  11 (35.5)  - - 2 (6.5) - - - 
 
Age group:              
   16 – 57y 38  9 (23.7) 1 (2.6)  8 (21.1)  - - 1 (2.6) 1 (2.6) 1 (2.6) - 
   58-99y 42  1 (2.4) 2 (4.8)  16 (38.1)  - 1 (2.4) 1 (2.4) - - - 
 
Anatomic sites:              
   Buccal mucosa 3  - -  2 (66.7)  - - - - - - 
   Floor of the mouth 12  1 (8.3) 1 (8.3)  6 (50.0)  - - - - - - 
   Gingivae 4  - 1 (25.0)  2 (50.0)  - - - - - - 
   Hard palate -  - -  -  - - - - - - 
   Soft palate 34  9 (26.5) -  7 (20.6)  - - 1 (2.9) 1 (2.9) 1 (2.9) - 
   Upper lip -  - -  -  - - - - - - 
   Lower lip 4  - -  2 (50.0)  - - - - - - 
   Retromolar pad 3  - -  -  - - - - - - 
   Skin -  - -  -  - - - - - - 
   Tongue 20  - 1 (5.0)  5 (25.0)  - 1 (5.0) 1 (5.0) - - - 
              
Disease status:              
   No recurrence 75  10 (13.3) 3 (4.0)  22 (29.3)  - 1 (1.3) 2 (2.7) 1 (1.3) 1 (1.3) - 
   Recurrence 5  - -  2 (40.0)  - - - - - - 
              
Disease outcome (N=80):              
   Alive 45  10 (22.2) 1 (2.2)  10 (22.2)  - - 1 (2.2) 1 (2.2) 1 (2.2) - 
   Dead 35  - 2 (5.7)  14 (40.0)  - 1 (2.9) 1 (2.9) - - - 
              
Subtotal   10 (76.9) 3 (23.1)  24 (100.0)  - 1 (20.0) 2 (40.0) 1 (20.0) 1 (20.0) - 
TOTAL (N = 80)   13 (16.3)  24 (30.0)     5 (6.3)   
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Table 4.9: The distribution of HPV types within histopathological parameters in carcinoma group (N = 42) 
 
 
Parameters N  HR α-HPV (%)  LR α-HPV (%)  Other HPV types (%)  HPV16 HPV18  HPV6  HPV33 HPV64 HPV100 HPV103 HPV109 HPV113 
              
Tumour size:              
   T1 41  10 (24.4) 1 (2.4)  9 (22.0)  - - - 1 (2.4) 1 (2.4) - 
   T2 22  - 1 (4.5)  6 (27.3)  - 1 (4.5) - - - - 
   T3 13  - -  7 (53.8)  - - 2 (15.4) - - - 
   T4 4  - 1 (25.0)  2 (50.0)  - - - - - - 
 
Regional Lymph Nodes:              
   N0 67  10 (14.9) 1 (1.5)  17 (25.4)  - 1 (1.5) 2 (3.0) 1 (1.5) 1 (1.5) - 
   N1 7  - 1 (14.3)  3 (42.9)  - - - - - - 
   N2 6  - 1 (16.7)  4 (66.7)  - - - - - - 
 
Histological grade:              
   Well differentiated 9  - -  2 (22.2)  - - - - - - 
   Moderately differentiated 58  10 (17.2) 2 (3.4)  15 (25.9)  - 1 (1.7) - 1 (1.7) 1 (1.7) - 
   Poorly differentiated 11  - 1 (9.1)  6 (54.5)  - - 2 (18.2) - - - 
   Basaloid 2  - -  1 (50.0)  - - - - - - 
              
Subtotal   10 (76.9) 3 (23.1)  24 (100.0)  - 1 (20.0) 2 (40.0) 1 (20.0) 1 (20.0) - 
TOTAL (N = 80)   13 (16.3)  24 (30.0)     5 (6.3)   
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 The distribution of high risk HPV types was comparable across age groups in 
benign tumours. This was not the case for carcinoma where it was more abundant in the 
younger groups although it has been previously demonstrated that the total frequency of 
high risk HPV types was similar in both pathological groups. HPV6, on the other hand, 
did not follow a similar distribution where in younger patients it was higher in benign 
tumours but lower in carcinoma compared to their counterparts.    
  
 We have to admit at this point the difficulties in drawing very conclusive evidence 
on the prevalence of HPV based on subsite analysis in each pathological group. Since 
there was a very uneven distribution of the available samples observed in each anatomic 
site, we focused on the sites which were significantly higher in representative samples 
for meaningful comparison. Therefore, within and between pathological groups, 
comparison could be made possible using the above criteria. In benign tumours for 
instance, buccal mucosa (n=41) and tongue (n=21) were the two more prominent 
subsites. Floor of the mouth (n=12), soft palate (n=34) and tongue (n=20) were 
significantly higher in carcinoma. Since we identified only a single candidate available 
for dysplasia which was floor of the mouth (n=8), comparing with its counterpart in 
carcinoma could be useful. Tongue was the suitable anatomic site to compare between 
benign and carcinoma.  
 
 In benign tissue, HPV6 was commonly present in most of the sites but was 
highest in buccal mucosa (n=15). The high risk HPV types were detected in four 
subsites, upper lip, lower lip, tongue and similarly buccal mucosa was the highest (n=7). 
For other HPV types, two were identified in the tongue, HPV33 and HPV113 and one in 
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buccal mucosa, HPV100. Only one candidate each, HPV16, HPV6 and HPV100 was 
observed in the floor of the mouth of dysplasia patients. 
 
 The last three clinicopathological parameters, tumour size, regional lymph nodes 
and histological grade are only applicable for carcinoma group (Table 4.9). All HPV16 
was only detected in patient’s tissue with 2 cm or less tumour size (T1) and no regional 
lymph node metastasis (N0). In addition, the majority of HPVs were identified in 
patient’s tissue with moderately differentiated. Although HPV6 DNA was amplified in 
all subcategories of clinicopathological parameters concerned, it uniquely demonstrated 
the highest frequency in which HPV16 was present. HPV18, on the other hand, did not 
follow the pattern as such. Thus far, no association was found between typical pattern of 
HPV distribution and specific HPV type. 
      
 Pearson Chi-squared tests were carried out in each clinicopathological groups 
(benign, dysplasia and carcinoma) using the frequency of HPV positivity to determine if 
there is a statistically significant relationship. Phi value (Φ) measures the size effect and 
for 2x2 cross-tabulation with nominal data (df=1) and Cramer’s V for larger crosstabs 
(df=n-1), n is the number of variable. Fisher’s Exact Test was utilised to interpret the 
results for small samples in which chi-squared would be violated. This is the case where 
more than 20% of the cells have expected frequencies less than 5 (Coakes and Steed, 
2000). 
  
 There were no significant differences observed in overall HPV status (Appendix 
44), α-HPV status (Appendix 45) and LR α-HPV status (Appendix 46) in all clinical 
parameters tested. Unlike previous observations, there were significant differences in 
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the frequency of HR α-HPV status (Appendix 47) and  mostly in carcinoma samples for 
age group (p<0.05), disease status (p<0.05), DNA purity (p<0.01) and tumour size 
(p<0.05). Similarly, in benign group this difference was observed only in DNA purity 
(p<0.05). In addition, this frequency appeared comparable in dysplasia group. The phi 
value observed ranging from 0.224 to 0.332 and thus the effect of size is considered to 
be small to medium according to Cohen (1988).  
 
4.8 ODDS RATIO ANALYSIS AMONG DEMOGRAPHIC AND CLINICAL 
PARAMETERS BY HPV STATUS 
 
The analysis of demographic, and clinical  (Table 4.10 and Table 4.11) and 
histopathological risk factor characteristics (Table 4.12 and Table 4.13) of oral cancer in 
each pathological group by overall HPV types and high risk HPV types status were 
carried out. Histopathological risk factor characteristics were applicable only for the 
carcinoma group. It was observed that a statistically significant estimate of odds ratio 
was observed in relation to high risk HPV status for certain parameters but this was not 
the case for overall HPV types for all parameters. In the high risk HPV group, benign 
and carcinoma patients had significant less relative risk in males compared to their 
counterpart [0.2 (0.1-0.5), p<0.001 for benign and 0.3 (0.2-0.6), p<0.001 for carcinoma 
group]. Similarly for age group, older patients had significant less relative risk 
compared to reference group [0.1 (0.1-0.3), p<0.001 for benign and 0.4 (0.2-0.7), 
p<0.001for carcinoma]. For disease status and disease outcome, only carcinoma group 
had significant less relative risk compared to their counterpart [for disease recurrence 
and for living patients] 
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Table 4.10: Demographic and risk factor characteristics of oral cancer by HPV status in each pathological group 
  
 
Parameter 
 
N 
Benign (N=84)  Dysplasia (N=12)  Carcinoma (N=80) 
  HPV- 
(%) 
HPV+ 
(%) 
OR (95%CI) p value  HPV- 
(%) 
HPV+ 
(%) 
OR (95%CI) p value  HPV- 
(%) 
HPV+ 
(%) 
OR (95%CI) p value 
                
Gender 
   Femaleα 
   Male 
 
 
99 
77 
 
21 (51.2) 
20 (48.8) 
 
24 (55.8) 
19 (44.2) 
 
1.0 
0.8 (0.4-2.0) 
 
0.673 
  
4 (57.1) 
3 (42.9) 
 
1 (20.0) 
4 (80.0) 
 
1.0 
0.3 (0.0-2.2) 
 
0.215 
  
22 (57.9) 
16 (42.1) 
 
27 (64.3) 
15 (35.7) 
 
1.0 
1.2 (0.7-2.2) 
 
0.476 
Age group 
   16-57yα 
   58-99y 
 
 
92 
84 
 
 
26 (63.4) 
15 (36.6) 
 
26 (60.5) 
17 (39.5) 
 
1.0 
1.1 (0.5-2.7) 
 
0.781 
  
0(0) 
7 (100.0) 
 
2 (40.0) 
3 (60.0) 
 
N/E 
 
0.999 
  
17 (44.7) 
21 (55.3) 
 
21 (50.0) 
21 (50.0) 
 
1.0 
1.2 (0.7-2.3) 
 
0.517 
Anatomic site 
   Buccal mucosaα 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
10 
3 
39 
2 
8 
4 
1 
41 
 
 
18 (43.9) 
2 (4.9) 
4 (9.8) 
2 (4.9) 
1 (2.4) 
1 (2.4) 
2 (4.9) 
0 (0) 
1 (2.4) 
10 (24.4) 
 
 
23 (53.5) 
1 (2.3) 
2 (4.7) 
0 (0) 
2 (4.7) 
1 (2.3) 
2 (4.7) 
1 (2.3) 
0 (0) 
11 (25.6) 
 
 
1.0 
0.4 (0.0-4.7) 
0.4 (0.1-2.4) 
N/E 
1.6 (0.1-18.7) 
0.8 (0.0-13.4) 
0.8 (0.1-6.1) 
N/E 
N/E 
0.9 (0.3-2.5) 
 
 
0.995 
0.458 
0.309 
0.999 
0.723 
0.866 
0.815 
1.000 
1.000 
0.781 
  
0 (0) 
5 (71.4) 
0 (0) 
1 (14.3) 
1 (14.3) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
1 (20.0) 
3 (60.0) 
0 (0) 
0 (0) 
1 (20.0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
1.0 
N/E 
 
0.6 (0.1-2.5) 
N/E 
 
0.921 
 
 
0.484 
  
1 (2.6) 
4 (10.5) 
1 (2.6) 
0 (0) 
15 (39.5) 
0 (0) 
2 (5.3) 
3 (7.9) 
0 (0) 
12 (31.6) 
 
 
2 (4.8) 
8 (19.0) 
3 (7.1) 
0 (0) 
19 (45.2) 
0 (0) 
2 (4.8) 
0 (0) 
0 (0) 
8 (19.0) 
 
 
1.0 
2.0 (0.2-22.1) 
2.0 (0.6-6.6) 
 
3.0 (0.3-28.8) 
 
1.3 (0.6-2.5) 
1.0 (0.1-7.1) 
 
N/E 
 
0.812 
0.571 
0.258 
 
0.341 
 
0.494 
1.000 
 
0.999 
Disease status  
   No recurrenceα 
   Recurrence 
 
 
171 
5 
 
41 (100.0) 
0 (0) 
 
43 (100.0) 
0 (0) 
 
N/A 
 
 
N/A 
  
7 (100.0) 
0 (0) 
 
5 (100.0) 
0 (0) 
 
N/A 
 
N/A 
  
35 (92.1) 
3 (7.9) 
 
 
40 (95.2) 
2 (4.8) 
 
1.0 
1.1 (0.7-1.8) 
 
0.564 
Disease outcome  
    Aliveα 
    Dead 
 
45 
35 
 
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
 
N/A 
 
N/A 
  
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
 
N/A 
 
N/A 
  
21 (55.3) 
17 (44.7) 
 
24 (57.1) 
18 (42.9) 
 
1.1 (0.5-2.1) 
1.0 
 
0.866 
                
 α – reference group; N/A – not available; N/E not estimable 
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Table 4.11: Demographic and risk factor characteristics of oral cancer by high risk-HPV status in each pathological group 
  
 
 
Parameter 
 
N 
 
Benign (N = 84) 
  
Dysplasia (N = 12) 
  
Carcinoma (N = 80) 
  hrHPV- 
(%) 
hrHPV+ 
(%) 
OR (95%CI) p value  hrHPV- 
(%) 
hrHPV+ 
(%) 
OR (95%CI) p value  hrHPV- 
(%) 
hrHPV+ 
(%) 
OR (95%CI) p value 
                
Gender 
   Femaleα 
   Male 
 
 
99 
77 
 
37 (52.9) 
33 (47.1) 
 
8 (57.1) 
6 (42.9) 
 
1.0 
0.8 (0.3-2.7) 
 
0.769 
  
5 (45.5) 
6 (54.5) 
 
0 (0) 
1 (100.0) 
 
N/E 
 
0.999 
  
38 (56.7) 
29 (43.3) 
 
11 (84.6) 
2 (15.4) 
 
1.0 
0.3 (0.2-0.6) 
 
0.000 
Age group 
   16-57yα 
   58-99y 
 
 
92 
84 
 
 
47 (67.1) 
23 (32.9) 
 
5 (35.7) 
9 (64.3) 
 
1.0 
3.7 (1.1-12.2) 
 
0.034 
  
1(9.1) 
10 (90.9) 
 
1 (100.0) 
0 (0) 
 
1.0 (0.1-16.0) 
 
1.000 
  
28 (41.8) 
39 (58.2) 
 
10 (76.9) 
3 (23.1) 
 
1.0 
0.4 (0.2-0.7) 
 
0.005 
Anatomic site 
   Buccal mucosaα 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
  
 
45 
23 
10 
3 
39 
2 
8 
4 
1 
41 
 
 
33 (47.1) 
3 (4.3) 
5 (7.1) 
2 (2.9) 
3 (4.3) 
1 (1.4) 
2 (2.9) 
1 (1.4) 
1 (1.4) 
19 (27.1) 
 
 
8 (57.1) 
0 (0) 
1 (7.1) 
0 (0) 
0 (0) 
1 (7.1) 
2 (14.3) 
0 (0) 
0 (0) 
2 (14.3) 
 
 
1.0 
 
0.8 (0.1-8.1) 
 
 
4.1 (0.2-73.3) 
4.1 (0.5-33.9) 
 
 
0.4 (0.1-2.3) 
 
 
0.892 
0.999 
0.869 
0.999 
0.999 
0.334 
0.187 
1.000 
1.000 
0.321 
 
  
1 (9.1) 
7 (63.6) 
0 (0) 
1 (9.1) 
2 (18.2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
0 (0) 
1 (100.0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
 
1.0 
N/E 
 
0.1 (0-1.2) 
N/E 
 
0.346 
 
 
0.069 
  
3 (4.5) 
10 (14.9) 
3 (4.5) 
0 (0) 
25 (37.3) 
0 (0) 
4 (6.0) 
3 (4.5) 
0 (0) 
19 (28.4) 
 
 
0 (0) 
2 (15.4) 
1 (7.7) 
0 (0) 
9 (69.2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
1 (7.7) 
 
 
1.0 
N/E 
0.2 (0-0.9) 
 
0.3 (0-3.2) 
 
0.4 (0.2-0.8) 
N/E 
 
N/E 
 
0.059 
0.999 
0.038 
 
0.341 
 
0.009 
0.999 
 
0.999 
Disease status  
   No recurrenceα 
   Recurrence 
 
 
171 
5 
 
70 (100.0) 
0 (0) 
 
14 (100.0) 
0 (0) 
 
N/A 
 
 
N/A 
  
11 (100) 
0 (0) 
 
1 (100) 
0 (0) 
 
N/A 
 
N/A 
  
62 (95.5) 
5 (7.5) 
 
 
13 (100.0) 
0 (0) 
 
1.0 
0.2 (0.1-0.4) 
 
0.000 
Disease outcome  
    Alive 
    Deadα 
 
45 
35 
 
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
 
N/A 
 
N/A 
  
0 (0) 
0 (0) 
 
0 (0) 
0 (0) 
 
N/A 
 
N/A 
  
34 (50.7) 
33 (49.3) 
 
11(84.6) 
2 (15.4) 
 
0.1 (0-0.3) 
1.0 
 
0.000 
                
 α – reference group; N/A – not available; N/E not estimable 
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Table 4.12: Histopathological risk factor properties by HPV status in carcinoma 
group 
 
 
 
Parameter 
 
 
N 
 
Carcinoma (N = 80) 
  HPV- 
(%) 
HPV+ 
(%) 
OR (95%CI) p value 
      
Tumour size 
   T1 (<2 cm)α 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades adjacent structures 
 
 
41 
22 
13 
4 
 
 
19 (50.0) 
14 (36.8) 
4 (10.5) 
1 (2.6) 
 
22 (52.4) 
8 (19.0) 
9 (21.4) 
3 (7.1) 
 
1.0 
1.2 (0.6-2.1) 
0.6 (0.2-1.4) 
2.3 (0.7-7.3) 
 
0.304 
0.640 
0.207 
0.177 
Regional Lymph Nodes 
   N0α 
   N1 
   N2 
 
67 
7 
6 
 
34 (89.5) 
3 (7.9) 
1 (2.6) 
 
33 (78.6) 
4 (9.5) 
5 (11.9) 
 
1.0 
1.0 (0.6-1.6) 
1.3 (0.3-6.0) 
 
0.925 
0.903 
0.706 
      
Histological grade  
   Well differentiatedα 
   Moderately differentiated 
   Poorly differentiated 
   Basaloid 
 
9 
58 
11 
2 
 
7 (18.4) 
28 (73.7) 
2 (5.3) 
1 (2.6) 
 
2 (4.8) 
30 (71.4) 
9 (21.4) 
1 (2.4) 
 
1.0 
1.0 (0.1-16.0) 
4.5 (1.0-21.0) 
1.1 (0.6-0.18) 
 
0.287 
1.000 
0.054 
0.793 
        α – reference group for odds ratio determination; N/A – not available; N/E not estimable 
 
Table 4.13: Histopathological risk factor properties by high risk HPV status in 
carcinoma group 
 
 
 
Parameter 
 
 
N 
 
Carcinoma (N = 80) 
  hrHPV- 
(%) 
hrHPV+ 
(%) 
OR 
(95%CI) 
p 
value 
      
Tumour size 
   T1 (<2 cm)α 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent 
structures 
 
 
41 
22 
13 
4 
 
 
30 
(44.8) 
21 
(31.3) 
13 
(19.4) 
3 (4.5) 
 
11 
(84.6) 
1 (7.7) 
0 (0) 
1 (7.7) 
 
1.0 
0.4 (0.2-0.7) 
0.6 (0-0.4) 
N/E 
 
0.001 
0.004 
0.003 
0.998 
Regional Lymph Nodes 
   N0α 
   N1 
   N2 
 
67 
7 
6 
 
56 
(83.6) 
6 (9.0) 
5 (7.5) 
 
11 
(84.6) 
1 (7.7) 
1 (7.7) 
 
1.0 
1.0 (0.2-0.4) 
1.3 (0-1.4) 
 
0.000 
0.000 
0.097 
      
Histological grade  
   Well differentiatedα 
   Moderately differentiated 
   Poorly differentiated 
   Basaloid 
 
9 
58 
11 
2 
 
9 (13.4) 
46 
(68.7) 
10 
(14.9) 
2 (3.0) 
 
0 (0) 
1 (7.7) 
12 
(92.3) 
0 (0) 
 
1.0 
N/E 
0.1 (0-0.8) 
0.3 (0.1-0.5) 
 
0.000 
0.999 
0.028 
0.000 
       α – reference group for odds ratio determination; N/A – not available; N/E not estimable 
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4.9 CORRELATION BETWEEN DEMOGRAPHIC AND CLINICAL 
PARAMETERS WITH HPV STATUS 
 
The correlation analysis was undertaken to look for any association between clinical 
parameters with HPV status in benign (Appendix 48) dysplasia (Appendix 49) and 
carcinoma (Appendix 50). In each pathological group, comparison were individually 
made based on sub-categories of HPV group i.e. overall HPV status, α-HPV status, LR-
HPV and HR-HPV. 
 
 No significant association was observed in benign and dysplasia for overall HPV, 
α-HPV, LR-HPV status. HR-HPV on the other hand, demonstrated significant 
negatively association for DNA purity in benign (r=-0.224, p<0.05) and age group in 
dysplasia (r=-0.674, p<0.05). 
 
 Most of the associations between HPV status and the parameters concerned were 
found in carcinoma patients. HR-HPV status for instance, was positively associated 
with disease status (r=0.252, p<0.05) and DNA purity (r=-0.332, p<0.01) and yet, 
negatively correlated with age group (r=-0.260, p<0.05). Moreover, significant 
association observed between α-HPV/LR-HPV status and regional lymph nodes, 
(r=0.227, p<0.05) and (r=-0.251, p<0.05), respectively. Only single correlation 
observed in this group to positively linked between LR-HPV with tumour size (r=0.242, 
p<0.05) but exhibited negative association between overall HPV and histological grade 
(r=-0.250, p<0.05).    
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4.10 SURVIVAL ANALYSIS (N=80)  
 
Survival was measured in months from the date of diagnosis until death or until the 
patient was last known to be alive. The Kaplan-Meier curve of survival followed by Log 
Rank (Mantel-Cox) test was used to investigate whether there was an association 
between the clinical parameters and patients survival. All survival curves were 
generated in SPSS ver.16. Continuous data values were divided by the median and 
comparisons were made using the log-rank test. Since the above technique is the 
univariate version of survival analysis, later by performing Cox regression analysis it 
will further assisting the actual effect of confounders on the survival of the patient.  
 
 Cox proportional hazard models were used to assess the relationships between 
HPV and clinical/histopathological characteristics and to adjust for factors previously 
found to be prognostically significant in oral cancer. These analyses included gender, 
age group, anatomic site, tumour site, regional lymph nodes, histological grade, disease 
recurrence and HPV status also were examined in separate models. All variables were 
assessed for the proportional hazard assumption before inclusion in the models. The 
magnitude of the associations was assessed with hazard ratios (HRs) calculated from the 
Cox regression models. Statistically significance was based on two-tailed tests and p-
values < 0.05. Statistical analyses were performed using SPSS 16.0. 
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4.10.1 Kaplan-Meier Survival Analysis 
 
The results suggested that the overall patient survival was worst in six groups (Table 
4.14): 
1. Male compared with female (p<0.01) (Figure 4.4). 
2. Older patients age 58 to 99 (p<0.01) (Figure 4.5). 
3. Anatomic site (p<0.01) (Figure 4.6). 
4. Tumour size (p<0.01) (Figure 4.7). 
5. Regional lymph nodes (p<0.01) (Figure 4.8). 
6. Histological grade (p<0.01) (Figure 4.9). 
 
Table 4.14: The prognostic significance from overall survival 
analysis in carcinoma patients 
 
 
Parameter (N=80) Log Rank (Mantel-Cox) 
Chi-Square df Sig. 
    
Gender 11.869 1 0.001** 
Age group 14.055 1 0.000** 
Anatomic site 29.181 6 0.000** 
Tumour size 38.353 3 0.000** 
Regional Lymph Nodes  18.751 2 0.000** 
Histological grade 16.088 3 0.001** 
Recurrence 0.395 1 0.530 
HPV status    0.002 1 0.963 
α-HPV status 0.014 1 0.906 
High risk HPV    3.915 1 0.048* 
Low risk HPV      3.561 1 0.059 
HPV16 status    6.918 1 0.009** 
Other HPV types 0.021 1 0.885 
    
     N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
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Figure 4.4: An association between gender and overall 
survival as generated by Kaplan-Meier test. Vertical tick 
marks on curves indicate censored observations. 
 
 
Figure 4.5: An association between age group and overall 
survival as generated by Kaplan-Meier test. 
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Figure 4.6: An association among anatomic sites and overall 
survival as generated by Kaplan-Meier test. 
 
 
 
Figure 4.7: An association among tumour size and overall 
survival as generated by Kaplan-Meier test. 
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Figure 4.8: An association among regional lymph nodes and 
overall survival as generated by Kaplan-Meier test. 
 
 
Figure 4.9: An association among histological grade and 
overall survival as generated by Kaplan-Meier test. 
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4.10.2 Cox Regression Model 
 
Table 4.15: The summary of the survival analysis done by Cox regression 
 
 
 
Parameter (N=80) 
 
Cox Regression Model 
Wald df Sig. 
    
Gender 10.4888 1 0.001** 
Age group 11.763 1 0.001** 
Anatomic site 21.830 6 0.001** 
Tumour size 24.560 3 0.000** 
Regional Lymph Nodes  15.469 2 0.000** 
Histological grade 13.598 3 0.004** 
Recurrence 0.381 1 0.537 
HPV status    0.002 1 0.963 
α-HPV status 0.014 1 0.907 
High risk HPV    3.312 1 0.069 
Low risk HPV      3.363 1 0.067 
HPV16 status    2.699 1 0.100 
Other HPV types 0.021 1 0.886 
    
     N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
 
4.11 CONCLUSIONS 
 
Our results thus far from this cohort could conclude: 
1. DNA extraction from 183 FFPETs 
• The DNA extraction method that had been established in the pilot study was 
employed in this bigger cohort and successfully isolated DNA from 183 
FFPETs. 
• No significant difference was observed in relation to DNA yield and DNA 
purity amongst oral benign lesions, dysplasia, carcinoma and normal samples. 
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2. PCR amplification for L1 HPV detection 
• The first round of an initial DNA quality screening of FFPETs (as assessed by 
the amplification of the β-globin fragment by PCR) was 168/183 (91.8%), by 
repeating the process with the initial failures (15 samples) it finally increased 
the success rate to 100%.    
• Regardless of the pathological group, we successfully amplified 137/176 
(77.8%) of presumptive positive L1 HPV fragment by PCR.    
3. Purification and DNA sequencing of the PCR products 
• All 137 fragments were successfully purified and most of them by using a Gel 
Extraction Kit. 
• DNA sequencing of the shortest fragment, 140bp and multiple DNA sequence 
alignment confirmed the true L1 HPV amplicons were 90/137 (65.7%). 
• The justification not to omit 47 amplicons (which were finally identified as 
false positive PCR products) was due to the fact they resembled the expected 
amplicon size but had lower PCR band intensity, compared to the positive 
control.   
4. HPV prevalence in benign, dysplasia, carcinoma and normal samples 
• The distribution of HPV detected in each pathological group was 43/84 
(51.2%) in benign, 5/12 (41.7%) in dysplasia, 42/80 (52.5%) in carcinoma and 
1/7 (14.3%) in normal samples tested. 
• Overall HPV positivity, their prevalence was not statistically significant 
different amongst pathological groups. 
• A comparison based on HPV type specific demonstrated very significant 
differences especially for high risk HPV and HPV6. 
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5. Determination of an association between HPV status and disease progression 
• Across the pathological groups from benign to carcinoma, generally we found 
an increase in significant association between HPV status and 
demographic/clinical parameters.  
• At this point, we could deduce a generalisation by stating the relatedness of 
HPVs status on oral disease progression.  
• Despite dominating all the associations regardless of the pathological groups, 
HR-HPV appeared not to have any connection with clinical parameters. 
• If there was HPV-related case to clinical parameters, the candidate was LR-
HPV.  
6. Potential association with survival by HPV status 
• Kaplan-Meier test revealed that patient survival was worst in male, younger 
individuals, carcinoma located at the gingivae, T2 tumour size (2-4 cm), N1 
nodes and poorly differentiated tissues and these were confirmed by Cox 
Regression analysis.   
• Unfortunately, none of the factors could be related to HPV status. 
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CHAPTER 5 
 
p16 AND ORAL DISEASE PROGRESSION 
 
5.1 OVERVIEW 
 
An overview of the aims of this chapter is given as follows: 
• To investigate the expression of p16 of the benign oral lesions, dysplasias and 
carcinomas. 
• To investigate the p16 status, p16 staining intensity, demographic and 
clinicopathological parameters by comparison of the benign, dysplasia and 
carcinoma samples. 
• To investigate the correlation among demographic and clinical parameters 
associated with p16. 
• To investigate the potential association with survival for p16 (for carcinoma group 
since survival data was available for this group only). 
 
5.2 CLINICAL DATA 
 
A similar cohort of 183 cases with histologically confirmed benign, dysplasia and 
squamous cell carcinoma of various anatomic sites (which were previously utilised for 
HPV genotyping) was initially used in this study. The clinical details of 183 samples 
from those patients were previously described in appropriate section of Chapter 4. 
Unfortunately, two samples (NS02007899 1 and NS02008655 1A) of the benign group 
were excluded from this study due to insufficient tissue to be analysed. As a result, 82 
samples were available for p16 expression study in this group. Therefore, the total 
number in this cohort was 181 (Table 5.1). 
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Table 5.1: Clinical details of oral cancer patients 
 
 
Characteristic N  
Benign 
N (%) 
Dysplasia 
N (%) 
Carcinoma 
N (%) 
Total 
 
174  82 (47.1) 12 (6.9) 80 (46.0) 
Gender 
   Female 
   Male 
 
 
97 
77 
 
43 (44.3) 
39 (50.6) 
 
5 (5.2) 
7 (9.1) 
 
49 (50.5) 
31 (40.3) 
Age group1 (range, 16-99y) 
   16-57y 
   58-99y 
 
 
90 
84 
 
50 (55.6) 
32 (38.1) 
 
2 (2.2) 
10 (11.9) 
 
38 (42.2) 
42 (50.0) 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
9 
3 
39 
2 
8 
4 
1 
40 
 
 
41 (91.1) 
3 (13.0) 
5 (55.6) 
2 (66.7) 
3 (7.7) 
2 (100.0) 
4 (50.0) 
1 (25.0) 
1 (100.0) 
20 (50.0) 
 
 
1 (2.2) 
8 (34.8) 
0 (0.0) 
1 (33.3) 
2 (5.1) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
 
3 (6.7) 
12 (52.2) 
4 (44.4) 
0 (0.0) 
34 (87.2) 
0 (0.0) 
4 (50.0) 
3 (75.0) 
0 (0.0) 
20 (50.0) 
 
Disease status  
   No recurrence 
   Recurrence 
 
 
169 
5 
 
82 (48.5) 
0 (0.0) 
 
12 (7.1) 
0 (0.0) 
 
75 (44.4) 
5 (100.0) 
Disease outcome (N=80) 
    Alive 
    Dead 
 
 
45 
35 
 
0 (0.0) 
0 (0.0) 
 
0 (0.0) 
0 (0.0) 
 
45 (100.0) 
35 (97.2) 
Note: N, number of patients 1 Age group was based on median age 
 
5.3 RESULTS 
 
A representative of tissue specimens positively stained with the p16 antibody in the 
benign, dysplastic and carcinoma as compared with normal tissue are given in Figure 
5.1. The result of staining of all the normal tissues with anti-p16 antibody was negative.  
All p16 IHC slides were semi-quantitatively assessed as was described in Chapter 2 in 
which p16 positivity and p16 staining intensity were taken into account. As expected, 
variation exists within and between pathological groups in relation to p16 status, nuclear 
and/or cytoplasmic staining was considered for the simplicity of the p16 positivity and 
intensity determination.  
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Figure 5.1: Photomicrograph of p16 staining across pathological groups. 
(A) Normal, (B) Benign, (C) Dysplasia and (D) Carcinoma at x100 
magnification (rectangular) and x400 magnification (circle) 
A 
B 
C 
D 
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Figure 5.2: Overall p16 status in each pathological group 
 
 
Figure 5.3: The frequency of p16 staining intensity in each pathological 
group. N = number of samples; the frequency and the percentage (%) 
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5.3.1 A comparison of p16 expression in benign, dysplasia and carcinoma groups 
 
In this cohort, it was demonstrated that 110/174 cases (63.2%) were positive for p16 
staining and the rest, 64/174 cases (36.8%) were negative, regardless of their 
pathological groups. Figure 5.2 shows the positive expression of p16, 42/82 (51.2%) in 
benign, 8/12 (66.7%) in dysplasia and 60/80 (75.0%) in carcinoma samples. The 
Kruskal-Wallis test indicates that p16 positivity significantly differs across the three 
pathological groups (p < 0.01) [Table 5.2 (b)]. The Mann-Whitney U test was carried 
out separately, to compare p16 positivity between benign versus dysplasia groups, 
benign versus carcinoma groups and dysplasia versus carcinoma groups. We found that 
p16 positivity in the carcinoma group was significantly higher compared to benign 
group (p < 0.01) [Table 5.2 (d)]. Whereas, p16 positive between carcinoma and 
dysplasia groups (p = 0.542) or between dysplasia and benign groups (p = 0.319) was 
comparable.  
 
 We observed the proportion of p16 staining intensity (2+ score) in carcinoma was 
34/80 (42.5%), more than double that shown in benign group, 17/82 (20.7%). The final 
ratio of 3+ score of the former group was 4:1 compared to dysplasia group. The former 
group, on the contrary, exhibited more than fifty percent less negative p16 staining 
compared to the latter group. Similarly, there was a significantly different in overall p16 
staining intensity across pathological group (p < 0.001) [Table 5.3 (b)]. We revealed 
that overall p16 staining intensity in carcinoma group was significantly higher 
compared to benign group (p < 0.001) [Table 5.3 (d)]. In addition, p16 staining intensity 
in dysplasia group was significantly higher compared to benign group (p = 0.036). 
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There were no significant different between carcinoma and dysplasia groups (p = 
0.845). 
 
Table 5.2: Kruskal-Wallis and Mann-Whitney tests on p16 positivity 
(a) 
Ranks 
Pathological group N Mean Rank 
p16 positivity Benign 82 77.06 
Dysplasia 12 90.50 
Carcinoma 80 97.75 
Total 174  
 
(b) 
Test Statisticsa,b 
 p16 positivity 
Chi-Square 9.857 
df 2 
Asymp. Sig. .007 
a. Kruskal Wallis Test 
b. Grouping Variable: Pathological group 
 
(c) 
Ranks 
Pathological group N Mean Rank Sum of Ranks 
p16 positivity Benign 82 71.99 5903.00 
Carcinoma 80 91.25 7300.00 
Total 162   
 
(d) 
Test Statisticsa 
 p16 status 
Mann-Whitney U 2500.000 
Wilcoxon W 5903.000 
Z -3.124 
Asymp. Sig. (2-tailed) .002 
a. Grouping Variable: Pathological group 
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Table 5.3: Kruskal-Wallis and Mann-Whitney tests on p16 staining intensity 
(a) 
Ranks 
Pathological group  N Mean Rank 
p16 intensity Benign 82 70.52 
Dysplasia 12 103.17 
Carcinoma 80 102.55 
Total 174  
 
(b) 
Test Statisticsa,b 
 p16 intensity 
Chi-Square 19.559 
df 2 
Asymp. Sig. .000 
a. Kruskal Wallis Test 
b. Grouping Variable: Pathological group 
 
(c) 
Ranks 
Pathological group N Mean Rank Sum of Ranks 
p16 intensity Benign 82 66.62 5463.00 
Carcinoma 80 96.75 7740.00 
Total 162   
 
 
(d) 
Test Statisticsa 
 p16 intensity 
Mann-Whitney U 2060.000 
Wilcoxon W 5463.000 
Z -4.310 
Asymp. Sig. (2-tailed) .000 
a. Grouping Variable: Pathological group 
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Figure 5.4: Photomicrograph of p16 staining across histological grade.  
(A) Well differentiated (B) Moderately differentiated (C) Basaloid and (D) Poorly 
differentiated at x100 magnification (rectangular) and x400 magnification (circle) 
 
A 
B 
C 
D 
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5.3.2 A comparison of p16 status according to demographic and clinical 
parameters in each pathological group  
 
The Chi-squared, the Kruskal-Wallis H and the Mann-Whitney U tests were utilised for 
this comparison where appropriate. In benign and dysplasia groups, no significant 
difference was observed in both p16 positivity and p16 staining intensity across the 
following parameters, gender, age group, anatomic sites, diseases status and disease 
outcome (Table 5.4). Similar results were observed in both pathological groups in 
relation to p16 staining intensity (Table 5.5).  
 
 Unlike the first 2 groups, in carcinoma group, significantly higher p16 positivity 
and p16 staining intensity was found in males compared to their counterparts (p<0.01). 
Younger patients, on the other hand, demonstrated significantly less p16 positivity and 
staining intensity compared to the older ones (p<0.001). Overall comparison of p16 
status resulted in a significant difference based on anatomic sites at p<0.001 in both 
parameters (p16 positivity and p16 staining intensity). Among seven anatomic sites, we 
regrouped them into two distinct groups based on the overall percentage of p16 
positivity and p16 staining intensity. The first (with lower percentage of p16 positivity 
and p16 staining intensity) consisted of buccal mucosa, gingivae, retromolar pad and 
lower lip. The members of the second group (with higher percentage of p16 positivity 
and p16 staining intensity) were floor of the mouth, soft palate and the tongue. No 
significant difference was observed in both parameters compared to the first group. p16 
positivity and p16 staining intensity were demonstrated to be significantly different in 
the second group. Both parameters were significantly higher in the tongue compared to 
soft palate [(p<0.01) and (p<0.001) for p16 positivity and p16 staining intensity, 
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respectively]. Similarly, p16 positivity and p16 staining intensity were higher in floor of 
the mouth compared to soft palate at (p<0.05) and (p<0.01), respectively. The tongue 
and floor of the mouth appeared to be comparable for p16 status [(p=0.716) and 
(p=0.158)]. In addition, higher p16 positivity and p16 staining intensity observed in 
deceased patients at p<0.001 in both parameters. 
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Table 5.4: A comparison of p16 positivity in each pathological group 
 
 
 
 
Parameter 
 
 
N 
 
Benign (N = 82) 
  
Dysplasia (N = 12) 
  
Carcinoma (N = 80) 
  p16- 
(%) 
p16+ 
(%) 
χ2 p value  p16- 
(%) 
p16+ 
(%) 
χ2 p value  p16- 
(%) 
p16+ 
(%) 
χ2 p value 
                
Gender 
   Female 
   Male 
 
 
97 
77 
 
19 (47.5) 
21 (52.5) 
 
24 (57.1) 
18 (42.9) 
 
0.76 
 
 
0.382 
  
3 (75.0) 
1 (25.0) 
 
2 (25.0) 
6 (75.0) 
 
2.74 
 
 
0.098 
  
19 (95.0) 
1 (5.0) 
 
30 (50.0) 
30 (50.0) 
 
12.80** 
 
 
0.000 
Age group 
   16-57y 
   58-99y 
 
 
90 
84 
 
 
25 (62.5) 
15 (37.5) 
 
25 (59.5) 
17 (40.5) 
 
0.08 
 
 
0.782 
  
- 
4 (100.0) 
 
2 (25.0) 
6 (75.0) 
 
1.20 
 
0.273 
  
18 (90.0) 
2 (10.0) 
 
20 (33.3) 
40 (66.7) 
 
19.32** 
 
 
0.000 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
9 
3 
39 
2 
8 
4 
1 
40 
 
 
17 (42.5) 
1 (2.5) 
3 (7.5) 
2 (5.0) 
2 (5.0) 
1 (2.5) 
2 (5.0) 
1 (2.5) 
1 (2.5) 
10 (25.0) 
 
 
24 (57.1) 
2 (4.8) 
2 (4.8) 
- 
1 (2.4) 
1 (2.4) 
2 (4.8) 
- 
- 
10 (23.8) 
- 
 
6.02 
 
 
0.738 
  
- 
3 (75.0) 
- 
1 (25.0) 
- 
- 
- 
- 
- 
- 
 
 
1 (12.5) 
5 (62.5) 
- 
- 
2 (25.0) 
- 
- 
- 
- 
- 
 
 
3.56 
 
 
 
0.313 
 
 
 
  
- 
1 (5.0) 
1 (5.0) 
- 
18 (90.0) 
- 
- 
- 
- 
- 
 
 
3 (5.0) 
11 (18.3) 
3 (5.0) 
- 
16 (26.7) 
- 
4 (6.7) 
3 (5.0) 
- 
20 (33.3) 
 
 
25.94** 
 
 
0.000 
 
Disease status  
   No recurrence 
   Recurrence 
 
 
169 
5 
 
40 (100.0) 
- 
 
42 (100.0) 
- 
 
N/A 
 
 
N/A 
  
4 (100.0) 
- 
 
8 (100.0) 
- 
 
N/A 
 
N/A 
  
20 (100) 
- 
 
 
55 (91.7) 
2 (8.3) 
 
1.78 
 
 
0.182 
Disease outcome  
    Alive 
    Dead 
 
45 
35 
 
- 
- 
 
- 
- 
 
N/A 
 
N/A 
  
- 
- 
 
- 
- 
 
N/A 
 
N/A 
  
19 (95.0) 
1 (5.0) 
 
26 (43.3) 
34 (56.7) 
 
16.27** 
 
 
0.000 
                
N/A; not available; ** Statistically significant at the 0.01 level and * at the 0.05 level 
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Table 5.5: A comparison of p16 staining intensity in each pathological group 
 
 
 
 
Parameter 
 
 
N 
 
Benign (N = 82) 
  
Dysplasia (N = 12) 
  
Carcinoma (N = 80) 
  Neg  
(%) 
1+ 
(%) 
2+  
(%) 
3+ 
(%) 
χ2 p value  Neg  
(%) 
1+ 
(%) 
2+  
(%) 
3+ 
(%) 
χ2 p value  Neg  
(%) 
1+ 
(%) 
2+  
(%) 
3+ 
(%) 
χ2 p value 
                      
Gender 
   Female 
   Male 
 
 
97 
77 
 
19 (47) 
21 (53) 
 
14 (56) 
11 (44) 
 
10 (59) 
7 (41) 
 
- 
- 
 
0.80 
 
 
0.672 
  
3 (75) 
1 (25) 
 
- 
1 (100) 
 
1 (20) 
4 (80) 
 
1 (50) 
1 (50) 
 
3.57 
 
 
0.312 
  
19 (95) 
1 (5) 
 
11 (61) 
7 (39) 
 
17 (50) 
17 (50) 
 
2 (25) 
6 (75) 
 
15.84** 
 
 
0.001 
Age group 
   16-57y 
   58-99y 
 
 
90 
84 
 
 
25 (63) 
15 (37) 
 
14 (56) 
11 (44) 
 
11 (65) 
6 (35) 
 
- 
- 
 
0.40 
 
 
0.819 
  
- 
4 (100) 
 
1 (100) 
- 
 
1 (20) 
4 (80) 
 
- 
2 (100) 
 
6.24 
 
0.100 
  
18 (90) 
2 (10) 
 
9 (50) 
9 (50) 
 
 
9 (26) 
25 (74) 
 
2 (25) 
6 (75) 
 
22.19** 
 
 
0.000 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
9 
3 
39 
2 
8 
4 
1 
40 
 
 
17 (42) 
1 (2) 
3 (7) 
2 (5) 
2 (5) 
1 (2) 
2 (5) 
1 (2) 
1 (2) 
10 (25) 
 
 
15 (60) 
2 (8) 
1 (7) 
- 
- 
- 
2 (8) 
- 
- 
5 (20) 
 
 
9 (53) 
- 
1 (6) 
- 
1 (6) 
1 (6) 
- 
- 
- 
5 (29) 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
12.03 
 
 
0.845 
  
- 
3 (75) 
- 
1 (25) 
- 
- 
- 
- 
- 
- 
 
 
- 
1 (100) 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
1 (20) 
3 (60) 
- 
- 
1 (20) 
- 
- 
- 
- 
- 
 
 
- 
1 (50) 
- 
- 
1 (50) 
- 
- 
- 
- 
- 
 
 
5.93 
 
 
 
0.747 
 
 
 
  
- 
1 (5) 
1 (5) 
- 
18 (90) 
- 
- 
- 
- 
- 
 
 
- 
3 (17) 
1 (6) 
- 
7 (21) 
- 
2 (11) 
1 (6) 
- 
4 (22) 
 
 
3 (9) 
8 (24) 
2 (6) 
- 
7 (21) 
- 
2 (6) 
2 (6) 
- 
10 (29) 
 
 
- 
- 
- 
- 
2 (25) 
- 
- 
- 
- 
6 (75) 
 
 
41.57** 
 
 
0.001 
 
Disease status  
   No recurrence 
   Recurrence 
 
 
169 
5 
 
40 (100) 
- 
 
25 (100) 
- 
 
17 (100) 
- 
 
- 
- 
 
N/A 
 
 
N/A 
  
4 (100) 
- 
 
1 (100) 
- 
 
5 (100) 
- 
 
2 (100) 
- 
 
N/A 
 
N/A 
  
20 (100) 
- 
 
18 (100) 
- 
 
30 (88) 
4 (12) 
 
7 (87) 
1 (13) 
 
4.83 
 
 
0.185 
Disease outcome  
    Alive 
    Dead 
 
45 
35 
 
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
N/A 
 
N/A 
  
- 
- 
 
- 
- 
 
- 
- 
 
- 
- 
 
N/A 
 
N/A 
  
1 (5) 
19 (95) 
 
7 (39) 
11 (61) 
 
21 (62) 
13 (38) 
 
6 (75) 
2 (25) 
 
20.03** 
 
 
0.000 
                      
N/A - not available; ** Statistical significant at the 0.01 level and * at the 0.05 level 
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Table 5.6: A comparison of p16 positivity in carcinoma group only 
 
 
 
 
Parameter 
 
 
N 
 
Carcinoma (N = 80) 
  p16- 
(%) 
p16+ 
(%) 
χ2 p value 
      
Tumour size 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  
adjacent structures 
 
 
41 
22 
13 
4 
 
 
20 (100.0) 
0 (0) 
0 (0) 
0 (0) 
 
21 (35.5) 
22 (36.7) 
13 (21.7) 
4 (6.7) 
 
25.37** 
 
 
0.000 
 
Regional Lymph Nodes 
   N0 
   N1 
   N2 
 
67 
7 
6 
 
19 (95.0) 
0 (0) 
1 (5.0) 
 
48 (80.0) 
7 (11.7) 
5 (8.3) 
 
2.96 
 
 
0.228 
 
      
Histological grade  
   Well differentiated 
   Moderately differentiated 
   Basaloid 
   Poorly differentiated 
 
9 
58 
2 
11 
 
0 (0) 
19 (95.0) 
1 (5.0) 
0 (0) 
 
9 (15.0) 
39 (65.0) 
1 (1.7) 
11 (18.3) 
 
9.20* 
 
 
0.027 
 
      
  N/A - not available; ** Statistical significant at the 0.01 level and * at the 0.05 level 
 
 
Table 5.7: A comparison of p16 staining intensity in carcinoma group only 
 
 
 
 
Parameter 
 
 
N 
 
Carcinoma (N = 80) 
   Neg (%) 1+ (%) 2+ (%) 3+ (%) χ2 p value 
        
Tumour size 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  
adjacent structures 
 
 
41 
22 
13 
4 
 
 
20 (100.0) 
- 
- 
- 
 
11 (61.1) 
5 (27.8) 
- 
2 (11.1) 
 
9 (26.5) 
12 (35.3) 
11 (32.4) 
2 (5.9) 
 
1 (12.5) 
5 (62.5) 
2 (25.0) 
- 
 
40.62** 
 
 
0.000 
 
Regional Lymph Nodes 
   N0 
   N1 
   N2 
 
67 
7 
6 
 
19 (95.0) 
- 
1 (5.0) 
 
14 (77.8) 
2 (11.1) 
2 (11.1) 
 
26 (76.5) 
5 (14.7) 
3 (8.8) 
 
8 (100.0) 
- 
- 
 
5.95 
 
 
0.429 
 
        
Histological grade  
   Well differentiated 
   Moderately differentiated 
   Basaloid 
   Poorly differentiated 
 
9 
58 
2 
11 
 
- 
19 (95.0) 
1 (5.0) 
- 
 
4 (22.2) 
13 (72.2) 
- 
1 (5.6) 
 
4 (11.8) 
21 (61.8) 
1 (2.9) 
8 (23.5) 
 
9 (15.0) 
5 (62.5) 
- 
2 (25.0) 
 
14.15 
 
 
0.117 
 
        
N/A - not available; ** Statistical significant at the 0.01 level and * at the 0.05 level 
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 p16 positivity (Table 5.6) and p16 staining intensity (Table 5.7) were significantly 
different across tumour size in carcinoma group (χ2=25.4, p<0.001) and (χ2=40.6, 
p<0.001), respectively. Within tumour size comparisons were made and we observed T3 
and T2 tumour size, each were significantly higher compared to T1 for p16 status [each 
at p<0.01 and p<0.001 for p16 positivity and p16 staining intensity, respectively]. 
Comparison amongst T2, T3 and T4 for p16 status appeared to be comparable. No 
significant difference was observed for p16 status in the regional lymph nodes and 
similarly for p16 staining intensity in histological grade. This was not the case for p16 
positivity where overall histological grade was significantly different at p<0.05. p16 
positivity in well and poorly differentiated tissues were significantly higher over 
moderately differentiated tissues at p=0.044 and p=0.027, respectively. 
 
5.4 THE RISK FACTORS AMONG DEMOGRAPHIC AND CLINICAL 
PARAMETERS BY p16 STATUS 
 
The analysis of demographic and clinical (Table 5.8) and histopathological risk factor 
characteristics (Table 5.9) of oral cancer in each pathological group by p16 status were 
carried out. The data on histopathological risk factor characteristics were available only 
for carcinoma group for this study. In carcinoma patients, the odds ratio was statistically 
significant different for disease recurrence [OR=2.7, 95%CI (1.6-4.6), p<0.001] and 
regional lymph nodes [OR=2.5, 95%CI (1.5-4.3), p<0.01] by p16 status compared to 
reference group. 
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Table 5.8: Demographic and risk factor characteristics by p16 status in each pathological group 
 
 
 
 
Parameter 
 
 
N 
 
Benign (N = 82) 
  
Dysplasia (N = 12) 
  
Carcinoma (N = 80) 
  p16- 
(%) 
p16+ 
(%) 
OR (95%CI) p value  p16- 
(%) 
p16+ 
(%) 
OR (95%CI) p value  p16- 
(%) 
p16+ 
(%) 
OR (95%CI) p value 
                
Gender 
   Femaleα 
   Male 
 
 
97 
77 
 
19 (47.5) 
21 (52.5) 
 
24 (57.1) 
18 (42.9) 
 
1.0 
0.7 (0.3-1.6) 
 
0.383 
  
3 (75.0) 
1 (25.0) 
 
2 (25.0) 
6 (75.0) 
 
1.0 
0.7 (0.1-4.0) 
 
0.657 
  
19 (95.0) 
1 (5.0) 
 
30 (50.0) 
30 (50.0) 
 
1.0 
1.6 (0.9-2.8) 
 
0.119 
Age group 
   16-57yα 
   58-99y 
 
 
90 
84 
 
 
25 (62.5) 
15 (37.5) 
 
25 (59.5) 
17 (40.5) 
 
1.0 
1.1 (0.5-2.8) 
 
0.782 
  
- 
4 (100.0) 
 
2 (25.0) 
6 (75.0) 
 
N/E 
 
0.999 
  
18 (90.0) 
2 (10.0) 
 
20 (33.3) 
40 (66.7) 
 
1.0 
1.1 (0.6-2.1) 
 
0.746 
Anatomic site 
   Buccal mucosaα 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
    
 
45 
23 
9 
3 
39 
2 
8 
4 
1 
40 
 
 
17 (42.5) 
1 (2.5) 
3 (7.5) 
2 (5.0) 
2 (5.0) 
1 (2.5) 
2 (5.0) 
1 (2.5) 
1 (2.5) 
10 (25.0) 
 
 
24 (57.1) 
2 (4.8) 
2 (4.8) 
- 
1 (2.4) 
1 (2.4) 
2 (4.8) 
- 
- 
10 (23.8) 
- 
 
1.0 
1.4 (0.1-16.9) 
0.5 (0.1-3.1) 
N/E 
0.4 (0.0-4.2) 
0.7 (0.0-12.1) 
0.7 (0.1-5.5) 
N/E 
N/E 
0.7 (0.2-2.1) 
 
 
0.997 
0.783 
0.437 
0.999 
0.412 
0.812 
0.742 
1.000 
1.000 
0.529 
 
  
- 
3 (75.0) 
- 
1 (25.0) 
- 
- 
- 
- 
- 
- 
 
 
1 (12.5) 
5 (62.5) 
- 
- 
2 (25.0) 
- 
- 
- 
- 
- 
 
 
1.0 
N/E 
 
1.7 (0.4-7.0) 
N/E 
 
0.921 
 
 
0.484 
  
- 
1 (5.0) 
1 (5.0) 
- 
18 (90.0) 
- 
- 
- 
- 
- 
 
 
3 (5.0) 
11 (18.3) 
3 (5.0) 
- 
16 (26.7) 
- 
- 
4 (6.7) 
3 (5.0) 
20 (33.3) 
 
 
1.0 
N/E 
11 (1.4-85.2) 
 
3.0 (0.3-28.8) 
 
0.9 (0.5-1.7) 
N/E 
 
N/E 
 
0.391 
0.999 
0.022 
 
0.341 
 
0.732 
0.999 
 
0.999 
Disease status  
   No recurrenceα 
   Recurrence 
 
 
169 
5 
 
40 (100.0) 
- 
 
42 (100.0) 
- 
 
N/A 
 
 
N/A 
  
4 (100.0) 
0 (0) 
 
8 (100.0) 
- 
 
N/A 
 
N/A 
  
20 (100) 
- 
 
 
55 (91.7) 
2 (8.3) 
 
1.0 
2.7 (1.6-4.6) 
 
0.000 
Disease outcome  
    Alive 
    Deadα 
 
45 
35 
 
- 
- 
 
- 
- 
 
 
N/A 
 
 
N/A 
  
- 
- 
 
- 
- 
 
N/A 
 
N/A 
  
19 (95.0) 
1 (5.0) 
 
26 (43.3) 
34 (56.7) 
 
1.4 (0.8-2.5) 
1.0 
 
0.299 
                
α – reference group; N/A; not available; N/E – not estimable 
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Table 5.9: Histopathological risk factor properties by p16 status in carcinoma 
group 
 
 
 
 
Parameter 
 
 
N 
 
Carcinoma (N = 80) 
  p16- 
(%) 
p16+ 
(%) 
OR (95%CI) p value 
      
Tumour size 
   T1 (<2 cm)α 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent structures 
 
 
41 
22 
13 
4 
 
 
20 (100.0) 
- 
- 
- 
 
21 (35.5) 
22 (36.7) 
13 (21.7) 
4 (6.7) 
 
1.0 
1.1 (0.6-1.9) 
N/E 
N/E 
 
0.999 
0.876 
0.998 
0.998 
Regional Lymph Nodes 
   N0α 
   N1 
   N2 
 
67 
7 
6 
 
19 (95.0) 
- 
1 (5.0) 
 
48 (80.0) 
7 (11.7) 
5 (8.3) 
 
1.0 
2.5 (1.5-4.3) 
N/E 
 
0.003 
0.001 
0.999 
      
Histological grade  
   Well differentiatedα 
   Moderately differentiated 
   Poorly differentiated1 
   Basaloid 
 
9 
58 
11 
2 
 
- 
19 (95.0) 
- 
1 (5.0) 
 
9 (15.0) 
39 (65.0) 
11 (18.3) 
1 (1.7) 
 
1.0 
N/E 
2.1 (0.12-34.6) 
N/E 
 
0.010 
0.999 
0.618 
0.999 
      
  α – reference group; N/E – not estimable 
 
5.5 CORRELATION BETWEEN DEMOGRAPHIC/CLINICOPATHOLOGI-
CAL PARAMETERS AND p16 STATUS  
 
The correlation analysis was undertaken searching for any association between clinical 
parameters in benign, dysplasia and carcinoma with p16 positivity (Appendix 51) and 
p16 staining intensity (Appendix 52). No association was observed in all demographic 
and clinical parameters with p16 status in benign and dysplasia groups.  
 
 p16 positivity was associated with gender (r=0.400, p<0.001), age group 
(r=0.491, p<0.001), tumour size (r=0.416, p<0.001) but exhibited negative association 
for disease status (r=-0.451, p<0.001) in carcinoma patients. p16 staining intensity 
demonstrated positive correlation with gender (r=0.359, p<0.01), age group (r=0.524, 
p<0.001), anatomic site (r=0.242, p<0.001), disease outcome (rho=0.222, p<0.05), 
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p<0.001), tumour size (r=0.471, p<0.001) and was negatively associated in disease 
status (r=-0.448, p<0.001). 
 
5.6 SURVIVAL ANALYSIS 
 
This analysis is only applicable for the carcinoma group, in which relying upon the data 
of patient survival (alive/dead) and the sample size is 80. 
 
5.6.1 Kaplan-Meier Survival Analysis 
 
The results of this analysis suggested that the overall patient survival was worse in one 
group (Table 5.8): 
1. p16 positive patients compared with the negative ones (p<0.05) (Figure 5.5). 
 
 
Figure 5.5: An association between p16 positivity and overall 
survival as generated by Kaplan-Meier test. Vertical tick 
marks on curves indicate censored observations. 
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Table 5.10: The prognostic significance from overall survival 
analysis in carcinoma patients 
 
 
Parameter (N=80) Log Rank (Mantel-Cox) 
Chi-Square df Sig. 
    
p16 positivity 12.568 1 0.000** 
p16 staining intensity 16.192 3 0.001** 
p16/HPV status 13.433 3 0.004** 
p16/α-HPV status 13.660 3 0.003** 
p16/HR-HPV status  13.494 3 0.004** 
p16/LR-HPV status 15.663 3 0.001** 
p16/HPV16 status 16.009 3 0.001** 
p16/other HPV types 12.603 3 0.006** 
    
           N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
 
5.6.2 Cox Regression Model 
 
Multifactorial effect on patient survival as analysed by Cox regression model. These 
prognostic factors exhibited independently disagreement with overall survival analysis 
by Kaplan-Meier test except for p16 positivity (Table 5.11). 
 
Table 5.11: The summary of the survival analysis done by Cox regression 
 
Parameter (N=80) Cox Regression Analysis 
Wald df Sig. 
    
p16 positivity 4.483 1 0.034* 
p16 staining intensity 2.577 3 0.462 
p16/HPV status 0.666 3 0.881 
p16/α-HPV status 0.833 3 0.841 
p16/HR-HPV status  0.670 3 0.880 
p16/LR-HPV status 2.249 3 0.522 
p16/HPV16 status 5.417 3 0.144 
p16/Other HPV types 0.033 3 0.998 
    
           N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
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5.7 CONCLUSIONS 
 
Our results thus far for this cohort could conclude: 
1. p16 expression in benign, dysplasia and carcinoma groups 
• The percentage of p16 expression are as follow, 42/82 (51.2%) in benign, 8/12 
(66.7%) in dysplasia and 60/80 (75.0%) in carcinoma. 
• p16 positivity and p16 staining intensity were significantly higher in carcinoma 
compared to benign with (p<0.01) for both but were comparable between 
carcinoma-dysplasia and dysplasia-benign.   
2. A comparison of p16 expression based on demographic and clinicpatholo-
gical parameters in benign, dysplasia and carcinoma groups 
• No significant difference was observed for p16 status (positivity and staining 
intensity) in benign and dysplasia groups based on the following demographic 
and clinical parameters, gender, age group, anatomic site, disease status and 
disease outcome. 
• Carcinoma group, on the other hand, demonstrated significantly higher p16 
status for male, older patients, deceased patients compared to their respective 
counterparts and anatomic site in the following order (tongue > soft palate or 
floor of the mouth > soft palate). 
• In the carcinoma group, p16 status was significantly higher each in T2 and T3 
compared with T1 but p16 status were comparable amongst T2, T3 and T4.  
• No significant different in p16 status within regional lymph nodes in carcinoma 
group. 
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• In carcinoma group, p16 positivity was significantly higher in well and poorly 
differentiated tissues where each was compared with moderately differentiated 
tissues. 
• Two cases were identified in carcinoma where significant estimate for odds 
ratio observed by p16 status i.e. disease recurrence and N1 compared to each 
reference group.  
3. Correlation between demographic/clinicopathological parameters and p16 
status 
• Neither p16 positivity nor p16 staining intensity demonstrated any correlation 
with demographic and clinicopathological parameters in dysplasia patients. 
• In benign, a negative association was observed both for p16 positivity and p16 
staining intensity with anatomic site. 
• Generally, most of the association between p16 status and demographic/ 
clinicopathological parameters was observed in the carcinoma group. 
• Similarity in both parameters where positive associations were identified in 
gender, age group, tumour size and negatively associated in disease outcome. 
• In addition, p16 positivity in carcinoma was positively correlated with 
anatomic site and disease status. 
• At this stage, we could deduce the potential of p16 as an indicator for oral 
disease progression in parallel to HPV, as it follows the similar pattern as 
HPVs. 
4. Potential association with survival for p16  
• The survival of the patients was worst in positively identified p16 status 
compared to the negative ones based on Kaplan-Meier test and this was 
confirmed by Cox regression analysis. 
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CHAPTER 6 
 
CORRELATION BETWEEN HPVs AND p16 EXPRESSION  
IN HEAD AND NECK CANCER 
 
6.1 OVERVIEW 
 
An overview of the aims of this chapter is given as follows: 
• To analyse the pooled data of 140 head and neck carcinomas (60 FFPETs from 
the pilot study and 80 FFPETs from the oral disease progression study). 
• To determine whether there is any association between HPV prevalence and p16 
status with demographic and clinicopathological parameters. 
• To determine whether there is an association between HPV and p16 in head and 
neck carcinomas. 
 
6.2 CLINICAL DATA 
 
The cohort included 140 patients with primarily squamous cell carcinoma and a small 
minority with carcinoma in situ and severe dysplasia. The male:female ratio was 16:19 
with the mean age of 67.5 years, ranging from 36-99 years. An average age was 67.2 
and 59.8 for male and female, respectively. As for the tumour sites, 49 cases (35%) 
were on the tongue; soft palate, 37 cases (26.4%); floor of the mouth, 22 cases (15.7%); 
retromolar pad, 12 cases (8.6%); lower lip, 5 cases (3.6%); four cases each (2.9%) for 
buccal mucosa, alveolus and gingivae and one case each (0.7%) for pharynx, 
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supraglottis and tonsil. The clinicopathological parameters recorded in each tumour 
consist of the tumour size and regional lymph node as shown in Table 6.1. 
 
Table 6.1: Clinical details of oral cancer patients 
 
 
Parameters 
 
N 
 
% 
 
 
Total 
 
Gender 
   Female 
   Male 
 
Age groupα (range, 36-99y)  
   36-64y 
   65-99y 
 
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent structures 
 
Regional lymph nodes 
   Negative 
   N0 
   N1 
   N2 
 
Disease status 
   No recurrence 
   Recurrence 
 
Disease outcome 
   Alive 
   Dead 
 
 
140 
 
 
76 
64 
 
 
75 
65 
 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
 
 
2 
65 
41 
14 
18 
 
 
71 
35 
16 
18 
 
 
129 
11 
 
 
81 
59 
 
 
 
 
 
54.3 
45.7 
 
 
53.6 
46.4 
 
 
2.9 
15.7 
2.9 
2.9 
26.4 
0.7 
3.6 
8.6 
0.7 
35.0 
0.7 
 
 
1.4 
46.4 
29.3 
10.0 
12.9 
 
 
50.7 
25.0 
11.4 
12.9 
 
 
92.1 
7.9 
 
 
57.9 
42.1 
 
  Abbreviation: N, number of cases;  α It was based on median age 
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6.3 HPVs EXPRESSION IN ORAL MUCOSA 
 
The conventional PCR (semi-nested and nested PCR) was utilised for α-HPV detection 
in both cohorts. Therefore, the results of similar techniques from the pilot study were 
included in the pooled data of 140 carcinomas. We have to note that the detection of β-
HPV types was not investigated in the larger sample of 80 carcinomas. Therefore, the 
data from the pilot study involving β-HPV types was excluded in the pooled data of 140 
carcinomas and we focused our discussion more on HR-HPV and LR-HPV. Table 6.2 
and Figure 6.1 show the positively detected HPV types in this cohort. In total 82/140 
cases (58.6%) were positive for HPV regardless the type of HPV. The highest 
proportion was led by LR α-HPV types, 58/140 (41.4%) followed by HR α-HPV types, 
24/140 (17.1%), and other HPV types 16/140 (11.4%). Figure 6.2 and 6.3 illustrate the 
distribution of positively detected HPV types.   
 
Table 6.2: Overall HPV types detected in oral carcinoma (N=140)  
 
HPV group HPV type HPV type 
N (%) 
HPV group 
N (%) 
 
Low risk α-HPV 
 
HPV6 
 
58 (41.4) 
 
58 (41.4) 
High risk α-HPV HPV16 
HPV18 
HPV35 
Untypable 
17 (12.1) 
4 (2.9) 
1 (0.7) 
2 (1.4) 
24 (17.1) 
Other HPV types HPV64 
HPV100 
HPV103 
HPV109 
β-HPV from pilot study 
 
1 (0.7) 
2 (1.4) 
1 (0.7) 
1 (0.7) 
11 (7.9) 
 
16 (11.4) 
 
 
 
 
    
Total  LR-HPV and HR-HPV(positive) 82  
 Percentage 58.6  
 Total sample 140  
    
 N – number of sample; The percentage was calculated based on the total number of sample, 140 
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Figure 6.1: The total of HPV positively detected in the pooled data of oral 
carcinomas 
 
 
 
 
Figure 6.2: The distribution of HPV types detected  
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Figure 6.3: The distribution of HPV types detected 
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 Table 6.3 illustrates the distribution of HPV types across demographic and clinical 
characteristics. Appendix 53 (Table A) shows results of Pearson’s Chi-Square test for 
HPV prevalence related to dichotomous variables in demographic and 
clinicopathological parameters including gender, age group, disease status and disease 
outcome. Appendix 53 (Table C) demonstrates results of Cramer’s V test for HPV 
prevalence related to larger crosstabs in demographic and clinicopathological 
parameters which consist of anatomic site, tumour size and regional lymph nodes.  
 
 It was found that significantly more females were positive for HR-HPV than other 
types. Nevertheless the distribution of LR-HPV types was nearly comparable in both 
sexes. HPV16 type was predominantly present within the HR-HPV group in females, 
(χ2=6.14, df=1, N=140, p<0.05). LR-HPV types was statistically more frequently 
detected in older individuals compared to their counterparts, (χ2=4.36, df=1, N=140, 
p<0.05). The vast majority of HPVs (pooled data of LR-HPV and HR-HPV) were 
identified among patients with no disease recurrence 73/82 (89.0%), appeared to reflect 
its proportion in the study 129/140 (92.1%). Within HR-HPV, HPV16 was detected 
relatively more in sample from living patients (χ2=7.32, df=1, N=140, p<0.01). 
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Table 6.3: The distribution of HR-HPV and LR-HPV types within demographic 
characteristics 
 
 
 HR α-HPV (%)   LR α-HPV (%)  HPV16 HPV18 HPV35 Untypable  HPV6  
Gender:        
   Female 14 (82.4) 1 (25) - 1 (50)  30 (51.7)  
   Male 3 (17.6) 3 (75) 1 (100) 1 (50)  28 (48.3)  
        
Age group:        
   36 – 64y 12 (70.6) 3 (75) 1 (100) -  25 (43.1)  
   65 – 99y 5 (29.4) 1 (25) - 2 (100)  33 (56.9)  
        
Disease status:        
   No recurrence 15 (88.2) 4 (100) 1 (100) 2 (100)  51 (87.9)  
   Recurrence 2 (11.8) - - -  7 (12.1)  
        
Disease outcome:        
   Alive 15 (11.8) 2 (50) 1 (100) 1 (50)  31 (53.4)  
   Dead 2 (88.2) 2 (50) - 1 (50)  27 (46.6)  
        
Anatomic sites:        
   Buccal mucosa - - - -  3 (5.2)  
   Floor of the mouth 1 (5.9) 1 (25) - 1 (50)  10 (17.2)  
   Alveolus 1 (5.9) - - -  3 (5.2)  
   Gingivae - 1 (25) - -  2 (3.4)  
   Soft palate 10 (58.8) - - -  8 (13.8)  
   Pharynx - - - -  1 (1.7)  
   Lower lip - - - -  3 (5.2)  
   Retromolar pad 2 (11.8) - - -  7 (12.1)  
   Supraglottis - - - -  1 (1.7)  
   Tongue 3 (17.6) 2 (50) 1 (100) 1 (50)  20 (34.5)  
   Tonsil - - - -  -  
        
Tumour size:        
   Negative - - - -  1 (1.7)  
   T1 14 (82.4) 2 (50) - 1 (50)  22 (37.9)  
   T2 2 (11.8) 1 (25) 1 (100) -  14 (24.1)  
   T3 - - - -  7 (12.1)  
   T4 1 (5.6) 1 (25) - 1 (50)  14 (24.1)  
        
Regional lymph nodes:        
   Negative 10 (58.8) 2 (50) - -  19 (32.8)  
   N0 5 (29.4) 1 (25) 1 (100) -  18 (31.0)  
   N1 - 1 (25) - 2 (100)  8 (13.8)  
   N2 2 (11.8) - - -  13 (22.4)  
        
Subtotal 17 (70.8) 4 (16.7) 1 (4.2) 2 (8.3)   58 (100.0)  
TOTAL (N = 82)  24 (29.3)    58 (70.7)  
 
 
 
 
 
 
 
262 
 The distribution of LR-HPV identified was scattered across all anatomic sites 
concerned in this cohort except for tonsil. Within HR-HPV types, HPV16 was the only 
type detected in alveolus, soft palate and retromolar pad. None of the HR-HPV types 
were identified in buccal mucosa, pharynx, lower lip, supraglottis and tonsil. Even 
though, the available samples were dominated by floor of the mouth, tongue and soft 
palate for this cohort, but the number of different HPV types detected was led by the 
tongue. Results from Cramer’s V test revealed that the prevalence of all HPV types was 
not statistically significantly different across the anatomic sites. 
 
 Similar Cramer’s V results were observed for tumour size as for anatomic site but 
that was not the case for HPV6 (χ2=0.30, df=4, N=140, p<0.05) and HPV16 (χ2=0.27, 
df=4, N=140, p<0.05). Generally, there was a very heterogeneous distribution of all 
HPV types observed and predominantly with HPV6 in most tumour sizes especially T4, 
14/18 (77.8%) and T3, 7/14 (50%). Although the initial samples at T2 were more than 
double compared to T4, the final frequency of HPV6 detected was comparable between 
these two tumour sizes. HPV16 and HPV18 were identified of tumour size T1, T2 and T4 
but the former was predominant at T1. 
  
 A very typical overall HPV prevalence was observed where the percentage of 
HPV types detected was directly proportional to the level of regional lymph nodes, 
37/71 (52%) for negative, 28/35 (80%) for N0, 15/16 (94%) for N1 and 18/18 (100%) 
for N2. The present of HPV6 was distinctly distributed mainly at N0 and N2 of regional 
lymph nodes compared to other HPV types (χ2=0.33, df=4, N=140, p<0.01). Within 
HR-HPV types detected, the frequency of HPV16 appeared to nearly reflect the initial 
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proportion of samples according to the level of regional lymph nodes. None of the other 
HPV types were detected in the positive lymph nodes cases. 
 
6.4 p16 EXPRESSION IN ORAL MUCOSA 
 
The same cohort of 140 specimens (as mentioned in section 6.1) was semi-
quantitatively assessed for p16 by immunohistochemistry until consensus agreements 
were achieved among observers. A total of 107 cases (76.4%) were positive for p16 
(Figure 6.4). The results of overall p16 staining intensity in this cohort are shown in 
Figure 6.5. The proportion of positively scored for p16 staining are as follows, 41/140 
(29.3%) for 1+, 55/140 (39.3%) for 2+ and 11/140 (7.8%) for 3+.  
 
 Appendix 53 (Table B) shows results of Pearson’s Chi-Square test for p16 
positivity related to dichotomous variables in demographic and clinicopathological 
parameters including gender, age group, disease status and disease outcome. Since p16 
staining intensity had four levels, Cramer’s V test was more appropriate for this 
parameter.  Appendix 53 (Table D) demonstrates results of Cramer’s V test for both p16 
status related to larger crosstabs in clinicopathological parameters which consist of 
anatomic site, tumour size and regional lymph nodes. 
 
 p16 positivity was significantly higher in males (χ2=8.02, df=1, N=140, p<0.01), 
older patients (χ2=8.55, df=1, N=140, p<0.01) and samples taken from deceased patients  
(χ2=15.96, df=1, N=140, p<0.001) compared with their counterparts. The p16 positivity 
was significantly different across anatomic sites (Cramer’s V=0.41, df=10, N=140, 
p<0.01) and tumour size (Cramer’s V=0.37, df=4, N=140, p<0.01). Further analyses 
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using Kruskal-Wallis H and Mann-Whitney U were carried out to compare p16 
positivity across anatomic site and tumour size. Since only single samples were 
available for each subsite, we excluded pharynx, supraglottis and tonsil for gross subsite 
comparison. We found that p16 positivity was significantly lower in soft palate 
compared each with floor of the mouth (p=0.020), lower lip (p=0.042) and the tongue 
(p=0.00). The alveolus was significantly lower in p16 positivity compared with the 
tongue (p=0.025). The rest of the subsite comparisons were not significantly different. 
p16 positivity was significantly lower in T1 compared with T2 (p=0.001) and T3 
(p=0.004). 
  
 p16 staining intensity was significantly different between genders (Cramer’s 
V=0.26, df=3, N=140, p<0.05), age group (Cramer’s V=0.30, df=3, N=140, p<0.01), 
disease outcome (Cramer’s V=0.40, df=3, N=140, p<0.001) and within tumour size 
(Cramer’s V=0.31, df=4, N=140, p<0.001). Further analyses using Mann-Whitney U 
were carried out to compare p16 staining intensity between gender, age group and 
disease outcome. Kruskal-Wallis and followed by Mann-Whitney U tests were used for 
comparison within tumour size. We found that p16 staining intensity was significantly 
higher in males (p=0.004), older patients (p=0.001) and deceased patients (p=0.000). 
p16 staining intensity was significantly lower in T1 compared each with T2 (p=0.000) 
and T3 (p=0.000); T2 was significantly lower compared with T3 (p=0.047). At this point, 
further correlation analysis would confirm an association between p16 staining intensity 
with increasing tumour size. No significant difference for p16 staining intensity was 
observed in disease status, anatomic site and regional lymph nodes. 
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Figure 6.4: Overall p16 positivity in this cohort 
 
 
 
 
Figure 6.5: Overall p16 staining intensity in this cohort 
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6.5 CORRELATION ANALYSES 
 
Correlation analysis was carried out in searching for any association that may exist as 
follows: 
• Relationship within demographic and clinicopathological parameters, HPVs 
and p16 status 
• Relationship between demographic and clinicopathological parameters and 
HPVs status 
• Relationship between demographic and clinicopathological parameters and p16 
status 
• Relationship between HPVs and p16 status 
 
Table 6.4 shows a significant association within demographic and clinicopathological 
parameters. It was found that disease outcome negatively correlated with gender, age 
group, anatomic site and tumour size. On the contrary, anatomic site was positively 
associated with gender, tumour size and regional lymph nodes. Similarly, tumour size 
was positively linked with gender and regional lymph nodes. None of the associations 
could relate disease recurrence with other demographic and clinicopathological 
parameters. Overall associations above could be summarised using schematic 
representation as illustrated in Figure 6.6. The positive correlation within HPVs status 
was transformed into a diagrammatic representation as shown in Figure 6.7. The 
correlation between p16 status appeared to be straight forward by overlapping of two 
circles to indicate significant correlation between p16 positivity and p16 staining 
intensity. Table 6.4 shows significant association between demographic and 
clinicopathological parameters and HPVs and p16. Most of the parameters compared 
were positively associated except for disease outcome in which gender, age group, 
anatomic site and tumour size were negatively correlated. 
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Table 6.4: Significant correlations within demographic and clinical parameters,  
HPVs and p16 status 
 
  
 
Parameter 1 
 
Parameter 2 
Pearson Correlation  Spearman’s rho 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Correlation 
coefficient 
Sig.  
(2-tailed) 
 
Within demographic/clinicopathological parameters: 
 
Disease outcome 
 
Gender 
Age group 
Anatomic site 
Tumour size 
 
 
-0.262** 
-0.308** 
-0.252** 
-0.383** 
 
0.002 
0.000 
0.003 
0.000 
  
-0.262** 
-0.308** 
-0.253** 
-0.472** 
 
0.002 
0.000 
0.003 
0.000 
Anatomic site Gender 
Tumour size 
Regional Lymph Nodes 
 
0.179* 
0.354** 
0.287** 
0.035 
0.000 
0.001 
 0.173* 
0.071 
0.238** 
0.040 
0.407 
0.005 
Tumour size Gender 
Regional Lymph Nodes 
 
0.172* 
0.354** 
0.042 
0.000 
 0.220** 
0.344** 
0.009 
0.000 
 
Recurrence No association 
 
- 
 
- 
 
 - - 
 
 
Within HPVs status: 
 
Overall HPV status 
 
α-HPV status 
HR-HPV 
LR-HPV 
HPV16 
 
 
0.853** 
0.383** 
0.707** 
0.313** 
 
0.000 
0.000 
0.000 
0.000 
  
0.853** 
0.383** 
0.707** 
0.313** 
 
0.000 
0.000 
0.000 
0.000 
α-HPV status HR-HPV 
LR-HPV 
HPV16 
0.448** 
0.771** 
0.366** 
0.000 
0.000 
0.000 
 0.448** 
0.771** 
0.366** 
0.000 
0.000 
0.000 
 
HR-HPV HPV16 
 
0.817** 
 
0.000 
 
 0.817** 
 
0.000 
 
 
Within p16 status: 
 
 
 
 
     
p16 positivity p16 staining intensity 0.794** 0.000  0.775** 0.000 
       
*. Correlation is significant at the 0.05 level (2-tailed); **. Correlation is significant at the 0.01 level (2-
tailed). 
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Figure 6.6: Schematic representation of correlations within 
demographic and clinicopathological parameters. 
 
Figure 6.7: Schematic representation of correlations within HPV 
status. 
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Table 6.5 shows a significant correlation related to each HPVs and p16 status with 
demographic and clinicopathological parameters. For the former, its association could 
be categorised into two major groups. The first group was positively associated in all 
cases and the second group, the association was positive in one case but negative in the 
other case. HPV, α-HPV and LR-HPV were in the first group whereas HR-HPV and 
HPV16 were in the second group. The actual association was more complex but was 
simplified for the purpose of visualisation. Figure 6.8 shows a schematic representation 
of all the associations between demographic/clinicopathological parameters related to 
HPVs status. Figure 6.9 illustrates all the associations between demographic/clinico-
pathological parameters related to p16 status. 
  
 
Figure 6.8: Schematic representation of correlations within 
demographic and clinicopathological parameters. The sign (+ve) to 
represent positive association and (-ve) for negative association. 
 
 
 
 
 
 
 
 
270 
Table 6.5: Significant correlations between demographic and clinical parameters;  
HPVs and p16 status 
 
 
 
Parameter 1 
 
Parameter 2 
Pearson Correlation  Spearman’s rho 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Correlation 
coefficient 
Sig.  
(2-tailed) 
 
Between demographic/clinical parameters and HPVs status: 
 
Tumour size 
 
HPVs 
HR-HPV 
LR-HPV 
HPV16 
 
 
0.166* 
-0.139 
0.259** 
-0.201* 
 
0.049 
0.102 
0.002 
0.018 
  
0.129 
-0.176* 
0.217* 
-0.232** 
 
0.130 
0.037 
0.010 
0.006 
Regional Lymph Nodes HPVs 
α-HPV 
LR-HPV 
 
0.180* 
0.157 
0.314** 
0.033 
0.063 
0.000 
 0.179* 
0.168* 
0.320** 
0.035 
0.048 
0.000 
Disease outcome HR-HPV 
HPV16 
 
0.196* 
0.229** 
0.020 
0.007 
 0.196* 
0.229** 
0.020 
0.007 
 
Age group LR-HPV 
 
0.177* 
 
0.037  0.177* 0.037 
 
Gender HPV16 
 
-0.209* 
 
0.013 
 
 -0.209* 0.013 
 
Recurrence No association 
 
- 
 
- 
 
 - - 
 
 
Between demographic/clinical parameters and p16 status: 
 
Tumour size 
 
p16 positivity 
p16 staining 
intensity 
 
 
0.247** 
0.279** 
 
 
0.003 
0.001 
 
  
0.299** 
0.356** 
 
 
0.000 
0.000 
 
Anatomic site p16 positivity 
p16 staining 
intensity 
 
0.179* 
0.203* 
 
0.034 
0.016 
 
 0.170* 
0.184* 
 
0.044 
0.030 
 
Disease outcome p16 positivity 
p16 staining 
intensity 
 
-0.338** 
-0.401** 
 
0.000 
0.000 
 
 -0.338** 
-0.401** 
 
 
0.000 
0.000 
 
Age group p16 positivity 
p16 staining 
intensity 
 
0.247** 
0.290** 
 
0.003 
0.001 
 
 0.247** 
0.292** 
 
0.003 
0.000 
 
Gender p16 positivity 
p16 staining 
intensity 
0.239** 
0.248** 
0.004 
0.003 
 0.239** 
0.245** 
0.004 
0.004 
 
Recurrence 
 
No association 
 
- 
 
- 
  
- 
 
- 
       
*. Correlation is significant at the 0.05 level (2-tailed); **. Correlation is significant at the 0.01 level (2-
tailed). 
 
 
 
 
271 
 
 
Figure 6.9: Schematic representation of correlations between 
demographic/clinicopathological parameters and p16 status. The sign 
(+ve) to represent positive association and (-ve) for negative association. 
 
 
Table 6.6: Correlation analyses between HPVs and p16 status 
 
 
 
Parameter 1 
 
Parameter 2 
Pearson Correlation  Spearman’s rho 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Correlation 
coefficient 
Sig.  
(2-tailed) 
 
Between HPVs and p16 status: 
 
Overall HPVs status 
 
p16 positivity 
p16 staining intensity 
 
 
-0.125 
-0.060 
 
 
0.140 
0.485 
 
  
-0.125 
-0.056 
 
 
0.140 
0.509 
 
α-HPV status p16 positivity 
p16 staining intensity 
 
-0.110 
-0.098 
 
0.196 
0.248 
 
 -0.110 
-0.091 
 
0.196 
0.287 
 
HR-HPV status p16 positivity 
p16 staining intensity 
 
-0.149 
-0.094 
 
0.078 
0.271 
 
 -0.149 
-0.098 
 
0.078 
0.250 
 
LR-HPV status p16 positivity 
p16 staining intensity 
0.023 
0.012 
0.788 
0.886 
 0.023 
0.020 
0.788 
0.814 
 
HPV16 status p16 positivity 
p16 staining intensity 
-0.206* 
-0.127 
0.015 
0.134 
 -0.206* 
-0.135 
0.015 
0.111 
       
*. Correlation is significant at the 0.05 level (2-tailed); **. Correlation is significant at the 0.01 level (2-
tailed). 
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Table 6.6 shows the results of correlation analyses between HPVs and p16 status. None 
of the parameters compared demonstrated any significant correlation except for HPV16 
status and p16 positivity. Both parameters were negatively associated (r=-0.206, N=140, 
p<0.05). Further analyses were carried out searching for an in depth association 
between p16 and HPVs status and only three parameters, gender, age group and disease 
status did produce significant correlation as shown in Table 6.8. 
 
Table 6.7: Correlation analyses between p16 positivity and HPV status 
 
  
 
Parameter 1 
 
Parameter 2 
Male (N=64)  Female (N=76) 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Pearson 
Correlation 
Sig.  
(2-tailed) 
 
p16 positivity 
 
Overall HPV status 
α-HPV status 
 
 
0.060 
0.000 
 
0.639 
1.000 
  
-0.239* 
-0.178 
 
0.037 
0.125 
 LR-HPV status 
HPV16 status 
 
-0.048 
0.084 
 
0.709 
0.510 
 
 0.050 
-0.245* 
 
0.669 
0.033 
 
Parameter 1 
 
Parameter 2 
Age 36-64y (N=75)  Age 65-99y (N=65) 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Pearson 
Correlation 
Sig.  
(2-tailed) 
 
p16 positivity 
 
 
 
 
 
 
Overall HPV status 
α-HPV status 
HR-HPV status 
LR-HPV status 
HPV16 status 
 
-0.228* 
-0.245* 
-0.253* 
-0.040 
-0.309** 
 
0.049 
0.034 
0.028 
0.733 
0.007 
  
-0.007 
-0.099 
0.140 
0.006 
0.108 
 
0.953 
0.431 
0.265 
0.964 
0.391 
       
 
Parameter 1 
 
Parameter 2 
No recurrence (N=129)  Recurrence (N=11) 
Pearson 
Correlation 
Sig.  
(2-tailed) 
 Pearson 
Correlation 
Sig.  
(2-tailed) 
 
p16 positivity 
 
Overall HPV status 
α-HPV status 
HR-HPV status 
LR-HPV status 
HPV16 status 
 
-0.160 
-0.148 
-0.169 
-0.013 
-0.240** 
 
0.070 
0.094 
0.055 
0.885 
0.006 
  
0.418 
0.418 
0.149 
0.418 
0.149 
 
0.200 
0.200 
0.662 
0.200 
0.662 
       
*. Correlation is significant at the 0.05 level (2-tailed);  
**. Correlation is significant at the 0.01 level (2-tailed). 
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 Only Pearson’s correlation results are shown in Table 6.7 as Spearman’s rho 
produced exactly the same value. No significant association related to p16 staining 
intensity and HPV status was observed. In depth correlation results are about to confirm 
that negative association between p16 positivity and HPV16 status significantly related 
to females (r=-0.245, p<0.05), young patients (r=-0.309, p<0.01) and patients with no 
disease recurrence (r=-0.240, p<0.01). In addition, p16 positivity was negatively 
correlated with overall HPV status in females (r=-0.239, p<0.05) and young patients 
(r=-0.228, p<0.05). In young patients, α-HPV and HR-HPV were negatively associated 
with p16 positivity, (r=-0.245, p<0.05) and (r=-0.253, p<0.05), respectively. 
 
Table 6.8: Cross-tabulation of HPV versus p16 expression 
 
 
HPV expression 
 
p16 expression 
 
Concordanceα 
(%) 
 
Discordanceβ 
(%) 
 
 
κ 
p16 negative 
(%) 
p16 positive 
(%)  
 
All samples (N = 140) 
 
      Overall HPV negative 
      Overall HPV positive   
    
 
 
 
10 (30.3) 
23 (69.7) 
 
 
 
48 (44.9) 
59 (55.1) 
 
 
 
49.3 
 
 
 
50.7 
 
 
 
-0.12 
 
      α-HPV negative 
      α-HPV positive 
      
13 (39.4) 
20 (60.6) 
56 (52.3) 
51 (47.7) 
45.7 
 
 
54.3 -0.09 
 
      HR α-HPV negative 
      HR α-HPV positive 
      
24 (72.7) 
9 (27.3) 
92 (86.0) 
15 (14.0) 
27.9 
 
 
72.1 -0.07 
 
      LR α-HPV negative 
      LR α-HPV positive 
   
20 (60.6) 
13 (39.4) 
62 (57.9) 
45 (42.1) 
46.4 
 
 
53.6 0.018 
 
     HPV16 negative 
     HPV16 positive 
   
25 (75.8) 
8 (24.2) 
98 (91.6) 
9 (8.4) 
24.3 
 
 
75.7 -0.081 
 
 α(Concordance positive and concordance negative)x100/total specimens, N;  β – 100% - Concordance 
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Table 6.8 illustrates the results of Cohen’s Kappa test for reliability or agreement 
between HPV and p16 expression. We demonstrated a very weak agreement relating LR 
α-HPV status to p16 expression since the kappa value must be positive for reliability 
measures. The percentage of concordance ranges from 29% to 46%. The highest 
percentage of discordance was 75.7% relating HPV16 to p16 expression. This results 
seemed consistent with the previous correlation analyses which demonstrated that 
HPV16 was negatively associated with p16 expression (r=-0.206, N=140, p<0.05) as 
previously shown in Table 6.6. 
 
6.6 CONCLUSIONS 
 
Our results thus far from the oral disease progression study could conclude: 
1. HPV prevalence comparison by demographic and clinicopathological 
parameters. 
• The overall HPV prevalence was 82/140 (58.6%).  
• We have postulated the presence of single, double and multiple HPV infections 
within a single specimen. 
• 41% of LR-HPV, 17% of HR-HPV and 11% of other HPV types were detected 
regardless the mode of HPV infections. 
• HPV16 was predominantly present in female patients. 
• LR-HPV type, HPV6 was commonly detected in older patients. 
• HR-HPV types or HPV16 were frequently identified in patients who still 
survived. 
• Overall HPV prevalence (except for HPV6 and HPV16) was not significant 
different across anatomic site and tumour size. 
 
 
 
275 
• HPV6 was predominantly present across the regional lymph nodes compared to 
the rest of HPV types concerned. 
2. p16 status comparison by demographic and clinicopathological parameters. 
• It was reported that 107/140 cases (76.4%) were positive for p16. 
• The overall score of p16 staining intensity in this cohort are as follows: 33% 
negative, 29% for 1+, 39% for 2+ and 8% for 3+. 
• p16 positivity and p16 staining intensity were significant higher in samples 
taken from males, older patients and deceased patients compared with their 
counterparts. 
• p16 positivity was significant different across anatomic site and tumour size. 
• Individual comparison of selected subsites demonstrated that p16 positivity 
was significantly lower in soft palate compared to floor of the mouth, lower lip 
and the tongue; p16 positivity in alveolus was significantly lower than the 
tongue. 
• According to tumour size, p16 positivity was significantly higher in T2 and T3 
compared each with T1.   
• p16 staining intensity was significantly higher in males, older patients and 
deceased patients. 
• p16 staining intensity was significantly higher in T3 compared with T2; T3 and 
T2 were significantly higher compared each with T1. 
• No significant difference was observed in p16 staining intensity for disease 
status, anatomic site and regional lymph nodes. 
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3. An association between HPV and p16 with carcinomas 
• Within demographic and clinicopathological parameters, a positive association 
was observed as follows: anatomic site with gender, tumour size and regional 
lymph nodes; tumour size with gender and regional lymph nodes. 
• In contrast, a negative association was observed between disease outcome and 
gender, age group, anatomic site and tumour size. 
• No correlation was found between disease recurrence and other parameters. 
• Generally, a positive correlation was observed between different HPV types by 
their status (the presence/the absence of HPV types in the specimens). 
• Similarly, a positive association was found within p16 status. 
• A positive association was observed related to regional lymph nodes with 
overall HPV, α-HPV and LR-HPV status; age group with LR-HPV; HR-
HPV/HPV16 with disease outcome. 
• A negative association was observed related to tumour size with HR-
HPV/HPV16 status. 
• A positive association was observed related to p16 positivity/p16 staining 
intensity with tumour size, anatomic site, age group and gender. 
• A negative association was observed relating p16 positivity/p16 staining 
intensity with disease outcome. 
• Finally, we found that HPV16 expression was negatively associated with 
p16 expression. 
• In depth correlation results supported a negative association between p16 
positivity and HPV16 status, significantly related to female, young patients and 
patients with no disease recurrence.  
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CHAPTER 7 
 
THE PROGNOSTIC IMPLICATION OF HPV AND p16 
 
7.1 OVERVIEW 
 
An overview of the aims of this chapter is as follows: 
• To determine potential risk factors associated with patients overall survival (OS) 
and recurrence free-survival (RFS) using Kaplan-Meier survival estimates. 
• To evaluate the significant prognosticators and other related confounders by 
univariate and multivariate analysis on OS and RFS using Cox regression model. 
• To perform individual analyses of HPV and p16 status and followed by combined 
HPV/p16 status using Cox proportional hazard models with adjustments to assess 
their prognostic value. 
• To assess the prognostic implication of HPV and p16 in head and neck cancer. 
 
7.2 SURVIVAL ANALYSIS AND COX PROPORTIONAL HAZARD 
MODELS 
 
Survival was measured in months from the date of diagnosis until death or until the 
patient was last known to be alive. Survival rates for OS and RFS were estimated 
according to the Kaplan-Meier survival estimates. Continuous data values were divided 
by the median and all survival curves were generated in SPSS ver.16. A p value <0.05 
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was considered significant. The Kaplan-Meier curve of the survival followed by Log 
Rank (Mantel-Cox) test was used to investigate whether there was an association 
between the clinical parameters and patients survival. Since the above technique is the 
univariate version of survival analysis, later by performing Cox regression analysis it 
will further assist the actual effect of confounders on the survival of the patient. For OS 
and RFS, univariate and multivariate analysis were performed by Cox regression using 
the “enter” method. All clinicopathologic variables significant in univariate analysis to 
OS and RFS were adjusted for multivariate analysis. The Wald statistic and hazard ratio 
with 95% confidence interval (CI) were used to assess risk of molecular alterations and 
reference categories were selected as the lowest risk categories for prognostic variables. 
 
 These analyses included gender, age group, anatomic site, tumour size and 
regional lymph nodes, survival and disease recurrence also were examined in separate 
models. Test for interactions among risk factors were generated using both logistic 
regression and proportional hazard regression methods. All variables were assessed for 
the proportional hazard assumption before inclusion in the models. Cox proportional 
hazard models were used to assess the relationships between HPV and p16 and to adjust 
for factors previously found to be prognostically significant in cancer. For HPV status 
which consisted of overall HPV types (we will refer as HPV for short), α-HPV types, 
high risk HPV (HR-HPV), low risk HPV (LR-HPV) and HPV16.  Meanwhile, p16 
positivity and p16 staining intensity were the selected parameters to represent p16 
status. An assessment was carried out separately and then four groups for instance 
combined HPV/p16 status: HPV/p16+ (reference group), HPV/p16-negative, HPV-
negative/p16+, HPV-negative/p16-negative. The magnitude of the associations was 
assessed with hazard ratios (HRs) calculated from the Cox regression models. The 
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significant level was based on two-tailed tests and p-values < 0.05. Statistical analyses 
were performed using SPSS 16.0. 
 
 A total of 140 patients were included in the survival analysis. For OS, the median 
was 38 months, with range of 7.60 to 68.40 months; for RFS, it was 60 months, with a 
range of 59.45 to 60.55 months. Univariate and multivariate survival analysis was 
performed to identify factors with an independent effect on risk of death and disease 
recurrence from head and neck cancer using Cox proportional hazard regression model. 
Table 7.1 and Table 7.2 show assessment results from Kaplan-Meier test for OS and 
RFS, respectively.   
 
Table 7.1: The prognostic significance risk factors on OS from Kaplan-Meier test  
Parameter  Log Rank (Mantel-Cox) 
Chi-Square df Sig. 
    
Gender 8.575** 1 0.003 
Age group 12.155** 1 0.000 
Anatomic site 31.124** 8 0.000 
Tumour size 49.058** 2 0.000 
Regional Lymph Nodes  6.878* 2 0.032 
Overall HPVstatus 0.546 1 0.460 
α-HPV status 0.111 1 0.739 
High risk HPV status    4.244* 1 0.039 
Low risk HPVstatus      1.287 1 0.257 
HPV16 status      5.884* 1 0.015 
p16 status   14.718** 1 0.000 
p16 staining intensity   18.838** 1 0.000 
    
      N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
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Table 7.2: The prognostic significance risk factors on RFS from Kaplan-Meier test  
Parameter  Log Rank (Mantel-Cox) 
Chi-Square df Sig. 
    
Gender 5.711* 1 0.017 
Age group 3.613 1 0.057 
Anatomic site 19.493* 8 0.012 
Tumour size 43.306** 2 0.000 
Regional Lymph Nodes  17.396** 2 0.000 
Overall HPVstatus 1.110 1 0.292 
α-HPV status 0.060 1 0.806 
High risk HPV status    2.466 1 0.116 
Low risk HPVstatus      1.456 1 0.228 
HPV16 status      6.303* 1 0.012 
p16 status   10.535** 1 0.001 
p16 staining intensity   11.214** 1 0.001 
    
      N – number of samples, ** Statistically significant at the 0.01 level and * at the 0.05 level 
 
 In total patients, univariate analysis for OS demonstrated that besides gender 
(p=0.005), age group (p=0.001), anatomic site (p=0.005), tumour size (p=0.000) and 
regional lymph nodes (p=0.032), the significant potential prognosticators were high risk 
HPV (p=0.048), HPV16 (p=0.029), p16 positivity (p=0.001) and p16 staining intensity 
(p=0.000). In Cox multivariate analysis, after adjusting for gender, age group, anatomic 
site, tumour size and regional lymph nodes, only p16 staining intensity (p=0.016) 
remained a significant predictor of OS (Table 7.3). The Kaplan-Meier survival curve for 
OS indicated that 39% of patients with higher intensity in p16 staining (2+/3+) group 
[denoted as p16 (2+/3+)] was significantly associated with patient poor survival 
compared with 74% of patients with negative/weak (1+) p16 staining [denoted as p16 
(neg/1+)] (log-rank = 18.8, df = 1, p = 0.000) (Figure 7.1). 
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Figure 7.1: Total patients, significantly worse OS noted in patients with higher 
intensity of p16 staining (2+/3+) compared with those with p16 negative/weak 
staining (1+). 
  
Univariate analysis for RFS in total patients demonstrated that besides tumour size 
(p=0.000) and regional lymph nodes (p=0.002), the significant potential prognosticators 
were p16 positivity (p=0.021) and p16 staining intensity (p=0.006). In Cox multivariate 
analysis, after adjusting for tumour size and regional lymph nodes, none of the factors 
remained significant predictor of RFS (Table 7.4). 
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Table 7.3: Univariate and multivariate of OS in total patients (N=140) 
 
 
 
Variable 
 
 
HR (95% CI) 
 
p value 
   
Univariate analysis:   
   
Gender 2.137 (1.265-3.612) 0.005 
Age group 2.487 (1.458-4.243) 0.001 
Anatomic site 1.095 (1.028-1.167) 0.005 
Tumour size 1.649 (1.339-2.031) 0.000 
Regional Lymph Nodes  1.278 (1.021-1.600) 0.032 
Overall HPVstatus 1.216 (0.720-2.052) 0.464 
α-HPV status 1.090 (0.654-1.816) 0.741 
High risk HPV status    0.397 (0.159-0.994) 0.048 
Low risk HPVstatus      1.341 (0.803-2.240) 0.262 
HPV16 status      0.209 (0.051-0.855) 0.029 
p16 positivity   5.731 (2.074-15.838) 0.001 
p16 staining intensity   2.015 (1.501-2.705) 0.000 
   
Multivariate analysis*:   
   
High risk HPV status    0.884 (0.320-2.446) 0.813 
HPV16 status      0.856 (0.181-4.043) 0.844 
p16 positivity   2.197 (0.721-6.694) 0.166 
p16 staining intensity   1.600 (1.091-2.346) 0.016 
   
      N – number of patients; HR, hazard ratio; CI, confidence interval. 
       * Adjusted for gender, age group, tumour size and regional lymph nodes. 
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Table 7.4: Univariate and multivariate of RFS in total patients (N=140) 
 
 
 
Variable 
 
 
HR (95% CI) 
 
p value 
   
Univariate analysis:   
   
Gender 0.729 (0.515-1.032) 0.075 
Age group 1.287 (0.908-1.825) 0.156 
Anatomic site 1.031 (0.989-1.075) 0.151 
Tumour size 1.420 (1.217-1.657) 0.000 
Regional Lymph Nodes  1.287 (1.095-1.514) 0.002 
Overall HPVstatus 1.149 (0.810-1.630) 0.437 
α-HPV status 1.033 (0.731-1.458) 0.856 
High risk HPV status    0.768 (0.485-1.217) 0.261 
Low risk HPVstatus      1.177 (0.803-2.240) 0.368 
HPV16 status      0.619 (0.361-1.062) 0.082 
p16 positivity   1.607 (1.075-2.401) 0.021 
p16 staining intensity   1.296 (1.077-1.560) 0.006 
   
Multivariate analysis*:   
   
p16 positivity   1.337 (0.871-2.052) 0.185 
p16 staining intensity   1.224 (0.991-1.511) 0.060 
   
      N – number of patients; HR, hazard ratio; CI, confidence interval. 
 * Adjusted for tumour size and regional lymph nodes. 
 
 There was a drop in the odds ratio associated with p16+ status after inclusion of 
gender, age group, tumour size, regional lymph nodes, survival and disease recurrence 
in the adjusted ORs. As a result, males and older patients were no longer statistically 
significantly associated with p16 expression but living patients remained significant 
(Table 7.5). Despite a significant drop in the odds ratio associated with p16+ status due 
to inclusion factors, the risk of tumours of the alveolus remained significantly elevated 
compared to reference group but it was not the case for lower lip.   
 
 
 
284 
Table 7.5: Demographic and risk factor characteristics of head and neck cancer by 
p16 status 
 
 
 
Characteristics 
 
 
 
N 
 
p16 - 
N (%) 
 
p16+ 
N (%) 
 
 
Unadjusted 
OR (95% CI) 
 
Adjusted 
OR (95% CI) 
      
Total 140 33 107   
      
Gender 
   Femaleα 
   Male 
    
 
76 
64 
 
25 (75,8) 
8 (24.2) 
 
51 (47.7) 
56 (52.3) 
 
1.0 
2.0 (1.3 – 3.3) 
 
1.0 
0.8 (0.3 – 2.0) 
Age group 
   36-64yα 
   65-99y    
 
75 
65 
 
25 (75.8) 
8 (24.2) 
 
50 (46.7) 
57 (53.3) 
 
1.0 
2.0 (1.2 – 3.2) 
 
 
1.0 
0.5 (0.2 – 1.3) 
Anatomic site 
   Pharynx/supraglottis/tonsilα 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Lower lip 
   Retromolar pad 
   Tongue 
 
3 
4 
22 
4 
4 
37 
5 
12 
49 
 
- 
- 
4 (12.1) 
2 (6.1) 
1 (3.0) 
18 (54.5) 
- 
3 (9.1) 
5 (15.2) 
 
3 (2.8) 
4 (3.7) 
18 (16.8) 
2 (1.9) 
3 (2.8) 
19 (17.8) 
5 (4.7) 
9 (8.4) 
44 (41.1) 
 
1.0 
N/E 
N/E 
4.5 (1.5-13.3) 
1.0 
3.0 (0.3-28.8) 
1.1 (0.6-2.0) 
N/E 
3.0 (0.8-11.1) 
 
 
1.0 
N/E 
N/E 
1.3 (0.3 – 5.7) 
0.2 (0.01 – 3.3) 
0.1 (0.0 – 1.9) 
0.2 (0.0 – 0.8) 
N/E 
0.6 (0.1 – 4.2) 
Tumour size 
   Negative/T1α 
   T2 
   T3 
 
67 
41 
32 
 
26 (78.8) 
4 (12.1) 
3 (9.1) 
 
41 (38.3) 
57 (34.6) 
29 (27.1) 
 
1.0 
1.6 (1.0 – 2.6) 
9.3 (3.3-26.0) 
 
1.0 
0.7 (0.2 – 2.1) 
2.0 (0.5 – 7.9) 
 
Regional Lymph Nodes 
   Negativeα 
   N0 
   N1/N2 
 
 
71 
35 
34 
 
 
20 (60.6) 
8 (24.2) 
5 (15.2) 
 
 
51 (47.7) 
27 (25.2) 
29 (27.1) 
 
 
1.0 
2.6 (1.5 – 4.3) 
3.4 (1.5 – 7.4) 
 
 
 
1.0 
1.8 (0.6 – 6.0) 
1.9 (0.6 – 7.0) 
 
Disease outcome 
   Deadα 
   Alive 
    
 
 
59 
81 
 
 
4 (12.1) 
29 (87.9) 
 
 
55 (51.4) 
52 (48.6) 
 
 
1.0 
13.8 (5.0 – 37.9) 
 
 
1.0 
5.5 (1.7 – 17.9) 
Disease status 
   No recurrenceα 
   Recurrence    
 
129 
11 
 
32 (97.0) 
1 (3.0) 
 
97 (90.7) 
10 (9.3) 
 
1.0 
3.0 (2.0 – 4.5) 
 
 
1.0 
2.3 (0.7 – 7.1) 
      
N – number of samples, OR - odds ratio α  - reference group for odds ratio;  N/E – not estimable 
Adjusted OR for gender, age group and tumour size, regional lymph nodes, disease outcome and disease status 
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Table 7.6: Prognostic significance of risk factors of HPVs by p16 status 
 
 
 
Characteristics 
 
 
 
N 
 
p16- 
N (%) 
 
p16+ 
N (%) 
 
 
Unadjusted 
OR (95% CI) 
 
Adjusted 
OR (95% CI) 
      
Total 140 33 107   
      
HPV status 
   Negativeα 
   Positive 
    
 
58 
82 
 
10 (30.3) 
23 (69.7) 
 
48 (44.9) 
59 (55.1) 
 
1.0 
4.8 (2.4 – 9.5) 
 
1.0 
2.8 (1.1 – 7.4) 
α-HPV status 
   Negativeα 
   Positive    
 
69 
71 
 
13 (39.4) 
20 (60.6) 
 
56 (52.3) 
51 (47.7) 
 
1.0 
4.3 (2.4 – 7.9) 
 
1.0 
2.3 (0.9 – 5.6) 
 
HR-HPV 
   Negativeα 
   Positive    
 
 
116 
24 
 
 
24 (72.7) 
9 (27.3) 
 
 
92 (86.0) 
15 (14.0) 
 
 
1.0 
3.8 (2.5 – 6.0) 
 
 
1.0 
2.1 (0.8 – 5.4) 
 
LR-HPV 
   Negativeα 
   Positive    
 
 
82 
58 
 
 
20 (60.6) 
13 (39.4) 
 
 
62 (57.9) 
45 (42.1) 
 
 
1.0 
3.1 (1.9 – 5.1) 
 
 
1.0 
1.5 (0.6 – 4.0) 
 
HPV16 
   Negativeα 
   Positive   
 
 
123 
17 
 
 
25 (75.8) 
8 (24.2) 
 
 
98 (91.6) 
9 (8.4) 
 
 
1.0 
3.9 (2.5 – 6.1) 
 
 
1.0 
2.9 (1.0 – 8.4) 
      
N – number of samples, OR odds ratio α  - reference group for odds ratio;  
Adjusted OR for gender, age group and tumour size, regional lymph nodes, disease outcome and disease status 
 
 Table 7.6 shows the prognostic significance of the risk factors of head and neck 
cancer by HPVs and p16 status. HPV and HPV16 status were significantly associated 
with p16 over-expression after adjustment for gender, age group, tumour size, regional 
lymph nodes, survival and disease recurrence. The risk remained statistically 
significantly elevated in the p16+ patients for HPV-positive and HPV16-positive in 
ascending order of ORs compared to the reference group. Unfortunately, after inclusion 
of other clinicopathologic characteristics in the adjusted ORs, α-HPV, HR-HPV and 
LR-HPV were no longer statistically significantly associated with p16 expression.  
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Table 7.7: Adjusted hazard ratios for p16/HPV models of survival and recurrence 
 
 
 
Characteristics 
  
Overall Survival 
  
Recurrence-Free Survival 
  Model 1β Model 2γ  Model 1β Model 2δ 
       
p16 statusβ 
   p16+ 
   p16-α 
    
  
0.2 (0.1 – 0.5) 
1.0 
 
0.4 (0.1 – 1.0) 
1.0 
  
0.6 (0.4 – 0.9) 
1.0 
 
0.8 (0.5 – 1.2) 
1.0 
 HPV statusβ 
   HPV+ 
   HPV-α 
  
0.8 (0.5 – 1.4) 
1.0 
 
0.8 (0.5 – 1.4) 
1.0 
  
0.9 (0.6 – 1.2) 
1.0 
 
0.9 (0.6 – 1.3) 
1.0 
 
HPV16 statusβ 
   HPV16+ 
   HPV16-α 
    
  
 
0.2 (0.1 – 0.9) 
1.0 
 
 
1.5 (0.3 – 6.7) 
1.0 
  
 
0.6 (0.4 – 1.1) 
1.0 
 
 
1.1 (0.6 – 2.0) 
1.0 
 
HPV/p16 status 
   HPV+/p16+α 
   HPV+/p16- 
   HPV-/p16+ 
   HPV-/p16-    
  
 
1.0 
N/E 
N/E 
N/E 
 
 
1.0 
N/E 
N/E 
N/E 
  
 
1.0 
2.1 (1.0 – 4.3) 
1.3 (0.6 – 2.7) 
1.7 (0.8 – 3.5) 
 
 
1.0 
1.6 (0.8 – 3.3) 
1.1 (0.5 – 2.5) 
1.3 (0.6 – 2.8) 
 
HPV16/p16 status 
   HPV16+/p16+α 
   HPV16+/p16- 
   HPV16-/p16+ 
   HPV16-/p16-  
   
  
 
1.0 
1.6 (0.3 – 8.7) 
N/E 
4.6 (1.6 – 12.6) 
 
 
1.0 
1.8 (0.3 – 10.0) 
N/E 
2.6 (0.9 – 7.7) 
  
 
1.0 
0.9 (0.4 – 2.2) 
0.9 (0.4 – 1.9) 
1.6 (1.0 – 2.6) 
 
 
1.0 
1.0 (0.4 – 2.4) 
1.3 (0.6 – 3.1) 
1.4 (0.9 – 2.4) 
α  - reference group for hazard ratio (HR); N/E – not estimable  
β HRs not adjusted for p16 and HPV, gender, age group, tumour size and regional lymph nodes 
γ HRs are adjusted for p16 and HPV, gender, age group, tumour size and regional lymph nodes 
δ HRs are adjusted for p16 and HPV, tumour size and regional lymph nodes 
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Table 7.7: (Continued) 
 
 
 
Characteristics 
  
Overall Survival 
  
Recurrence-Free Survival 
  Model 1β Model 2γ  Model 1β Model 2δ 
       
 
p16 staining intensityβ 
   Negative/1+α 
   2+/3+    
  
 
1.0 
3.1 (1.8 – 5.4) 
 
 
1.0 
2.1 (1.2 – 3.8) 
  
 
1.0 
1.6 (1.1 – 2.2) 
 
 
1.0 
1.3 (0.9 – 1.9) 
 
HPV/p16 staining intensity 
   HPV+/ p16(Negative/1+)α 
   HPV+/p16(2+/3+) 
   HPV-/ p16(Negative/1+) 
   HPV-/p16(2+/3+)    
  
 
1.0 
3.4 (1.6 – 7.3) 
0.8 (0.3 – 1.9) 
2.0 (0.8 – 4.5) 
 
 
1.0 
2.3 (1.0 – 5.3) 
0.9 (0.3 – 2.2) 
1.5 (0.6 – 3.6) 
  
 
1.0 
1.9 (1.2 – 3.1) 
1.0 (0.6 – 1.6) 
1.3 (0.7 – 2.2) 
 
 
1.0 
1.5 (0.9 – 2.6) 
1.0 (0.6 – 1.6) 
1.1 (0.7 – 2.0) 
 
HPV16/p16 staining intensity 
   HPV16+/ p16(Negative/1+)α 
   HPV16+/p16(2+/3+) 
   HPV16-/ p16(Negative/1+) 
   HPV16-/p16(2+/3+) 
    
  
 
1.0 
1.6 (0.4 – 6.8) 
N/E 
2.6 (1.5 – 4.6) 
 
 
1.0 
2.1 (0.4 – 9.4) 
N/E 
1.9 (1.0 – 3.5) 
  
 
1.0 
0.9 (0.3 – 2.5) 
0.7 (0.4 – 1.3) 
1.5 (1.1 – 2.2) 
 
 
1.0 
0.9 (0.3 – 2.5) 
1.0 (0.5 – 2.0) 
1.4 (0.9 -2.2) 
 
Gender 
  
0.5 (0.3 – 0.8) 
 
0.8 (0.4 – 1.3) 
  
0.7 (0.5 – 1.0) 
 
1.0 (0.7 – 1.4) 
Age group 
 
Tumour size 
   Negative/T1α 
   T2 
   T3   
 0.4 (0.2 – 0.7) 
 
 
1.0 
0.1 (0.1 – 0.3) 
1.3 (0.7 – 2.2) 
0.5 (0.3 – 0.8) 
 
 
1.0 
0.2 (0.1 – 0.4) 
1.3 (0.7 – 2.4) 
 0.8 (0.5 – 1.1) 
 
 
1.0 
0.4 (0.3 – 0.6) 
1.0 (0.6 – 1.6) 
0.9 (0.6 – 1.3) 
 
 
1.0 
0.5 (0.2 – 0.7) 
1.0 (0.6 – 1.7) 
 
Regional Lymph Nodes 
   Negativeα 
   N0 
   N1/N2   
  
 
1.0 
0.5 (0.3 – 0.8) 
0.6 (0.3 – 1.2)  
 
 
1.0 
1.0 (0.6 – 1.9) 
1.2 (0.6 – 2.5) 
  
 
1.0 
0.5 (0.3 – 0.7) 
0.6 (0.4 – 1.1) 
 
 
1.0 
0.7 (0.4 – 1.1) 
0.9 (0.5 – 1.5) 
       
Anatomic site 
   Pharynx/supraglottis/tonsilα 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Lower lip 
   Retromolar pad 
   Tongue    
  
1.0 
1.7 (0.4 – 7.2) 
2.0 (0.6 – 6.6) 
0.2 (0.1 – 0.7) 
0.4 (0.1 – 2.7) 
2.4 (0.8 – 6.8) 
0.3 (0.1 – 0.6) 
1.0 (0.3 – 3.2) 
0.7 (0.3 – 1.7) 
 
1.0 
1.2 (0.3 – 5.4) 
1.5 (0.4 – 5.6) 
0.3 (0.1 – 0.8) 
0.5 (0.1 – 3.8) 
2.2 (0.7 – 6.7) 
0.9 (0.4 – 2.2) 
2.4 (0.6 – 9.4) 
0.7 (0.3 – 1.8) 
  
1.0 
3.2 (1.0 – 10.3) 
1.3 (0.4 – 4.2) 
0.7 (0.4 – 1.3) 
0.9 (0.3 – 3.0) 
1.6 (0.6 – 4.6) 
0.6 (0.4 – 1.0) 
1.1 (0.4 – 2.7) 
1.0 (0.5 – 2.0) 
 
1.0 
2.1 (0.6 – 7.2) 
1.2 (0.3 – 4.2) 
0.7 (0.4 – 1.2) 
0.9 (0.3 – 3.3) 
1.5 (0.5 – 4.4) 
1.4 (0.8 – 2.6) 
2.0 (0.7 – 5.7) 
1.0 (0.5 – 2.1) 
       
α  - reference group for hazard ratio (HR); N/E – not estimable 
β HRs not adjusted for p16 and HPV, gender, age group, tumour size and regional lymph nodes 
γ HRs are adjusted for p16 and HPV, gender, age group, tumour size and regional lymph nodes 
δ HRs are adjusted for p16 and HPV, tumour size and regional lymph nodes 
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 Table 7.7 shows the adjusted hazard ratios (HRs) of OS and RFS for p16 
positivity and p16 staining intensity, HPV and HPV16 status. Model 1 represented 
unadjusted HRs whereas Model 2 for adjusted HRs by appropriate significant 
confounders determined from the previous analyses. Multivariate analyses demonstrated 
that gender, age group, tumour size and regional lymph nodes were associated with OS 
and should be included in the appropriate models. Meanwhile, tumour size and regional 
lymph nodes were associated with clinical outcomes in RFS were included in the final 
models. Compared to those with p16 positivity, patients who did not exhibit p16 had 
significantly better OS and RFS (log rank=14.718, p=0.000) and (log rank=10.535, 
p=0.001), respectively. In contrast, patients who did not exhibit HPV16 had 
significantly worse OS (log rank=5.888, p=0.015) and RFS (log rank=6.303, p=0.012). 
There were no significant differences in outcomes for HPV cases in OS and RFS.  
 
 Subsequently, we investigated the combined HPV/p16 and HPV16/p16 groups for 
clinical outcomes in comparison to those based on their previously separated analyses. 
OS and RFS were significantly worse among those who were HPV+/p16+ (log 
rank=16.558, p=0.001) and (log rank=13.116, p=0.004) (Figure 7.2A and 7.2B). 
Patients who had HPV-/p16- tumours also had better RFS than those who did express 
p16. HPV-/p16- group would not have been predicted in OS due to the fact they were 
censored (n=10). Even though the HPV+/p16- group was associated with an increased 
risk of disease recurrence (Model 1, HR = 2.1, 1.0 – 4.3) but adjusted HRs indicated 
that association was no longer significant (Table 7.7). Patients with HPV-/p16+ had the 
least elevated risk of disease recurrence compared to the reference group. The risk of 
death and median time to death was not estimable. The median time to disease 
recurrence was shorter in HPV+/p16+ (45 months) compared to each of the other 
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groups: HPV+/p16- (60 months), HPV-/p16+ (54 months) and HPV-/p16- (60 months). 
HPV+/p16- group had better 5-year OS compared to the other groups: 82.6% versus 
52.1% HPV-/p16+ and 45.8%, HPV+p16+. HPV+/p16+ group had better 5-year RFS 
compared to the other groups: 11.9% versus 10% HPV-/p16-, 0%, HPV+p16- and 6.3%, 
HPV-/p16+. 
 
 Prognosis based on the individual biomarkers, HPV and p16, was compared to 
those based on the joint group effects. OS and RFS among those who express p16 were 
worse than among who did not, but for HPV cases were statistically comparable. The 
distinctions in prognostic outcomes were more apparent once both markers were 
examined together. Considering p16 status alone failed to differentiate the greater risk 
of disease recurrence by HPV status among the p16-negative groups (Model 1, HR=1.0 
versus HPV/p16, HRs 1.7 and 2.1). No further distinction could be made by examining 
HPV status alone since its prognostic outcomes were comparable in OS and RFS. The 
addition of HPV status showed that the risk of disease recurrence was actually greater 
among those who were HPV+/p16- than among either HPV-/p16- or HPV-/p16+ group. 
 
 OS and RFS were significantly worse among those who were HPV16-/p16+ (log 
rank=18.177, p=0.000) and (log rank=15.184, p=0.002), respectively (Figure 7.3A and 
7.3B). The patterns of OS and RFS were almost similar by HPV16/p16 status except 
HPV16+/p16- group would not have been predicted in OS as ts they were censored 
(n=8). HPV16-/p16- group had better 5-year OS compared to the other groups: 84.0% 
versus 77.8% HPV16+/p16+, 45.9%, HPV16-/p16+. HPV16+/p16+ group had better 5-
year RFS compared to the other groups: 22.2% versus 8.2% HPV16-/p16+, 4.0%, 
HPV16-/p16- and 0%, HPV+/p16-. The median time to death was not estimable. The 
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median time to disease recurrence was shorter in the HPV16-/ p16+ (48 months) 
compared to each of the other groups: HPV16+/p16+ (60 months), HPV16+/p16- (60 
months) and HPV16-/p16- (60 months). Although HPV16-/p16- group had the greatest 
likelihood of death and disease recurrence but after adjusted HRs, it was no longer 
significantly associated with OS and RFS. Prognosis based on the individual 
biomarkers, HPV and p16, was compared to those based on the joint group effects. OS 
and RFS among those who express HPV16 were better than among who did not. The 
addition of p16 status showed that the risk of death and disease recurrence was actually 
lower among HPV16-/p16- group and HPV16+/p16+ group, respectively. 
 
 Compared to those with p16 staining intensity, patients who exhibit p16 
(negative/1+) had significantly better OS (log rank=18.838, p=0.000) and RFS (log 
rank=11.214, p=0.001). Next, we investigated separately p16 staining intensity each 
with overall HPV and HPV16 groups for clinical outcomes in comparison to those 
based on their previously separated analyses. OS and RFS were significantly worse 
among those who were HPV+/p16(Neg/1+) (log rank=23.797, p=0.000) and (log 
rank=15.652, p=0.001), respectively (Figure 7.4A and 7.4B). HPV+/p16 (2+/3+) group 
had better 5-year OS compared to the other groups: 77.3% versus 70.0% HPV-
/p16(2+/3+), 50.0%, HPV-/p16(Neg/1+) and 31.6%, HPV+/p16(Neg/1+). HPV-
/p16(Neg/1+) group had better 5-year RFS compared to the other groups: 10.7% versus 
10.5% HPV+/p16(Neg/1+), 6.8%, HPV+/p16(2+/3+) and 3.3%, HPV-/p16(2+/3+). 
Besides adjusted HRs, HPV+/p16(2+/3+) group was significantly associated with an 
increased risk of death (HR = 2.3, 1.0 – 5.3). Although HPV+/p16(2+/3+) group had the 
greatest likelihood of disease recurrence but after adjusted HRs, it was no longer 
significantly associated with RFS. The median time to death was shorter in the 
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HPV+/p16(Neg/1+) group (20 months) compared to  HPV-/ p16(Neg/1+) group (60 
months). The median time to disease recurrence was shorter in the HPV+/ p16(Neg/1+) 
(28 months) compared to each of the other groups: HPV-/p16(Neg/1+) (53 months),  
HPV+/p16(2+/3+) (60 months) and HPV-/p16(2+/3+) (60 months). 
 
 OS was significantly better among those who were HPV16-/p16(2+/3+) group 
(log rank=22.133, p=0.000) and HPV16+/p16(2+/3+) for RFS (log rank=15.717, 
p=0.001), respectively (Figure 7.5A and 7.5B). HPV16-/p16(2+/3+) group had better 5-
year OS compared to the other groups: 69.4% versus 42.4% HPV16+/p16(Neg/1+), 
237.7%, HPV16/p16(Neg/1+). HPV16-/p16(2+/3+) group would not have been 
predicted in OS due to censored (n=12). HPV16+/p16(Neg/1+) had better 5-year RFS 
compared to the other groups: 20.0% versus 9.8% HPV16-/p16(Neg/1+), 8.3%, 
HPV16+/p16(2+/3+) and 4.8%, HPV16/p16(Neg/1+). Although HPV16-/p16(2+/3+) 
group had the greatest likelihood of death and disease recurrence but after adjusted HRs, 
it was only significantly associated with OS (HR = 1.9, 1.0 – 3.5). Unfortunately, the 
median time to death was unestimable. The median time to disease recurrence was 
shorter in the HPV16-/p16(Neg/1+) (39 months) compared to each of the other groups: 
HPV16+/p16(Neg/1+) (60 months), HPV16+/p16(2+/3+) (60 months) and HPV16-
/p16(2+/3+) (60 months). Prognosis based on the individual biomarkers, HPV16 and 
p16 staining intensity, were compared to those based on the joint group effects. By 
jointly investigating with HPV16 status, the greater risk of death by p16 staining 
intensity among HPV16- group could be distinguished. Adjusted HRs revealed that 
older patients remained significantly associated a lower risk of death compared with the 
reference group. Adjusted HRs demonstrated that within tumour size, T2 tumours 
appeared significantly associated with lower risk of death and disease recurrence 
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compared to reference group. Tumours of the alveolus seemed significantly associated 
with lower risk of death compared to pharynx tumours. 
 
 
Figure 7.2A: OS by HPV/p16 status as generated by Kaplan-Meier test. 
Vertical tick marks on curves indicate censored observations. 
 
Figure 7.2B: RFS by HPV/p16 status as generated by Kaplan-Meier test. 
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Figure 7.3A: OS by HPV16/p16 status as generated by Kaplan-Meier test. 
 
 
 
Figure 7.3B: RFS by HPV16/p16 status as generated by Kaplan-Meier test. 
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Figure 7.4A: OS by HPV/p16 staining intensity as generated by Kaplan-Meier test. 
 
 
 
Figure 7.4B: RFS by HPV/p16 staining intensity as generated by Kaplan-Meier 
test. 
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Figure 7.5A: OS by HPV16/p16 staining intensity as generated by Kaplan-Meier 
test. 
  
 
Figure 7.5B: RFS by HPV16/p16 staining intensity as generated by Kaplan-Meier 
test. 
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7.3 CONCLUSIONS 
 
1. The determination of prognostic significance risk factors on OS and RFS 
• Kaplan-Meier survival analysis demonstrated that gender, age group, anatomic 
site, tumour size, regional lymph nodes, high risk HPV, HPV16, p16 positivity 
and p16 staining intensity were the potentially significant prognostic risk 
factors for patients OS. 
• Similarly, above potential prognostic risk factors were also found significantly 
associated with patients RFS except for age group factor.   
2. Univariate and multivariate analysis on OS and RFS using Cox regression 
model. 
• In univariate analysis of total patients, high risk HPV, HPV16, p16 positivity, 
p16 staining intensity and HPV/p16 status predicted OS. 
• Nevertheless, the predictors for RFS were p16 positivity and p16 staining 
intensity according to univariate analyses. 
• In Cox multivariate analysis, adjusted HRs for gender, age group, anatomic 
site, tumour size and regional lymph nodes, p16 staining intensity was 
independently associated with OS. 
• Meanwhile, none of the potential independent predictors remained significant 
for RFS after adjusting for tumour size and regional lymph nodes based on Cox 
multivariate analysis.  
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3. Cox proportional hazard models for prognostic value assessment. 
• After the inclusion of the following factors, gender, age group, tumour size, 
regional lymph nodes, survival and disease recurrence in the adjusted ORs, 
living patients was the only factor that remained significantly associated with 
p16 expression. 
• With regard to tumours of the alveolus the risk remained significantly lowered 
and associated with p16 status despite adjustment in odds ratio compared to 
reference group. Nevertheless, for other anatomic sites the drop in odds ratio 
were not significantly associated with p16 status. 
• Overall HPV and HPV16 status were significantly associated with p16 over-
expression after adjustment for gender, age group, tumour size, regional lymph 
nodes, patient survival and disease recurrence. 
• The associated covariates with OS based on multivariate analyses were gender, 
age group, tumour size and regional lymph nodes and should be included in 
developing appropriate models. 
• The tumour size and regional lymph nodes were the inclusion factors in the 
final models since their significant association with clinical outcomes in RFS.      
4. The prognostic implications of HPV and p16 
• Individual analyses of significant prognosticators involving p16 and HPV 
status revealed that patients who exhibited p16-negative and p16 (neg/1+) had 
significantly better OS and RFS. 
• In contrast, patients who did not exhibit HPV16 had significantly worse OS 
and RFS. 
• Nevertheless, there was no significant difference in clinical outcomes for 
overall HPV cases in OS and RFS. 
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• Four combinations of HPV and p16 status (each with four subgroups) were 
generated for further clinical outcome comparison in association with patients 
OS and RFS. 
• The first two were related to p16 positivity were as follows: HPV/p16 and 
HPV16/p16; the second two were related to p16 staining intensity.  
• We found that OS and RFS were significantly worse among those who were 
HPV+/p16+ and this seemed consistent with individual analyses. 
• The addition of HPV status revealed that the risk of disease recurrence was 
greater among patients who exhibited HPV+/p16-.  
• The risk of death would not have been predicted by HPV/p16 status since the 
results were not estimable.   
• Despite their contradictory results with the first two combinations above, OS 
and RFS with regard to HPV16/p16 status were significantly worse among 
patients who exhibited HPV16-/p16+. Thus, at this point the consistency with 
their previous separate analyses appeared to be well established. 
• The combined HPV/p16 status analyses revealed that the risk of death and 
disease recurrence was lower among HPV16-/p16- group compared with 
reference group, HPV+/p16+. 
• We demonstrated that 5-year OS and RFS were better in HPV16-/p16- and 
HPV+/p16+ groups, respectively. 
• Thus far, with regard to p16 status, joint group effects satisfy that p16-negative 
was a better predictor for higher risk of disease recurrence compared to HPV 
tumours status. 
• The similar patterns follow as for HPV status consideration in combined 
HPV/p16 status by p16 staining intensity. 
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• Generally, by taking into account p16 staining intensity into the combined 
assessment, p16(neg/1+) was a better predictor for lower risk of death and 
disease recurrence compared to tumour status.  
• The combined HPV/p16 status data demonstrates an association with 
survival and disease recurrence for head and neck cancer compared to 
each, HPV and p16 evaluated separately.  
• Therefore, these findings could suggest that HPV and p16 status are 
independent predictors for patients risk of death and disease recurrence. 
They should be assessed in other larger studies to allow better prediction 
of prognosis to assist target HNC treatment. 
• Adjusted HRs revealed that older patients remained significantly associated in 
lower risk of death compared with reference group.  
• Adjusted HRs demonstrated that within tumour size, T2 tumours appeared 
significantly associated with lower risk of death and disease recurrence 
compared to reference group.  
• Tumours of the alveolus seemed significantly associated with lower risk of 
death compared to tumours of the reference group. 
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CHAPTER 8 
 
DISCUSSION 
 
8.1 INTRODUCTION 
 
There is a wealth of literature reporting the successful detection of HPV DNA in human 
cancers, especially studies on the role of HPV in cervical carcinomas. The proposal that 
HPV was involved in the aetiology of head and neck was reported as early as 1983 by 
(Syrjänen et al., 1983). Since then HPV has been recognised as a major aetiological 
factor in oral cancer (Schwart et al., 2001). Many head and neck studies have been 
published, but often the primary site is oropharyngeal rather than oral carcinoma. These 
studies have suggested that HPV positive oropharyneal cancers respond well to 
chemoradiotherapy and are associated with an improved prognosis. Therefore, knowing 
the HPV status for oropharyngeal carcinomas could impact on management and patient 
survival.  In contrast, the primary treatment modality for oral cancer is surgery, so 
knowing the HPV status might not necessarily change the treatment but it might impact 
on prognosis. In many centres, p16 immunohistochemical staining is used as a surrogate 
marker for HPV for oropharyngeal cancer. However, it remains to be established 
whether p16 is a surrogate marker of the presence of HPV DNA in oral carcinoma. 
Despite the volume of literature on this topic, methodological differences between 
studies make comparisons of results difficult and any conclusions have to be interpreted 
with this caveat in mind.  
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It is important to consider that HPV infection involves highly complex 
mechanisms which are still poorly understood. There are various detection methods and 
the majority of them focus on the prime targets of HPV in their sampling, i.e. 
keratinocytes (Galan-Sanchez and Rodriguez-Iglesias, 2010 and Snidjer et al., 2010). A 
few controversial issues still underline the details of the mechanism of the HPV-host 
interaction (Letian and Tianyu, 2010; Horvath et al., 2010; Pittayakhajonwut and 
Angeletti, 2010; Syrjänen, 2010; Chow et al., 2010; Pim and Bank, 2010 and Steinberg 
and Norrild, 2010). There is no doubt that the holistic understanding of the significant 
role of HPV in oral carcinogenesis might be exploited for its diagnosis, prognosis and 
treatment.  
 
As a routine test, it would be advantageous to develop screening tools for a larger 
population which would not have a significant economic impact and would therefore be 
more acceptable to the government. P16 imunohistochemistry seems relatively cheaper 
when compared to HPV genotyping. Many studies on head and neck cancer have 
utilised p16 as a surrogate marker for HPV DNA (Li et al., 2001; Klussmann et al., 
2003; Wittekindt et al., 2005; Begum et al., 2005; König et al., 2007; Hafkamp et al., 
2008; Smith et al., 2008; Smith et al., 2010 and Singhi and Westra, 2010). Yet, the 
evidence for such a use for p16 in oral cancer is somewhat limited, unconvincing and, in 
some cases, controversial (Nemes et al., 2008; Greer Jr. et al., 2008 and Friedrich et al., 
2010). Nevertheless, in the majority of cases, the presence of HPV would not change 
the management of oral carcinoma, which is primarily surgical, as opposed to 
radiotherapy as is the case with oropharyngeal carcinoma.  The translational potential 
for this work could be to identify patients with improved prognosis or potentially it 
could be used to inform patient management. 
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A few challenging questions have provided the motivation to embark upon this 
investigation. Would the finding of a high incidence of high risk HPV provide support 
for a vaccination programme for at risk groups, if indeed we could identify such a group 
of patients? This is an important issue and has already had an influence at a political 
level with the introduction of a vaccination programme for those at risk of cervical 
carcinoma. We found that 15% of our head and neck (predominantly oral) cancer cases 
were high-risk HPV positive. This would suggest that HPV may only be involved in a 
small subset of cases.  So, to answer the question about vaccination, how do we identify 
those at risk? The subsequent question that is quite relevant, is how does HPV have an 
impact on prognosis, is HPV positivity associated with improved prognosis in oral 
cancer? If vaccination was offered to a group of patients at risk of oral carcinoma, 
lacking the traditional risk factor of smoking, do these carcinomas behave differently? 
Unfortunately, the data for smoking was only available for the cases in the pilot study, 
which was prospectively collected, but not for the larger retrospective study cohort. 
Another area of concern relates to the survival data. The death certificates were 
requested for the carcinoma cases but these often gave disseminated cancer as a cause of 
death, but this was determined without reference to a post mortem examination.  We 
therefore do not really know whether the data is disease specific. Ultimately, our sample 
is relatively small in comparison to studies on cervical and other cancers. These issues 
are among the major challenges of our studies. 
 
 
 
 
 
 
 
303 
8.2 H PV  PR E V A L E NC E  I N H E A D A ND NE C K  C A NC E R  
 
Generally tissue specimens are available as FFPETs. Most studies reported that 
there are problems related to difficulties in the extraction of nucleic acids from FFPETs, 
especially related to low DNA yield due to DNA degradation and poor DNA quality 
(Coombs et al., 1999; Wickham et al., 2000; Sato et al., 2001; Kim and Chae, 2001; 
Man et al., 2001; Wu et al., 2002 and Simonato et al., 2007). It was important to 
optimise the DNA extraction during the pilot study in order that our optimised protocol 
could be utilised in the larger cohort of tissue i.e. the oral disease progression study. 
There was concern about the possible sources of contamination that might have 
jeopardised our findings. The implementation of a standard operating procedure and 
very strict measures in relation to sample handling, gave us the greatest quality 
assurance of the specimens for this study. As an investigator, the precautions 
undertaken in the laboratory were to irradicate any source of contamination.  
 
For the pilot study, we utilised various PCR-based techniques including 
conventional PCR, SPF10-LiPA25 (version 1) and PM-PCR RHA. In terms of cost, the 
first method was relatively cheap compared to the latter two techniques. The rational 
behind attempting various PCR-based approaches was to compare the methodologies to 
determine which one was better to use for the larger cohort. Analogically, we used a 
“single bullet for at least two targets”. First and foremost, we gained invaluable 
experience dealing with the various protocols. Secondly, we benefited from the results 
generated by each technique in that we could verify the results using the simplest 
technique by the other two. In that way we could be sure that the results of our pilot 
study were accurate and provided information on HPV prevalence and evidence of 
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multiple HPV infections. Due to budget constraints we were unable to utilise all three 
methods in the larger cohort. Upon completion of the pilot study, the conventional PCR 
method was selected, as it had been shown to be reliable. One of the set backs of this 
option is that we were unable to identify multiple HPV infections in the larger cohort.  
 
 The prevalence of all HPV types detected in the pilot study (n=60) was 67%, but 
by increasing the sample size (n=140) the overall HPV positivity was 59%. Another 
oral study, which had a similar methodology to ours, reported that the prevalence of 
HPV in 15 oral carcinomas as 60% and all of them HR-HPV (Zarei et al., 2007). In this 
study, HPV16 was detected in a smaller proportion of the sample in that only 8 of the 
60 cases were HPV16 positive but ours was a much larger study. Even in our combined 
carcinoma cohort of 140 samples the actual number of cases that were HPV16 was 17. 
The overall HPV prevalence was not statistically significant different across 
pathological groups. In the benign lesions (n=84), dysplasias (n=12) and carcinomas 
(n=80) the percentage of HPV-positive were 51%, 42% and 53%, respectively. There 
were no normal tissues used as a control group in this study. However, the reported  
HPV incidence in normal oral mucosa varies from as low as 0% (Bouda et al., 2000; 
ÓFlatharta et al., 2003, Gonzalez et al., 2007) to as high as 36-55% (Sugiyama et al., 
2003; Giovannelli et al., 2006 and Zhang et al., 2004).  
 
 We performed a literature search for studies carried out on the prevalence of HPV 
in oral mucosal lesions and carcinomas over the period of ten years between 2000 and 
2010, We restricted the outputs of our searches with other preset selection criteria such 
as the type of samples, DNA extraction methods and HPV detection techniques used 
which were similar to the current study. Only two studies were identified that reported 
 
 
 
305 
HPV16 prevalence in oral dysplasia using detection methods. Both studies reported that 
more than a 60% HPV16 positivity (Patiman et al., 2001 and Sugiyama et al., 2003). In 
fact, the differences in the sample size might not affect the overall percentage 
statistically in both studies (n=30 and n=51) in respect to the current study. We treated 
our findings in the dysplasia cohort with caution as our sample size was relatively small. 
As for the benign lesions, there have been reports of as high as 91% positivity 
(Gonzalez et al., 2007). However, the sample size was very small (n=11), so this result 
might not reflect the actual HPV prevalence. If we consider the other three studies that 
are relatively comparable in their sample size (n=35-40), they reported the incidence of 
HPV ranging from 26-55% (ÓFlatharta et al., 2003, Llamas-Martinez et al., 2008 and 
Jimenez et al., 2001). Our results suggest that our findings are comparable even though 
our sample was more than double the size of those studies. Fourteen studies on HPV 
prevalence in head and neck carcinomas were successfully retrieved from the databases, 
only ten of them clearly identified themselves as studies related to oral carcinomas.  A 
large variation of HPV prevalence was reported within these ten studies ranging from 
8% (Kansky et al., 2003) to as high as 92% (Patiman et al., 2001). Therefore, we pooled 
the data of ten studies (n=496) to obtain an average prevalence of HPV in oral 
carcinomas which was 40%. These results emerged not to be significantly different 
from our findings.  
 
 We categorised our results from the pilot study based on specific HPV types into 
three major groups including HR-HPV, LR-HPV and β-HPV types. The last group was 
not applicable for respective comparison with the larger cohort or oral disease 
progression since β-HPV genotyping was only undertaken in the pilot study. We found 
18% HR-HPV, 57% LR-HPV and 18% β-HPV types in our pilot study samples. In the 
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pooled data cohort, we found the percentage of HR-HPV increased to 25% but was not 
significantly different for LR-HPV at 59%. The oral disease progression study 
demonstrated that in oral benign lesions, 14% were HR-HPV and 31% were LR-HPV; 
in dysplasias, 8% were HR-HPV and 17% were LR-HPV and in carcinoma, 16% were 
HR-HPV and 30% were LR-HPV. From the results of the oral disease progression 
study, we observed no significant difference in the prevalence of either HR-HPV or LR-
HPV but the ratio based on percentage between HR-HPV to LR-HPV was 
approximately 1:2 across each pathological group. Our results were in contrast to  
Miller and Johnstone, (2001) who estimated that HR-HPV was approximately 3 times 
more frequent than LR-HPV in carcinomas (Miller and Johnstone, 2001). Generally, 
within carcinomas, the percentage of LR-HPV prevalent in the pilot study, pooled data 
or oral disease progression study was consistent with a range of 57-59%. In oral benign 
lesions, other studies reported that HR-HPV was detected at 30% (Gonzalez et al., 
2007) and 40% (Llamas-Martinez et al., 2008). It seems that both results are relatively 
consistent with our current findings. The latter study specifically stated that the sole 
contributor to the total percentage was HPV16. We were unable to make appropriate 
comparisons since the authors did not provide the actual percentage of HR-HPV in their 
cohorts (Patiman et al., 2001 and Sugiyama et al., 2003). Within carcinomas, three 
studies reported a slightly higher percentage of HR-HPV prevalence compared to the 
current study, 33% (Llamas-Martinez et al., 2008), 42% (Chang et al., 2003) and 52% 
(Gonzalez et al., 2007). None of the reports related to LR-HPV prevalence in oral 
benign lesions and oral dysplastic tissues, but one study did report data for carcinomas 
(Kansky et al., 2006). Unfortunately, the total prevalence reported was presented as the 
pooled data of HPV6 and HPV16 positivity. Two out of forty HPV types in our pilot 
study were not identifiable for their type specificity by using the current SPF10-LiPA25 
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(version 1) method. This may suggest that these may potentially emerge to be novel 
HPV types. 
 
 We are not the first group to report the presence of β-HPV in oral mucosal 
lesions. Earlier, de Villier and colleagues reported the presence of seven novel HPV 
types of which six were β-HPV types comprising HPV type 98, 99, 100, 104, 105, and 
113 and one  α-HPV type, HPV94 (de Villier et al., 2009). We referred to the earlier 
publication of the same investigators who had reported that HPV types 15, 23, 36, 38, 
76, 80 and 93 as we found in the current study, were identified as β-HPV types and 
these are more commonly found in human cutaneous lesions (de Villier et al., 2004). de 
Koning et al. (2007) later confirmed that all seven β-HPV types of our current findings 
were actually persistently present in plucked eyebrow hairs of healthy individuals (de 
Koning et al., 2007). Based on our strict measures and the precautions taken in sample 
handling, we are fully confident that these are true findings and very unlikely to be 
contamination. Unfortunately, the actual role played by those HPV types in oral mucosa 
remains unresolved. To the best of our knowledge, there are no previous reports of the 
actual prevalence of β-HPV in oral mucosal lesions. This may be an area for future 
research to determine whether β-HPV plays an active role in oral carcinoma. Pfister 
(2003) reported that HPV8 and HPV5 had a significant role in which both were 
classified as ‘high-risk’ among β-HPV types (Pfister, 2003). In addition, it was believed 
that those β-HPV types were associated with patients who had been diagnosed with the 
rare hereditary disease, epidermodysplasia verruciformis. Three out of eleven β-HPV 
types in our pilot study were not identifiable for their type specific by using current PM-
PCR RHA method and these may emerge as the novel HPV types. 
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 We investigated the possibility that there were multiple HPV infections in our 
pilot study cohorts. We observed that within positively detected HPV, 68% exhibited 
single type infection, 25% double types of HPV and 8% multiple HPV infections. Terai 
and colleagues (1999) reported that the prevalence of multiple HPV infections in normal 
oral cavity was 56% of 30 adults (Terai et al., 1999). In our study HPV6 was the only 
LR-HPV detected, the discussion related to LR-HPV refers to HPV6. In single 
infections, LR-HPV demonstrated the highest proportion at 35%, 3% for HR-HPV 
(HPV16 and HPV18) and 7% infection related to β-HPV types. In double infections, 
co-infection of HPV6 and HPV16 was detected at 8.3% and 13% was related to co-
existing of HPV6 with other β-HPV types and 3% involving HPV6 with HPV18 
infections. One problem encountered was that we were unable to determine which HPV 
type was the dominant type possibly playing a significant role in the aetiology of 
cancer. A number of studies suggested that viral load assessment could address this 
issue. Seven studies attempted to quantify viral load of HPV in cervical specimens by 
utilising hybrid Capture II (Ferreira Santos et al., 2003), real-time PCR (Swan et al., 
1999; Flores-Munguia et al., 2004; Guo et al., 2007; Fontaine et al., 2008; Marks et al., 
2009; and Tadokoro et al., 2009) or a combination of real-time PCR and PCR-EIA 
(Hesselink et al., 2005). Klussmann and colleagues (2003) relied on nested PCR for 
viral load estimation in tonsillar carcinomas (Klussmann et al., 2003). Three studies 
suggested the utilisation of PCR-Enzyme-Linked Immunosorbent Assay (PCR-ELISA) 
in oral or oropharyngeal studies (Kreimer et al., 2005), a combination of multiplex PCR 
and in situ hybridisation (D’Souza et al., 2007; Gillison et al., 2008).  Another four 
studies reviewed the effectiveness of this approach in assessing the predominant HPV 
type (Chaudhary et al., 2009; Goon et al., 2009 and Salem, 2009) and one in cervical 
cancer (Lillo and Uberti-Foppa, 2006). Two untypable α-HPVs (both were present in 
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combination with another HPV type) and three untypable β-HPVs (two were detected in 
postulated single HPV infection and one as multiple HPV infection with α-HPV types) 
could also be novel HPV types. Since conventional PCR, PM-PCR-RHA and SFP10-
LiPA25 (version 1) approaches failed to identify them in our pilot study, other methods 
should be employed for further HPV genotyping purposes. 
 
 In the combined carcinoma group, we observed that HPV16 was more 
frequently encountered in females compared to males, and HPV6 was common in older 
patients. There is a postulated relationship between HR-HPV and past sexual history 
which could possibly explain the gender difference, but this aspect was out-with the 
scope of this study (Dahlstrom et al., 2011).  In addition, HPV16 was frequently 
identified in patients who survived. The overall HPV prevalence was not significantly 
different across anatomic site and tumour size but HPV6 was found at higher proportion 
in cases with lymph node metastasis compared to the rest of HPV types concerned. To 
the best of our knowledge thus far, we are unable to provide any satisfactory 
comparison from other related studies on the relatively high prevalence of low risk HPV 
in our study. 
 
8.3 p16 EXPRESSION IN HEAD AND NECK CANCER 
 
In the carcinomas of the pilot study 78% were p16 positive and in the combined 
carcinomas group it was 76%. There were no normal tissues used as a control group in 
this study. However, the reported p16 expression in normal oral mucosa varies from 0% 
(Angiero et al., 2008 and Buajeeb et al., 2009), 1.45% (Angiero et al., 2009) to as high 
as 23% (Bilde et al., 2009). Within pathological groups the percentage of p16 positivity 
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increased from 51% in oral benign lesions, to 67% in dysplasias and then 75% in 
carcinomas. Shintani et al. (2002) reported that the percentage of p16 expression in the 
oral cavity was 100% in normal tissues normal (n=20), 88.1% in dysplasia (n=42) and 
30.8% in carcinomas (n=117). These results seem to contradict our current findings, but 
we could argue the discrepancies observed could be attributed to differences in sample 
size and the scoring scheme used for p16 assessment. Two studies reported a 
significantly lower percentage of p16 positivity, 43-58% compared to our study in 
benign oral lesions (Cao et al., 2010 and Fregonesi et al., 2003). Six studies on p16 
expression in oral dysplastic tissues reported that the percentage varied from 0-90% 
(Buajeeb et al., 2009; Bilde et al., 2009; Cunningham et al., 2006; Cao et al., 2010; 
Bradley et al., 2006; Angiero et al., 2008 and Fregonesi et al., 2003). The pooled data of 
these six studies (n=258) suggested an average percentage of p16 positivity of 34% 
(approximately 50% lower than our study). In fact, we could argue that the number of 
samples in our dysplasic group (n=12) may not reflect the actual percentage of p16 
expression in this pathological group. We also found seven studies investigating the 
expression of p16 in oral carcinomas using immunohistochemistry and found that the 
percentage of p16 positivity varied from 13-94% (Muirhead et al., 2006; Buajeeb et al., 
2009; Weinberger et al., 2004; Suzuki et al., 2006; Bilde et al., 2009; Angiero et al., 
2008 and Fregonesi, et al., 2003). We pooled the data of seven studies (n=326) and 
calculated that the average percentage of p16 expression in oral carcinomas was 27%.  
 
There was a decreasing pattern of p16 expression across pathological groups 
based on an average percentage of the pooled data demonstrated by Shintani et al., 
(2002), but the percentage of p16 positivity of dysplastic and carcinomas appeared to be 
comparable. A summary of the published data on p16 staining for each pathological site 
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is as follows: oral benign lesions from 43 to 58% positive (two studies), dysplasias were 
0-90% positive, (six studies) and carcinomas 13-94% positive (seven studies). It was 
difficult to make a generalisation on p16 expression across pathological groups mainly 
related to dysplasias and carcinomas as both exhibited larger variations in p16 
expression. However, in benign groups, the percentage of p16 expression observed in 
the present study seemed within the range. 
 
In the pilot study, p16 status (positivity/staining intensity) was significantly 
associated with male gender, older patients, T3 tumour size, N2 nodal metastasis and 
disease recurrence. Similarly, in the combined carcinomas cohort significant association 
was observed but only for the male gender and the older patients by p16 status. Within 
this larger cohort, p16 status was significantly associated with T1 tumour size and 
patient survival. In addition, p16 positivity was significantly different in anatomic site 
(alveolus and lip). An in depth comparison within this cohort found that p16 status was 
significantly higher in males, older age patients, tumour size T3 and T2, and patients 
who did not survive. Generally in oral benign lesions and dysplastic tissues the p16 
status was not significantly associated with gender, age group, anatomic site, patient 
disease outcome and status. However, in carcinomas the p16 status was significantly 
higher in males, older patients and patients who had not survived, tumours of the tongue 
and floor of the mouth compared to soft palate, tumour size, T3 and T2 compared to T1 
and in well and poorly differentiated tissues compared with moderately differentiated 
tissues. Yuen et al. (2002), on the other hand, did not find a significant correlation 
between p16 expression and gender, age group, disease recurrence or survival (Yuen et 
al., 2002). However, our results were in agreement with Yuen et al. (2002) that no 
significant association was observed between p16 expression and nodal metastasis. Our 
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results appeared in accordance with Muirhead et al. (2006) in that no significant 
correlation was observed between p16 expression, tumour stage and patient’s survival. 
 
8.4 CORRELATION AMONG DEMOGRAPHIC AND CLINICOPATHOLO-
GICAL PARAMETERS, HPV AND p16 EXPRESSION 
 
The pilot study and the pooled carcinoma cohort produced similar results in that no 
association was observed between HPV status and disease recurrence. No direct 
comparison could be made between both cohorts for some of the parameters such as 
smoking and alcohol, since the data were not available for the larger cohort. Earlier, we 
reported a significant association between HPV status and smokers based on our pilot 
study results. These results are consistent with the findings of Reimer et al., (2007).  In 
the pilot study, no significant association was observed between HPV status and 
clinicopathological parameters for tumour size, nodal metastasis, age group and gender 
but this was not the case for the pooled carcinomas cohort. In this larger cohort, overall 
HPV and LR-HPV status were associated with patients who had tumour more than 2 cm 
in size and nodal metastasis. HR-HPV or specific to HPV16 status were associated with 
patient survival who had a tumour of less than 2-cm. In addition, α-HPV, LR-HPV and 
HPV16 were associated with nodal metastasis, older patients and female gender, 
respectively. Generally, across pathological groups, from benign to carcinoma, we 
found an increase in the significance of the association between HPV status and 
demographic and clinicopathological parameters. Therefore, we could suggest that HPV 
status was associated with oral disease progression. Regardless of the pathological 
group, HR-HPV appeared not to have any association with clinical parameters. 
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However, studies done on oral leukoplakia patients did not find any association between 
HPV status and malignant transformation (Yang et al., 2009).  
 
 Similar results were found in the pilot study and the combined carcinomas cohort 
with regard to p16 status (p16 positivity and p16 staining intensity) which was not 
associated with disease recurrence or nodal metastasis. In addition, p16 staining 
intensity was negatively associated with patient survival and was observed in both 
cohorts. However, both cohorts differed in that a significant association was only 
observed in the combined carcinoma cohort between p16 status and male gender, older 
age patients, tumours of the alveolus and tumour size more than 2 cm. No significant 
association was found between p16 expression and clinical parameters in oral benign 
lesions and dysplastic tissues. However in the combined carcinoma group, p16 status 
was significantly associated with male gender, older age patients, tumours of the floor 
of the mouth and the tongue, patient survival, tumour size, T2 and T3. In addition, p16 
positivity was significantly associated with histological grade and this finding is 
consistent with that of another study (Reimers et al., 2007). 
  
In the pilot study, we found that results form Kappa Cohen’s and Chi-square 
demonstrated that overall HPV status and p16 expression was not significantly 
associated. However, p16 staining intensity was significantly associated with HPV 
status specifically HR-HPV and HPV16 and these findings appeared consistent with 
another related study (Kong et al., 2009). The results from the larger combined 
carcinoma cohort further confirmed this association in that HPV16 was inversely 
associated with p16 status (positivity and staining intensity). A recent meta-analysis 
involving 34 studies to include 5681 patients with HNSCC reported that the prevalence 
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of overall HPV and HPV16 were 22% and 19%, respectively (Dayyani et al., 2010).  
They also concluded that the overall HPV status was correlated with p16 expression and 
HPV16 was the predominant contributor for these associations, 87%.  
 
Smith et al. (2008) investigated the association between HPV and p16 status in 
oropharyngeal cancers (n=301) reported that positive concordance (HR-HPV+/p16+) 
and negative concordance (HPV-/p16-) were 21% and 59%, respectively (Smith et al., 
2008). Smeets et al. (2007) investigated a smaller cohort for association between 
HPV16 and p16 status in unspecified head and neck cancers from FFPETs (n=48) 
reported that positive concordance (HPV16+/p16+) and negative concordance (HPV16-
/p16-) were 31% and 44%, respectively (Smeets et al., 2007). Comparing results from 
the former study with our current pooled carcinomas results (n=140), we found that 
positive concordance (HR-HPV+/p16+) and negative concordance (HPV-/p16-) were 
17% and 42%, respectively. For comparison with the latter study, our current study 
results were positive concordance (HPV16+/p16+) and negative concordance (HPV16-
/p16-) were 6% and 18%, respectively. Differences with our results could be attributed 
to the different sample sizes and also additional contributing factors such as the site 
specific proportion of the samples, HPV detection system and p16 expression 
methodology used.  
 
Our results disagreed with other studies that concluded HPV was positively 
associated with p16 expression. We found twelve highly related studies in terms of 
methodologies with our study which reported an association between HPV and p16 
expression in various sites: oral dysplasia (Cunningham et al., 2006); oropharyngeal 
carcinoma (Kumar et al., 2008, Smith et al., 2008; Nichols et al., 2009 and Al-Swiahb et 
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al., 2010); tonsillar carcinoma (Klussmann et al., 2003, Li et al., 2004, Begum et al., 
2005 and Hafkamp et al., 2008); head and neck carcinoma (Smith et al., 2008 and Smith 
et al., 2010) and cervical carcinoma (Lambert et al., 2006). Other studies also reported 
similar conclusions about the HPV/p16 association, but these studies differed from our 
study in that they utilised in situ hybridisation for HPV detection. These twelve studies 
are as the follows: OSCC (Fregonessi et al., 2003), head and neck carcinoma (König et 
al., 2007 and Singhi and Westra, 2010) and cervical carcinoma (Sano et al., 1998; Sano 
et al., 2002; Tsai et al., 2005 and Lakshmi et al., 2009). On the other hand, five studies 
did not find any association between HPV and p16 expression (Greer Jr. et al., 2008; 
Nemes et al., 2006; Cao et al., 2010; Samama et al., 2006 and Galmiche et al., 2006). 
Despite the conflicting reports of the correlation between HPV and p16, our findings 
thus far suggest that p16 could be potentially acts as a surrogate marker for high risk 
HPV. 
 
8.5  RISK ASSESSMENT WITH DEMOGRAPHIC AND CLINICOPATHO-
LOGICAL PARAMETERS ASSOCIATED WITH HPV AND p16 STATUS 
 
In the pilot study, we demonstrated that smokers, patients who were still alive and those 
with disease recurrence were significantly associated with an elevated risk by HPV 
status compared with each with reference group (non-smokers, dead and recurrence-free 
patients, respectively). The present investigation’s result on smoking was consistent 
with Dayyani et al. (2010), OR=4.0, 95%CI (1.3-12.0) and OR=3.53, 95% (2.69-4.64), 
respectively. We observed that in the pilot study, the pooled carcinomas cohort and 
across pathological groups, all demographic and clinicopathological parameters 
concerned including gender, age group and anatomic site were not significantly 
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associated with risk by overall HPV status. In addition, across pathological groups, 
patient survival and patient with disease recurrence were not significantly associated 
with risk by overall HPV status. Similarly, in dysplastic tissues, the above mentioned 
parameters were not associated with risk by HR-HPV status. In oral benign lesions and 
carcinomas, female gender and younger patients were significantly associated with 
elevated risk by HR-HPV status. Tumours of the buccal mucosa were significantly 
associated with elevated risk compared with the tumours of the floor of the mouth and 
tonsil in benign groups by HR-HPV status. In carcinomas, patient that were still alive 
with disease recurrence, had tumour size T2 and T3, nodal metastasis N1, poorly and 
basaloid differentiated tissue were significantly associated lower risk by HR-HPV 
status. Smith and colleagues, (2007) reported that antibodies against HPV16 E6 or E7 
were correlated with risk of nodal status (Smith et al., 2007). 
 
In the pilot study and pooled carcinomas cohort, male gender, older patients who 
had T2 and T3 tumour size, nodal metastasis, N0, N1 and N2 and disease recurrence were 
significantly associated with an increase risk by p16 status. No significant association 
was observed in the combined carcinomas cohort for anatomic site and tissue 
differentiation grade with risk by p16 status. In this cohort, the caveats to our findings 
were the sample size and the fact that sub-site analysis could not be undertaken. We 
observed that across pathological groups, all demographic and clinicopathological 
parameters concerned were not significantly associated with risk by p16 status except in 
the carcinomas group for patients with disease recurrence and nodal metastasis. In the 
combined carcinoma group, older patients remained significantly associated with a good 
prognosis after adjusted HRs. Tumour size T2 appeared significantly associated with a 
good prognosis and non-recurrence. 
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8.6 SURVIVAL ANALYSIS AND PROGNOSTIC IMPLICATIONS OF HPV 
AND p16 
 
In the pilot study, a survival analysis suggested that tumours of the pharynx, lower lip, 
tonsil and buccal mucosa and tumour size, T3 could be independent prognosticators for 
poor patient overall survival (OS). No association was found for HPV and p16 status or 
combined HPV/p16 status. In the combined carcinoma study, the survival analysis 
demonstrated that female gender, younger age patients, tumours of the soft palate, 
tumour size, T1, negative nodal metastasis, HR-HPV-positive, HPV16-positive, p16-
negative and p16 (neg/1+) were the potentially significant prognostic factors for patients 
OS. Similarly, the above mentioned risk factors were also found significantly associated 
with patients RFS except for age group. The associated covariates with OS based on 
multivariate analyses using Cox regression model were gender, age group, tumour size 
and regional lymph nodes and should be included in developing appropriate risk 
models. The tumour size and nodal metastasis were the inclusion factors in the final 
models since they were significantly associated with clinical outcomes in RFS. We 
found that overall HPV and HPV16 status were significantly associated with p16 over-
expression after adjustment for gender, age group, tumour size, nodal metastasis, patient 
survival and disease recurrence. Smith and colleagues (2008) reported that p16 
expression was 35%, and the prevalence of HR-HPV was 27% from 301 paraffin-
embedded tissues (Smith et al., 2008). More than fifty five percent of their samples 
were from the oral cavity. Two major differences were found between this study and 
our work in relation to the HPV detection method used, and the semi-quantitative scale 
used for p16 expression scoring. They utilised a dot blot hybridisation technique 
together with PCR amplification for HPV detection and applied unspecified percentage, 
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but the borderline for p16 positivity was lower than 10% positive staining whereas for 
the present study we set 10% as the cut of point for p16 positivity. We suggest that the 
differences in the sample proportion together with the chosen methods for HPV and p16 
expression contributed to the discrepancies in the results. 
 
Individual analyses of significant prognosticators involving p16 and HPV status 
revealed that patients who exhibited p16-negative and p16 (neg/1+) had significantly 
better OS and RFS. Our results were not in agreement with those of Smith et al. (2008). 
However, HPV16 positive patients had a significantly better OS and RFS in agreement 
with Smith et al. (2008) but we treated our findings with caution since the latter study 
did not specifically refer to HPV16 but the pooled data of HR-HPV. Dayyani et al. 
(2010) later reported in a meta-analysis of 34 studies on 5681 HNSCC patients that 
HPV positive patients were associated with a significantly better survival (Dayyani et 
al., 2010). They reported that there was an improved OS by HPV status as (HR=0.42, 
95% CI=0.27-0.56, p<0.0001) compared to our present findings (HR=0.40, 95% 
CI=0.16-1.0, p<0.05). OS and RFS with regard to HPV16/p16 status were significantly 
worse among patients who exhibited HPV16-/p16+. The combined HPV16/p16 status 
data demonstrated an association with survival and disease recurrence for head and neck 
cancer compared with HPV16 and p16 in isolation. In agreement with the suggestion 
made by Smith et al. (2008) that HPV and p16 should be accessed together for better 
predict prognosis (Smith et al., 2008). Therefore, our findings could suggest that 
HPV16 and p16 status are the independent predictors for patient risk of death and 
disease recurrence and may improve the prediction of prognosis which may also benefit 
in the targeted management of the head and neck cancer. 
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CHAPTER 9 
 
CONCLUSIONS 
 
The prevalence of all HPV types detected in carcinomas was 67% for the pilot study of 
which 18% were HR-HPV and 59% for the combined carcinoma sample of which 25% 
were HR-HPV. The majority of HR-HPV was HPV16. In addition, the HPV prevalence 
was 51%, 42% and 53% for the benign lesions, the dysplasias and carcinoma 
respectively in the disease progression study. More specifically, the prevalence of HR-α 
HPV was 14% in benign lesions, 8% in dysplasias and 16% in carcinomas. The similar 
prevalence of HR-HPV in benign and malignant lesions raises some question over the 
role of HR-HPV in oral carcinoma. This similarity might be a function of the sample 
size.  In the combined carcinoma cohort the proportion of HR-HPV was greater. This 
may suggest that the study may have been insufficiently powered.  Future work should 
be based on larger sample sizes in order to determine whether there is a subset of 
HNSCC where HR-HPV has an important possible causal role. 
 
We demonstrated the presence of multiple HPV types in head and neck tissue both low 
risk and high risk in the same tissue and in some cases alpha and beta HPV. However, 
we were unable to determine which genotype was the dominant one.  Future work 
investigating viral load could address this issue  The finding of β-HPV types in our 
mucosal specimen is a relatively novel finding and the actual role played by the 
cutaneous type in head and neck mucosa merits further investigation.  
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Analysis of the combined carcinoma data showed an association between HPV status 
and gender, age group, survival, nodal metastasis and T3 tumour size. HPV16 was 
predominantly present in female patients.  This finding of a gender difference for HR-
HPV may suggest a relationship between HR-HPV and past sexual history.  However, 
this issue of sexual history was beyond the scope of this study. No association was 
found between overall HPV status and survival or disease recurrence. However, HPV16 
was associated with improved overall survival and recurrence-free survival. In the pilot 
study where we had data on other aetiological factors we found that HPV status was 
positively associated with smoking. 
 
p16 positivity varied from 76-78% in carcinomas and the p16 positivity increased 
proportionally by a comparison of benign lesions with dysplasias and carcinomas. This 
is in contrast to the findings of HPV overall and HR-HPV in a comparison of benign 
with malignant tissues. p16 status (p16 positivity and p16 staining intensity) was not 
associated with disease recurrence and positive nodal disease. In addition, positive p16 
staining and high staining intensity was associated with a poorer overall survival. In 
carcinomas, p16 status was significantly associated with male gender, an older age 
group, anatomic site (alveolus and lower lip), and T2 tumour size. In addition, p16 
positivity was significantly associated with histological grade.  
 
We found that overall HPV status was not correlated with p16 expression. Nevertheless, 
p16 staining intensity was significantly associated with HPV status specifically HR- 
HPV and HPV16. However, a correlation was found between p16 and HPV16 which 
may suggest that p16 could potentially act as a surrogate marker for high risk HPV. 
However, the lack of concordance between HPV and p16 would suggest that in 
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isolation p16 may not be a reliable marker for HR-HPV and should not be relied upon 
in isolation in predominantly oral carcinoma. Interestingly, a better overall survival was 
found with carcinomas that were HPV16 negative and p16 negative. Our findings could 
suggest that HPV16 and p16 status may be independent predictors for prognosis and 
disease recurrence.  
 
Future work to compare HPV and p16 on specifically oral carcinoma with 
oropharyngeal may provide greater insight into the differences between these two 
closely related sites and the potential use of p16 in isolation. Future work may improve 
the understating of the role of HPV in pre-malignant and malignant oral lesions and 
may help to identify those lesions that are likely to progress to OSCC. These high risk 
patients could then be targeted for closer follow up and there may be a role for 
vaccination against HPV. However, vaccination is a contentious issue in that it would 
be difficult to identify at risk groups. 
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Appendix 1 
 
PCR reagents preparation 
Distilled water: 
Distilled water was molecular biology grade, DNase and RNase free, ordered from Sigma 
(W4502, 1 liter quantity). Distilled water was aliquoted into 20 ml aliquots and stored at 
ambient temperature. 
Primers: 
Universal primer sets (GH20/PC04, MY11/MY09/GP6 and GP5+/GP6+) and type-
specific primer pairs (SPF1/2) for HPV genotype 16, 18, 31 and 33 were ordered in a 200 
ηmole quantity from Invitrogen. Each primer pellet was resuspended in sterile distilled 
water to make 100 µM stock separately. For each primer pairs, 6 µl stock was added to 94 
µl sterile distilled water to make 6 µM which is equivalent to 6 ρmole/µl. 
dNTPs: 
dNTP set comprising 500 µl of each dATP, dCTP, dGTP and dTTP at 10 mM 
concentration were ordered from AB gene (order number AB-0241). 100 µl of each 
dATP, dCTP, dGTP and dTTP stock were mixed to prepare a dNTP mix with final 
concentration of 2.5 mM of each nucleotide. 
Amplitaq Gold enzyme: 
Amplitaq Gold 6 comprising 6 x 250 units of Amplitaq Gold at 5U/µl, 10x PCR buffer II 
and 25 mM MgCl2 solution was ordered from Applied Biosystems (order number N808-
0243). 
GoTaq® Green Master Mix, 2X (Cat. # M7112, for 100 reactions), Promega Corp. 
 It was supplied with GoTaq® DNA polymerase, GoTaq® Reaction Buffer (pH 8.5, with 
yellow and blue loading dyes), 400 µM dATP, 400 µM dGTP, 400 µM dCTP, 400 µM 
dTTP and 3 mM MgCl2 and Nuclease-Free Water. 
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Appendix 2 
 
Positive Control DNAs 
 
Isolation of DNA from 3T3 Embryonic Mouse Fibroblast Cells 
 
Two vials containing a pellet of 3T3 embryonic mouse fibroblast cells, each of which 
contained 0.9 x 106 (B1) and 1.1 x 106 (B2) cells was used as a positive control for DNA 
extraction and each was resuspended with 100 µl of sterile distilled water. DNA extractions 
were carried out using Qiagen techniques and DNA yield and DNA purity were later 
determined.  
 
Isolation of DNA from Human Salivary Glands 
 
Two vials containing pellet of human salivary glands cells, 1.0 x 106 (A1) and 1.6 x 105 (A2) 
cells was used as a positive control for DNA extraction, β-globin and HPV gene detection 
and each was resuspended with 100 µl of sterile distilled water. DNA extractions were 
carried out using Qiagen techniques and DNA yield and DNA purity were determined. 
 
Plasmid DNAs containing HPV genes 
 
Plasmids (λ) containing HPV genomic DNA, HPV6 and HPV8 (courtesy of Dr. Karin Purdie, 
Queen Mary, University of London) and HPV16 (courtesy of Mr. Maurits de Koning, DDL 
Laboratory, The Netherlands). Each plasmid was provided at the concentration of 100 ηg/µl 
and was used as a positive control in HPV gene detection. 
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Appendix 3 
 
Reagents preparation for Fast Blast DNA stain 
 
100X Fast Blast DNA stain for quick staining (15 min) 
100 ml of 500X Fast Blast DNA was added to 400 ml of deionised water in 1 litre conical 
flask. The diluted solution was thoroughly mixed and the flask was covered and stored at 
ambient temperature.  
 
1X Fast Blast DNA stain for overnight staining (overnight) 
1 ml of 500X Fast Blast was added and gently mixed to 499 ml of deionised water in 1 litre 
conical flask. Alternatively, 5 ml of 100X Fast Blast was added to 495 ml of deionised water 
and thoroughly mixed. The flask was covered and stored at room temperature.  
 
Destaining solution 
A large container with 500-700 ml of clean, warm tap water was used to remove the 
background staining from Fast Blast in the agarose gel. This destaining procedure only was 
required for quick staining procedure with 100X Fast Blast DNA.  
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Appendix 4 
 
Human β-globin DNA sequence 
LOCUS       NG_000007              81706 bp    DNA     linear   PRI 25-JAN-2009 
DEFINITION  Homo sapiens beta globin region (HBB@); and hemoglobin, beta (HBB); 
            and hemoglobin, delta (HBD); and hemoglobin, epsilon 1 (HBE1); and 
            hemoglobin, gamma A (HBG1); and hemoglobin, gamma G (HBG2), on 
            chromosome 11. 
ACCESSION   NG_000007 
VERSION     NG_000007.3  GI:28380636 
KEYWORDS    RefSeqGene. 
SOURCE      Homo sapiens (human) 
  ORGANISM  Homo sapiens 
 
 
>GH20 primer 
GAAGAGCCAAGGACAGGTAC (70400 to 70419) 
>PC04 primer 
GGTGAACGTGGATGAAGTTG (70648 to 70669) 
human beta globin gene (70545 to 72150)- shaded area 
 
ORIGIN       
        
... 
... 
 
    70021 tttcttttct taccagaagg ttttaatcca aataaggaga agatatgctt agaaccgagg 
    70081 tagagttttc atccattctg tcctgtaagt attttgcata ttctggagac gcaggaagag 
    70141 atccatctac atatcccaaa gctgaattat ggtagacaaa actcttccac ttttagtgca 
    70201 tcaacttctt atttgtgtaa taagaaaatt gggaaaacga tcttcaatat gcttaccaag 
    70261 ctgtgattcc aaatattacg taaatacact tgcaaaggag gatgttttta gtagcaattt 
    70321 gtactgatgg tatggggcca agagatatat cttagaggga gggctgaggg tttgaagtcc 
                              GH20 
    70381 aactcctaag ccagtgccag aagagccaag gacaggtacg gctgtcatca cttagacctc 
    70441 accctgtgga gccacaccct agggttggcc aatctactcc caggagcagg gagggcagga 
    70501 gccagggctg ggcataaaag tcagggcaga gccatctatt gcttacattt gcttctgaca 
    70561 caactgtgtt cactagcaac ctcaaacaga caccatggtg catctgactc ctgaggagaa 
    70621 gtctgccgtt actgccctgt ggggcaaggt gaacgtggat gaagttggtg gtgaggccct 
                                                        PC04 
    70681 gggcaggttg gtatcaaggt tacaagacag gtttaaggag accaatagaa actgggcatg 
    70741 tggagacaga gaagactctt gggtttctga taggcactga ctctctctgc ctattggtct 
    70801 attttcccac ccttaggctg ctggtggtct acccttggac ccagaggttc tttgagtcct 
    70861 ttggggatct gtccactcct gatgctgtta tgggcaaccc taaggtgaag gctcatggca 
    70921 agaaagtgct cggtgccttt agtgatggcc tggctcacct ggacaacctc aagggcacct 
    70981 ttgccacact gagtgagctg cactgtgaca agctgcacgt ggatcctgag aacttcaggg 
    71041 tgagtctatg ggacgcttga tgttttcttt ccccttcttt tctatggtta agttcatgtc 
    71101 ataggaaggg gataagtaac agggtacagt ttagaatggg aaacagacga atgattgcat 
    71161 cagtgtggaa gtctcaggat cgttttagtt tcttttattt gctgttcata acaattgttt 
    71221 tcttttgttt aattcttgct ttcttttttt ttcttctccg caatttttac tattatactt 
    71281 aatgccttaa cattgtgtat aacaaaagga aatatctctg agatacatta agtaacttaa 
    71341 aaaaaaactt tacacagtct gcctagtaca ttactatttg gaatatatgt gtgcttattt 
    71401 gcatattcat aatctcccta ctttattttc ttttattttt aattgataca taatcattat 
    71461 acatatttat gggttaaagt gtaatgtttt aatatgtgta cacatattga ccaaatcagg 
    71521 gtaattttgc atttgtaatt ttaaaaaatg ctttcttctt ttaatatact tttttgttta 
    71581 tcttatttct aatactttcc ctaatctctt tctttcaggg caataatgat acaatgtatc 
    71641 atgcctcttt gcaccattct aaagaataac agtgataatt tctgggttaa ggcaatagca 
    71701 atatctctgc atataaatat ttctgcatat aaattgtaac tgatgtaaga ggtttcatat 
    71761 tgctaatagc agctacaatc cagctaccat tctgctttta ttttatggtt gggataaggc 
    71821 tggattattc tgagtccaag ctaggccctt ttgctaatca tgttcatacc tcttatcttc 
    71881 ctcccacagc tcctgggcaa cgtgctggtc tgtgtgctgg cccatcactt tggcaaagaa 
    71941 ttcaccccac cagtgcaggc tgcctatcag aaagtggtgg ctggtgtggc taatgccctg 
    72001 gcccacaagt atcactaagc tcgctttctt gctgtccaat ttctattaaa ggttcctttg 
    72061 ttccctaagt ccaactacta aactggggga tattatgaag ggccttgagc atctggattc 
    72121 tgcctaataa aaaacattta ttttcattgc aatgatgtat ttaaattatt tctgaatatt 
... 
... 
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Appendix 5 
 
 
Base-nucleic acid codes 
 
 
The Nomenclature Committee of the International Union of Biochemistry (NC-IUB) has 
established a standard code to represent uncertain or ambiguous bases in addition to the 
existing standard four base symbols, A, C, G and T in a nucleic acid from raw DNA sequence 
data.  
 
 
 
Abbreviation 
 
Base/s 
 
Description 
 
 
A 
C 
G 
T 
R 
Y 
M 
K 
S 
W 
H 
B 
V 
D 
N 
 
 
A 
C 
G 
T 
A or G 
C or T 
A or C 
G or T 
C or G 
A or T 
A, C or T; not G 
C, G or T; not A 
A, C of G; not T (not U) 
A, G or T; not C 
A, C, G or T 
 
Adenine 
Cytosine 
Guanine 
Thymine 
puRine 
pYrimidine 
aMino 
Keto 
Strong interactions 3 hydrogen bonds 
Weak interactions 2 hydrogen bonds 
H follows G in alphabet 
B follows A in alphabet 
V follows U in alphabet 
D follows C in alphabet 
Any base 
Adapted from NC-IUB (1985) 
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Appendix 6 
 
Table A. Quality and quantity of extracted DNA within positive controls (HSGs) 
 
ID Replication A260 A280 
DNA purity 
(A260/A280) 
DNA yield 
(µg/µl) 
A1.1 1 0.039 0.015 2.600 0.40 
A1.1 2 0.027 0.016 1.688 0.39 
A1.1 3 0.037 0.013 2.846 0.38 
A1.2 1 0.049 0.036 1.361 0.53 
A1.2 2 0.037 0.027 1.370 0.69 
A1.2 3 0.049 0.035 1.400 0.69 
A2.1 1 0.034 0.018 1.889 0.38 
A2.1 2 0.040 0.020 2.000 0.42 
A2.1 3 0.037 0.018 2.056 0.35 
A2.2 1 0.104 0.064 1.625 1.04 
A2.2 2 0.101 0.066 1.530 1.05 
A2.2 3 0.102 0.054 1.889 1.06 
Note: A1 and A2 – DNA extracted from human salivary glands (HSGs) in duplicate 
 
 
 
Table B. Comparison between positive controls (HSGs and 3T3) 
 
 
ID Replication A260 A280 
DNA purity 
(A260/A280) 
DNA yield 
(µg/µl) 
A1 1 0.037 0.017 2.244 0.39 
A1 2 0.034 0.018 1.844 0.41 
A1 3 0.037 0.016 2.451 0.37 
A2 1 0.077 0.050 1.493 0.79 
A2 2 0.069 0.047 1.450 0.87 
A2 3 0.076 0.045 1.644 0.88 
B1 1 0.074 0.050 1.480 0.68 
B1 2 0.069 0.050 1.380 0.71 
B1 3 0.061 0.049 1.245 0.75 
B2 1 0.015 0.003 5.000 0.28 
B2 2 0.025 0.011 2.273 0.29 
B2 3 0.016 0.007 2.286 0.29 
Notes:  
A1 and A2 – DNA extracted from HSGs (average measurements from Table A) 
B1 and B2 – DNA extracted from 3T3 embryonic mouse fibroblasts  
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Appendix 7 
 
Table A. Quality and quantity of extracted DNA within randomly selected FFPETs 
 
ID Replication A260 A280 
DNA purity 
(A260/A280) 
DNA yield 
(µg/µl) 
C1 1 0.113 0.067 1.687 0.91 
C1 2 0.109 0.074 1.473 0.90 
C1 3 0.106 0.075 1.413 1.01 
C1 1 0.025 0.021 1.190 0.25 
C1 2 0.025 0.021 1.190 0.25 
C1 3 0.026 0.022 1.182 0.23 
C2 1 0.044 0.040 1.100 0.53 
C2 2 0.042 0.041 1.024 0.54 
C2 3 0.047 0.042 1.119 0.52 
C2 1 0.042 0.035 1.200 0.34 
C2 2 0.036 0.035 1.029 0.35 
C2 3 0.034 0.034 1.000 0.42 
Note: C1 and C2 – DNA extracted from selected FFPETs in duplicate 
 
Table B. Comparison between randomly selected 6 FFPETs 
 
ID Replication A260 A280 
DNA purity 
(A260/A280) 
DNA yield 
(µg/µl) 
C1 1 0.069 0.044 1.439 0.58 
C1 2 0.067 0.048 1.332 0.58 
C1 3 0.066 0.049 1.298 0.62 
C2 1 0.035 0.031 1.145 0.39 
C2 2 0.034 0.031 1.107 0.40 
C2 3 0.037 0.032 1.150 0.38 
C3 1 0.027 0.022 1.227 0.27 
C3 2 0.026 0.018 1.444 0.25 
C3 3 0.020 0.013 1.538 0.28 
C4 1 0.019 0.020 0.950 0.01 
C4 2 0.020 0.017 1.176 0.11 
C4 3 0.017 0.018 0.944 0.08 
C5 1 0.027 0.025 1.080 0.20 
C5 2 0.025 0.024 1.042 0.26 
C5 3 0.029 0.024 1.208 0.24 
C6 1 0.004 0.001 4.000 0.04 
C6 2 0.007 0.002 3.500 0.04 
C6 3 0.009 0.015 0.600 0.05 
Notes:  
C1 and C2 – DNA extracted from FFPETs (average measurements from Table A) 
C3 to C6 –DNA extracted from randomly selected FFPETs  
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DNA quantification of selected five FFPETs using Qiagen kit (QIAamp DNA FFPE) 
 
   Sections     Reading 1 Reading 2 Reading 3 DNA purity DNA yield 
No. (5 µm) Tissue Replication A260 A280 Ratio A260 A280 Ratio A260 A280 Ratio (Average) (µg/µl) 
1 3 D1 1 0.458 0.339 1.351 0.462 0.338 1.367 0.459 0.338 1.358 1.359 4.597 
2     2 0.471 0.345 1.365 0.471 0.345 1.365 0.471 0.343 1.373 1.368 4.710 
3     3 0.448 0.327 1.370 0.448 0.326 1.374 0.446 0.323 1.381 1.375 4.470 
4   D2 1 0.461 0.337 1.368 0.462 0.339 1.363 0.461 0.338 1.364 1.365 4.617 
5     2 0.469 0.341 1.375 0.473 0.344 1.375 0.472 0.344 1.372 1.374 4.723 
6     3 0.450 0.326 1.380 0.449 0.328 1.369 0.450 0.330 1.364 1.371 4.487 
7   D3 1 0.454 0.338 1.343 0.459 0.339 1.354 0.457 0.342 1.336 1.344 4.560 
8    2 0.466 0.343 1.359 0.467 0.345 1.354 0.470 0.347 1.354 1.356 4.670 
9     3 0.443 0.326 1.359 0.442 0.326 1.356 0.443 0.326 1.359 1.358 4.447 
10   D4 1 0.444 0.339 1.310 0.445 0.339 1.313 0.451 0.345 1.307 1.310 4.447 
11     2 0.464 0.345 1.345 0.451 0.345 1.307 0.454 0.343 1.324 1.325 4.543 
12     3 0.427 0.326 1.310 0.430 0.324 1.327 0.428 0.321 1.333 1.323 4.280 
13   D5 1 0.457 0.337 1.356 0.459 0.340 1.350 0.460 0.337 1.365 1.357 4.617 
14     2 0.468 0.344 1.360 0.470 0.343 1.370 0.469 0.344 1.363 1.365 4.677 
15     3 0.441 0.325 1.357 0.442 0.323 1.368 0.441 0.322 1.370 1.365 4.393 
16 5 D1 1 0.456 0.341 1.337 0.456 0.338 1.349 0.456 0.339 1.345 1.344 4.560 
17     2 0.467 0.357 1.308 0.467 0.353 1.323 0.467 0.346 1.350 1.327 4.670 
18     3 0.441 0.326 1.353 0.445 0.327 1.361 0.444 0.327 1.358 1.357 4.493 
19   D2 1 0.458 0.332 1.380 0.460 0.334 1.377 0.459 0.335 1.370 1.376 4.580 
20     2 0.468 0.341 1.372 0.467 0.335 1.394 0.467 0.339 1.378 1.381 4.667 
21     3 0.476 0.350 1.360 0.477 0.350 1.363 0.443 0.328 1.351 1.358 4.643 
22   D3 1 0.453 0.333 1.360 0.454 0.331 1.372 0.453 0.334 1.356 1.363 4.537 
23    2 0.460 0.344 1.337 0.464 0.339 1.369 0.464 0.337 1.377 1.361 4.637 
24     3 0.443 0.320 1.384 0.443 0.329 1.347 0.443 0.321 1.380 1.370 4.413 
25   D4 1 0.454 0.331 1.372 0.457 0.330 1.385 0.457 0.330 1.385 1.380 4.550 
26     2 0.465 0.338 1.376 0.465 0.338 1.376 0.468 0.337 1.389 1.380 4.647 
27     3 0.443 0.321 1.380 0.442 0.322 1.373 0.442 0.324 1.364 1.372 4.443 
28   D5 1 0.458 0.335 1.367 0.457 0.338 1.352 0.457 0.334 1.368 1.362 4.593 
29     2 0.464 0.338 1.373 0.469 0.338 1.388 0.467 0.337 1.386 1.382 4.687 
30     3 0.441 0.322 1.370 0.445 0.319 1.395 0.445 0.319 1.395 1.387 4.457 
31 10 D1 1 0.447 0.330 1.355 0.448 0.333 1.345 0.449 0.335 1.340 1.347 4.503 
32     2 0.456 0.337 1.353 0.455 0.335 1.358 0.456 0.335 1.361 1.358 4.557 
33     3 0.436 0.321 1.358 0.435 0.320 1.359 0.439 0.322 1.363 1.360 4.390 
34   D2 1 0.455 0.334 1.362 0.454 0.333 1.363 0.455 0.334 1.362 1.363 4.550 
35     2 0.459 0.338 1.358 0.462 0.335 1.379 0.466 0.336 1.387 1.375 4.640 
36     3 0.443 0.320 1.384 0.443 0.320 1.384 0.443 0.316 1.402 1.390 4.450 
37   D3 1 0.461 0.337 1.368 0.463 0.339 1.366 0.466 0.336 1.387 1.374 4.627 
38    2 0.471 0.340 1.385 0.469 0.341 1.375 0.472 0.347 1.360 1.374 4.730 
39     3 0.446 0.325 1.372 0.449 0.327 1.373 0.452 0.327 1.382 1.376 4.490 
40   D4 1 0.452 0.332 1.361 0.464 0.335 1.385 0.456 0.334 1.365 1.371 4.563 
41     2 0.467 0.344 1.358 0.465 0.338 1.376 0.469 0.342 1.371 1.368 4.670 
42     3 0.443 0.322 1.376 0.448 0.325 1.378 0.447 0.323 1.384 1.379 4.450 
43   D5 1 0.455 0.335 1.358 0.460 0.333 1.381 0.457 0.330 1.385 1.375 4.573 
44     2 0.462 0.342 1.351 0.466 0.335 1.391 0.465 0.339 1.372 1.371 4.653 
45     3 0.449 0.324 1.386 0.446 0.325 1.372 0.453 0.326 1.390 1.383 4.463 
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Appendix 9 
 
One-way ANOVA on extracted DNA using Qiagen kit 
 
Descriptives 
  
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum   Lower Bound Upper Bound 
DNA purity 3 coupes 15 1.35433 0.019963 0.005154 1.34328 1.36539 1.310 1.375 
5 coupes 15 1.36667 0.016167 0.004174 1.35771 1.37562 1.327 1.387 
10 coupes 15 1.37093 0.010633 0.002746 1.36504 1.37682 1.347 1.390 
Total 45 1.36398 0.017222 0.002567 1.35880 1.36915 1.310 1.390 
DNA concentration 3 coupes 15 4.54920 0.127201 0.032843 4.47876 4.61964 4.280 4.723 
5 coupes 15 4.57180 0.088838 0.022938 4.52260 4.62100 4.413 4.687 
10 coupes 15 4.55393 0.096707 0.024970 4.50038 4.60749 4.390 4.730 
Total 45 4.55831 0.103595 0.015443 4.52719 4.58943 4.280 4.730 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
DNA purity 2.322 2 42 0.111 
DNA concentration 1.252 2 42 0.296 
 
ANOVA 
  Sum of Squares df Mean Square F Sig. 
DNA purity Between Groups 0.002 2 0.001 4.326 0.020 
Within Groups 0.011 42 0.000   
Total 0.013 44    
DNA concentration Between Groups 0.004 2 0.002 0.191 0.827 
Within Groups 0.468 42 0.011   
Total 0.472 44    
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Appendix 9 (contd.) 
 
Post Hoc Test: Multiple Comparisons 
Dependent Variable 
(I) Coupe 
number 
(J) Coupe 
number Mean Difference (I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
DNA purity Tukey HSD 3 coupes 5 coupes -0.012333 0.005861 0.101 -0.02657 0.00191 
10 coupes -0.016600* 0.005861 0.019 -0.03084 -0.00236 
5 coupes 3 coupes 0.012333 0.005861 0.101 -0.00191 0.02657 
10 coupes -0.004267 0.005861 0.748 -0.01851 0.00997 
10 coupes 3 coupes 0.016600* 0.005861 0.019 0.00236 0.03084 
5 coupes 0.004267 0.005861 0.748 -0.00997 0.01851 
Games-Howell 3 coupes 5 coupes -0.012333 0.006633 0.170 -0.02878 0.00412 
10 coupes -0.016600* 0.005840 0.025 -0.03130 -0.00190 
5 coupes 3 coupes 0.012333 0.006633 0.170 -0.00412 0.02878 
10 coupes -0.004267 0.004996 0.674 -0.01674 0.00820 
10 coupes 3 coupes 0.016600* 0.005840 0.025 0.00190 0.03130 
5 coupes 0.004267 0.004996 0.674 -0.00820 0.01674 
DNA concentration Tukey HSD 3 coupes 5 coupes -0.022600 0.038543 0.828 -0.11624 0.07104 
10 coupes -0.004733 0.038543 0.992 -0.09837 0.08891 
5 coupes 3 coupes 0.022600 0.038543 0.828 -0.07104 0.11624 
10 coupes 0.017867 0.038543 0.889 -0.07577 0.11151 
10 coupes 3 coupes 0.004733 0.038543 0.992 -0.08891 0.09837 
5 coupes -0.017867 0.038543 0.889 -0.11151 0.07577 
Games-Howell 3 coupes 5 coupes -0.022600 0.040060 0.840 -0.12237 0.07717 
10 coupes -0.004733 0.041257 0.993 -0.10722 0.09776 
5 coupes 3 coupes 0.022600 0.040060 0.840 -0.07717 0.12237 
10 coupes 0.017867 0.033906 0.859 -0.06606 0.10180 
10 coupes 3 coupes 0.004733 0.041257 0.993 -0.09776 0.10722 
5 coupes -0.017867 0.033906 0.859 -0.10180 0.06606 
*. The mean difference is significant at the 0.05 level.      
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Appendix 10 
 
DNA quantification of selected five FFPETs using PROMEGA kit (Magnesil Genomic) 
 
   Sections     Reading 1 Reading 2 Reading 3 DNA purity DNAyield 
No. (5 µm) Tissue Replication A260 A280 Ratio A260 A280 Ratio A260 A280 Ratio (average) (µg/µl) 
1 3 D1 1 0.437 0.316 1.383 0.431 0.314 1.373 0.433 0.312 1.388 1.381 4.320 
2     2 0.433 0.315 1.375 0.435 0.313 1.390 0.430 0.317 1.356 1.374 4.323 
3     3 0.401 0.289 1.388 0.400 0.290 1.379 0.398 0.287 1.387 1.385 3.997 
4   D2 1 0.434 0.313 1.387 0.434 0.314 1.382 0.432 0.313 1.380 1.383 4.327 
5     2 0.439 0.318 1.381 0.442 0.322 1.373 0.441 0.318 1.387 1.380 4.413 
6     3 0.421 0.302 1.394 0.421 0.302 1.394 0.423 0.302 1.401 1.396 4.220 
7   D3 1 0.428 0.310 1.381 0.426 0.312 1.365 0.432 0.310 1.394 1.380 4.290 
8    2 0.446 0.326 1.368 0.446 0.324 1.377 0.446 0.326 1.368 1.371 4.463 
9     3 0.424 0.305 1.390 0.424 0.306 1.386 0.427 0.308 1.386 1.387 4.247 
10   D4 1 0.455 0.340 1.338 0.455 0.331 1.375 0.457 0.332 1.377 1.363 4.557 
11     2 0.467 0.344 1.358 0.467 0.336 1.390 0.466 0.339 1.375 1.374 4.663 
12     3 0.427 0.305 1.400 0.428 0.309 1.385 0.428 0.309 1.385 1.390 4.280 
13   D5 1 0.426 0.318 1.340 0.422 0.322 1.311 0.423 0.316 1.339 1.330 4.223 
14     2 0.445 0.332 1.340 0.444 0.334 1.329 0.444 0.333 1.333 1.334 4.433 
15     3 0.430 0.326 1.319 0.432 0.324 1.333 0.430 0.320 1.344 1.332 4.313 
16 5 D1 1 0.429 0.314 1.366 0.430 0.311 1.383 0.429 0.313 1.371 1.373 4.290 
17     2 0.459 0.341 1.346 0.462 0.345 1.339 0.462 0.337 1.371 1.352 4.620 
18     3 0.434 0.317 1.369 0.437 0.323 1.353 0.433 0.316 1.370 1.364 4.370 
19   D2 1 0.449 0.341 1.317 0.451 0.347 1.300 0.464 0.343 1.353 1.323 4.483 
20     2 0.452 0.331 1.366 0.455 0.331 1.375 0.452 0.339 1.333 1.358 4.540 
21     3 0.425 0.313 1.358 0.425 0.313 1.358 0.429 0.312 1.375 1.364 4.310 
22   D3 1 0.428 0.327 1.309 0.429 0.323 1.328 0.429 0.321 1.336 1.324 4.300 
23    2 0.460 0.340 1.353 0.466 0.338 1.379 0.455 0.341 1.334 1.355 4.553 
24     3 0.432 0.325 1.329 0.433 0.323 1.341 0.435 0.326 1.334 1.335 4.343 
25   D4 1 0.446 0.328 1.360 0.448 0.327 1.370 0.451 0.328 1.375 1.368 4.457 
26     2 0.455 0.338 1.346 0.460 0.338 1.361 0.459 0.340 1.350 1.352 4.587 
27     3 0.430 0.312 1.378 0.429 0.313 1.371 0.430 0.312 1.378 1.376 4.297 
28   D5 1 0.433 0.317 1.366 0.435 0.318 1.368 0.436 0.315 1.384 1.373 4.343 
29     2 0.434 0.319 1.361 0.437 0.317 1.379 0.439 0.314 1.398 1.379 4.360 
30     3 0.431 0.314 1.373 0.430 0.312 1.378 0.430 0.309 1.392 1.381 4.290 
31 10 D1 1 0.448 0.330 1.358 0.452 0.328 1.378 0.448 0.331 1.353 1.363 4.483 
32     2 0.455 0.333 1.366 0.456 0.329 1.386 0.456 0.332 1.373 1.375 4.567 
33     3 0.426 0.306 1.392 0.424 0.308 1.377 0.427 0.310 1.377 1.382 4.273 
34   D2 1 0.450 0.329 1.368 0.448 0.333 1.345 0.449 0.330 1.361 1.358 4.483 
35     2 0.446 0.325 1.372 0.445 0.324 1.373 0.443 0.322 1.376 1.374 4.440 
36     3 0.423 0.308 1.373 0.419 0.307 1.365 0.419 0.305 1.374 1.371 4.217 
37   D3 1 0.417 0.313 1.332 0.416 0.317 1.312 0.417 0.312 1.337 1.327 4.160 
38    2 0.450 0.327 1.376 0.438 0.326 1.344 0.436 0.327 1.333 1.351 4.360 
39     3 0.414 0.310 1.335 0.412 0.308 1.338 0.411 0.315 1.305 1.326 4.113 
40   D4 1 0.438 0.328 1.335 0.439 0.338 1.299 0.438 0.327 1.339 1.325 4.390 
41     2 0.445 0.332 1.340 0.451 0.335 1.346 0.446 0.336 1.327 1.338 4.460 
42     3 0.404 0.293 1.379 0.404 0.294 1.374 0.405 0.295 1.373 1.375 4.050 
43   D5 1 0.453 0.329 1.377 0.453 0.332 1.364 0.453 0.332 1.364 1.369 4.540 
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44     2 0.456 0.335 1.361 0.458 0.335 1.367 0.458 0.334 1.371 1.367 4.580 
45     3 0.437 0.318 1.374 0.438 0.321 1.364 0.438 0.318 1.377 1.372 4.373 
 
Appendix 11 
 
One-way ANOVA on extracted DNA using Promega kit 
Descriptives 
  
N Mean Std. Deviation Std. Error 
95% Confidence Interval for Mean 
Minimum Maximum   Lower Bound Upper Bound 
DNA purity 3 coupes 15 1.37067 0.021540 0.005561 1.35874 1.38259 1.330 1.396 
5 coupes 15 1.35847 0.018715 0.004832 1.34810 1.36883 1.323 1.381 
10 coupes 15 1.35820 0.019865 0.005129 1.34720 1.36920 1.325 1.382 
Total 45 1.36244 0.020475 0.003052 1.35629 1.36860 1.323 1.396 
DNA concentration 3 coupes 15 4.33793 0.156419 0.040387 4.25131 4.42456 3.997 4.663 
5 coupes 15 4.40953 0.118641 0.030633 4.34383 4.47523 4.290 4.620 
10 coupes 15 4.36593 0.168178 0.043423 4.27280 4.45907 4.050 4.580 
Total 45 4.37113 0.148831 0.022186 4.32642 4.41585 3.997 4.663 
 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
DNA purity 0.127 2 42 0.881 
DNA concentration 0.576 2 42 0.566 
 
 
ANOVA 
  Sum of Squares df Mean Square F Sig. 
DNA purity Between Groups 0.002 2 0.001 1.888 0.164 
Within Groups 0.017 42 0.000   
Total 0.018 44    
DNA concentration Between Groups 0.039 2 0.020 .877 0.424 
Within Groups 0.936 42 0.022   
Total 0.975 44    
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Appendix 12 
 
DNA qualification and quantification comparison between  
QIAGEN kit (QIAamp DNA FFPE) and PROMEGA kit (Magnesil Genomic) 
 
  Sections   DNA Average Average DNA 
No. (5 µm) Tissue Kits1 purity concentration (µg/µl) 
1 3 D1 P 1.380 4.213 
2     Q 1.367 4.592 
3   D2 P 1.386 4.320 
4     Q 1.370 4.609 
5   D3 P 1.379 4.333 
6     Q 1.353 4.559 
7   D4 P 1.376 4.500 
8     Q 1.320 4.423 
9   D5 P 1.332 4.323 
10     Q 1.362 4.562 
11 5 D1 P 1.363 4.427 
12     Q 1.343 4.574 
13   D2 P 1.348 4.444 
14     Q 1.372 4.630 
15   D3 P 1.338 4.399 
16     Q 1.365 4.529 
17   D4 P 1.365 4.447 
18     Q 1.378 4.547 
19   D5 P 1.378 4.331 
20     Q 1.377 4.579 
21 10 D1 P 1.373 4.441 
22     Q 1.355 4.483 
23   D2 P 1.367 4.380 
24     Q 1.376 4.547 
25   D3 P 1.335 4.211 
26     Q 1.374 4.616 
27   D4 P 1.346 4.300 
28     Q 1.373 4.561 
29   D5 P 1.369 4.498 
30     Q 1.376 4.563 
 
Note: 
1  P for Promega, DNA Extraction Kits (Magnesil Genomic) and  
   Q for Qiagen, DNA Extraction Kits (QIAamp DNA FFPE) 
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Appendix 13 
 
Quantification of 60 extracted DNA (QIAamp FFPE DNA kit) 
 
Sample   Reading 1 Reading 2 Reading 3 Average DNA conc. Dilution for PCR 10 ηg/µl (µl) 
no. Pathology ID A260 A280 Ratio A260 A280 Ratio A260 A280 Ratio purity (µg/µl) DNA dH2O Total 
1 01209199 2 0.036 0.040 0.900 0.049 0.050 0.980 0.040 0.040 1.000 0.960 0.477 4 196 200 
2 954593 B 0.044 0.035 1.257 0.047 0.045 1.044 0.047 0.045 1.044 1.115 0.463 4 196 200 
3 NS00196904 1 0.062 0.061 1.016 0.068 0.065 1.046 0.063 0.061 1.033 1.032 0.603 3 197 200 
4 NS00442204 1L 0.059 0.040 1.475 0.047 0.033 1.424 0.057 0.043 1.326 1.408 0.647 3 197 200 
5 NS00642004 1 0.050 0.040 1.250 0.048 0.045 1.067 0.050 0.046 1.087 1.135 0.497 4 196 200 
6 NS00671203 1 0.047 0.040 1.175 0.049 0.033 1.485 0.041 0.038 1.079 1.246 0.510 4 196 200 
7 NS00711302 1B 0.018 0.013 1.385 0.017 0.008 2.125 0.020 0.015 1.333 1.614 0.200 10 190 200 
8 NS00848002 3D 0.065 0.063 1.032 0.067 0.062 1.081 0.067 0.066 1.015 1.043 0.680 3 197 200 
9 NS01/68103 1A 0.052 0.047 1.106 0.054 0.048 1.125 0.054 0.051 1.059 1.097 0.543 4 196 200 
10 NS01/68103 1B 0.059 0.058 1.017 0.058 0.060 0.967 0.054 0.056 0.964 0.983 0.557 4 196 200 
11 NS01020203 3K 0.054 0.049 1.102 0.049 0.041 1.195 0.037 0.047 0.787 1.028 0.340 6 194 200 
12 NS01029003 1 0.064 0.061 1.049 0.061 0.065 0.938 0.063 0.065 0.969 0.986 0.653 3 197 200 
13 NS01076404 1B 0.009 0.019 0.474 0.005 0.001 5.000 0.004 0.007 0.571 2.015 0.063 32 168 200 
14 NS01258903 1C 0.079 0.090 0.878 0.088 0.085 1.035 0.089 0.085 1.047 0.987 0.927 2 198 200 
15 NS01291204 1C 0.066 0.058 1.138 0.065 0.055 1.182 0.068 0.057 1.193 1.171 0.680 3 197 200 
16 NS01404702 1B 0.015 0.007 2.143 0.014 0.010 1.400 0.014 0.015 0.933 1.492 0.153 13 187 200 
17 NS01643002 1A 0.066 0.058 1.138 0.067 0.060 1.117 0.067 0.058 1.155 1.137 0.667 3 197 200 
18 NS01803103 1 0.039 0.033 1.182 0.037 0.036 1.028 0.039 0.031 1.258 1.156 0.370 5 195 200 
19 NS01864704 1B 0.017 0.004 4.250 0.006 0.010 0.600 0.013 0.003 4.333 3.061 0.147 14 186 200 
20 NS01960104 1 0.032 0.048 0.667 0.021 0.047 0.447 0.036 0.055 0.655 0.589 0.567 4 196 200 
21 NS02060804 1 0.065 0.058 1.121 0.057 0.049 1.163 0.050 0.054 0.926 1.070 0.650 3 197 200 
22 TS00012706 1 0.003 0.017 0.176 0.016 0.026 0.615 0.001 0.020 0.050 0.281 0.273 7 193 200 
23 TS00044505 1 0.074 0.082 0.902 0.062 0.081 0.765 0.086 0.080 1.075 0.914 0.850 2 198 200 
24 TS00055407 1 0.053 0.033 1.606 0.049 0.042 1.167 0.052 0.044 1.182 1.318 0.490 4 196 200 
25 TS00059407 1 0.038 0.023 1.652 0.036 0.027 1.333 0.041 0.029 1.414 1.466 0.347 6 194 200 
26 TS00109407 2F 0.065 0.053 1.226 0.071 0.060 1.183 0.070 0.052 1.346 1.252 0.703 3 197 200 
27 TS00148106 1 0.044 0.035 1.257 0.035 0.027 1.296 0.036 0.029 1.241 1.265 0.387 5 195 200 
28 TS00164406 3C 0.031 0.024 1.292 0.025 0.023 1.087 0.029 0.021 1.381 1.253 0.303 7 193 200 
29 TS00187207 1 HED1D2 0.058 0.062 0.935 0.065 0.059 1.102 0.061 0.054 1.130 1.056 0.630 3 197 200 
30 TS00213305 1B 0.031 0.030 1.033 0.029 0.033 0.879 0.035 0.031 1.129 1.014 0.343 6 194 200 
31 TS00232207 1 0.024 0.022 1.091 0.011 0.011 1.000 0.015 0.014 1.071 1.054 0.227 9 191 200 
32 TS00267305 3E 0.095 0.082 1.159 0.086 0.087 0.989 0.096 0.089 1.079 1.075 0.857 2 198 200 
33 TS00315505 1G 0.028 0.034 0.824 0.031 0.034 0.912 0.032 0.030 1.067 0.934 0.303 7 193 200 
34 TS00338107 2G 0.056 0.026 2.154 0.057 0.018 3.167 0.024 0.020 1.200 2.174 0.563 4 196 200 
35 TS00486606 1A 0.084 0.059 1.424 0.056 0.071 0.789 0.085 0.068 1.250 1.154 0.853 2 198 200 
36 TS00507307 2B 0.046 0.033 1.394 0.048 0.018 2.667 0.043 0.031 1.387 1.816 0.457 4 196 200 
37 TS00624606 1 0.072 0.028 2.571 0.043 0.048 0.896 0.072 0.048 1.500 1.656 0.557 4 196 200 
38 TS00629005 1 0.081 0.076 1.066 0.095 0.072 1.319 0.091 0.083 1.096 1.161 0.833 2 198 200 
39 TS00727706 1 0.047 0.038 1.237 0.058 0.045 1.289 0.058 0.042 1.381 1.302 0.567 4 196 200 
40 TS00854605 3M 0.048 0.027 1.778 0.047 0.032 1.469 0.037 0.029 1.276 1.507 0.483 4 196 200 
41 TS00858906 1C 0.095 0.075 1.267 0.093 0.080 1.163 0.076 0.079 0.962 1.130 0.937 2 198 200 
42 TS00965006 3C 0.057 0.028 2.036 0.058 0.039 1.487 0.053 0.039 1.359 1.627 0.577 3 197 200 
43 TS01129306 1B 0.039 0.026 1.500 0.014 0.027 0.519 0.038 0.023 1.652 1.224 0.377 5 195 200 
44 TS01218406 1 0.064 0.065 0.985 0.057 0.057 1.000 0.055 0.062 0.887 0.957 0.697 3 197 200 
45 TS01292806 2K 0.037 0.045 0.822 0.031 0.025 1.240 0.028 0.025 1.120 1.061 0.560 4 196 200 
46 TS01298705 1 0.020 0.041 0.488 0.028 0.039 0.718 0.033 0.040 0.825 0.677 0.520 4 196 200 
47 TS01353006 1 0.045 0.051 0.882 0.035 0.043 0.814 0.049 0.051 0.961 0.886 0.490 4 196 200 
48 TS01371006 1A 0.037 0.034 1.088 0.031 0.026 1.192 0.036 0.034 1.059 1.113 0.293 7 193 200 
49 TS01388406 4F 0.034 0.036 0.944 0.049 0.031 1.581 0.046 0.030 1.533 1.353 0.460 4 196 200 
50 TS01390006 1E 0.074 0.068 1.088 0.077 0.074 1.041 0.077 0.073 1.055 1.061 0.773 3 197 200 
51 TS01399006 1 0.011 0.022 0.500 0.005 0.020 0.250 0.005 0.016 0.313 0.354 0.113 18 182 200 
52 TS01423506 3H 0.040 0.028 1.429 0.034 0.025 1.360 0.036 0.026 1.385 1.391 0.260 8 192 200 
53 TS01514806 3D 0.006 0.004 1.500 0.010 0.003 3.333 0.007 0.006 1.167 2.000 0.123 16 184 200 
54 TS01596705 1 0.008 0.016 0.500 0.011 0.018 0.611 0.007 0.019 0.368 0.493 0.147 14 186 200 
55 TS01898205 1 0.015 0.014 1.071 0.014 0.013 1.077 0.014 0.014 1.000 1.049 0.137 15 185 200 
56 TS01958205 1 0.010 0.009 1.111 0.007 0.010 0.700 0.007 0.008 0.875 0.895 0.067 30 170 200 
57 TS02131305 2D 0.047 0.037 1.270 0.048 0.042 1.143 0.044 0.037 1.189 1.201 0.497 4 196 200 
58 TS02184105 2L 0.036 0.027 1.333 0.041 0.028 1.464 0.041 0.019 2.158 1.652 0.350 6 194 200 
59 TS02338805 1 0.025 0.012 2.083 0.024 0.010 2.400 0.022 0.005 4.400 2.961 0.223 9 191 200 
60 TS02518405 1 0.002 0.007 0.286 0.007 0.011 0.636 0.011 0.004 2.750 1.224 0.103 19 181 200 
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Appendix 14A 
 
 
Positive PCR amplification results for β-globin and L1 of alpha HPV 
 
 
No ID Pathology code 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp status 
        
1 1 01209199 2 + - - + + 
2 2 954593 B + - - + + 
3 3 NS00196904 1 + - + + + 
4 4 NS00442204 1L + - - + + 
5 6 NS00671203 1 + - + + + 
6 7 NS00711302 1B + - - + + 
7 8 NS00848002 3D + - - + + 
8 9 NS01/68103 1A + - - + + 
9 10 NS01/68103 1B + - - + + 
10 11 NS01020203 3K + - - + + 
11 12 NS01029003 1 + - - + + 
12 13 NS01076404 1B + - - + + 
13 15 NS01291204 1C + - - + + 
14 16 NS01404702 1B + - + + + 
15 22 TS00012706 1 + - - + + 
16 27 TS00148106 1 + - + + + 
17 32 TS00267305 3E + - - + + 
18 33 TS00315505 1G + - - + + 
19 37 TS00624606 1 + - + + + 
20 43 TS01129306 1B + - + - + 
21 45 TS01292806 2K + + + + + 
22 46 TS01298705 1 + + + + + 
23 47 TS01353006 1 + + + + + 
24 48 TS01371006 1A + + + + + 
25 49 TS01388406 4F + + + + + 
26 50 TS01390006 1E + + + + + 
27 52 TS01423506 3H + + + + + 
28 53 TS01514806 3D + + + + + 
29 54 TS01596705 1 + + + + + 
30 55 TS01898205 1 + + + + + 
31 56 TS01958205 1 + + + + + 
32 57 TS02131305 2D + + + + + 
33 58 TS02184105 2L + + + + + 
34 60 TS02518405 1 + + + + + 
        
  Total: 34 14 
 
20 
 
33 (55.0) 34 
  Percentage: 56.7 23.3 33.3 55.0 56.7 
  Grand total: 60 60 60 60 60 
        
Note: +   Positive  PCR and  -   Negative PCR 
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PCR amplification results for β-globin (positive) and L1 of α-HPV (negative) 
 
 
No ID Pathology code 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp status 
        
1 5 NS00642004 1 + - - - - 
2 14 NS01258903 1C + - - - - 
3 17 NS01643002 1A + - - - - 
4 18 NS01803103 1 + - - - - 
5 19 NS01864704 1B + - - - - 
6 20 NS01960104 1 + - - - - 
7 21 NS02060804 1 + - - - - 
8 23 TS00044505 1 + - - - - 
9 24 TS00055407 1 + - - - - 
10 25 TS00059407 1 + - - - - 
11 26 TS00109407 2F + - - - - 
12 28 TS00164406 3C + - - - - 
13 29 TS00187207 1 HED1D2 + - - - - 
14 30 TS00213305 1B + - - - - 
15 31 TS00232207 1 + - - - - 
16 34 TS00338107 2G + - - - - 
17 35 TS00486606 1A + - - - - 
18 36 TS00507307 2B + - - - - 
19 38 TS00629005 1 + - - - - 
20 39 TS00727706 1 + - - - - 
21 40 TS00854605 3M + - - - - 
22 41 TS00858906 1C + - - - - 
23 42 TS00965006 3C + - - - - 
24 44 TS01218406 1 + - - - - 
25 51 TS01399006 1 + - - - - 
26 59 TS02338805 1 + - - - - 
        
  Total: 26 - - - 26 
  Percentage: 43.3    43.3 
  Grand total: 60    60 
        
Note: +   Positive  PCR and  -   Negative PCR 
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DNA quantification of the PCR products prior to automated DNA sequencing 
  
    PCR  Purification  Amplicon DNA purity DNA yield Volume (µl) 10 ηg/µl 
No. Sample no. (tube no.)  Methodsα Methodsβ size (bp) A260/A280 (ηg/µl) DNA dH2O (µl) 
1 45 (Tube #89) iPCR B 450 1.061 55 4 16 20 
2 46 (Tube #91) iPCR B 450 0.677 140 1 19 20 
3 47 (Tube #93) iPCR A 450 0.886 60 3 17 20 
4 48 (Tube #95) iPCR B 450 1.113 35 6 14 20 
5 49 (Tube #97) iPCR A 450 1.353 95 2 18 20 
6 50 (Tube #99) iPCR B 450 1.061 40 5 15 20 
7 52 (Tube #103) iPCR B 450 1.391 40 5 15 20 
8 53 (Tube #105) iPCR B 450 2.000 40 5 15 20 
9 54 (Tube #107) iPCR A 450 0.493 30 7 13 20 
10 55 (Tube #109) iPCR B 450 1.049 30 7 13 20 
11 56 (Tube #111) iPCR A 450 0.895 50 4 16 20 
12 57 (Tube #114) iPCR A 450 1.201 45 4 16 20 
13 58 (Tube #115) iPCR A 450 1.652 85 2 18 20 
14 60 (Tube #119) iPCR A 450 1.224 55 4 16 20 
15 3 (Tube #5) iPCR B 190 1.032 25 8 12 20 
16 6 (Tube #11) iPCR B 190 1.079 30 7 13 20 
17 16 (Tube #31) iPCR B 190 1.492 15 13 7 20 
18 27 (Tube #53) iPCR B 190 1.265 62 3 17 20 
19 37 (Tube #73) iPCR B 190 1.656 85 2 18 20 
20 43 (Tube #85) iPCR B 190 1.224 60 3 17 20 
21 45 (Tube #89) snPCR A 190 1.421 125 2 18 20 
22 46 (Tube #91) snPCR A 190 1.070 165 1 19 20 
23 47 (Tube #93) snPCR A 190 0.886 120 2 18 20 
24 48 (Tube #95) snPCR A 190 0.910 145 1 19 20 
25 49 (Tube #97) snPCR A 190 0.925 140 1 19 20 
26 50 (Tube #99) snPCR A 190 1.140 135 1 19 20 
27 52 (Tube #103) snPCR A 190 1.541 150 1 19 20 
28 53 (Tube #105) snPCR A 190 2.361 150 1 19 20 
29 54 (Tube #107) snPCR A 190 1.132 185 1 19 20 
30 55 (Tube #109) snPCR A 190 0.936 80 2 18 20 
31 56 (Tube #111) snPCR A 190 1.044 70 3 17 20 
32 57 (Tube #114) snPCR A 190 1.270 70 3 17 20 
33 58 (Tube #115) snPCR A 190 1.500 70 3 17 20 
34 60 (Tube #119) snPCR A 190 1.032 95 2 18 20 
35 1 (Tube #1) iPCR B 140 0.980 80 3 17 20 
36 2 (Tube #3) iPCR B 140 1.257 55 4 16 20 
37 3 (Tube #5) iPCR B 140 1.115 55 4 16 20 
38 4 (Tube #7) iPCR B 140 1.475 45 4 16 20 
39 6 (Tube #11) iPCR B 140 1.485 30 7 13 20 
40 7 (Tube #13) iPCR B 140 2.125 15 13 7 20 
41 8 (Tube #15) iPCR B 140 1.412 95 2 18 20 
42 9 (Tube #17) iPCR B 140 1.125 20 10 10 20 
43 10 (Tube #20) iPCR B 140 1.333 20 10 10 20 
44 11 (Tube #21) iPCR B 140 1.109 35 6 14 20 
45 12 (Tube #23) iPCR B 140 1.098 55 4 16 20 
46 13 (Tube #25) iPCR B 140 1.275 75 3 17 20 
47 15 (Tube #30) iPCR B 140 1.262 30 7 13 20 
48 16 (Tube #31) iPCR B 140 2.143 60 3 17 20 
49 22 (Tube #43) iPCR B 140 1.039 25 8 12 20 
50 27 (Tube #53) iPCR B 140 1.297 55 4 16 20 
51 32 (Tube #63) iPCR B 140 1.269 40 5 15 20 
52 33 (Tube #65) iPCR B 140 1.100 130 2 18 20 
53 37 (Tube #73) iPCR B 140 1.500 205 1 19 20 
54 45 (Tube #80) nPCR A 140 1.547 150 1 19 20 
55 46 (Tube #91) nPCR A 140 1.089 145 1 19 20 
56 47 (Tube #93) nPCR A 140 0.961 145 1 19 20 
57 48 (Tube #95) nPCR A 140 1.192 105 2 18 20 
58 49 (Tube #97) nPCR A 140 1.581 105 2 18 20 
59 50 (Tube #99) nPCR A 140 1.318 120 2 18 20 
60 52 (Tube #103) nPCR A 140 1.429 100 2 18 20 
61 53 (Tube #105) nPCR A 140 1.333 85 2 18 20 
62 54 (Tube #107) nPCR A 140 1.167 80 3 17 20 
63 55 (Tube #109) nPCR A 140 1.077 80 3 17 20 
64 56 (Tube #111) nPCR A 140 1.188 80 3 17 20 
65 57 (Tube #114) nPCR A 140 1.189 90 2 18 20 
66 58 (Tube #115) nPCR A 140 1.464 110 2 18 20 
67 60 (Tube #119) nPCR A 140 1.125 100 2 18 20 
Notes: 
 α - PCR methods: iPCR – Independent PCR; snPCR - Semi-nested PCR; and nPCR - Nested PCR 
 β - PCR product purification methods: A - QIAquick PCR Purification Kit (Qiagen); B - QIAquick Gel Extraction Kit (Qiagen) 
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Appendix 16 
 
Automated DNA sequencing results (actual size obtained from contig) 
  
    PCR  Purification  Expected amplicon Actual amplicon size 
No. Sample no. (tube no.)  Methodsa Methodsb size (bp) size (bp) 
1 45 (Tube #89) iPCR B 450 422 
2 46 (Tube #91) iPCR B 450 447 
3 47 (Tube #93) iPCR A 450 453 
4 48 (Tube #95) iPCR B 450 451 
5 49 (Tube #97) iPCR A 450 452 
6 50 (Tube #99) iPCR B 450 454 
7 52 (Tube #103) iPCR B 450 444 
8 53 (Tube #105) iPCR B 450 447 
9 54 (Tube #107) iPCR A 450 450 
10 55 (Tube #109) iPCR B 450 451 
11 56 (Tube #111) iPCR A 450 451 
12 57 (Tube #114) iPCR A 450 451 
13 58 (Tube #115) iPCR A 450 451 
14 60 (Tube #119) iPCR A 450 447 
15 3 (Tube #5) iPCR B 190 183 
16 6 (Tube #11) iPCR B 190 179 
17 16 (Tube #31) iPCR B 190 205 
18 27 (Tube #53) iPCR B 190 181 
19 37 (Tube #73) iPCR B 190 179 
20 43 (Tube #85) iPCR B 190 180 
21 45 (Tube #89) snPCR A 190 146 (partial) 
22 46 (Tube #91) snPCR A 190 147 (partial) 
23 47 (Tube #93) snPCR A 190 181 
24 48 (Tube #95) snPCR A 190 190 
25 49 (Tube #97) snPCR A 190 145 (partial) 
26 50 (Tube #99) snPCR A 190 144 (partial) 
27 52 (Tube #103) snPCR A 190 143 (partial) 
28 53 (Tube #105) snPCR A 190 152 (partial) 
29 54 (Tube #107) snPCR A 190 144 (partial) 
30 55 (Tube #109) snPCR A 190 181 
31 56 (Tube #111) snPCR A 190 153 (partial) 
32 57 (Tube #114) snPCR A 190 141 (partial) 
33 58 (Tube #115) snPCR A 190 144 (partial) 
34 60 (Tube #119) snPCR A 190 148 (partial) 
35 1 (Tube #1) iPCR B 140 141 
36 2 (Tube #3) iPCR B 140 141 
37 3 (Tube #5) iPCR B 140 141 
38 4 (Tube #7) iPCR B 140 141 
39 6 (Tube #11) iPCR B 140 141 
40 7 (Tube #13) iPCR B 140 141 
41 8 (Tube #15) iPCR B 140 141 
42 9 (Tube #17) iPCR B 140 141 
43 10 (Tube #20) iPCR B 140 141 
44 11 (Tube #21) iPCR B 140 141 
45 12 (Tube #23) iPCR B 140 141 
46 13 (Tube #25) iPCR B 140 141 
47 15 (Tube #30) iPCR B 140 141 
48 16 (Tube #31) iPCR B 140 141 
49 22 (Tube #43) iPCR B 140 141 
50 27 (Tube #53) iPCR B 140 141 
51 32 (Tube #63) iPCR B 140 141 
52 33 (Tube #65) iPCR B 140 141 
53 37 (Tube #73) iPCR B 140 145 
54 45 (Tube #80) nPCR A 140 141 
55 46 (Tube #91) nPCR A 140 141 
56 47 (Tube #93) nPCR A 140 141 
57 48 (Tube #95) nPCR A 140 147 
58 49 (Tube #97) nPCR A 140 141 
59 50 (Tube #99) nPCR A 140 141 
60 52 (Tube #103) nPCR A 140 139 
61 53 (Tube #105) nPCR A 140 139 
62 54 (Tube #107) nPCR A 140 139 
63 55 (Tube #109) nPCR A 140 139 
64 56 (Tube #111) nPCR A 140 139 
65 57 (Tube #114) nPCR A 140 138 
66 58 (Tube #115) nPCR A 140 140 
67 60 (Tube #119) nPCR A 140 138 
Notes: 
 a - PCR methods: iPCR – Independent PCR; snPCR - Semi-nested PCR; and nPCR - Nested PCR 
 b - PCR product purification methods: A - QIAquick PCR Purification Kit (Qiagen); B - QIAquick Gel Extraction Kit (Qiagen) 
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Appendix 17 
 
CLUSTAL W (1.83) multiple sequences alignment of L1 HPVs 
                        
                                    
 
45_422 (sample) --------------CCAAAAGGATACTGATCCAATTCACTAGAAAACTTTTCTTTTAAAT 
hsg_391         ----------TCGTCCAAAAGGATACTGATCTAAGTCTAAAGAAAACTTTTCCTTTAAAT 
HPV16           AGTGGTTCTATGGTTACCTCTGATGCCCAAATATTCAATAAACCTTATTGGTTACAACGA 
HPV6            AGCGGCTCTTTGGTGTCCTCTGAGGCACAATTGTTTAATAAGCCATATTGGCTACAAAAA 
HPV18           AGTGGCTCTATTGTTACCTCTGACTCCCAGTTGTTTAATAAACCATATTGGTTACATAAG 
                                                                            
 
45_422 (sample) TAACCTCCCAAAAACTAAGGTTCTTATAGGGATC-TGGCTTTTCCTTTTCAGGAGTGGGC 
hsg_391         CCACATTCCAAAACTTTAACTTATCATAGGGATC-CTTATTTTCAGCCGGTGCAGCATCC 
HPV16           GCACAGGGCCACAATAATGGCATTTGTTGGGGTAACCAACTATTTGTTACTGTTGTTGAT 
HPV6            GCCCAGGGACATAACAATGGTATTTGTTGGGGTAATCAACTGTTTGTTACTGTGGTAGAT 
HPV18           GCACAGGGTCATAACAATGGTGTTTGCTGGCATAATCAATTATTTGTTACTGTGGTAGAT 
                                                                          
 
45_422 (sample) TTTTGACA-GGTAATGGCCTGTGACTGCACATACCTATAGGTATCTTCTAATGTACC--A 
hsg_391         TTTTGACA-GGTAATAGCAACAGATTGTACAAAACGATATGTATCCACCAAACTAGT--A 
HPV16           ACTACACGCAGTACAAATATGTCATTATGTGCTGCCATATCTACTTCAGAAACTAC---A 
HPV6            ACCACACGCAGTACCAACATGACATTATGTGCATCCGTAACTACATCTT---CCAC---A 
HPV18           ACCACTCCCAGTACCAATTTAACAATATGTGCTTCTACACAGTCTCCTGTACCTGGGCAA 
                                                                             
 
45_422 (sample) TTTGGGGGAGGCGATAACCCAAAGTTCC--AGTCTTCCAAAACAGAGGGATTC------- 
hsg_391         GTTGGCGGGGGGGGAACACCAAAGTTCC--AATCCTCTAAAATACTGCTATTC------- 
HPV16           TATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGTTT 
HPV6            TACACCAATTCTGATTATAAAGAGTACATGCGTCATGTGGAAGAGTATGATTTACAATTT 
HPV18           TATGATGCTACCAAATTTAAGCAGTATAGCAGACATGTTGAGGAATATGATTTGCAGTTT 
                                                             *          
 
45_422 (sample) ATTGTGTGAATATAGGCCATTACTTCAGCAGACAATGTAATGCTACATAATTGAAAAATA 
hsg_391         ATACTATGAATATAGGACATAACATCTGCAGTTAAAGTAATAGTACACAACTGAAAAATA 
HPV16           ATTTTTCAACTGTGCAAAATAACCTTAACTGCAGACGTTATGACATACATACATTCTATG 
HPV6            ATTTTTCAATTATGTAGCATTACATTGTCTGCTGAAGTAATGGCCTATATTCACACAATG 
HPV18           ATTTTTCAGTTGTGTACTATTACTTTAACTGCAGATGTTATGTCCTATATTCATAGTATG 
                    *     * *      * **     * *   * ** **     * *        **  
 
45_422 (sample) AATTGTA-AATCATACTCTTCCACATGACGCATGTACTCTTTATAATCAGAATTGGTGTA 
hsg_391         AACTGCA-AATCATATTCCTCAACATGTCTGCTATACTGCTTAAATTTGGTAGCATCATA 
HPV16           AATTCCACTATTTTGGAGGACTGGAATTTTGGTCTACAACCTCCCCCAGGAGGCACACTA 
HPV6            AATCCCTCTGTTTTGGAAGACTGGAACTTTGGGTTATCGCCTCCCCCAAATGGTACATTA 
HPV18           AATAGCAGTATTTTAGAGGATTGGAACTTTGGTGTTCCCCCCCCCCCAACTACTAGTTTG 
                          *                                                  
 
45_422 (sample) TGTGGAAGATGTAGT------TACGGATGCACATAATGTCATGTTGGTACTGCGTGTGGT 
hsg_391         TTGCCCAGGTACAGGAGACTGTGTAGAAGCACATATTGTTAAATTGGTACTGCGA----- 
HPV16           GAAGATACTTATAGG----TTTGTAACC---CAGGCAATTGCTTGTCAAAAACATACACC 
HPV6            GAAGATACCTATAGG----TATGTGCAGTCACAGGCCATTACCTGTCAAAAGCCCA---C 
HPV18           GTGGATACATATCGT----TTTGTACAATCTGTTGCTATTACCTGTCAAAAGGATG---C 
                                                                             
 
45_422 (sample) ATCTACCACAGTAACAAACAGTTGATTACCCCAACA------------------------ 
hsg_391         ------------------------------------------------------------ 
HPV16           TCCAGCACCTAAAGAAGATGATCCCCTTAAAAAATACACTTTTTGGGAAGTAAATTTAAA 
HPV6            TCCTGAAAAGGAAAAGCCAGATCCCTATAAGAACCTTAGTTTTTGGGAGGTTAATTTAAA 
HPV18           TGCACCGGCTGAAAATAAGGATCCCTATGATAAGTTAAAGTTTTGGAATGTGGATTTAAA 
                                                                             
 
45_422 (sample) ------------------------------------------------------------ 
hsg_391         ------------------------------------------------------------ 
HPV16           GGAAAAGTTTTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTTACTACAAGC 
HPV6            AGAAAAGTTTTCTAGTGAATTGGATCAGTATCCTTTGGGACGCAAGTTTTTGTTACAAAG 
HPV18           GGAAAAGTTTTCTTTAGACTTAGATCAATATCCCCTTGGACGTAAATTTTTGGTTCAGGC 
         _____________________________________________________________________________ 
Note:  
 
  *  - To denote nucleotide/s which are identical in all DNA sequences compared (sample and controls) 
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Results of the DNA sequencing alignment of L1 α-HPV 
 
 
No ID Pathology code 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
       
1 1 01209199 2 - - HPV6 HPV6 
2 2 954593 B - - HPV6 HPV6 
3 3 NS00196904 1 - HPV6 HPV6 HPV6 
4 4 NS00442204 1L - - HPV6 HPV6 
5 6 NS00671203 1 - HPV6 HPV6 HPV6 
6 7 NS00711302 1B - - HPV6 HPV6 
7 8 NS00848002 3D - - HPV6 HPV6 
8 9 NS01/68103 1A - - HPV6 HPV6 
9 10 NS01/68103 1B - - HPV6 HPV6 
10 11 NS01020203 3K - - HPV6 HPV6 
11 12 NS01029003 1 - - HPV6 HPV6 
12 13 NS01076404 1B - - HPV6 HPV6 
13 15 NS01291204 1C - - HPV6 HPV6 
14 16 NS01404702 1B - HPV6 HPV6 HPV6 
15 22 TS00012706 1 - - HPV6 HPV6 
16 27 TS00148106 1 - HPV16 HPV16 HPV16 
17 32 TS00267305 3E - - HPV6 HPV6 
18 33 TS00315505 1G - - HPV6 HPV6 
19 37 TS00624606 1 - HPV35 HPV35 HPV35 
20 43 TS01129306 1B - HPV6 - HPV6 
21 45 TS01292806 2K HPV6 HPV6 HPV6 HPV6 
22 46 TS01298705 1 HPV6 HPV6 HPV6 HPV6 
23 47 TS01353006 1 HPV6 HPV6 HPV6 HPV6 
24 48 TS01371006 1A HPV6 HPV6 HPV6 HPV6 
25 49 TS01388406 4F HPV6 HPV6 HPV6 HPV6 
26 50 TS01390006 1E HPV6 HPV6 HPV6 HPV6 
27 52 TS01423506 3H HPV6 HPV6 HPV6 HPV6 
28 53 TS01514806 3D HPV6 HPV6 HPV6 HPV6 
29 54 TS01596705 1 HPV6 HPV6 HPV6 HPV6 
30 55 TS01898205 1 HPV6 HPV6 HPV6 HPV6 
31 56 TS01958205 1 HPV6 HPV6 HPV6 HPV6 
32 57 TS02131305 2D HPV6 HPV6 HPV6 HPV6 
33 58 TS02184105 2L HPV6 HPV6 HPV6 HPV6 
34 60 TS02518405 1 HPV6 HPV6 HPV6 HPV6 
       
  Total: 14 
 
20 
 
33 34 
  Percentage: 23.3 33.3 55.0 56.7 
  Grand total: 60 60 60 60 
       
Note: -   Negative PCR 
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α-HPV genotyping: Raw data of SPF-DEIA analysis (microtiter plate layout) 
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α-HPV genotyping: Raw data of SPF10-LiPA25 (version 1) 
 
 
 
 
LiPA strip Sample ID Reactive probes Genotyping results Remark 
1 1 (Tube #1)  4,26 HPV18  
2 2 (Tube #3) 1,28 HPV6  
3  4 (Tube #7) 3 HPV16  
4 10 (Tube #20) 3 HPV16  
5 11 (Tube #21) 1 HPV6 DEIA negative but elevated 
6 22 (Tube #43) - X  
7 29 (Tube #57) 1,28 HPV6  
8 37 (Tube #73) 10 HPV35  
9 46 (Tube #91) 1,28 HPV6  
10 49 (Tube #97) - X  
11 50 (Tube #99) 1,28 HPV6  
12 51 (Tube #101) 1,3,28 HPV6,HPV16  
13 54 (Tube #107) - Negative DEIA negative but elevated 
14 56 (Tube #111) 3 HPV16  
15  57 (Tube #114) 3 HPV16  
16 58 (Tube #115) 3 HPV16  
17 PCR control (+) 4,26 HPV18  
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Appendix 20 (Continued) 
 
 
α-HPV genotyping: Raw data of SPF10- LiPA25 (version 1) 
 
 
 
 
 
LiPA strip Sample ID Reactive probes Genotyping results Remark 
1 16 (Tube #31) 1,28 HPV6  
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Interpretation sheet for α-HPV genotyping: SPF10- LiPA25 (version 1) 
 
Note:- 
 Reproduced with written permission from DDL, Voorburg, The Netherlands 
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Alpha HPV genotyping by using SPF10-LiPA25 (version 1) 
 
Sample 
no. Pathology code 
SPF-DEIA 
SPF10-LiPA 
SPF10-LiPA25 
status Plate OD Status 
       
1 01209199 2 D1 1.751 + HPV18 HPV18 
2 954593 B E1 2.070 + HPV6 HPV6 
3 NS00196904 1 F1 0.087 - - - 
4 NS00442204 1L G1 2.301 + HPV16 HPV16 
5 NS00642004 1 H1 0.101 - - - 
6 NS00671203 1 A2 0.085 - - - 
7 NS00711302 1B B2 0.079 - - - 
8 NS00848002 3D C2 0.078 - - - 
9 NS01/68103 1A D2 0.078 - - - 
10 NS01/68103 1B E2 1.956 + HPV16 HPV16 
11 NS01020203 3K F2 0.198 + HPV6 HPV6 
12 NS01029003 1 G2 0.074 - - - 
13 NS01076404 1B H2 0.079 - - - 
14 NS01258903 1C A3 0.087 - - - 
15 NS01291204 1C B3 0.076 - - - 
16 NS01404702 1B C3 0.827 + HPV6 HPV6 
17 NS01643002 1A D3 0.074 - - - 
18 NS01803103 1 E3 0.069 - - - 
19 NS01864704 1B F3 0.071 - - - 
20 NS01960104 1 G3 0.071 - - - 
21 NS02060804 1 H3 0.076 - - - 
22 TS00012706 1 A4 2.716 + N/I N/I 
23 TS00044505 1 B4 0.078 - - - 
24 TS00055407 1 C4 0.072 - - - 
25 TS00059407 1 D4 0.074 - - - 
26 TS00109407 2F E4 0.072 - - - 
27 TS00148106 1 F4 0.070 - - - 
28 TS00164406 3C G4 0.073 - - - 
29 TS00187207 1 
 
H4 2.182 + HPV6 HPV6 
30 TS00213305 1B A5 0.088 - - - 
31 TS00232207 1 B5 0.083 - - - 
32 TS00267305 3E C5 0.072 - - - 
33 TS00315505 1G D5 0.075 - - - 
34 TS00338107 2G E5 0.072 - - - 
35 TS00486606 1A F5 0.070 - - - 
36 TS00507307 2B G5 0.072 - - - 
37 TS00624606 1 H5 2.580 + HPV35 HPV35 
38 TS00629005 1 A6 0.094 - - - 
39 TS00727706 1 B6 0.084 - - - 
40 TS00854605 3M C6 0.073 - - - 
41 TS00858906 1C D6 0.080 - - - 
42 TS00965006 3C E6 0.074 - - - 
43 TS01129306 1B F6 0.087 - - - 
44 TS01218406 1 G6 0.073 - - - 
45 TS01292806 2K H6 0.084 - - - 
46 TS01298705 1 A7 1.899 + HPV6 HPV6 
47 TS01353006 1 B7 0.085 - - - 
48 TS01371006 1A C7 0.078 - - - 
49 TS01388406 4F D7 1.299 + N/I N/I 
50 TS01390006 1E E7 2.945 + HPV6 HPV6 
51 TS01399006 1 F7 2.954 + HPV6/16 HPV6/16 
52 TS01423506 3H G7 0.074 - - - 
53 TS01514806 3D H7 0.079 - - - 
54 TS01596705 1 A8 0.131 - neg. neg. but elevated 
55 TS01898205 1 B8 0.089 - - - 
56 TS01958205 1 C8 1.135 + HPV16 HPV16 
57 TS02131305 2D D8 3.125 + HPV16 HPV16 
58 TS02184105 2L E8 1.715 + HPV16 HPV16 
59 TS02338805 1 F8 0.082 - - - 
60 TS02518405 1 G8 0.079 - - - 
 Positive A1 3.260    
 Borderline B1 0.531    
 Negative C1 0.088    
 HPV18 H8 2.677    
   Positive 16 16 16 
   Percentage 26.7 26.7 26.7 
   Total 60 60 60  
Note:  + positive, HPV present; - negative, HPV absent; N/I not identified 
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Overall alpha HPV types detected by several methods in pilot study samples 
 
Sample 
no. 
Pathology code Low risk α-HPV High risk α-HPV α-HPV status 
HPV6 HPV16 HPV18 HPV35 
       
1 01209199 2 +δ  +ε  DI; HPV6, HPV18 
2 954593 B +δ,ε    SI; HPV6 
3 NS00196904 1 +δ    SI; HPV6 
4 NS00442204 1L +δ +ε   DI; HPV6, HPV16 
5 NS00642004 1 - - - - Negative 
6 NS00671203 1 +δ    SI; HPV6 
7 NS00711302 1B +δ    SI; HPV6 
8 NS00848002 3D +δ    SI; HPV6 
9 NS01/68103 1A +δ    SI; HPV6 
10 NS01/68103 1B +δ +ε   DI; HPV6, HPV16 
11 NS01020203 3K +δ,ε    SI; HPV6 
12 NS01029003 1 +δ    SI; HPV6 
13 NS01076404 1B +δ    SI; HPV6 
14 NS01258903 1C - - - - Negative 
15 NS01291204 1C +δ    SI; HPV6 
16 NS01404702 1B +δ,ε    SI; HPV6 
17 NS01643002 1A - - - - Negative 
18 NS01803103 1 - - - - Negative 
19 NS01864704 1B - - - - Negative 
20 NS01960104 1 - - - - Negative 
21 NS02060804 1 - - - - Negative 
22 TS00012706 1 +δ,ε (+)ε (+)ε (+)ε DI; HPV6; α-HPV untypable 
23 TS00044505 1 - - - - Negative 
24 TS00055407 1 - - - - Negative 
25 TS00059407 1 - - - - Negative 
26 TS00109407 2F - - - - Negative 
27 TS00148106 1  +δ   SI; HPV16 
28 TS00164406 3C - - - - Negative 
29 TS00187207 1 HED1D2 +ε    SI; HPV6 
30 TS00213305 1B - - - - Negative 
31 TS00232207 1 - - - - Negative 
32 TS00267305 3E +δ    SI; HPV6 
33 TS00315505 1G +δ    SI; HPV6 
34 TS00338107 2G - - - - Negative 
35 TS00486606 1A - - - - Negative 
36 TS00507307 2B - - - - Negative 
37 TS00624606 1    +δ,ε SI; HPV35 
38 TS00629005 1 - - - - Negative 
39 TS00727706 1 - - - - Negative 
40 TS00854605 3M - - - - Negative 
41 TS00858906 1C - - - - Negative 
42 TS00965006 3C - - - - Negative 
43 TS01129306 1B +δ    SI; HPV6 
44 TS01218406 1 - - - - Negative 
45 TS01292806 2K +δ    SI; HPV6 
46 TS01298705 1 +δ,ε    SI; HPV6 
47 TS01353006 1 +δ    SI; HPV6 
48 TS01371006 1A +δ    SI; HPV6 
49 TS01388406 4F +δ,ε (+)ε (+)ε (+)ε DI; HPV6, α-HPV untypable 
50 TS01390006 1E +δ,ε    SI; HPV6 
51 TS01399006 1 +ε +ε   DI; HPV6, HPV16 
52 TS01423506 3H +δ    SI; HPV6 
53 TS01514806 3D +δ    SI; HPV6 
54 TS01596705 1 +δ    SI; HPV6 
55 TS01898205 1 +δ    SI; HPV6 
56 TS01958205 1 +δ +ε   DI; HPV6, HPV16 
57 TS02131305 2D +δ +ε   DI; HPV6, HPV16 
58 TS02184105 2L +δ +ε   DI; HPV6, HPV16 
59 TS02338805 1 - - - - Negative 
60 TS02518405 1 +δ    SI; HPV6 
       
 Positive: 34 7 1 1 36 
 Percentage: 56.7 11.7 1.7 1.7 60.0 
 Total: 60 60 60 60 60 
 
Note:  
 SI – single infection; DI – double infections; +  positive; (+)  positive for α-HPV untypable;  - negative 
 δ – Positive results obtained by using PCR and automated DNA sequencing methods 
 ε – Positive results obtained by using SPF10-LiPA25 method 
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Appendix 24 
 
 
Raw data - Beta HPV genotyping 
 
 
 
 
Strip Sample ID Reactive probes Genotyping results Remark 
1 1 (Tube #1)    
2 2 (Tube #3) 18 HPV36  
3 3 (Tube #5)    
4 4 (Tube #7) 1 β-HPV untypable  
5 5 (Tube #9)    
6 6 (Tube #11)    
7 7 (Tube #13)    
8 8 (Tube #15)    
9 9 (Tube #17)    
10 10 (Tube #20)    
11 11 (Tube #21)    
12 12 (Tube #23)    
13 13 (Tube #25)    
14 14 (Tube #27)    
15 15 (Tube #29)    
16 16 (Tube #31)    
17 17 (Tube #33)    
18 18 (Tube #35)    
19 19 (Tube #37) 8 HPV15  
20 20 (Tube #39)    
21 Paraffin    
22 Reagent    
23 Water    
24 Control (HPV8) 1,2,3,4,10,12 5,8,19  
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Appendix 24 (Continued) 
 
 
Raw data - Beta HPV genotyping 
 
 
 
 
Strip Sample ID Reactive probes Genotyping results Remark 
1 21 (Tube #41)    
2 22 (Tube #43) 1,15 HPV23  
3 23 (Tube #45)    
4 24 (Tube #47)    
5 25 (Tube #49) 1 β-HPV untypable  
6 26 (Tube #51)    
7 27 (Tube #53)    
8 28 (Tube #55)    
9 29 (Tube #57)    
10 30 (Tube #59)    
11 31 (Tube #61)    
12 32 (Tube #63)    
13 33 (Tube #65)    
14 34 (Tube #67)    
15 35 (Tube #69)    
16 36 (Tube #71)    
17 37 (Tube #73)    
18 38 (Tube #75)    
19 39 (Tube #77) 1 β-HPV untypable  
20 40 (Tube #79)    
21 Paraffin    
22 Reagent    
23 Water    
24 Control (HPV8) 1,3,4,10,12 5,8,19  
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Appendix 24 (Continued) 
 
 
Raw data - Beta HPV genotyping 
 
 
 
 
Strip Sample ID Reactive probes Genotyping results Remark 
1 41 (Tube #81)    
2 42 (Tube #83)    
3 43 (Tube #85) 27 HPV93  
4 44 (Tube #87)    
5 45 (Tube #89)    
6 46 (Tube #91)    
7 47 (Tube #93)    
8 48 (Tube #95)    
9 49 (Tube #97) 1,27 HPV93  
10 50 (Tube #99) 20 HPV38  
11 51 (Tube #101)    
12 52 (Tube #103)    
13 53 (Tube #105) 1,25 HPV80  
14 54 (Tube #107)    
15 55 (Tube #109)    
16 56 (Tube #111)    
17 57 (Tube #114)    
18 58 (Tube #115)    
19 59 (Tube #117) 24 HPV76  
20 60 (Tube #119)    
21 Paraffin    
22 Reagent    
23 Water    
24 Control (HPV8) 1,2,4 5,8  
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Appendix 25 
 
 
DIASSAY Skin (beta) HPV genotyping strip 
 
Genotyping Interpretation sheet 
 
Probe line  HPV5 HPV8 HPV9 HPV12 HPV14 HPV15 HPV17 HPV19 HPV20 HPV21 HPV22 HPV23 HPV24 HPV25 HPV36 HPV37 HPV38 HPV47 HPV49 HPV75 HPV76 HPV80 HPV92 HPV93 HPV96 
1 Uni ( + ) ( + ) + ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) ( + ) 
2 HPV 5 +                          
3 HPV 8 i  ( + ) +   ( + )                     
4 HPV 8 ii  + +                ( + )        
5 HPV 9    +                       
6 HPV 12     +                      
7 HPV 14      +                     
8 HPV 15       +                    
9 HPV 17        +                   
10 HPV 19         +                  
11 HPV 20          +                 
12 HPV 21   ( + )   ( + )     +                
13 cHPV 21          ( + ) + ( + )               
14 HPV 22            +               
15 HPV 23             +              
16 HPV 24              +             
17 HPV 25               +            
18 HPV 36                +           
19 HPV 37                 +          
20 HPV 38                  +         
21 HPV 47  ( - )                 +        
22 HPV 49                    +       
23 HPV 75                     +      
24 HPV 76                      +     
25 HPV 80                       +    
26 HPV 92                        +   
27 HPV 93                         +  
28 HPV 96                          + 
 
 
- The c HPV 21 probe is only used for type interpretation when the probeline above is positive 
- HPV type 8 is recognized by probe lines 3 and 4, or, in absence of probe line 21, only by probe line 4 
- In a mixed infection with HPV types 14 and 47 the presence of HPV type 8 cannot be established 
- In a mixed infection with a combination of HPV types 8 or 14 on the one hand and HPV types 20 or 22 on the other, the presence of HPV type 21 cannot be established 
- ( + ): Sometimes appears; not required for the determination of a genotype 
- ( - ): Required to be  negative 
 
Note: 
 
 Reproduced with written permission from DDL, Voorburg, The Netherlands
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Appendix 26 
 
Beta HPV types detected by PM-PCR and RHA methods in pilot study samples 
 
Sample 
no. 
Pathology code β-HPV type β-HPV status 
 
    
1 01209199 2 - Negative 
2 954593 B HPV36 SI; HPV36 
3 NS00196904 1 - Negative 
4 NS00442204 1L (+) SI; β-HPV untypable 
5 NS00642004 1 - Negative 
6 NS00671203 1 - Negative 
7 NS00711302 1B - Negative 
8 NS00848002 3D - Negative 
9 NS01/68103 1A - Negative 
10 NS01/68103 1B - Negative 
11 NS01020203 3K - Negative 
12 NS01029003 1 - Negative 
13 NS01076404 1B - Negative 
14 NS01258903 1C - Negative 
15 NS01291204 1C - Negative 
16 NS01404702 1B - Negative 
17 NS01643002 1A - Negative 
18 NS01803103 1 - Negative 
19 NS01864704 1B HPV15 SI; HPV15 
20 NS01960104 1 - Negative 
21 NS02060804 1 - Negative 
22 TS00012706 1 HPV23 SI; HPV23 
23 TS00044505 1 - Negative 
24 TS00055407 1 - Negative 
25 TS00059407 1 (+) SI; β-HPV untypable 
26 TS00109407 2F - Negative 
27 TS00148106 1 - Negative 
28 TS00164406 3C - Negative 
29 TS00187207 1 HED1D2 - Negative 
30 TS00213305 1B - Negative 
31 TS00232207 1 - Negative 
32 TS00267305 3E - Negative 
33 TS00315505 1G - Negative 
34 TS00338107 2G - Negative 
35 TS00486606 1A - Negative 
36 TS00507307 2B - Negative 
37 TS00624606 1 - Negative 
38 TS00629005 1 - Negative 
39 TS00727706 1 (+) SI; β-HPV untypable 
40 TS00854605 3M - Negative 
41 TS00858906 1C - Negative 
42 TS00965006 3C - Negative 
43 TS01129306 1B HPV93 SI; HPV93 
44 TS01218406 1 - Negative 
45 TS01292806 2K - Negative 
46 TS01298705 1 - Negative 
47 TS01353006 1 - Negative 
48 TS01371006 1A - Negative 
49 TS01388406 4F HPV93 SI; HPV93 
50 TS01390006 1E HPV38 SI; HPV38 
51 TS01399006 1 - Negative 
52 TS01423506 3H - Negative 
53 TS01514806 3D HPV80 SI; HPV80 
54 TS01596705 1 - Negative 
55 TS01898205 1 - Negative 
56 TS01958205 1 - Negative 
57 TS02131305 2D - Negative 
58 TS02184105 2L - Negative 
59 TS02338805 1 HPV76 SI; HPV76 
60 TS02518405 1 - Negative 
    
 Positive: 11 11 
 Percentage: 18.3 18.3 
 Total: 60 60 
 
  Note:  
  SI – single infection; (+)  positive, β-HPV untypable; - negative  
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Appendix 27 
 
Overall α- and β-HPV types detected by several methods in pilot study samples 
 
Sample 
no. 
Pathology code LR α-HPV HR α-HPV β-HPV α- and β-HPV status 
HPV6 HPV16 HPV18 HPV35  
        
1 01209199 2 +δ  +ε  - DI; HPV6, HPV18 
2 954593 B +δ,ε    HPV36 DI; HPV6; HPV36 
3 NS00196904 1 +δ    - SI; HPV6 
4 NS00442204 1L +δ +ε   (+) MI; HPV6, HPV16; β-HPV untypable 
5 NS00642004 1 - - - - - Negative 
6 NS00671203 1 +δ    - SI; HPV6 
7 NS00711302 1B +δ    - SI; HPV6 
8 NS00848002 3D +δ    - SI; HPV6 
9 NS01/68103 1A +δ    - SI; HPV6 
10 NS01/68103 1B +δ +ε   - DI; HPV6, HPV16 
11 NS01020203 3K +δ,ε    - SI; HPV6 
12 NS01029003 1 +δ    - SI; HPV6 
13 NS01076404 1B +δ    - SI; HPV6 
14 NS01258903 1C - - - - - Negative 
15 NS01291204 1C +δ    - SI; HPV6 
16 NS01404702 1B +δ,ε    - SI; HPV6 
17 NS01643002 1A - - - - - Negative 
18 NS01803103 1 - - - - - Negative 
19 NS01864704 1B - - - - HPV15 SI: HPV15 
20 NS01960104 1 - - - - - Negative 
21 NS02060804 1 - - - - - Negative 
22 TS00012706 1 +δ,ε (+)ε (+)ε (+)ε HPV23 MI; HPV6; α-HPV untypable; HPV23 
23 TS00044505 1 - - - - - Negative 
24 TS00055407 1 - - - - - Negative 
25 TS00059407 1 - - - - (+) SI; β-HPV untypable 
26 TS00109407 2F - - - - - Negative 
27 TS00148106 1  +δ   - SI; HPV16 
28 TS00164406 3C - - - - - Negative 
29 TS00187207 1 HED1D2 +ε    - SI; HPV6 
30 TS00213305 1B - - - - - Negative 
31 TS00232207 1 - - - - - Negative 
32 TS00267305 3E +δ    - SI; HPV6 
33 TS00315505 1G +δ    - SI; HPV6 
34 TS00338107 2G - - - - - Negative 
35 TS00486606 1A - - - - - Negative 
36 TS00507307 2B - - - - - Negative 
37 TS00624606 1    +δ,ε - SI; HPV35 
38 TS00629005 1 - - - - - Negative 
39 TS00727706 1 - - - - (+) SI; β-HPV untypable 
40 TS00854605 3M - - - - - Negative 
41 TS00858906 1C - - - - - Negative 
42 TS00965006 3C - - - - - Negative 
43 TS01129306 1B +δ    HPV93 DI; HPV6; HPV93 
44 TS01218406 1 - - - - - Negative 
45 TS01292806 2K +δ    - SI; HPV6 
46 TS01298705 1 +δ,ε    - SI; HPV6 
47 TS01353006 1 +δ    - SI; HPV6 
48 TS01371006 1A +δ    - SI; HPV6 
49 TS01388406 4F +δ,ε (+)ε (+)ε (+)ε HPV93 MI; HPV6, α-HPV untypable; HPV93 
50 TS01390006 1E +δ,ε    HPV38 DI; HPV6; HPV38 
51 TS01399006 1 +ε +ε   - DI; HPV6, HPV16 
52 TS01423506 3H +δ    - SI; HPV6 
53 TS01514806 3D +δ    HPV80 DI; HPV6; HPV80 
54 TS01596705 1 +δ    - SI; HPV6 
55 TS01898205 1 +δ    - SI; HPV6 
56 TS01958205 1 +δ +ε   - DI; HPV6, HPV16 
57 TS02131305 2D +δ +ε   - DI; HPV6, HPV16 
58 TS02184105 2L +δ +ε   - DI; HPV6, HPV16 
59 TS02338805 1 - - - - HPV76 SI; HPV76 
60 TS02518405 1 +δ    - SI; HPV6 
        
 Positive: 34 7 1 1 11 40 
 Percentage: 56.7 11.7 1.7 1.7 18.3 66.7 
 Total: 60 60 60 60 60 60 
 
Note:  
 SI – single infection; DI – double infections; +  positive; (+)   positive but α-or β-HPV untypable (not counted in total);  - negative 
 δ – Positive results obtained by using PCR and automated DNA sequencing methods 
 ε – Positive results obtained by using SPF10-LiPA25 method 
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Appendix 28 
 
The association of tobacco smoking and alcohol consumption with HPV status 
 
No. Pathology code Genderγ Age Age 
groupδ 
Tobacco smoking and 
alcohol consumption 
statusε 
HPV status§ 
α-HPV β-HPV Overall  Type of 
infectionη LR-HPV HR-HPV 
           
1 01209199 2 M 64 1 1 HPV6 HPV18 - + DI 
2 954593 B F 68 2 0 HPV6 - HPV36 + DI 
3 NS00196904 1 F 97 2 0 HPV6 - - + SI 
4 NS00442204 1L F 97 2 0 HPV6 HPV16 (+) + MI 
5 NS00642004 1 M 78 2 3 - - - - - 
6 NS00671203 1 M 69 2 3 HPV6 - - + SI 
7 NS00711302 1B F 55 1 2 HPV6 - - + SI 
8 NS00848002 3D F 55 1 2 HPV6 - - + SI 
9 NS01/68103 1A M 74 2 3 HPV6 - - + SI 
10 NS01/68103 1B M 74 2 3 HPV6 HPV16 - + DI 
11 NS01020203 3K M 62 1 2 HPV6 - - + SI 
12 NS01029003 1 M 64 1 3 HPV6 - - + SI 
13 NS01076404 1B M 67 2 3 HPV6 - - + SI 
14 NS01258903 1C M 64 1 3 - - - - - 
15 NS01291204 1C M 77 2 2 HPV6 - - + SI 
16 NS01404702 1B M 60 1 N/I HPV6 - - + SI 
17 NS01643002 1A M 60 1 N/I - - - - - 
18 NS01803103 1 M 67 2 3 - - - - - 
19 NS01864704 1B F 78 2 3 - - HPV15 + SI 
20 NS01960104 1 M 66 2 3 - - - - - 
21 NS02060804 1 F 66 2 2 - - - - - 
22 TS00012706 1 M 65 1 3 HPV6 (+) HPV23 + MI 
23 TS00044505 1 M 52 1 2 - - - - - 
24 TS00055407 1 M 75 2 3 - - - - - 
25 TS00059407 1 M 55 1 3 - - (+) + SI 
26 TS00109407 2F F 59 1 3 - - - - - 
27 TS00148106 1 M 59 1 3  HPV16 - + SI 
28 TS00164406 3C M 65 1 3 - - - - - 
29 TS00187207 1 HED1D2 F 65 1 3 HPV6 - - + SI 
30 TS00213305 1B F 62 1 3 - - - - - 
31 TS00232207 1 F 63 1 3 - - - - - 
32 TS00267305 3E M 66 2 3 HPV6 - - + SI 
33 TS00315505 1G M 52 1 2 HPV6 - - + SI 
34 TS00338107 2G M 75 2 3 - - - - - 
35 TS00486606 1A M 36 1 3 - - - - - 
36 TS00507307 2B F 63 1 3 - - - - - 
37 TS00624606 1 M 62 1 2  HPV35 - + SI 
38 TS00629005 1 F 46 1 3 - - - - - 
39 TS00727706 1 M 67 2 3 - - (+) + SI 
40 TS00854605 3M F 46 1 3 - - - - - 
41 TS00858906 1C M 67 2 3 - - - - - 
42 TS00965006 3C F 66 2 1 - - - - - 
43 TS01129306 1B F 81 2 3 HPV6 - HPV93 + DI 
44 TS01218406 1 F 62 1 2 - - - - - 
45 TS01292806 2K M 69 2 3 HPV6 - - + SI 
46 TS01298705 1 M 84 2 3 HPV6 - - + SI 
47 TS01353006 1 F 63 1 3 HPV6 - - + SI 
48 TS01371006 1A F 75 2 1 HPV6 - - + SI 
49 TS01388406 4F F 81 2 3 HPV6 (+) HPV93 + MI 
50 TS01390006 1E F 62 1 2 HPV6 - HPV38 + DI 
51 TS01399006 1 F 59 1 2 HPV6 HPV16 - + DI 
52 TS01423506 3H F 59 1 2 HPV6 - - + SI 
53 TS01514806 3D F 75 2 1 HPV6 - HPV80 + DI 
54 TS01596705 1 F 78 2 2 HPV6 - - + SI 
55 TS01898205 1 M 64 1 2 HPV6 - - + SI 
56 TS01958205 1 F 70 2 3 HPV6 HPV16 - + DI 
57 TS02131305 2D F 70 2 3 HPV6 HPV16 - + DI 
58 TS02184105 2L M 62 1 2 HPV6 HPV16 - + DI 
59 TS02338805 1 M 70 2 1 - - HPV76 + SI 
60 TS02518405 1 M 62 1 3 HPV6 - - + SI 
           
Note:- 
γ - Gender; M – Male;   F - Female 
δ - Age group was divided into two based on median age, Group 1 (age 16-65y), Group 2 (age 66-97). 
ε - Tobacco smoking and alcohol consumption: 0 (no smoking, no drinking), 1 (no smoking, drinking), 2 (smoking, no drinking) and 3 (smoking and drinking). 
Two data (#16 and #17 with shaded) were not included in the analysis due to smoking and alcohol consumption status were not available.   
§ - +   HPV positive;    -   HPV negative 
η - The type of HPV infection: single infection (SI), double infection (DI) and multiple infection (MI).   
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Appendix 29 
 
Semi-quantitative assessment of p16 immunohistochemistry staining 
 
 
No  
  
 
Pathology ID 
  
  
Field I S 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
  
I P I P I P I P I P I P I P I P I P I P 
1 01209199 2                       Neg Neg 
2 954593 B                       Neg Neg 
3 NS00196904 1 1 2
 
2 4
 
2 4
 
2 4
 
2 4
 
2 3
 
2 4
 
1 3
 
1 2
 
1 3
 
2 + 
4 NS00442204 1L 3 1
 
3 1
 
3 1
 
2 1
 
3 5 2 5 3 1
 
3 5 3 1
 
2 5 3 + 
5 NS00642004 1 3 2 0 0 0 0 0 0
 
0 0 0 0 1 1 2 1 0 0 0 0 1 + 
6 NS00671203 1 2 1
 
2 1
 
1 1
 
1 4
 
1 2
 
2 1
 
1 1
 
2 1
 
2 2
 
2 1
 
2 + 
7 NS00711302 1B                     Neg Neg 
8 NS00848002 3D                     Neg Neg 
9 NS01/68103 1A                     Neg Neg 
10 NS01/68103 1B 1 4
 
1 1
 
1 3
 
3 5
 
3 7
 
2 4
 
3 3
 
3 5
 
2 2
 
3 5
 
2 + 
11 NS01020203 3K                     Neg Neg 12 NS01029003 1                     Neg Neg 
13 NS01076404 1B 2 2
 
1 3
 
1 4
 
1 4
 
1 3
 
1 3
 
1 3
 
1 3
 
1 3
 
1 6
 
1 + 
14 NS01258903 1C                     Neg Neg 15 NS01291204 1C 2 2
 
2 2
 
2 2
 
1 3
 
1 2
 
1 2
 
2 3
 
2 1
 
2 3
 
1 1
 
2 + 
16 NS01404702 1B 1 3 1 1 1 1 2 3 2 4 1 3 1 3 1 4 1 4 1 3 1 + 
17 NS01643002 1A 1 4
 
1 3
 
1 3
 
1 3
 
1 2
 
1 3
 
1 4
 
1 3
 
1 4
 
1 3
 
1 + 
18 NS01803103 1 1 1
 
1 3
 
1 3
 
1 2
 
1 3
 
1 4
 
2 5
 
1 2
 
2 5
 
1 5
 
1 + 
19 NS01864704 1B                       Neg Neg 
20 NS01960104 1                       Neg Neg 
21 NS02060804 1                       Neg Neg 
22 TS00012706 1 2 1
 
1 1
 
1 1
 
2 1
 
2 1
 
2 1
 
2 1
 
1 1
 
1 2
 
1 2
 
2 + 
23 TS00044505 1                     Neg Neg 24 TS00055407 1 2 3 3 6 3 7 2 3 2 2 1 3 2 2 3 5 3 6 3 4 2 + 
25 TS00059407 1 3 4 2 4 2 3 2 2 2 2 2 2 2 1 1 1 2 3 2 1 2 + 
26 TS00109407 2F 1 1
 
1 2
 
2 6
 
1 1
 
1 3
 
2 7
 
2 4
 
2 7
 
2 6
 
1 6
 
2 + 
27 TS00148106 1 3 2
 
3 2
 
3 2
 
3 4
 
2 3
 
3 4
 
2 3
 
2 3
 
2 6
 
2 2
 
3 + 
28 TS00164406 3C 3 3
 
2 2
 
2 4
 
2 3
 
2 3
 
3 4
 
2 2
 
2 2
 
2 1
 
2 1
 
2 + 
29 TS00187207 1 HED1D2 2 2
 
2 3
 
2 2
 
2 2
 
2 1
 
2 2
 
2 2
 
2 2
 
2 3
 
2 2
 
2 + 
30 TS00213305 1B 1 2
 
1 1
 
1 1
 
1 2
 
1 1
 
1 1
 
1 1
 
1 1
 
1 2
 
1 2
 
1 + 
31 TS00232207 1 2 8
 
2 8
 
2 7
 
2 8
 
2 9
 
2 9
 
2 9
 
2 9
 
2 9
 
2 9
 
2 + 
32 TS00267305 3E 1 1
 
1 1
 
1 1
 
2 6
 
2 3
 
1 3
 
2 2
 
2 1
 
1 1
 
2 2
 
2 + 
33 TS00315505 1G 1 1
 
1 1
 
1 2
 
2 1
 
1 1
 
1 1
 
1 2
 
1 2
 
1 1
 
1 2
 
1 + 
34 TS00338107 2G 2 3
 
2 3
 
2 2
 
2 2
 
2 2
 
2 2
 
2 1
 
2 2
 
2 3
 
2 3
 
2 + 
35 TS00486606 1A 1 7
 
1 6
 
2 1
 
1 5
 
1 4
 
1 3
 
1 4
 
1 2
 
1 2
 
1 2
 
1 + 
36 TS00507307 2B 2 8
 
2 7
 
2 6
 
2 7
 
2 6
 
2 6
 
2 4
 
2 3
 
2 3
 
2 3
 
2 + 
37 TS00624606 1 1 7
 
1 6
 
1 6
 
1 6
 
1 8
 
1 8
 
1 9
 
1 8
 
1 8
 
1 7
 
1 + 
38 TS00629005 1 2 3
 
2 4
 
2 2
 
2 2
 
2 3
 
2 3
 
2 3
 
2 2
 
2 2
 
2 2
 
2 + 
39 TS00727706 1 1 4
 
1 2
 
1 2
 
1 2
 
1 3
 
1 1
 
1 1
 
1 2
 
1 1
 
1 2
 
1 + 
40 TS00854605 3M 1 2
 
1 2
 
2 1
 
1 1
 
2 2
 
1 3
 
1 2
 
1 2
 
2 2
 
2 2
 
1 + 
41 TS00858906 1C 1 2
 
1 2
 
1 1
 
1 1
 
1 1
 
1 2
 
1 1
 
1 1
 
1 2
 
1 1
 
1 + 
42 TS00965006 3C 1 9
 
1 7
 
1 7
 
1 7
 
1 8
 
1 6
 
1 3
 
1 6
 
1 2
 
1 5
 
1 + 
43 TS01129306 1B                       Neg Neg 
44 TS01218406 1 2 3
 
1 5 1 5 1 5 1 1
 
1 2
 
1 3
 
2 5 2 4
 
1 2
 
1 + 
45 TS01292806 2K 1 1 1 1 2 5 2 5 2 5 1 5 1 1 1 5 1 1 1 1 1 + 
46 TS01298705 1 3 1
 
3 2
 
2 2
 
2 1
 
2 2
 
2 2
 
2 1
 
3 2
 
2 1
 
3 1
 
2 + 
47 TS01353006 1 2 2
 
2 3
 
2 2
 
2 2
 
2 3
 
2 3
 
2 2
 
2 1
 
2 2
 
2 3
 
2 + 
48 TS01371006 1A 1 2
 
2 1
 
2 1
 
1 1
 
1 5 1 5 1 5 2 2
 
2 1
 
2 5 2 + 
49 TS01388406 4F 1 4
 
1 3
 
1 1
 
1 3
 
1 2
 
1 2
 
1 1
 
1 2
 
1 1
 
1 2
 
1 + 
50 TS01390006 1E 1 5 1 5 1 1 1 5 2 1 2 1 1 5 1 1 1 5 1 1 1 + 
51 TS01399006 1 1 1 1 2 1 5 1 5 1 1 1 1 1 5 2 5 1 1 2 1 1 + 
52 TS01423506 3H 1 2
 
1 1
 
1 1
 
1 5 1 5 1 1
 
1 5 2 1
 
2 1
 
2 5 1 + 
53 TS01514806 3D 1 8
 
1 5
 
1 5
 
1 2
 
2 3
 
1 4
 
1 3
 
1 1
 
1 3
 
1 2
 
1 + 
54 TS01596705 1 1 1
 
1 1
 
1 2
 
1 1
 
1 1
 
1 1
 
2 1
 
2 1
 
2 1
 
1 1
 
1 + 
55 TS01898205 1 1 5 1 1 1 5 2 1 2 5 1 5 1 1 1 1 1 1 1 1 1 + 
56 TS01958205 1 3 1
 
2 2
 
2 2
 
2 2
 
2 2
 
3 2
 
2 2
 
3 4
 
3 2
 
3 1
 
3 + 
57 TS02131305 2D 1 1
 
1 1
 
2 3
 
2 2
 
1 2
 
1 2
 
2 2
 
1 1
 
2 2
 
1 1
 
1 + 
58 TS02184105 2L 1 2
 
2 2
 
2 3
 
1 3
 
2 2
 
1 1
 
2 1
 
2 1
 
1 2
 
1 2
 
2 + 
59 TS02338805 1 2 1
 
2 1
 
2 1
 
2 1
 
2 1
 
2 1
 
2 1
 
2 1
 
2 1
 
1 2
 
2 + 
60 TS02518405 1 2 2 2 2 3 4 2 4 2 3 3 3 2 2 2 3 2 2 2 2 2 + 
 
Abbreviations:  
I – Staining intensity; IC – intensity category (Neg=negative staining, 1 = 1+, 2 = 2+, 3 = 3+); 
P – Percentage of positive staining (1=10%, 2=20%,…. 10=100%);  
S – p16 status; Neg -negative, + positive 
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(A) Clinical and histopathology parameters of 176 DNA samples for oral disease progression 
study 
 
No. Plate Pathology  no. Block Gα Age Anatomic site Codeβ Pathology Diff.γ Tδ Nε Survivalη Status 
1 1A NS01006314 1 M 39 BM B lichenoid reaction          
2 1B NS01017460 5J M 69 Tongue C SCC well 2 0 60 dead 
3 1C NS01017677 2 F 49 BM B lichenoid reaction          
4 1D NS01017679 1 F 45 Tongue B Fep          
5 1E NS01017750 1 M 30 Tongue B lichenoid reaction          
6 1F NS01017826 4D F 64 Fom C SCC mod 4 2 8 dead 
7 1G NS01018047 1 M 50 Tongue B lymphoid tissue          
8 1H NS01018047 2 M 50 Tongue B lymphoid tissue          
9 2B NS01018532 1 F 73 lower lip B Fep          
10 2C NS01018560 1 F 61 BM B LP          
11 2E NS02000314 2 M 68 BM B Fep          
12 2F NS02000316 7C F 66 Fom C SCC mod 1 0 60 alive 
13 2G NS02000370 1 M 35 Tongue B Fep          
14 2H NS02000373 1 M 54 Gingivae B LP          
15 3A NS02000961 1 F 45 Tongue B LP          
16 3B NS02001012 1A F 45 soft palate C SCC mod 1 0 60 alive 
17 3C NS02001012 1B F 45 soft palate C SCC mod 1 0 60 alive 
18 3D NS02001012 1C F 45 soft palate C SCC mod 1 0 60 alive 
19 3E NS02001012 1D F 45 soft palate C SCC mod 1 0 60 alive 
20 3F NS02001012 1E F 45 soft palate C SCC mod 1 0 60 alive 
21 3G NS02001012 1F F 45 soft palate C SCC mod 1 0 60 alive 
22 3H NS02001012 1G F 45 soft palate C SCC mod 1 0 60 alive 
23 4A NS02001012 1H F 45 soft palate C SCC mod 1 0 60 alive 
24 4B NS02001012 1I F 45 soft palate C SCC mod 1 0 60 alive 
25 4C NS02001012 1J F 45 soft palate C SCC mod 1 0 60 alive 
26 4D NS02001012 1K F 45 soft palate C SCC mod 1 0 60 alive 
27 4E NS02001012 1L F 45 soft palate C SCC mod 1 0 60 alive 
28 4F NS02001012 1M F 45 soft palate C SCC mod 1 0 60 alive 
29 4G NS02001012 1N F 45 soft palate C SCC mod 1 0 60 alive 
30 4H NS02001012 1O F 45 soft palate C SCC mod 1 0 60 alive 
31 5A NS02001012 1P F 45 soft palate C SCC mod 1 0 60 alive 
32 5B NS02001012 2A F 45 soft palate C SCC mod 1 0 60 alive 
33 5C NS02001012 2B F 45 soft palate C SCC mod 1 0 60 alive 
34 5D NS02001012 2C F 45 soft palate C SCC mod 1 0 60 alive 
35 5E NS02001012 2D F 45 soft palate C SCC mod 1 0 60 alive 
36 5F NS02001012 2E F 45 soft palate C SCC mod 1 0 60 alive 
37 5G NS02001012 2F F 45 soft palate C SCC mod 1 0 60 alive 
38 5H NS02001012 2G F 45 soft palate C SCC mod 1 0 60 alive 
39 6A NS02001012 2H F 45 soft palate C SCC mod 1 0 60 alive 
40 6B NS02001012 2I F 45 soft palate C SCC mod 1 0 60 alive 
41 6C NS02001012 2J F 45 soft palate C SCC mod 1 0 60 alive 
42 6D NS02001012 2K F 45 soft palate C SCC mod 1 0 60 alive 
43 6E NS02001012 2L F 45 soft palate C SCC mod 1 0 60 alive 
44 6G NS02001225 1 M 46 BM B lichenoid reaction          
45 6H NS01001286 1B M 32 Skin B Inflame          
46 7A NS02001288 1 M 34 Gingivae B LP          
47 7B NS02001290 1 M 49 RMP B Fep          
48 7C NS02001293 1 F 46 BM B Fep          
49 7D NS02001294 1 F 72 BM B lichenoid reaction          
50 7F NS02001647 1 M 46 BM B LP          
51 7G NS02001832 1 M 66 Tongue B Fep          
52 8A NS02001962 1D M 60 Fom D Cis          
53 8B NS02001967 1 M 32 Tongue B lichenoid reaction          
54 8C NS02001970 1 F 52 BM B LP          
55 8D NS02002097 1 F 79 soft palate C SCC basaloid 2 0 13 dead 
56 8E NS02002098 1 M 63 soft palate C SCC mod 2 0 20 dead 
57 8F NS02002098 2 M 63 soft palate C SCC mod 2 0 20 dead 
58 8G NS02002185 1 M 59 Fom C SCC mod 3 0 60 alive 
59 8H NS02002359 1 F 62 BM B Fep           
Note:  α - Gender, F – Female, M - Male; β – Pathological status, B – benign, D – dysplasia,  C – carcinoma;  Anatomic site, BM – buccal mucosa, Fom – Floor of the mouth, RMP – 
Retromolar pad, Pathology, SCC – squamous cell carcinoma, LP – lichen planus, Cis – carcinoma in situ, Fep – fibrioepithelioma of Pinkus; mod – moderate; γ – Cellular differentiation; 
mod – moderately differentiated,  δ – Tumour size; ε – Regional Lymph Nodes; η – Survival Time (months); Grey shaded samples,  #56, #57, #73, #80 and #105 exhibited  recurrence. 
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Appendix 30 (Continued) 
 
(A) Clinical and histopathology parameters of 176 DNA samples for oral disease progression 
study 
 
No. Plate Pathology  no. Block Gα Age Anatomic site Codeβ Pathology Diff.γ Tδ Nε Survivalη Status 
60 9A NS02002447 1 F 65 hard palate D severe dysplasia           
61 9B NS02002905 1 M 48 Tongue B LP           
62 9C NS02002906 1 F 64 Fom B LP           
63 9D NS02003275 3J M 81 Fom C SCC basaloid 1 0 60 alive 
64 9E NS02003306 1A F 57 BM B Fep           
65 9F NS02003307 1B F 38 BM B Fep           
66 9G NS02003409 1 M 35 BM B Fep           
67 9H NS02003552 3A M 59 Fom C SCC mod 2 0 60 alive 
68 10A NS02003610 1 F 47 Fom B Fep           
69 10B NS02003612 1 F 88 lower lip B Fep           
70 10C NS02003710 1 F 40 upper lip B Fep           
71 10D NS02003712 1 F 61 BM B LP           
72 10E NS02003914 1 M 57 upper lip B Fep           
73 10F NS02004213 1 F 66 Fom C SCC mod 2 0 60 alive 
74 10G NS02004435 1 F 64 BM B LP           
75 10H NS02004442 3B M 63 RMP C SCC mod 2 0 20 dead 
76 11A NS02004521 1 F 62 BM B Fep           
77 11C NS02005157 1 M 84 lower lip C SCC mod 1 0 60 alive 
78 11D NS02005229 3B F 66 Fom C SCC mod 1 0 60 alive 
79 11E NS02005343 1 F 34 BM B Fep           
80 11F NS02005525 1C M 75 Tongue C SCC mod 2 0 19 dead 
81 11G NS02005565 1 M 53 BM B lichenoid reaction           
82 11H NS02005568 1 F 59 BM B Fep           
83 12A NS02005642 1B M 71 Tongue C SCC well 2 0 2 dead 
84 12B NS02006000 1A M 66 Tongue B Fep           
85 12C NS02006000 1B M 66 Tongue B Fep           
86 12E NS02006074 1 F 34 BM B Fep           
87 12F NS02006089 1 M 55 Tongue C SCC mod 2 0 31 dead 
88 13A NS02006419 1A M 74 Tongue C SCC mod 2 0 29 dead 
89 13C NS02006721 1B M 84 lower lip C SCC mod 1 0 60 alive 
90 13D NS02006728 3 F 67 Tongue C SCC mod 2 0 1 dead 
91 13E NS02006829 1 F 41 BM B Fep           
92 13F NS02006965 1 M 35 hard palate B LP           
93 13G NS02007068 3A M 55 Tongue C SCC mod 2 1 31 dead 
94 13H NS02007111 1A F 78 Fom D Cis           
95 14A NS02007112 1A F 86 Tongue C SCC mod 3 0 4 dead 
96 14B NS02007115 1 F 57 Tongue B Fep           
97 14C NS02007236 1C M 84 lower lip C SCC well 1 0 40 dead 
98 14D NS02007455 1B M 16 BM B Fep           
99 14E NS02007591 1A F 62 Tongue B LP           
100 14F NS02007598 1 F 57 Gingivae B LP           
101 14G NS02007665 1 M 65 Gingivae B Fep           
102 14H NS02007740 1 M 49 BM D severe dysplasia           
103 15A NS02007766 1 F 71 Tongue C SCC mod 1 0 60 alive 
104 15B NS02007899 1 F 46 Tongue B Fep           
105 15C NS02008161 1A F 71 Tongue C SCC mod 1 0 60 alive 
106 15D NS02008655 1A F 57 Gingivae B Inflame           
107 15E NS02008741 1 F 79 BM C SCC poor 3 0 3 dead 
108 15F NS02008759 1 M 43 soft palate B Fep           
109 15G NS02009289 1 M 85 BM C SCC mod 2 0 3 dead 
110 15H NS02009377 1 M 65 BM B Fep           
111 16A NS02009378 1 F 45 Fom B Inflame           
112 16B NS02009385 1 F 59 soft palate B LP           
113 16C NS02009890 1 M 53 Tongue B LP           
114 16D NS02009892 1 F 45 Tongue B LP           
115 16E NS02010172 1 M 37 BM B LP           
116 16F NS02010172 2 M 75 BM B Fep           
117 16G NS02010245 1 M 75 BM B Fep           
118 16H NS02010301 1 F 23 Gingivae B Fep           
119 17A NS02010352 1 M 90 RMP C SCC mod 2 0 2 dead 
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(A) Clinical and histopathology parameters of 176 DNA samples for oral disease progression 
study 
 
No. Plate Pathology  no. Block Gα Age Anatomic site Codeβ Pathology Diff.γ Tδ Nε Survivalη Status 
120 17B NS02010409 1 F 61 BM B Fep           
121 17C NS02010583 1 F 81 soft palate B Fep           
122 17D NS02010642 1A M 54 RMP C SCC well 3 0 60 alive 
123 17E NS02010835 1 F 60 Tongue B Inflame           
124 17F NS02010904 1 M 28 BM B LP           
125 17G NS02011108 1A M 91 lower lip C SCC well 1 0 17 dead 
126 17H NS02011344 1 M 90 Fom C SCC well 2 0 60 alive 
127 18A NS02011372 1A M 51 Tongue C SCC poor 3 0 60 alive 
128 18B NS02011466 2A F 68 Tongue C SCC mod 3 0 60 dead 
129 18C NS02011734 1 M 63 soft palate D Cis           
130 18D NS02011761 1B F 73 Tongue C SCC poor 3 0 39 dead 
131 18E NS02011779 1 M 56 BM B LP           
132 18F NS02012088 1A M 63 Tongue B LP           
133 18G NS02012156 1 F 99 Tongue C SCC well 2 0 3 dead 
134 18H NS02012233 1 M 63 Fom D mod dyplasia           
135 19A NS02012381 1 F 68 BM B LP           
136 19B NS02012538 1A M 77 lower lip B Inflame           
137 19C NS02012753 1 M 43 BM B Fep           
138 19D NS02012797 1 M 54 Fom C SCC mod 3 0 14 dead 
139 19E NS02012798 2 M 72 soft palate C SCC poor 3 0 56 dead 
140 19F NS02013040 1 F 57 BM B LP           
141 19G NS02013296 3C M 80 Fom C SCC mod 4 2 60 alive 
142 19H NS02013597 1 M 63 soft palate D severe dysplasia           
143 20A NS02013634 1B F 54 Tongue B LP           
144 20B NS02013654 1 M 38 BM B LP           
145 20C NS02013666 3O M 63 Tongue C SCC poor 4 2 2 dead 
146 20D NS02013773 1 F 82 BM B LP           
147 20E NS02013919 1 F 44 Tongue B Fep           
148 20F NS02013948 1C M 69 Tongue C SCC well 1 0 60 alive 
149 20G NS02014046 1D M 54 Gingivae C SCC mod 2 1 13 dead 
150 20H NS02014101 1A F 60 BM C SCC mod 2 0 60 alive 
151 21A NS02014375 1 M 50 BM B Fep           
152 21B NS02014416 2B F 73 Tongue C SCC mod 1 0 33 dead 
153 21C NS02014462 1 F 53 lower lip B Fep           
154 21D NS02014490 1A F 71 soft palate C SCC mod 4 2 54 dead 
155 21E NS02014538 1 M 30 BM B LP           
156 21F NS02014854 1 F 65 BM B Fep           
157 21G NS02014921 1 M 45 Fom D mild dysplasia           
158 21H NS02015136 1 M 56 Tongue B Inflame           
159 22A NS02015366 1B F 72 Gingivae C SCC mod 1 2 8 dead 
160 22B NS02015903 1 F 64 Fom D severe dysplasia           
161 22C NS02016061 1 M 57 soft palate C SCC poor 3 0 13 dead 
162 22D NS02016362 2A M 78 Fom C SCC mod 1 1 14 dead 
163 22E NS02016901 8D F 68 Fom D Cis           
164 22F NS02017209 1 F 56 BM B LP           
165 22G NS02017309 1A F 58 BM B Fep           
166 22H NS02017374 1 F 67 Fom D Cis           
167 23A NS02017375 2 M 71 hard palate B LP           
168 23B NS02017558 1 M 97 Fom D Cis           
169 23C NS02017642 5Q F 62 Gingivae C SCC well 2 0 60 dead 
170 23D NS02017902 1 M 65 Gingivae C SCC poor 3 1 8 dead 
171 23E NS02017946 2F M 57 Fom C SCC poor 3 2 11 dead 
172 23F NS02018053 1 F 77 Tongue C SCC poor 3 1 60 alive 
173 23G NS02018054 1 F 63 BM B LP           
174 23H NS02018368 4F F 80 BM B LP        
175 24A NS02018494 1A F 47 Tongue C SCC poor 2 1  3 dead  
176 24B NS02018494 1B F 47 Tongue C SCC poor 2 1  3 dead  
 
 
 
406 
Appendix 30 (Continued) 
 
(B) Clinical and histopathology parameters of 7 DNA samples (normal tissues) 
 
 
No. Plate Pathology  no. Block Gα Age Anatomic site Codeβ Pathology Status 
1 2D NS02000126 1 M 77 Tongue N Normal Dead 
2 6F NS02001175 1D F 64 Tonsil N Normal   
3 7E NS02001437 1 M 68 RMP N Normal   
4 11B NS02004522 1 F 52 Tongue N Normal   
5 12D NS02006017 1 F 27 BM N Normal   
6 12G NS02006394 1 M 46 Tongue N Normal   
7 12H NS02006395 1 M 47 lower lip N Normal   
Note:  α - Gender, F – Female, M - Male; β – Pathological status, N – normal; Anatomic site, BM – buccal mucosa, RMP – Retromolar pad. 
 
(C) DNA purity and DNA yield of 7 extracted DNA samples (normal tissues) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
1 2D NS02000126 1 4.83 5.13 4.72 5.09 4.70 5.01 0.936 0.238 8.4 191.6 200 
2 6F NS02001175 1D 25.03 23.66 25.81 24.55 25.90 24.64 1.759 0.143 14.0 186.0 200 
3 7E NS02001437 1 18.29 17.48 18.60 17.78 18.75 17.90 1.768 0.095 21.0 179.0 200 
4 11B NS02004522 1 7.91 7.78 8.17 8.05 8.17 8.04 1.016 0.404 4.9 195.1 200 
5 12D NS02006017 1 2.51 2.75 2.47 2.71 2.41 2.68 0.908 0.123 16.2 183.8 200 
6 12G NS02006394 1 1.41 1.61 1.52 1.73 1.48 1.72 0.872 0.074 27.2 172.8 200 
7 12H NS02006395 1 3.91 4.14 4.07 4.29 4.09 4.33 0.946 0.201 9.9 190.1 200 
 
(D) PCR results for β-globin and L1 for α-HPV (normal tissues) 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
1 2D NS02000126 1 + - + + + 
2 6F NS02001175 1D + - + + + 
3 7E NS02001437 1 + - - + + 
4 11B NS02004522 1 + - + + + 
5 12D NS02006017 1 + - - - - 
6 12G NS02006394 1 + - + + + 
7 12H NS02006395 1 + - - - - 
         
  PCR positive (%): 7 (100.0) 0 (0.0) 4 (57.1) 5 (71.4) 5 (71.4) 
  PCR negative (%): 0 (0.0) 7 (100.0) 3 (42.9) 2 (28.6) 2 (28.6) 
  Total samples: 7 7 7 7 7 
 
Note: +   Positive  PCR and  -   Negative PCR 
 
(E) DNA sequencing and multiple sequences alignment results (normal tissues) 
 
    Pathology code Block Expected amplicon PCR purification HPV identification 
No. Plate   size (bp) methodsα  
1 2D NS02000126 1 190 PCR Negative 
2 6F NS02001175 1D 140 PCR Negative 
3 7E NS02001437 1 140 PCR Negative 
4 11B NS02004522 1 140 Gel HPV 16 
5 12G NS02006394 1 140 PCR Negative 
Notes: 
 
α -  PCR product purification methods: PCR - QIAquick PCR Purification Kit (Qiagen); Gel - QIAquick Gel Extraction Kit (Qiagen) 
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DNA purity and DNA yield of 84 extracted DNA samples (Benign) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
1 1A NS01006314 1 0.61 0.54 0.73 0.67 0.88 0.82 1.098 0.037 54.1 145.9 200 
2 1C NS01017677 2 7.62 8.08 5.88 6.38 5.42 5.90 0.928 0.315 6.3 193.7 200 
3 1D NS01017679 1 4.41 4.28 4.39 4.26 4.39 4.27 1.836 0.014 140.5 59.5 200 
4 1E NS01017750 1 12.97 12.64 13.05 12.77 12.92 12.65 2.456 0.025 80.0 120.0 200 
5 1G NS01018047 1 28.14 27.05 28.82 27.73 28.83 27.75 2.320 0.096 20.9 179.1 200 
6 1H NS01018047 2 5.15 4.96 5.15 4.96 5.12 4.92 2.044 0.019 106.2 93.8 200 
7 2B NS01018532 1 2.35 2.29 2.59 2.52 2.73 2.73 0.975 0.126 15.9 184.1 200 
8 2C NS01018560 1 2.92 2.93 3.2 3.24 3.81 3.62 1.006 0.167 12.0 188.0 200 
9 2E NS02000314 2 2.87 3.35 2.57 3.06 - - 0.849 0.136 14.7 185.3 200 
10 2G NS02000370 1 23.83 23.46 24.37 24.07 24.38 24.05 1.753 0.039 51.5 148.5 200 
11 2H NS02000373 1 13.92 13.55 14.23 13.85 14.35 13.95 2.179 0.036 55.8 144.2 200 
12 3A NS02000961 1 12.38 12.12 12.64 12.34 12.62 12.34 2.460 0.024 84.5 115.5 200 
13 6G NS02001225 1 15.35 14.73 15.50 14.89 15.56 14.92 1.733 0.074 27.1 172.9 200 
14 6H NS01001286 1B 15.24 14.65 15.44 14.86 15.50 14.93 1.784 0.066 30.3 169.7 200 
15 7A NS02001288 1 1.37 1.51 1.97 2.07 2.58 2.72 1.069 0.105 19.0 181.0 200 
16 7B NS02001290 1 15.48 15.02 15.71 15.25 15.76 15.26 1.652 0.060 33.3 166.7 200 
17 7C NS02001293 1 4.47 4.26 3.78 3.59 3.68 3.49 1.052 0.199 10.1 189.9 200 
18 7D NS02001294 1 14.12 13.61 14.36 13.81 14.31 13.78 1.846 0.058 34.6 165.4 200 
19 7F NS02001647 1 0.44 0.43 0.55 0.53 0.63 0.61 1.032 0.027 74.1 125.9 200 
20 7G NS02001832 1 0.27 0.19 0.65 0.51 0.79 0.65 1.300 0.028 70.3 129.7 200 
21 8B NS02001967 1 22.05 20.95 22.70 21.51 22.76 21.58 1.867 0.125 16.1 183.9 200 
22 8C NS02001970 1 0.55 0.46 0.28 0.18 0.43 0.34 1.326 0.021 95.5 104.5 200 
23 8H NS02002359 1 19.13 18.36 20.03 19.26 20.18 19.39 2.121 0.074 27.2 172.8 200 
24 9B NS02002905 1 30.19 29.78 32.59 32.31 33.35 32.91 2.223 0.037 53.6 146.4 200 
25 9C NS02002906 1 17.36 16.68 17.67 16.99 17.79 17.09 1.778 0.079 25.5 174.5 200 
26 9E NS02003306 1A 12.49 12.19 12.57 12.30 12.49 12.22 2.061 0.027 73.6 126.4 200 
27 9F NS02003307 1B 11.05 10.80 11.15 10.91 11.18 10.94 2.423 0.021 97.6 102.4 200 
28 9G NS02003409 1 17.09 16.41 17.33 16.66 17.40 16.72 1.875 0.073 27.6 172.4 200 
29 10A NS02003610 1 15.19 14.56 15.42 14.80 15.49 14.80 1.925 0.067 29.7 170.3 200 
30 10B NS02003612 1 17.95 17.52 18.34 17.86 18.37 17.91 1.643 0.058 34.3 165.7 200 
31 10C NS02003710 1 21.64 20.68 21.55 20.64 21.44 20.56 2.015 0.091 22.0 178.0 200 
32 10D NS02003712 1 1.00 1.11 0.78 0.93 0.69 0.85 0.851 0.041 48.6 151.4 200 
33 10E NS02003914 1 25.91 24.90 26.27 25.30 26.10 25.11 1.614 0.129 15.5 184.5 200 
34 10G NS02004435 1 10.94 10.69 11.03 10.78 11.00 10.77 2.406 0.021 96.0 104.0 200 
35 11A NS02004521 1 16.17 15.74 16.31 15.87 16.34 15.89 1.733 0.052 38.5 161.5 200 
36 11E NS02005343 1 18.19 17.57 18.40 17.75 19.41 17.76 1.615 0.084 23.8 176.2 200 
37 11G NS02005565 1 2.23 2.03 2.34 2.13 2.69 2.49 1.094 0.121 16.5 183.5 200 
38 11H NS02005568 1 3.96 3.93 0.96 0.92 1.21 1.13 1.041 0.102 19.6 180.4 200 
39 12B NS02006000 1A 2.20 2.12 3.77 3.67 4.38 4.25 1.032 0.173 11.6 188.4 200 
40 12C NS02006000 1B     0.41 0.39 0.49 0.49 1.026 0.023 88.9 111.1 200 
41 12E NS02006074 1 3.32 3.54 3.59 3.84 3.71 3.97 0.936 0.177 11.3 188.7 200 
42 13E NS02006829 1 1.36 1.59 1.38 1.65 1.37 1.62 0.846 0.069 29.2 170.8 200 
43 13F NS02006965 1 1.45 1.72 1.44 1.70 1.41 1.69 0.841 0.072 27.9 172.1 200 
44 14B NS02007115 1 7.05 7.01 7.30 7.21 7.28 7.19 1.010 0.361 5.5 194.5 200 
45 14D NS02007455 1B 0.70 0.72 0.66 0.70 0.64 0.69 0.948 0.033 60.0 140.0 200 
46 14E NS02007591 1A 4.5 4.25 3.93 3.61 2.63 2.39 0.941 0.171 11.7 188.3 200 
47 14F NS02007598 1 4.31 4.24 4.60 4.54 4.64 4.61 1.012 0.226 8.9 191.1 200 
48 14G NS02007665 1 21.75 21.34 22.59 22.16 22.67 22.27 1.019 1.117 1.8 198.2 200 
49 15B NS02007899 1 1.31 1.32 1.37 1.41 1.44 1.48 0.979 0.069 29.1 170.9 200 
50 15D NS02008655 1A 11.26 11.48 13.59 13.77 14.35 14.54 0.985 0.653 3.1 196.9 200 
51 15F NS02008759 1 9.33 9.43 10.85 10.92 11.28 11.42 0.990 0.524 3.8 196.2 200 
52 15H NS02009377 1 8.76 8.86 10.38 10.57 10.92 11.09 0.985 0.501 4.0 196.0 200 
53 16A NS02009378 1 1.58 1.58 1.75 1.77 1.80 1.84 0.989 0.086 23.4 176.6 200 
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DNA purity and DNA yield of 84 extracted DNA samples (Benign) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
54 16B NS02009385 1 0.23 0.23 0.27 0.29 0.28 0.30 0.933 0.013 155.4 44.6 200 
55 16C NS02009890 1 0.60 0.60 0.56 0.59 0.51 0.54 0.964 0.028 71.9 128.1 200 
56 16D NS02009892 1 0.53 0.49 0.47 0.45 0.42 0.42 1.042 0.024 84.5 115.5 200 
57 16E NS02010172 1 0.69 0.67 0.70 0.71 0.68 0.71 0.991 0.035 58.0 142.0 200 
58 16F NS02010172 2 4.40 4.36 4.56 4.54 4.42 4.41 1.005 0.223 9.0 191.0 200 
59 16G NS02010245 1 0.70 0.68 0.65 0.64 0.61 0.62 1.010 0.033 61.2 138.8 200 
60 16H NS02010301 1 1.10 1.09 1.00 1.00 0.95 0.96 1.000 0.051 39.3 160.7 200 
61 17B NS02010409 1 0.99 0.94 0.99 0.95 0.95 0.92 1.043 0.049 41.0 159.0 200 
62 17C NS02010583 1 0.49 0.48 0.44 0.43 0.41 0.41 1.015 0.022 89.6 110.4 200 
63 17E NS02010835 1 26.42 25.97 26.43 25.96 26.11 25.71 1.017 1.313 1.5 198.5 200 
64 17F NS02010904 1 0.76 0.73 0.71 0.71 0.72 0.72 1.014 0.037 54.8 145.2 200 
65 18E NS02011779 1 0.69 0.52 0.65 0.50 0.64 0.50 1.302 0.033 60.6 139.4 200 
66 18F NS02012088 1A 0.47 0.34 0.42 0.31 0.44 0.33 1.363 0.022 90.2 109.8 200 
67 19A NS02012381 1 0.72 0.69 0.73 0.69 0.73 0.71 1.043 0.036 55.0 145.0 200 
68 19B NS02012538 1A 19.77 19.34 19.61 19.21 19.62 19.23 1.021 0.983 2.0 198.0 200 
69 19C NS02012753 1 0.37 0.32 0.36 0.32 0.36 0.32 1.149 0.018 110.1 89.9 200 
70 19F NS02013040 1 0.45 0.45 0.47 0.48 0.50 0.53 0.974 0.024 84.5 115.5 200 
71 20A NS02013634 1B 0.29 0.18 0.42 0.28 0.55 0.38 1.533 0.021 95.4 104.6 200 
72 20B NS02013654 1 2.25 2.15 2.24 2.14 1.69 1.56 0.945 0.098 20.5 179.5 200 
73 20D NS02013773 1 21.88 21.36 23.09 22.68 22.96 22.62 1.019 1.132 1.8 198.2 200 
74 20E NS02013919 1 1.46 0.95 1.73 1.22 2.05 1.51 1.438 0.087 22.9 177.1 200 
75 21A NS02014375 1 20.58 19.90 19.87 19.25 19.66 19.06 1.032 1.002 2.0 198.0 200 
76 21C NS02014462 1 1.44 1.43 1.53 1.44 1.23 1.13 0.951 0.067 30.0 170.0 200 
77 21E NS02014538 1 21.11 20.67 20.63 20.14 20.31 19.89 1.022 1.034 1.9 198.1 200 
78 21F NS02014854 1 2.52 2.74 1.89 2.12 1.19 1.29 0.911 0.093 21.4 178.6 200 
79 21H NS02015136 1 0.35 0.23 0.60 0.46 0.79 0.65 1.338 0.029 69.0 131.0 200 
80 22F NS02017209 1 1.19 1.15 0.94 0.99 1.25 1.31 1.022 0.058 34.8 165.2 200 
81 22G NS02017309 1A 28.48 28.20 31.82 31.48 31.45 31.21 1.010 1.529 1.3 198.7 200 
82 23A NS02017375 2 1.21 1.28 2.08 2.09 3.11 3.06 0.990 0.107 18.8 181.3 200 
83 23G NS02018054 1 24.51 24.11 25.66 25.31 23.31 22.98 1.015 1.225 1.6 198.4 200 
84 23H NS02018368 4F 25.23 24.68 25.76 25.28 23.96 23.49 1.020 1.249 1.6 198.4 200 
 
 
 
 
 
 
 
 
 
 
 
 
409 
Appendix 32 
 
DNA purity and DNA yield of 12 extracted DNA samples (Dysplasia) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
1 8A NS02001962 1D 4.49 4.58 4.55 4.60 4.53 4.64 0.982 0.226 8.8 191.2 200 
2 9A NS02002447 1 20.25 19.83 20.66 20.21 20.68 20.23 1.617 0.058 34.7 165.3 200 
3 13H NS02007111 1A 1.12 1.27 1.47 1.64 1.48 1.69 0.885 0.068 29.5 170.5 200 
4 14H NS02007740 1 0.40 0.39 0.49 0.48 0.52 0.51 1.022 0.024 85.1 114.9 200 
5 18C NS02011734 1 1.40 1.07 1.39 1.07 1.35 1.05 1.298 0.069 29.0 171.0 200 
6 18H NS02012233 1 24.20 23.86 24.48 24.15 24.44 24.12 1.014 1.219 1.6 198.4 200 
7 19H NS02013597 1 0.35 0.31 0.57 0.51 0.63 0.55 1.132 0.026 77.4 122.6 200 
8 21G NS02014921 1 2.77 2.58 1.48 1.3 1.18 1.02 0.891 0.082 24.5 175.5 200 
9 22B NS02015903 1 1.45 1.32 1.36 1.19 0.95 0.81 0.879 0.055 36.1 163.9 200 
10 22E NS02016901 8D 30.12 29.71 28.21 27.77 26.24 25.82 1.015 1.409 1.4 198.6 200 
11 22H NS02017374 1 1.38 1.38 1.60 1.57 2.05 2.00 1.015 0.084 23.9 176.1 200 
12 23B NS02017558 1 26.80 26.29 27.58 27.05 26.60 26.14 1.019 1.350 1.5 198.5 200 
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DNA purity and DNA yield of 80 extracted DNA samples (Carcinoma) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
1 1B NS01017460 5J 6.84 6.61 6.75 6.53 6.62 6.40 1.712 0.027 75.0 125.0 200 
2 1F NS01017826 4D 17.97 17.06 17.93 17.07 17.81 16.95 2.439 0.073 27.3 172.7 200 
3 2F NS02000316 7C 21.12 20.20 21.51 20.65 21.52 20.69 2.075 0.084 23.8 176.2 200 
4 3B NS02001012 1A 10.52 10.29 10.60 10.35 10.62 10.36 1.954 0.025 79.5 120.5 200 
5 3C NS02001012 1B 14.22 13.59 13.14 12.66 12.81 12.34 2.082 0.051 39.3 160.7 200 
6 3D NS02001012 1C 1.16 0.69 1.28 0.91 1.68 1.28 0.689 0.048 41.7 158.3 200 
7 3E NS02001012 1D 11.30 10.94 11.34 11.00 11.34 11.00 1.912 0.036 55.0 145.0 200 
8 3F NS02001012 1E 4.31 4.17 4.32 4.18 4.31 4.18 2.391 0.012 168.5 31.5 200 
9 3G NS02001012 1F 12.75 12.35 12.88 12.47 12.91 12.51 1.720 0.048 41.5 158.5 200 
10 3H NS02001012 1G 28.72 28.49 30.64 30.46 30.90 30.57 1.717 0.030 66.7 133.3 200 
11 4A NS02001012 1H 8.09 7.95 8.12 7.98 8.11 7.97 1.902 0.015 134.2 65.8 200 
12 4B NS02001012 1I 8.57 8.39 8.59 8.42 8.57 8.40 1.810 0.019 103.4 96.6 200 
13 4C NS02001012 1J 0.95 1.05 1.32 1.43 1.6 1.71 1.086 0.070 28.6 171.4 200 
14 4D NS02001012 1K 16.56 15.96 16.88 16.25 16.92 16.30 1.723 0.074 27.2 172.8 200 
15 4E NS02001012 1L 13.59 13.32 13.77 13.51 13.79 13.52 1.640 0.034 58.5 141.5 200 
16 4F NS02001012 1M 0.56 0.68 0.72 0.84 0.93 1.03 1.163 0.043 47.1 152.9 200 
17 4G NS02001012 1N 16.26 15.72 16.69 16.17 16.77 16.26 1.748 0.061 32.7 167.3 200 
18 4H NS02001012 1O 11.14 10.93 11.25 11.05 11.33 11.10 2.044 0.021 96.8 103.2 200 
19 5A NS02001012 1P 11.73 11.43 12.55 12.27 12.60 12.33 1.715 0.034 58.8 141.2 200 
20 5B NS02001012 2A 6.30 6.28 6.26 6.27 6.23 6.22 1.001 0.313 6.4 193.6 200 
21 5C NS02001012 2B 20.28 19.42 20.56 19.66 20.76 19.84 1.993 0.090 22.3 177.7 200 
22 5D NS02001012 2C 12.64 12.16 12.79 12.29 12.84 12.35 1.782 0.056 35.8 164.2 200 
23 5E NS02001012 2D 16.94 16.23 17.24 16.50 17.25 16.55 1.757 0.083 24.0 176.0 200 
24 5F NS02001012 2E 8.60 8.40 8.64 8.45 8.66 8.46 1.825 0.022 92.3 107.7 200 
25 5G NS02001012 2F 8.55 8.39 8.63 8.45 8.64 8.47 1.796 0.020 101.7 98.3 200 
26 5H NS02001012 2G 14.90 14.34 15.10 14.53 15.12 14.56 1.853 0.061 32.7 167.3 200 
27 6A NS02001012 2H 16.40 15.76 16.65 16.00 16.70 16.06 1.919 0.067 29.8 170.2 200 
28 6B NS02001012 2I 15.18 14.60 15.58 14.99 15.66 15.09 1.973 0.059 34.0 166.0 200 
29 6C NS02001012 2J 6.08 5.94 6.09 5.97 6.10 5.98 1.801 0.014 139.5 60.5 200 
30 6D NS02001012 2K 17.62 16.90 17.85 17.14 17.94 17.22 1.689 0.088 22.8 177.2 200 
31 6E NS02001012 2L 19.49 18.56 19.65 18.76 19.74 18.86 1.726 0.107 18.7 181.3 200 
32 8D NS02002097 1 16.22 15.48 16.39 15.61 16.40 15.66 1.753 0.088 22.8 177.2 200 
33 8E NS02002098 1 11.44 11.11 11.42 11.11 11.42 11.12 2.189 0.029 69.4 130.6 200 
34 8F NS02002098 2 1.06 0.63 1.02 0.60 1.04 0.63 1.678 0.052 38.5 161.5 200 
35 8G NS02002185 1 20.15 19.21 20.23 19.31 20.24 19.32 1.733 0.110 18.3 181.7 200 
36 9D NS02003275 3J 24.43 23.03 25.02 23.61 25.13 23.73 2.277 0.125 16.0 184.0 200 
37 9H NS02003552 3A 1.93 1.44 1.90 1.43 1.92 1.48 1.322 0.096 20.9 179.1 200 
38 10F NS02004213 1 13.15 12.78 13.33 12.96 13.33 12.99 1.819 0.040 50.0 150.0 200 
39 10H NS02004442 3B 22.37 21.32 22.42 21.42 22.38 21.36 1.760 0.119 16.9 183.1 200 
40 11C NS02005157 1 14.61 14.21 14.64 14.22 14.63 14.21 1.850 0.045 44.4 155.6 200 
41 11D NS02005229 3B 18.20 17.46 18.35 17.64 18.40 17.68 1.668 0.090 22.1 177.9 200 
42 11F NS02005525 1C 0.01 0.12 8.09 7.53 6.91 6.31 0.737 0.250 8.0 192.0 200 
43 12A NS02005642 1B 18.06 17.36 18.36 17.68 18.42 17.72 1.981 0.071 28.3 171.7 200 
44 12F NS02006089 1 0.49 0.65 0.62 0.77 0.57 0.74 0.776 0.028 71.4 128.6 200 
45 13A NS02006419 1A 3.89 3.85 3.81 3.82 3.78 3.79 1.001 0.191 10.5 189.5 200 
46 13C NS02006721 1B 1.06 1.22 1.10 1.29 1.10 1.29 0.858 0.054 36.8 163.2 200 
47 13D NS02006728 3 1.79 2.11 1.90 2.20 1.89 2.21 0.856 0.093 21.5 178.5 200 
48 13G NS02007068 3A 4.61 4.51 4.85 4.82 4.84 4.84 1.009 0.238 8.4 191.6 200 
49 14A NS02007112 1A 2.86 3.07 2.89 3.13 2.87 3.12 0.925 0.144 13.9 186.1 200 
50 14C NS02007236 1C 21.17 20.69 21.81 21.38 21.67 21.24 1.021 1.077 1.9 198.1 200 
51 15A NS02007766 1 2.32 2.33 2.57 2.60 3.04 3.05 0.994 0.132 15.1 184.9 200 
52 15C NS02008161 1A 21.83 21.09 22.42 21.74 22.44 21.78 1.032 1.112 1.8 198.2 200 
53 15E NS02008741 1 5.76 5.92 6.84 6.97 - - 0.977 0.315 6.3 193.7 200 
54 15G NS02009289 1 20.66 20.21 20.98 20.51 20.97 20.54 1.022 1.043 1.9 198.1 200 
55 17A NS02010352 1 1.32 0.87 1.30 0.86 1.23 0.81 1.516 0.064 31.2 168.8 200 
56 17D NS02010642 1A 0.84 0.80 0.83 0.79 0.87 0.83 1.050 0.042 47.2 152.8 200 
57 17G NS02011108 1A 20.35 19.92 20.97 20.55 21.04 20.64 1.020 1.039 1.9 198.1 200 
58 17H NS02011344 1 1.34 1.09 1.29 1.06 1.25 1.02 1.224 0.065 30.9 169.1 200 
59 18A NS02011372 1A 1.11 0.88 1.05 0.82 0.89 0.67 1.290 0.051 39.3 160.7 200 
60 18B NS02011466 2A 17.09 16.57 16.94 16.41 16.81 16.33 1.031 0.847 2.4 197.6 200 
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Appendix 33 (Continued) 
 
DNA purity and DNA yield of 80 extracted DNA samples (Carcinoma) 
 
    Reading 1 Reading 2 Reading 3 DNA 
purity 
DNA yield 
(µg/µl) 
Dilution for PCR (10 ng/µl) 
No. Plate Pathology no. Block A260 A280 A260 A280 A260 A280 DNA dH2O Total 
61 18D NS02011761 1B 0.37 0.29 0.34 0.29 0.34 0.29 1.218 0.018 114.3 85.7 200 
62 18G NS02012156 1 0.58 0.55 0.56 0.54 0.55 0.53 1.043 0.028 71.0 129.0 200 
63 19D NS02012797 1 0.54 0.43 0.55 0.46 0.52 0.45 1.203 0.027 74.5 125.5 200 
64 19E NS02012798 2 0.93 0.84 0.88 0.82 0.88 0.80 1.093 0.045 44.6 155.4 200 
65 19G NS02013296 3C 24.05 23.22 21.42 20.65 20.70 19.98 1.036 1.103 1.8 198.2 200 
66 20C NS02013666 3O 2.57 1.07 2.71 1.22 3.14 1.65 2.177 0.140 14.3 185.7 200 
67 20F NS02013948 1C 2.37 1.98 2.76 2.33 3.17 2.74 1.183 0.139 14.4 185.6 200 
68 20G NS02014046 1D 22.84 21.90 22.54 21.64 22.38 21.46 1.043 1.129 1.8 198.2 200 
69 20H NS02014101 1A 25.37 24.96 24.96 24.54 24.53 24.10 1.017 1.247 1.6 198.4 200 
70 21B NS02014416 2B 26.60 26.00 25.79 25.23 25.07 24.50 1.023 1.291 1.5 198.5 200 
71 21D NS02014490 1A 25.48 24.58 24.54 23.68 24.16 23.30 1.037 1.236 1.6 198.4 200 
72 22A NS02015366 1B 23.54 23.19 23.08 22.78 22.76 22.50 1.013 1.156 1.7 198.3 200 
73 22C NS02016061 1 25.64 25.13 25.06 24.53 24.84 24.29 1.022 1.259 1.6 198.4 200 
74 22D NS02016362 2A 29.10 28.30 28.63 27.79 27.60 26.81 1.029 1.422 1.4 198.6 200 
75 23C NS02017642 5Q 25.73 25.07 26.89 26.35 26.73 26.22 1.021 1.322 1.5 198.5 200 
76 23D NS02017902 1 24.69 23.98 25.47 24.77 24.41 23.76 1.028 1.243 1.6 198.4 200 
77 23E NS02017946 2F 25.82 25.28 26.34 25.78 26.10 25.63 1.020 1.304 1.5 198.5 200 
78 23F NS02018053 1 23.28 22.85 23.35 22.90 21.85 21.45 1.019 1.141 1.8 198.2 200 
79 24A NS02018494 1A 25.92 25.52 28.56 28.09 25.88 25.45 1.017 1.339 1.5 198.5 200 
80 24B NS02018494 1B 26.34 25.93 25.39 25.05 24.69 24.35 1.015 1.274 1.6 198.4 200 
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Appendix 34 
 
PCR results for β-globin and L1 of alpha HPV (Benign) 
 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
1 1A NS01006314 1 + - + + + 
2 1C NS01017677 2 + - + + + 
3 1D NS01017679 1 + - + + + 
4 1E NS01017750 1 + - - + + 
5 1G NS01018047 1 + - + + + 
6 1H NS01018047 2 + - - - - 
7 2B NS01018532 1 + - + + + 
8 2C NS01018560 1 + - + + + 
9 2E NS02000314 2 + - + + + 
10 2G NS02000370 1 + - + + + 
11 2H NS02000373 1 + - + + + 
12 3A NS02000961 1 + - + + + 
13 6G NS02001225 1 + - - - - 
14 6H NS01001286 1B + - + + + 
15 7A NS02001288 1 + - + + + 
16 7B NS02001290 1 + - + + + 
17 7C NS02001293 1 + - - - - 
18 7D NS02001294 1 + - + + + 
19 7F NS02001647 1 + - - + + 
20 7G NS02001832 1 + - + + + 
21 8B NS02001967 1 + - + + + 
22 8C NS02001970 1 + - + + + 
23 8H NS02002359 1 + - + + + 
24 9B NS02002905 1 + - + + + 
25 9C NS02002906 1 + - + + + 
26 9E NS02003306 1A + - + + + 
27 9F NS02003307 1B + - + + + 
28 9G NS02003409 1 + - - - - 
29 10A NS02003610 1 + - + + + 
30 10B NS02003612 1 + - - - - 
31 10C NS02003710 1 + - + + + 
32 10D NS02003712 1 + - + + + 
33 10E NS02003914 1 + - + + + 
34 10G NS02004435 1 + - + + + 
35 11A NS02004521 1 + - + + + 
36 11E NS02005343 1 + - + + + 
37 11G NS02005565 1 + - + + + 
38 11H NS02005568 1 + - + + + 
39 12B NS02006000 1A + - + + + 
40 12C NS02006000 1B + - +ε - - 
41 12E NS02006074 1 + - + + + 
      +34 +35 +35 
Note: +   Positive  PCR and  -   Negative PCR; ε - False positive PCR 
 
 
 
 
 
 
 
 
 
413 
Appendix 34 (Continued) 
 
PCR results for β-globin and L1 of alpha HPV (Benign) 
 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
42 13E NS02006829 1 + - - - - 
43 13F NS02006965 1 + - - - - 
44 14B NS02007115 1 + - + + + 
45 14D NS02007455 1B + - + + + 
46 14E NS02007591 1A + - - - - 
47 14F NS02007598 1 + - - - - 
48 14G NS02007665 1 + - + + + 
49 15B NS02007899 1 + - + + + 
50 15D NS02008655 1A + - - - - 
51 15F NS02008759 1 + - + + + 
52 15H NS02009377 1 + - - - - 
53 16A NS02009378 1 + - + + + 
54 16B NS02009385 1 + - + + + 
55 16C NS02009890 1 + - + + + 
56 16D NS02009892 1 + - - - - 
57 16E NS02010172 1 + - +ε - - 
58 16F NS02010172 2 + - + + + 
59 16G NS02010245 1 + - - - - 
60 16H NS02010301 1 + - - - - 
61 17B NS02010409 1 + - +ε - - 
62 17C NS02010583 1 + - + + + 
63 17E NS02010835 1 + - + + + 
64 17F NS02010904 1 + - - - - 
65 18E NS02011779 1 + - +ε - - 
66 18F NS02012088 1A + - - - - 
67 19A NS02012381 1 + - - - - 
68 19B NS02012538 1A + - - - - 
69 19C NS02012753 1 + - - - - 
70 19F NS02013040 1 + - + + + 
71 20A NS02013634 1B + - + + + 
72 20B NS02013654 1 + - + + + 
73 20D NS02013773 1 + - + + + 
74 20E NS02013919 1 + - - + + 
75 21A NS02014375 1 + - + + + 
76 21C NS02014462 1 + - + + + 
77 21E NS02014538 1 + - + + + 
78 21F NS02014854 1 + - + + + 
79 21H NS02015136 1 + - - + + 
80 22F NS02017209 1 + - + + + 
81 22G NS02017309 1A + - + + + 
82 23A NS02017375 2 + - + + + 
83 23G NS02018054 1 + - + + + 
84 23H NS02018368 4F + - + + + 
      +27 +26 +26 
  PCR positive (%): 84 (100.0) 0 (0.0) 61 (72.6) 61 (72.6) 61 (72.6) 
  PCR negative (%): 0 (0.0) 84 (100.0) 23 (27.4) 23 (27.4) 23 (27.4) 
  Total samples: 84 84 84 84 84 
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PCR amplification results for β-globin and L1 of alpha HPV (Dysplasia) 
 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
1 8A NS02001962 1D + - + + + 
2 9A NS02002447 1 + - + + + 
3 13H NS02007111 1A + - + + + 
4 14H NS02007740 1 + + + + + 
5 18C NS02011734 1 + - - - - 
6 18H NS02012233 1 + - + + + 
7 19H NS02013597 1 + - + + + 
8 21G NS02014921 1 + - + + + 
9 22B NS02015903 1 + - + + + 
10 22E NS02016901 8D + - - - - 
11 22H NS02017374 1 + - + + + 
12 23B NS02017558 1 + - - - - 
        
  PCR positive (%): 12 (100.0) 1 (8.3) 9 (75.0) 9 (75.0) 9 (75.0) 
  PCR negative (%): 0 (0.0) 11 (91.7) 3 (25.0) 3 (25.0) 3 (25.0) 
  Total samples: 12 12 12 12 12 
        
Note: +   Positive  PCR and  -   Negative PCR 
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PCR results for β-globin and L1 of alpha HPV (Carcinoma) 
 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
1 1B NS01017460 5J + - - - - 
2 1F NS01017826 4D + - - + + 
3 2F NS02000316 7C + - + + + 
4 3B NS02001012 1A + - - + + 
5 3C NS02001012 1B + - - + + 
6 3D NS02001012 1C + - - + + 
7 3E NS02001012 1D + - - + + 
8 3F NS02001012 1E + - + + + 
9 3G NS02001012 1F + - + + + 
10 3H NS02001012 1G + - + + + 
11 4A NS02001012 1H + - + + + 
12 4B NS02001012 1I + - + + + 
13 4C NS02001012 1J + - + + + 
14 4D NS02001012 1K + - + + + 
15 4E NS02001012 1L + - + + + 
16 4F NS02001012 1M + - + + + 
17 4G NS02001012 1N + - + + + 
18 4H NS02001012 1O + - - - - 
19 5A NS02001012 1P + - + + + 
20 5B NS02001012 2A + - + + + 
21 5C NS02001012 2B + - + + + 
22 5D NS02001012 2C + - + + + 
23 5E NS02001012 2D + - + + + 
24 5F NS02001012 2E + - - + + 
25 5G NS02001012 2F + - + + + 
26 5H NS02001012 2G + - + + + 
27 6A NS02001012 2H + - + + + 
28 6B NS02001012 2I + - + + + 
29 6C NS02001012 2J + - + + + 
30 6D NS02001012 2K + - - - - 
31 6E NS02001012 2L + - - - - 
32 8D NS02002097 1 + - - + + 
33 8E NS02002098 1 + - + + + 
34 8F NS02002098 2 + - + + + 
35 8G NS02002185 1 + - + + + 
36 9D NS02003275 3J + - + + + 
37 9H NS02003552 3A + - + + + 
38 10F NS02004213 1 + - - - - 
39 10H NS02004442 3B + - + + + 
40 11C NS02005157 1 + - + + + 
41 11D NS02005229 3B + - + + + 
42 11F NS02005525 1C + - + + + 
43 12A NS02005642 1B + - + + + 
44 12F NS02006089 1 + - + + + 
45 13A NS02006419 1A + - - + + 
46 13C NS02006721 1B + - - + + 
47 13D NS02006728 3 + - + + + 
         
Note: +   Positive  PCR and  -   Negative PCR 
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PCR results for β-globin and L1 of alpha HPV (Carcinoma) 
 
 
No ID 
Pathology 
code 
 
Block 
β-globin 
(268 bp) 
L1 α-HPV  α-HPV  
450 bp 190 bp 140 bp Status 
         
48 13G NS02007068 3A + - + + + 
49 14A NS02007112 1A + - + + + 
50 14C NS02007236 1C + - + + + 
51 15A NS02007766 1 + - +ε - - 
52 15C NS02008161 1A + - + + + 
53 15E NS02008741 1 + - + + + 
54 15G NS02009289 1 + - + + + 
55 17A NS02010352 1 + - - + + 
56 17D NS02010642 1A + - + + + 
57 17G NS02011108 1A + - - - - 
58 17H NS02011344 1 + - + + + 
59 18A NS02011372 1A + + + + + 
60 18B NS02011466 2A + - - - - 
61 18D NS02011761 1B + - - + + 
62 18G NS02012156 1 + - + + + 
63 19D NS02012797 1 + - + + + 
64 19E NS02012798 2 + - + + + 
65 19G NS02013296 3C + - + + + 
66 20C NS02013666 3O + - - + + 
67 20F NS02013948 1C + - +ε - - 
68 20G NS02014046 1D + - - + + 
69 20H NS02014101 1A + - +ε - - 
70 21B NS02014416 2B + - + + + 
71 21D NS02014490 1A + - - - - 
72 22A NS02015366 1B + - + + + 
73 22C NS02016061 1 + - - + + 
74 22D NS02016362 2A + - + + + 
75 23C NS02017642 5Q + - - - - 
76 23D NS02017902 1 + - + + + 
77 23E NS02017946 2F + - + + + 
78 23F NS02018053 1 + - + + + 
79 24A NS02018494 1A + - - - - 
80 24B NS02018494 1B + - + + + 
         
  PCR positive (%): 80 (100.0) 1 (1.3) 56 (70.0) 67 (83.8) 67 (83.8) 
  PCR negative (%): 0 (0.0) 79 (98.7) 24 (30.0) 13 (16.2) 13 (16.2) 
  Total samples: 80 80 80 80 80 
 
 
Note: +   Positive  PCR and  -   Negative PCR; ε - False positive PCR 
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DNA sequencing and multiple sequences alignment results (Benign)  
 
    Pathology code Block Expected amplicon PCR purification HPV identification 
No. Plate   size (bp) methodsα  
1 1C NS01017677 2 140 Gel HPV 16 
2 1G NS01018047 1 140 Gel HPV 6 
3 2B NS01018532 1 140 Gel HPV 16 
4 2C NS01018560 1 190 PCR HPV 16 
5 2E NS02000314 2 190 PCR HPV 16 
6 2G NS02000370 1 140 Gel HPV 16 
7 3A NS02000961 1 190 Gel HPV 113 
8 7A NS02001288 1 190 PCR HPV 6 
9 7B NS02001290 1 140 Gel HPV 6 
10 7F NS02001647 1 140 PCR HPV 6 
11 7G NS02001832 1 140 Gel HPV 16 
12 8B NS02001967 1 140 Gel HPV 6 
13 8C NS02001970 1 140 Gel HPV 6 
14 8H NS02002359 1 140 Gel HPV 6 
15 9B NS02002905 1 140 Gel HPV 6 
16 9C NS02002906 1 140 Gel HPV 6 
17 9E NS02003306 1A 140 Gel HPV 6 
18 9F NS02003307 1B 140 Gel HPV 6 
19 10D NS02003712 1 190 Gel HPV 6 
20 10E NS02003914 1 190 PCR HPV 16 
21 10G NS02004435 1 140 Gel HPV 6 
22 11E NS02005343 1 190 PCR HPV 6 
23 12B NS02006000 1A 140 Gel HPV 6 
24 14B NS02007115 1 190 Gel HPV 33 
25 14D NS02007455 1B 190 PCR HPV 6 
26 14G NS02007665 1 190 PCR HPV 6 
27 15F NS02008759 1 190 PCR HPV 6 
28 16F NS02010172 2 140 Gel HPV 6 
29 17C NS02010583 1 140 Gel HPV 6 
30 19F NS02013040 1 140 Gel HPV 6 
31 20A NS02013634 1B 140 Gel HPV 6 
32 20B NS02013654 1 190 Gel HPV 100 
33 20D NS02013773 1 140 Gel HPV 6 
34 20E NS02013919 1 140 PCR HPV 6 
35 21A NS02014375 1 140 Gel HPV 6 
36 21C NS02014462 1 140 Gel HPV 18 
37 21E NS02014538 1 140 Gel HPV 6 
38 21H NS02015136 1 140 PCR HPV 6 
39 22F NS02017209 1 140 Gel HPV 18 
40 22G NS02017309 1A 190 Gel HPV 18 
41 23G NS02018054 1 140 Gel HPV 18 
42 23H NS02018368 4F 140 Gel HPV 6 
43 11H NS02005568 1 140 Gel HPV 18 
44 1A NS01006314 1 140 PCR Negative 
45 1D NS01017679 1 140 PCR Negative 
46 1E NS01017750 1 190 PCR Negative 
47 2H NS02000373 1 140 PCR Negative 
48 6H NS01001286 1B 190 PCR Negative 
49 7D NS02001294 1 140 Gel Negative 
50 10A NS02003610 1 140 Gel Negative 
51 10C NS02003710 1 190 Gel Negative 
52 11A NS02004521 1 140 PCR Negative 
53 11G NS02005565 1 140 PCR Negative 
54 12E NS02006074 1 140 Gel Negative 
55 15B NS02007899 1 140 PCR Negative 
56 16A NS02009378 1 140 Gel Negative 
57 16B NS02009385 1 140 Gel Negative 
58 16C NS02009890 1 140 PCR Negative 
59 17E NS02010835 1 190 PCR Negative 
60 21F NS02014854 1 190 PCR Negative 
61 23A NS02017375 2 140 Gel Negative 
Notes: 
 
α -  PCR product purification methods: PCR - QIAquick PCR Purification Kit (Qiagen); Gel - QIAquick Gel Extraction Kit (Qiagen) 
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DNA sequencing and multiple sequences alignment results (Dysplasia)  
 
    Pathology code Block Expected amplicon PCR purification HPV identification 
No. Plate   size (bp) methodsα  
1 14H NS02007740 1 450 Gel HPV 100 
2 18H NS02012233 1 140 Gel HPV 6 
3 19H NS02013597 1 140 Gel HPV 6 
4 21G NS02014921 1 190 PCR HPV 16 
5 22H NS02017374 1 190 Gel HPV 100 
6 8A NS02001962 1D 190 Gel Negative 
7 9A NS02002447 1 140 PCR Negative 
8 13H NS02007111 1A 140 PCR Negative 
9 22B NS02015903 1 190 PCR Negative 
 
Notes: 
 
α - PCR product purification methods: PCR - QIAquick PCR Purification Kit (Qiagen); Gel - QIAquick Gel Extraction Kit (Qiagen) 
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DNA sequencing and multiple sequences alignment results (Carcinoma)  
 
    Pathology code Block Expected amplicon PCR purification HPV identification 
No. Plate   size (bp) methodsα  
1 1F NS01017826 4D 140 Gel HPV 6 
2 2F NS02000316 7C 190 PCR HPV 16 
3 3B NS02001012 1A 140 Gel HPV 6 
4 3C NS02001012 1B 140 Gel HPV 16 
5 3D NS02001012 1C 140 PCR HPV 6 
6 3E NS02001012 1D 140 Gel HPV 6 
7 3F NS02001012 1E 190 PCR HPV 16 
8 3G NS02001012 1F 190 PCR HPV 16 
9 3H NS02001012 1G 140 Gel HPV 16 
10 4A NS02001012 1H 140 Gel HPV 16 
11 4B NS02001012 1I 140 Gel HPV 16 
12 4C NS02001012 1J 190 PCR HPV 16 
13 4D NS02001012 1K 190 PCR HPV 16 
14 4E NS02001012 1L 190 PCR HPV 16 
15 5A NS02001012 1P 140 Gel HPV 109 
16 5D NS02001012 2C 140 Gel HPV 103 
17 5F NS02001012 2E 140 Gel HPV 6 
18 5G NS02001012 2F 140 Gel HPV 6 
19 8D NS02002097 1 140 Gel HPV 6 
20 8F NS02002098 2 140 Gel HPV 6 
21 8G NS02002185 1 140 Gel HPV 6 
22 11C NS02005157 1 140 Gel HPV 6 
23 11D NS02005229 3B 140 Gel HPV 18 
24 11F NS02005525 1C 140 Gel HPV 6 
25 13D NS02006728 3 190 Gel HPV 64 
26 14C NS02007236 1C 190 PCR HPV 6 
27 15E NS02008741 1 140 Gel HPV 6 
28 15G NS02009289 1 190 PCR HPV 6 
29 17H NS02011344 1 140 Gel HPV 6 
30 18A NS02011372 1A 450 Gel HPV 100 
31 18D NS02011761 1B 140 PCR HPV 6 
32 19D NS02012797 1 140 Gel HPV 6 
33 19E NS02012798 2 190 Gel HPV 100 
34 19G NS02013296 3C 140 Gel HPV 6 
35 20C NS02013666 3O 140 Gel HPV 18 
36 20G NS02014046 1D 140 PCR HPV 18 
37 21B NS02014416 2B 140 Gel HPV 6 
38 22A NS02015366 1B 190 PCR HPV 6 
39 23D NS02017902 1 140 Gel HPV 6 
40 23E NS02017946 2F 190 PCR HPV 6 
41 23F NS02018053 1 140 Gel HPV 6 
42 24B NS02018494 1B 140 Gel HPV 6 
43 13A NS02006419 1A 140 Gel Negative 
44 4F NS02001012 1M 140 Gel Negative 
45 4G NS02001012 1N 140 PCR Negative 
46 5B NS02001012 2A 140 PCR Negative 
47 5C NS02001012 2B 190 PCR Negative 
48 5E NS02001012 2D 140 PCR Negative 
49 5H NS02001012 2G 140 Gel Negative 
50 6A NS02001012 2H 140 Gel Negative 
51 6B NS02001012 2I 140 Gel Negative 
52 6C NS02001012 2J 140 Gel Negative 
53 8E NS02002098 1 140 Gel Negative 
54 9D NS02003275 3J 140 PCR Negative 
55 9H NS02003552 3A 140 PCR Negative 
56 10H NS02004442 3B 140 PCR Negative 
57 12A NS02005642 1B 140 PCR Negative 
58 12F NS02006089 1 140 PCR Negative 
59 13C NS02006721 1B 140 Gel Negative 
60 13G NS02007068 3A 190 Gel Negative 
61 14A NS02007112 1A 140 PCR Negative 
62 15C NS02008161 1A 140 Gel Negative 
63 17A NS02010352 1 140 Gel Negative 
64 17D NS02010642 1A 140 Gel Negative 
65 18G NS02012156 1 190 Gel Negative 
66 22C NS02016061 1 140 Gel Negative 
67 22D NS02016362 2A 140 Gel Negative 
Notes: 
 
a - PCR product purification methods: PCR - QIAquick PCR Purification Kit (Qiagen); Gel - QIAquick Gel Extraction Kit (Qiagen) 
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Table A: ANOVA and Independent-samples t-Test for means comparison 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Amplicon size 
DNA Purification Kits 
 
 
0.028 
0.000 
 
ANOVA 
t-Test 
 
 
0.241 
0.384 
 
0.045 
0.000 
 
ANOVA  
t-Test 
 
0.263 
0.000** 
 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
** Statistically significant at the 0.01 level and * at the 0.05 level;  
DNA yield of 140bp > 450 bp (p<0.01) and190bp > 450 bp (p<0.01) and   
QIAquick PCR Purification > QIAquick Gel Extraction (p<0.001) 
 
 
Table B: Kruskal-Wallis and Mann-Whitney Tests 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Amplicon size 
DNA Purification Kits 
 
 
Kruskal-Wallis 
Mann-Whitney 
 
 
0.075 
0.022* 
 
 
Kruskal-Wallis 
Mann-Whitney  
 
0.020* 
0.000** 
 
Notes:  
α -  Test for Equality of Means 
Cases less than two were excluded from Kruskal-Wallis Test 
** Statistically significant at the 0.01 level and * at the 0.05 level; 
DNA yield of 140bp > 450 bp (p<0.05), 190bp > 450 bp (p<0.05) and QIAquick PCR kits > QIAquick Gel 
kits (p<0.001) 
DNA purity of QIAquick PCR kits > QIAquick Gel kits (p<0.05)  
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Table A: Means comparison of the purified amplicons and kit used in benign samples  
 
Parameters 
 
N 
Mean + SD 
DNA purity  
(A260/A280) 
DNA yield  
(ng/µl) 
 
Amplicon size (N = 61) 
   140 bp 
   190 bp 
    
PCR Purification Kits (N = 61)  
   QIAquick PCR Purification 
   QIAquick Gel Extraction 
 
 
 
43 
18 
 
 
22 
39 
 
 
 
1.744 + 0.312 
1.831 + 0.150α 
 
 
1.808 + 0.131a 
1.748 + 0.331 
 
 
30.16 + 39.02 
46.40 + 40.86 
 
 
78.48 + 37.55a 
10.39 + 4.77 
 
 Note: N, number of amplicons; SD, standard deviation; α - Normal distribution data is assumed 
 
Table B: Independent-samples t-Test for means comparison (Benign) 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Amplicon size 
DNA Purification Kits 
 
 
0.028 
0.004 
 
t-Test 
t-Test 
 
 
0.262 
0.417 
 
0.830 
0.000 
 
t-Test  
t-Test 
 
0.149 
0.000** 
 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
** Statistically significant at the 0.01 level and * at the 0.05 level;  
DNA yield of 140bp > 450 bp (p<0.01) and190bp > 450 bp (p<0.01) and   
QIAquick PCR Purification > QIAquick Gel Extraction (p<0.001) 
 
Table C: Mann-Whitney Test for means comparison (Benign) 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Amplicon size 
DNA Purification Kits 
 
 
Mann-Whitney 
Mann-Whitney 
 
 
0.074 
0.084 
 
 
Mann-Whitney 
Mann-Whitney  
 
0.022* 
0.000** 
 
Notes:  
α - Test for Equality of Means 
Cases less than two were excluded from Kruskal-Wallis Test 
** Statistically significant at the 0.01 level and * at the 0.05 level; 
190bp > 140 bp in DNA yield (p<0.05)  
DNA yield of QIAquick PCR kits > QIAquick Gel kits (p<0.01)  
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Table A: Means comparison of the purified amplicons and kit used in dysplasia samples 
  
 
Parameters 
 
N 
Mean + SD 
DNA purity  
(A260/A280) 
DNA yield  
(ng/µl) 
 
Amplicon size (N = 9) 
   140 bp 
   190 bp 
   450 bp 
 
PCR Purification Kits (N = 9)  
   QIAquick PCR Purification 
   QIAquick Gel Extraction 
 
 
 
4 
4 
1 
 
 
4 
5 
 
 
 
1.819 + 0.502 
1.792 + 0.391α 
1.740 
 
 
1.884 + 0.531a 
1.625 + 0.364 
 
 
51.75 + 48.99 
35.34 + 31.90 
13.83 
 
 
76.34 + 26.96a 
11.37 + 2.04 
 
 Note: N, number of amplicons; SD, standard deviation; α Normal distribution data is assumed 
 
Table B: ANOVA and Independent-samples t-Test for means comparison (Dysplasia) 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Amplicon size 
DNA Purification Kits 
 
 
0.688 
0.757 
 
ANOVA 
t-Test 
 
 
0.505 
0.413 
 
0.094 
0.050 
 
ANOVA  
t-Test 
 
0.695 
0.001** 
 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
** Statistically significant at the 0.01 level and * at the 0.05 level;  
DNA yield of QIAquick PCR Purification > QIAquick Gel Extraction (p<0.001) 
 
Table C: Kruskal-Wallis and Mann-Whitney Tests (Dysplasia) 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Amplicon size 
DNA Purification Kits 
 
 
Kruskal-Wallis 
Mann-Whitney 
 
 
0.291 
0.556 
 
 
Kruskal-Wallis 
Mann-Whitney  
 
0.967 
0.016** 
 
Notes:  
α -  Test for Equality of Means 
Cases less than two were excluded from Kruskal-Wallis Test 
** Statistically significant at the 0.01 level and * at the 0.05 level; 
DNA yield of QIAquick PCR kits > QIAquick Gel kits (p<0.05) 
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Table A: Means comparison of the purified amplicons and kit used in carcinoma samples  
 
Parameters 
 
N 
Mean + SD 
DNA purity  
(A260/A280) 
DNA yield  
(ng/µl) 
 
Amplicon size (N = 67) 
   140 bp 
   190 bp 
   450 bp 
 
PCR Purification Kits (N = 67)  
   QIAquick PCR Purification 
   QIAquick Gel Extraction 
 
 
 
51 
15 
1 
 
 
23 
44 
 
 
 
1.809 + 0.404 
1.742 + 0.157α 
1.575 
 
 
1.800 + 0.130a 
1.786 + 0.437 
 
 
35.29 + 40.60 
44.13 + 28.24 
8.30 
 
 
79.06 + 34.31a 
14.81 + 12.82 
 
 Note: N, number of amplicons; SD, standard deviation; α Normal distribution data is assumed 
 
Table B: ANOVA and Independent-samples t-Test for means comparison (Carcinoma) 
 
 
 
Parameter 
 
DNA purity DNA yield 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
Levene 
statisticsα 
(sig.) 
 
Testβ 
 
Sig.  
(2-tailed) 
 
Amplicon size 
DNA Purification Kits 
 
 
0.037 
0.001 
 
ANOVA 
t-Test 
 
 
0.689 
0.877 
 
0.101 
0.000 
 
ANOVA  
t-Test 
 
0.556 
0.000** 
 
Notes:  
α - Levene’s Test for Equality of Variances 
β - Test for Equality of Means 
** Statistically significant at the 0.01 level and * at the 0.05 level;  
DNA yield of QIAquick PCR Purification > QIAquick Gel Extraction (p<0.001) 
 
Table C: Kruskal-Wallis and Mann-Whitney Tests (Carcinoma) 
 
 
 
Parameter 
DNA purity DNA yield 
 
Testα 
Asymp. 
sig. 
 
Testα 
Asymp. 
sig. 
 
Amplicon size 
DNA Purification Kits 
 
 
Kruskal-Wallis 
Mann-Whitney 
 
 
0.646 
0.168 
 
 
Kruskal-Wallis 
Mann-Whitney  
 
0.124 
0.000** 
 
Notes:  
α -  Test for Equality of Means 
Cases less than two were excluded from Kruskal-Wallis Test 
** Statistically significant at the 0.01 level and * at the 0.05 level; 
DNA yield of QIAquick PCR kits > QIAquick Gel kits (p<0.001)  
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Table A: Crosstabs with Chi-square and Phi Analyses of HPV positivity among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
HPV detection  
χ2 
 
p value 
 
N 
HPV detection  
χ2 
 
p value 
 
n 
HPV detection  
χ2 
 
p value positive negative positive negative positive negative 
                  
Gender 
   Female 
   Male 
Total 
 
45 
39 
84 
 
24 
19 
43 
 
21 
20 
41 
0.178 
 
 
df=1 
0.673 
 
 
Φ=(0.046) 
 
5 
7 
12 
 
1 
4 
5 
 
4 
3 
7 
1.656 
 
 
df=1 
0.198α 
 
 
Φ=0.371 
 
49 
31 
80 
 
27 
15 
42 
 
22 
16 
38 
0.343 
 
 
df=1 
0.558 
 
 
Φ=(0.066) 
 
Age group 
   16-57y 
   58-99y 
Total 
 
 
52 
32 
84 
 
 
26 
17 
43 
 
 
26 
15 
41 
 
0.077 
 
 
df=1 
 
0.781 
 
 
Φ=0.030 
 
 
2 
10 
12 
 
 
2 
3 
5 
 
 
0 
7 
7 
 
3.360 
 
 
df=1 
 
0.067α 
 
 
Φ=(0.529) 
 
 
38 
42 
80 
 
 
21 
21 
42 
 
 
17 
21 
38 
 
0.222 
 
 
df=1 
 
0.638 
 
 
Φ=(0.053) 
 
Disease outcome 
   Alive 
   Dead 
Total 
           
 
35 
45 
80 
 
 
18 
24 
42 
 
 
17 
21 
38 
 
0.029 
 
 
df=1 
 
0.866 
 
 
Φ=0.019 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
84 
0 
84 
 
 
43 
0 
43 
 
 
41 
0 
41 
 
N/A 
 
N/A 
 
 
12 
0 
12 
 
 
5 
0 
5 
 
 
7 
0 
7 
 
N/A 
 
N/A 
 
 
75 
5 
80 
 
 
40 
2 
42 
 
 
35 
3 
38 
 
0.334 
 
 
df=1 
 
0.563 
 
 
Φ=(0.065) 
 
DNA purity 
   < 1.043 
   1.043 and above 
Total 
 
 
45 
39 
84 
 
 
24 
19 
43 
 
 
21 
20 
41 
 
0.178 
 
 
df=1 
 
0.673 
 
 
Φ=(0.046) 
 
 
9 
3 
12 
 
 
4 
1 
5 
 
 
5 
2 
7 
 
0.114 
 
 
df=1 
 
0.735α 
 
 
Φ=(0.098) 
 
 
29 
51 
80 
 
 
13 
29 
42 
 
 
16 
22 
38 
 
1.074 
 
 
df=1 
 
0.300 
 
 
Φ=0.116 
 
DNA yield 
   < 0.074 µg/µl 
   0.074 and above 
Total 
 
 
 
45 
39 
84 
 
 
18 
25 
43 
 
 
27 
14 
41 
 
4.858* 
 
 
df=1 
 
 
0.028 
 
 
Φ=(0.240) 
 
 
6 
6 
12 
 
 
2 
3 
5 
 
 
4 
3 
7 
 
0.343 
 
 
df=1 
 
0.558α 
 
 
Φ=0.169 
 
 
40 
40 
80 
 
 
23 
19 
42 
 
 
17 
21 
38 
 
0.802 
 
 
df=1 
 
0.370 
 
 
Φ=(0.100) 
Note:  α  generated from Fisher’s Exact Test;  Φ in parentheses to denote negative value 
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Table B: Crosstabs with Chi-square and Cramer’s V analyses of HPV positivity among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
HPV detection  
χ2 
 
p value 
 
N 
HPV detection  
χ2 
 
p value 
 
n 
HPV detection  
χ2 
 
p value positive negative positive negative positive negative 
                  
Anatomic site 
   Tongue 
   Floor of the mouth 
   Soft palate 
   Retromolar pad 
   Lower lip 
   Buccal mucosa 
   Gingivae 
   Hard palate 
   Upper lip 
   Skin 
    
Total 
 
21 
3 
3 
1 
4 
41 
6 
2 
2 
1 
 
84 
 
11 
1 
2 
1 
2 
23 
2 
0 
1 
0 
 
43 
 
10 
2 
1 
0 
2 
18 
4 
2 
1 
1 
 
41 
5.946 
 
 
 
 
 
 
 
 
 
 
 
df=9 
0.745 
 
 
 
 
 
 
 
 
 
 
 
CV=0.266α 
 
- 
8 
2 
- 
- 
1 
- 
1 
- 
- 
 
12 
 
- 
3 
1 
- 
- 
1 
- 
0 
- 
- 
 
5 
 
- 
5 
1 
- 
- 
0 
- 
1 
- 
- 
 
7 
2.229 
 
 
 
 
 
 
 
 
 
 
 
df=3 
0.526 
 
 
 
 
 
 
 
 
 
 
 
CV=0.431α 
 
20 
12 
34 
3 
4 
3 
4 
- 
- 
- 
 
80 
 
8 
8 
19 
0 
2 
2 
3 
- 
- 
- 
 
42 
 
12 
4 
15 
3 
2 
1 
1 
- 
- 
- 
 
38 
6.754 
 
 
 
 
 
 
 
 
 
 
 
df=6 
0.344 
 
 
 
 
 
 
 
 
 
 
 
CV=0.291α 
 
Tumour size 
   T1 
   T2 
   T3 
   T4 
Total 
           
 
41 
22 
13 
4 
80 
 
 
22 
8 
9 
3 
42 
 
 
19 
14 
4 
1 
38 
 
4.590 
 
 
 
 
df=3 
 
0.204 
 
 
 
 
CV=0.240α 
 
Regional lymph nodes 
   N0 
   N1 
   N2 
Total 
           
 
67 
7 
6 
80 
 
 
33 
4 
5 
42 
 
 
34 
3 
1 
38 
 
2.631 
 
 
 
df=2 
 
0.268 
 
 
 
CV=0.181α 
 
Differentiation 
   Basal 
   Poor 
   Moderate 
   Well 
Total 
 
           
 
2 
11 
58 
9 
80 
 
 
1 
9 
30 
2 
42 
 
 
1 
2 
28 
7 
38 
 
7.119 
 
 
 
 
df=3 
 
0.068 
 
 
 
 
CV=0.298α 
Note:  α  generated from Cramer’s V Test
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Table A: Crosstabs with Chi-square and Phi Analyses of alpha HPV among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
alpha HPV detection  
χ2 
 
p value 
 
N 
alpha HPV detection  
χ2 
 
p value 
 
n 
alpha HPV detection  
χ2 
 
p value Positive Negative positive Negative positive negative 
                  
Gender 
   Female 
   Male 
Total 
 
45 
39 
84 
 
22 
18 
40 
 
23 
21 
44 
0.063 
 
 
df=1 
0.802 
 
 
Φ=(0.027) 
 
5 
7 
12 
 
0 
3 
3 
 
5 
4 
9 
2.857 
 
 
df=1 
0.091α 
 
 
Φ=0.488 
 
49 
31 
80 
 
24 
13 
37 
 
25 
18 
43 
0.379 
 
 
df=1 
0.538 
 
 
Φ=(0.069) 
 
Age group 
   16-57y 
   58-99y 
Total 
 
 
52 
32 
84 
 
 
23 
17 
40 
 
 
29 
15 
44 
 
0.628 
 
 
df=1 
 
0.428 
 
 
Φ=0.086 
 
 
2 
10 
12 
 
 
1 
2 
3 
 
 
1 
8 
9 
 
0.800 
 
 
df=1 
 
0.371α 
 
 
Φ=(0.258) 
 
 
38 
42 
80 
 
 
18 
19 
37 
 
 
20 
23 
43 
 
0.036 
 
 
df=1 
 
0.849 
 
 
Φ=(0.021) 
 
Disease outcome 
   Alive 
   Dead 
Total 
           
 
35 
45 
80 
 
 
16 
21 
37 
 
 
19 
24 
43 
 
0.007 
 
 
df=1 
 
0.932 
 
 
Φ=0.009 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
84 
0 
84 
 
 
40 
0 
40 
 
 
44 
0 
44 
 
N/A 
 
N/A 
 
 
12 
0 
12 
 
 
3 
0 
3 
 
 
9 
0 
9 
 
N/A 
 
N/A 
 
 
75 
5 
80 
 
 
35 
2 
37 
 
 
40 
3 
43 
 
0.084 
 
 
df=1 
 
0.772a 
 
 
Φ=(0.032) 
 
DNA purity 
   < 1.043 
   1.043 and above 
Total 
 
 
45 
39 
84 
 
 
22 
18 
40 
 
 
23 
21 
44 
 
0.063 
 
 
df=1 
 
0.802 
 
 
Φ=(0.027) 
 
 
9 
3 
12 
 
 
2 
1 
3 
 
 
7 
2 
9 
 
0.148 
 
 
df=1 
 
0.700α 
 
 
Φ=(0.111) 
 
 
29 
51 
80 
 
 
12 
25 
37 
 
 
17 
26 
43 
 
0.434 
 
 
df=1 
 
0.510 
 
 
Φ=0.074 
 
DNA yield 
   < 0.074 µg/µl 
   0.074 and above 
Total 
 
 
 
45 
39 
84 
 
 
17 
23 
40 
 
 
28 
16 
44 
 
3.763 
 
 
df=1 
 
 
0.052 
 
 
Φ=(0.212) 
 
 
6 
6 
12 
 
 
1 
2 
3 
 
 
5 
4 
9 
 
0.444 
 
 
df=1 
 
0.505α 
 
 
Φ=0.192 
 
 
40 
40 
80 
 
 
19 
18 
37 
 
 
21 
22 
43 
 
0.050 
 
 
df=1 
 
0.823 
 
 
Φ=(0.025) 
Note:  α  generated from Fisher’s Exact Test; Φ in parentheses to denote negative value 
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Table B: Crosstabs with Chi-square and Cramer’s V analyses of alpha HPV among clinicopathological parameters 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
alpha HPV detection  
χ2 
 
p value 
 
N 
alpha HPV detection  
χ2 
 
p value 
 
n 
alpha HPV detection  
χ2 
 
p value positive Negative positive Negative positive negative 
                  
Anatomic site 
   Tongue 
   Floor of the mouth 
   Soft palate 
   Retromolar pad 
   Lower lip 
   Buccal mucosa 
   Gingivae 
   Hard palate 
   Upper lip 
   Skin 
    
Total 
 
21 
3 
3 
1 
4 
41 
6 
2 
2 
1 
 
84 
 
9 
1 
2 
1 
2 
22 
2 
0 
1 
0 
 
40 
 
12 
2 
1 
0 
2 
19 
4 
2 
1 
1 
 
50 
5.804 
 
 
 
 
 
 
 
 
 
 
 
df=9 
0.759 
 
 
 
 
 
 
 
 
 
 
 
CV=0.263α 
 
- 
8 
2 
- 
- 
1 
- 
1 
- 
- 
 
12 
 
- 
2 
1 
- 
- 
0 
- 
0 
- 
- 
 
5 
 
- 
6 
1 
- 
- 
1 
- 
1 
- 
- 
 
7 
1.333 
 
 
 
 
 
 
 
 
 
 
 
df=3 
0.721 
 
 
 
 
 
 
 
 
 
 
 
CV=0.333α 
 
20 
12 
34 
3 
4 
3 
4 
- 
- 
- 
 
80 
 
6 
8 
16 
0 
2 
2 
3 
- 
- 
- 
 
37 
 
14 
4 
18 
3 
2 
1 
1 
- 
- 
- 
 
43 
8.583 
 
 
 
 
 
 
 
 
 
 
 
df=6 
0.198 
 
 
 
 
 
 
 
 
 
 
 
CV=0.328α 
 
Tumour size 
   T1 
   T2 
   T3 
   T4 
Total 
           
 
41 
22 
13 
4 
80 
 
 
20 
7 
7 
3 
37 
 
 
21 
15 
6 
1 
43 
 
3.581 
 
 
 
 
df=3 
 
0.310 
 
 
 
 
CV=0.212α 
 
Regional lymph nodes 
   N0 
   N1 
   N2 
Total 
           
 
67 
7 
6 
80 
 
 
28 
4 
5 
37 
 
 
39 
3 
1 
43 
 
4.189 
 
 
 
df=2 
 
0.123 
 
 
 
CV=0.229α 
 
Differentiation 
   Basal 
   Poor 
   Moderate 
   Well 
Total 
 
           
 
2 
11 
58 
9 
80 
 
 
1 
7 
27 
2 
37 
 
 
1 
4 
31 
7 
43 
 
3.441 
 
 
 
 
df=3 
 
0.328 
 
 
 
 
CV=0.207α 
Note:  α  generated from Cramer’s V Test 
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Table A: Crosstabs with Chi-square and Phi Analyses of Low risk α-HPV among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
LR α-HPV detection  
χ2 
 
p value 
 
N 
LR α-HPV detection  
χ2 
 
p value 
 
n 
LR α-HPV detection  
χ2 
 
p value Positive Negative positive Negative positive negative 
                  
Gender 
   Female 
   Male 
Total 
 
45 
39 
84 
 
14 
14 
28 
 
31 
25 
56 
0.215 
 
 
df=1 
0.643 
 
 
Φ=(0.051) 
 
5 
7 
12 
 
0 
2 
2 
 
5 
5 
10 
1.714 
 
 
df=1 
0.190α 
 
 
Φ=0.378 
 
49 
31 
80 
 
13 
11 
24 
 
36 
20 
56 
0.725 
 
 
df=1 
0.395 
 
 
Φ=(0.095) 
 
Age group 
   16-57y 
   58-99y 
Total 
 
 
52 
32 
84 
 
 
18 
10 
28 
 
 
34 
22 
56 
 
0.101 
 
 
df=1 
 
0.751 
 
 
Φ=(0.035) 
 
 
2 
10 
12 
 
 
0 
2 
2 
 
 
2 
8 
10 
 
0.480 
 
 
df=1 
 
0.488α 
 
 
Φ=(0.200) 
 
 
38 
42 
80 
 
 
8 
16 
24 
 
 
30 
26 
56 
 
2.759 
 
 
df=1 
 
0.097 
 
 
Φ=(0.186) 
 
Disease outcome 
   Alive 
   Dead 
Total 
           
 
35 
45 
80 
 
 
14 
10 
24 
 
 
21 
35 
56 
 
2.963 
 
 
df=1 
 
0.085 
 
 
Φ=(0.192) 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
84 
0 
84 
 
 
28 
0 
28 
 
 
56 
0 
56 
 
N/A 
 
N/A 
 
 
12 
0 
12 
 
 
2 
0 
2 
 
 
10 
0 
10 
 
N/A 
 
N/A 
 
 
75 
5 
80 
 
 
22 
2 
24 
 
 
53 
3 
56 
 
0.254 
 
 
df=1 
 
0.614α 
 
 
Φ=(0.056) 
 
DNA purity 
   < 1.043 
   1.043 and above 
Total 
 
 
45 
39 
84 
 
 
13 
15 
28 
 
 
32 
24 
56 
 
0.862 
 
 
df=1 
 
0.353 
 
 
Φ=(0.101) 
 
 
9 
3 
12 
 
 
1 
1 
2 
 
 
8 
2 
10 
 
0.800 
 
 
df=1 
 
0.371α 
 
 
Φ=(0.258) 
 
 
29 
51 
80 
 
 
12 
12 
24 
 
 
17 
39 
56 
 
2.805 
 
 
df=1 
 
0.094 
 
 
Φ=(0.187) 
 
DNA yield 
   < 0.074 µg/µl 
   0.074 and above 
Total 
 
 
 
45 
39 
84 
 
 
13 
15 
28 
 
 
32 
24 
56 
 
0.862 
 
 
df=1 
 
 
0.353 
 
 
Φ=(0.101) 
 
 
6 
6 
12 
 
 
1 
1 
2 
 
 
5 
5 
10 
 
0.000 
 
 
df=1 
 
1.000α 
 
 
Φ=0.000 
 
 
40 
40 
80 
 
 
11 
13 
24 
 
 
29 
27 
56 
 
0.238 
 
 
df=1 
 
0.626 
 
 
Φ=(0.055) 
Note:  α  generated from Fisher’s Exact Test; Φ in parentheses to denote negative value 
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Table B: Crosstabs with Chi-square and Cramer’s V analyses of Low risk α-HPV among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
LR α-HPV  
χ2 
 
p value 
 
N 
LR α-HPV  
χ2 
 
p value 
 
n 
LR α-HPV  
χ2 
 
p value positive Negative positive negative Positive negative 
                  
Anatomic site 
   Tongue 
   Floor of the mouth 
   Soft palate 
   Retromolar pad 
   Lower lip 
   Buccal mucosa 
   Gingivae 
   Hard palate 
   Upper lip 
   Skin 
    
Total 
 
21 
3 
3 
1 
4 
41 
6 
2 
2 
1 
 
84 
 
7 
1 
2 
1 
0 
15 
2 
0 
0 
0 
 
28 
 
14 
2 
1 
0 
4 
26 
4 
2 
2 
1 
 
56 
8.195 
 
 
 
 
 
 
 
 
 
 
 
df=9 
0.515 
 
 
 
 
 
 
 
 
 
 
 
CV=0.312α 
 
- 
8 
2 
- 
- 
1 
- 
1 
- 
- 
 
12 
 
- 
1 
1 
- 
- 
0 
- 
0 
- 
- 
 
2 
 
- 
7 
1 
- 
- 
1 
- 
1 
- 
- 
 
10 
2.100 
 
 
 
 
 
 
 
 
 
 
 
df=3 
0.552 
 
 
 
 
 
 
 
 
 
 
 
CV=0.418α 
 
20 
12 
34 
3 
4 
3 
4 
- 
- 
- 
 
80 
 
5 
6 
7 
0 
2 
2 
2 
- 
- 
- 
 
24 
 
15 
6 
27 
3 
2 
1 
2 
- 
- 
- 
 
56 
8.688 
 
 
 
 
 
 
 
 
 
 
 
df=6 
0.192 
 
 
 
 
 
 
 
 
 
 
 
CV=0.330α 
 
Tumour size 
   T1 
   T2 
   T3 
   T4 
Total 
           
 
41 
22 
13 
4 
80 
 
 
9 
6 
7 
2 
24 
 
 
32 
16 
6 
2 
56 
 
5.625 
 
 
 
 
df=3 
 
0.131 
 
 
 
 
CV=0.265α 
 
Regional lymph nodes 
   N0 
   N1 
   N2 
Total 
           
 
67 
7 
6 
80 
 
 
17 
3 
4 
24 
 
 
50 
4 
2 
56 
 
5.075 
 
 
 
df=2 
 
0.079 
 
 
 
CV=0.252α 
 
Differentiation 
   Basal 
   Poor 
   Moderate 
   Well 
Total 
           
 
2 
11 
58 
9 
80 
 
 
1 
6 
15 
2 
24 
 
 
1 
5 
43 
7 
56 
 
4.269 
 
 
 
 
df=3 
 
0.234 
 
 
 
 
CV=0.231α 
Note:  α  generated from Cramer’s V Test 
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Table A: Crosstabs with Chi-square and Phi Analyses of HR α-HPV among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
HR α-HPV  
χ2 
 
p value 
 
N 
HR α-HPV  
χ2 
 
p value 
 
n 
HR α-HPV  
χ2 
 
p value positive Negative positive negative Positive negative 
                  
Gender 
   Female 
   Male 
Total 
 
45 
39 
84 
 
8 
6 
14 
 
37 
33 
70 
0.086 
 
 
df=1 
0.769 
 
 
Φ=(0.032) 
 
5 
7 
12 
 
0 
1 
1 
 
5 
6 
11 
0.779 
 
 
df=1 
0.377α 
 
 
Φ=0.255 
 
49 
31 
80 
 
11 
2 
13 
 
38 
29 
67 
3.570 
 
 
df=1 
0.059 
 
 
Φ=(0.211) 
 
Age group 
   16-57y 
   58-99y 
Total 
 
 
52 
32 
84 
 
 
5 
9 
14 
 
 
47 
23 
70 
 
4.887* 
 
 
df=1 
 
0.027 
 
 
Φ=(0.241) 
 
 
2 
10 
12 
 
 
1 
0 
1 
 
 
1 
10 
11 
 
5.455* 
 
 
df=1 
 
0.020α 
 
 
Φ=(0.674) 
 
 
38 
42 
80 
 
 
10 
3 
13 
 
 
28 
39 
67 
 
5.389* 
 
 
df=1 
 
0.020 
 
 
Φ=(0.260) 
 
Disease outcome 
   Alive 
   Dead 
Total 
           
 
35 
45 
80 
 
 
2 
11 
13 
 
 
33 
34 
67 
 
5.075* 
 
 
df=1 
 
0.024 
 
 
Φ=(0.252) 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
84 
0 
84 
 
 
14 
0 
14 
 
 
70 
0 
70 
 
N/A 
 
N/A 
 
 
12 
0 
12 
 
 
1 
0 
1 
 
 
11 
0 
11 
 
N/A 
 
N/A 
 
 
75 
5 
80 
 
 
13 
0 
13 
 
 
62 
5 
67 
 
1.035 
 
 
df=1 
 
0.309α 
 
 
Φ=(0.114) 
 
DNA purity 
   < 1.043 
   1.043 and above 
Total 
 
 
45 
39 
84 
 
 
11 
3 
14 
 
 
34 
36 
70 
 
4.222* 
 
 
df=1 
 
0.040 
 
 
Φ=(0.224) 
 
 
9 
3 
12 
 
 
1 
0 
1 
 
 
8 
3 
11 
 
0.364 
 
 
df=1 
 
0.546α 
 
 
Φ=(0.174) 
 
 
29 
51 
80 
 
 
0 
13 
13 
 
 
29 
38 
67 
 
8.826** 
 
 
df=1 
 
0.003α 
 
 
Φ=(0.332) 
 
DNA yield 
   < 0.074 µg/µl 
   0.074 and above 
Total 
 
 
 
45 
39 
84 
 
 
4 
10 
14 
 
 
41 
29 
70 
 
4.222* 
 
 
df=1 
 
 
0.040 
 
 
Φ=(0.224) 
 
 
6 
6 
12 
 
 
0 
1 
1 
 
 
6 
5 
11 
 
1.091 
 
 
df=1 
 
0.296α 
 
 
Φ=0.302 
 
 
40 
40 
80 
 
 
8 
5 
13 
 
 
32 
35 
67 
 
0.827 
 
 
df=1 
 
0.363 
 
 
Φ=(0.102) 
Note:  α  generated from Fisher’s Exact Test; Φ in parentheses to denote negative value; * significant at the 0.05 level; ** significant at the 0.01 level 
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Table B: Crosstabs with Chi-square and Cramer’s V analyses of HR α-HPV among clinicopathological parameters 
 
 
 
Variable 
 
 
Benign (N=84) 
 
 
Dysplasia (N=12) 
 
   Carcinoma (N=80) 
 
N 
HR α-HPV  
χ2 
 
p value 
 
N 
HR α-HPV  
χ2 
 
p value 
 
N 
HR α-HPV  
χ2 
 
p value positive Negative positive negative positive negative 
                  
Anatomic site 
   Tongue 
   Floor of the mouth 
   Soft palate 
   Retromolar pad 
   Lower lip 
   Buccal mucosa 
   Gingivae 
   Hard palate 
   Upper lip 
   Skin 
    
Total 
 
21 
3 
3 
1 
4 
41 
6 
2 
2 
1 
 
84 
 
2 
0 
0 
0 
2 
8 
1 
0 
1 
0 
 
14 
 
19 
3 
3 
1 
2 
33 
5 
2 
1 
1 
 
70 
7.810 
 
 
 
 
 
 
 
 
 
 
 
df=9 
0.553 
 
 
 
 
 
 
 
 
 
 
 
CV=0.305α 
 
- 
8 
2 
- 
- 
1 
- 
1 
- 
- 
 
12 
 
- 
1 
0 
- 
- 
0 
- 
0 
- 
- 
 
1 
 
- 
7 
2 
- 
- 
1 
- 
1 
- 
- 
 
11 
0.545 
 
 
 
 
 
 
 
 
 
 
 
df=3 
0.909 
 
 
 
 
 
 
 
 
 
 
 
CV=0.213α 
 
20 
12 
34 
3 
4 
3 
4 
- 
- 
- 
 
80 
 
1 
2 
9 
0 
0 
0 
1 
- 
- 
- 
 
13 
 
19 
10 
25 
3 
4 
3 
3 
- 
- 
- 
 
67 
6.637 
 
 
 
 
 
 
 
 
 
 
 
df=6 
0.356 
 
 
 
 
 
 
 
 
 
 
 
CV=0.288α 
 
Tumour size 
   T1 
   T2 
   T3 
   T4 
Total 
           
 
41 
22 
13 
4 
80 
 
 
11 
1 
0 
1 
13 
 
 
30 
21 
13 
3 
67 
 
8.334* 
 
 
 
 
df=3 
 
0.040 
 
 
 
 
CV=0.323α 
 
Regional lymph nodes 
   N0 
   N1 
   N2 
Total 
           
 
67 
7 
6 
80 
 
 
11 
1 
1 
13 
 
 
56 
6 
5 
67 
 
0.022 
 
 
 
df=2 
 
0.989 
 
 
 
CV=0.017α 
 
Differentiation 
   Basal 
   Poor 
   Moderate 
   Well 
Total 
           
 
2 
11 
58 
9 
80 
 
 
0 
1 
12 
0 
13 
 
 
2 
10 
46 
9 
67 
 
3.389 
 
 
 
 
df=3 
 
0.335 
 
 
 
 
CV=0.206α 
Note:  α  generated from Cramer’s V Test; * significant at the 0.05 level; ** significant at the 0.01 level
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Table A: Pearson’s correlation between clinical parameters and HPV status in benign 
 
Clinical parameters 
 
HPV positivity (N=84) 
 
HPV α-HPV LR α-HPV HR α-HPV 
r Sig. r Sig. r Sig. r Sig. 
 
Gender 
 
 
-0.046 
 
0.677 
 
-0.027 
 
0.805 
 
0.051 
 
0.647 
 
-0.032 
 
0.772 
 
Age group 0.030 0.784 0.086 0.434 -0.035 0.754 0.241* 0.027 
 
Anatomic site -0.017 0.878 -0.069 0.533 -0.048 0.662 0.068 0.537 
 
DNA purity -0.046 0.677 -0.027 0.805 0.101 0.359 -0.224* 0.040 
 
DNA yield 0.240* 0.028 0.212 0.053 0.101 0.359 0.224* 0.040 
 
Note:  * significant at the 0.05 level 
 
Table B: Spearman’s correlation between clinical parameters and HPV status in benign 
 
Clinical parameters 
 
HPV positivity (N=84) 
 
HPV α-HPV LR α-HPV HR α-HPV 
rho Sig. rho Sig. rho Sig. rho Sig. 
 
Gender 
 
 
-0.046 
 
0.677 
 
-0.027 
 
0.805 
 
0.051 
 
0.647 
 
-0.032 
 
0.772 
 
Age group 0.030 0.784 0.086 0.434 -0.035 0.754 0.241* 0.027 
 
Anatomic site -0.050 0.654 -0.093 0.398 -0.055 0.621 0.079 0.474 
 
DNA purity -0.046 0.677 -0.027 0.805 0.101 0.359 -0.224* 0.040 
 
DNA yield 0.240* 0.028 0.212 0.053 0.101 0.359 0.224* 0.040 
 
Note:  * significant at the 0.05 level 
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Table A: Pearson’s correlation between clinical parameters and HPV status in dysplasia 
 
Clinical parameters 
 
HPV positivity (N=12) 
 
HPV α-HPV LR α-HPV HR α-HPV 
r Sig. r Sig. r Sig. r Sig. 
 
Gender 
 
 
0.371 
 
0.235 
 
0.488 
 
0.108 
 
0.378 
 
0.226 
 
0.255 
 
0.424 
Age group -0.529 0.077 -0.258 0.418 0.200 0.533 -0.674* 0.016 
 
Anatomic site -0.123 0.702 -0.192 0.551 -0.327 0.300 -0.140 0.664 
 
DNA purity -0.098 0.763 0.111 0.731 0.258 0.418 -0.174 0.588 
 
DNA yield 0.169 0.599 0.192 0.549 0.00 1.000 0.302 0.341 
 
Note:  * significant at the 0.05 level 
 
Table B: Spearman’s correlation between clinical parameters and HPV status in dysplasia 
 
Clinical parameters 
 
HPV positivity (N=12) 
 
HPV α-HPV LR α-HPV HR α-HPV 
rho Sig. rho Sig. rho Sig. rho Sig. 
 
Gender 
 
 
0.371 
 
0.235 
 
0.488 
 
0.108 
 
0.378 
 
0.226 
 
0.255 
 
0.424 
Age group -0.529 0.077 -0.258 0.418 0.200 0.533 -0.674* 0.016 
 
Anatomic site -0.204 0.524 -0.200 0.534 0.309 0.328 0.104 0.747 
 
DNA purity -0.098 0.763 0.111 0.731 0.258 0.418 -0.174 0.588 
 
DNA yield 0.169 0.599 0.192 0.549 0.000 1.000 0.302 0.341 
 
Note:  * significant at the 0.05 level 
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Table A: Pearson’s correlation between clinical parameters and HPV status in carcinoma 
 
Clinical parameters 
 
HPV positivity (N=80) 
 
HPV α-HPV LR α-HPV HR α-HPV 
r Sig. r Sig. r Sig. r Sig. 
 
Gender 
 
 
-0.066 
 
0.564 
 
-0.069 
 
0.544 
 
0.095 
 
0.401 
 
-0.211 
 
0.060 
Age group -0.053 0.643 -0.021 0.851 0.186 0.099 -0.260* 0.020 
 
Anatomic site -0.225* 0.044 -0.279* 0.012 0.182 0.106 0.151 0.180 
 
Disease outcome 0.019 0.868 0.009 0.934 -0.192 0.087 0252* 0.024 
 
Disease status -0.065 0.569 -0.032 0.776 0.056 0.620 -0.114 0.315 
 
Tumour size 0.097 0.391 0.063 0.581 0.242* 0.030 -0.216 0.054 
 
Regional lymph nodes 0.175 0.120 0.227* 0.043 0.251* 0.025 -0.005 0.964 
 
Histological differentiation -0.250* 0.026 -0.180 0.109 -0.195 0.083 -0.001 0.990 
 
DNA purity 0.116 0.306 0.074 0.516 -0.187 0.096 0.332** 0.003 
 
DNA yield -0.100 0.377 -0.025 0.825 0.055 0.631 -0.102 0.370 
 
Note:  ** significant at the 0.01 level.  * significant at the 0.05 level 
 
Table B: Spearman’s correlation between clinical parameters and HPV status in carcinoma 
 
Clinical parameters 
 
HPV positivity (N=80) 
 
HPV α-HPV LR α-HPV HR α-HPV 
rho Sig. rho Sig. rho Sig. rho Sig. 
 
Gender 
 
 
-0.066 
 
0.564 
 
-0.069 
 
0.544 
 
0.095 
 
0.401 
 
-0.211 
 
0.060 
Age group -0.053 0.643 -0.021 0.851 0.186 0.099 -0.260* 0.020 
 
Anatomic site -0.228* 0.042 -0.283* 0.011 -0.195 0.083 0.140 0.214 
 
Disease outcome 0.019 0.868 0.009 0.934 -0.192 0.087 0252* 0.024 
 
Disease status -0.065 0.569 -0.032 0.776 0.056 0.620 -0.114 0.315 
 
Tumour size 0.055 0.628 0.017 0.880 0.231* 0.040 -0.263* 0.018 
 
Regional lymph nodes 0.156 0.166 0.212 0.060 0.238* 0.034 -0.009 0.936 
 
Histological differentiation -0.277* 0.013 -0.196 0.082 -0.200 0.075 -0.016 0.889 
 
DNA purity 0.116 0.306 0.074 0.516 -0.187 0.096 0.332** 0.003 
 
DNA yield -0.100 0.377 -0.025 0.825 0.055 0.631 -0.102 0.370 
 
Note:  ** significant at the 0.01 level.  * significant at the 0.05 level 
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Table A: Pearson’s correlation between clinical parameters and p16 status 
 
Clinical parameters 
p16 positivity 
Benign (N=82) Dysplasia (N=12) Carcinoma (N=80) 
r Sig. r Sig. r Sig. 
 
Gender 
 
 
-0.097 
 
0.388 
 
0.478 
 
0.116 
 
0.400** 
 
0.000 
Age group 
 
0.030 0.786 -0.316 0.317 0.491** 0.000 
Anatomic site 
 
-0.103 0.355 0.047 0.885 0.202 0.072 
Disease outcome 
 
- - - - 0.149 0.187 
Disease status 
 
- - - - -0.451** 0.000 
Tumour size 
 
- - - - 0.416** 0.000 
Regional lymph nodes 
 
- - - - 0.206 0.066 
Histological grade 
 
- - - - -0.025 0.829 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
 
Table B: Spearman’s correlation between clinical parameters and p16 status 
 
Clinical parameters 
p16 positivity 
Benign (N=84) Dysplasia (N=12) Carcinoma (N=80) 
rho Sig. rho Sig. rho Sig. 
 
Gender 
 
 
-0.097 
 
0.388 
 
0.478 
 
0.116 
 
0.334** 
 
0.002 
Age group 
 
0.030 0.786 -0.316 0.317 0.463** 0.000 
Anatomic site 
 
-0.121 0.281 -0.031 0.925 0.130 0.252 
Disease outcome 
 
- - - - 0.129 0.254 
Disease status 
 
- - - - -0.441** 0.000 
Tumour size 
 
- - - - 0.461** 0.000 
Regional lymph nodes 
 
- - - - 0.219 0.051 
Histological grade 
 
- - - - 0.016 0.891 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table A: Pearson’s correlation between clinical parameters and p16 staining status 
 
Clinical parameters 
p16 staining intensity 
Benign (N=82) Dysplasia (N=12) Carcinoma (N=80) 
r Sig. r Sig. r Sig. 
 
Gender 
 
 
-0.095 
 
0.395 
 
0.439 
 
0.154 
 
0.359** 
 
0.001 
Age group 
 
-0.001 0.994 -0.073 0.823 0.524** 0.000 
Anatomic site 
 
-0.057 0.609 0.237 0.459 0.242* 0.031 
Disease outcome 
 
- - - - 0.217 0.053 
Disease status 
 
- - - - -0.448** 0.000 
Tumour size 
 
- - - - 0.471** 0.000 
Regional lymph nodes 
 
- - - - 0.059 0.602 
Histological grade 
 
- - - - -0.079 0.489 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
 
Table B: Spearman’s correlation between clinical parameters and p16 status 
 
Clinical parameters 
p16 staining intensity 
Benign (N=82) Dysplasia (N=12) Carcinoma (N=80) 
rho Sig. rho Sig. rho Sig. 
 
Gender 
 
 
-0.098 
 
0.383 
 
0.427 
 
0.167 
 
0.359** 
 
0.001 
Age group 
 
0.007 0.947 -0.035 0.913 0.520** 0.000 
Anatomic site 
 
-0.089 0.426 0.164 0.611 0.190 0.092 
Disease outcome 
 
- - - - 0.222* 0.048 
Disease status 
 
- - - - -0.440** 0.000 
Tumour size 
 
- - - - 0.544** 0.000 
Regional lymph nodes 
 
- - - - 0.061 0.594 
Histological grade 
 
- - - - -0.103 0.364 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table A: Crosstabs with Chi-square test of HPV status among clinicopathological parameters 
 
Parameters 
 
N 
 
Overall HPV  
 
χ2 
 
p value 
 
N 
 
 α-HPV 
 
χ2 
 
p value 
 negative positive negative positive 
             
Gender 
   Female 
   Male 
Total 
 
76 
64 
140 
 
31 
27 
58 
 
45 
37 
82 
0.028 
 
 
 
0.867 
 
 
 
 
76 
64 
140 
 
37 
32 
69 
 
39 
32 
71 
0.024 
 
 
 
0.877 
 
 
 
 
Age group 
   36-64y 
   65-99y 
Total 
 
 
75 
65 
140 
 
 
33 
25 
58 
 
 
42 
40 
82 
 
0.440 
 
 
 
 
0.507 
 
 
 
 
 
75 
65 
140 
 
 
37 
32 
69 
 
 
38 
33 
71 
 
0.000 
 
 
 
 
0.990 
 
 
 
 
Disease outcome 
   Alive 
   Dead 
Total 
 
 
81 
59 
140 
 
 
35 
23 
58 
 
 
46 
36 
82 
 
0.251 
 
0.616 
 
 
81 
59 
140 
 
 
 
40 
29 
69 
 
 
41 
30 
71 
 
0.001 
 
0.979 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
129 
11 
140 
 
 
54 
4 
58 
 
 
75 
7 
82 
 
0.126 
 
0.722 
 
 
129 
11 
140 
 
 
65 
4 
69 
 
 
64 
7 
71 
 
0.798 
 
0.372 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table A: Crosstabs with Chi-square test of HPV status among clinicopathological parameters 
 
Parameters 
 
N 
 
HR- HPV  
 
χ2 
 
p value 
 
N 
 
 LR-HPV 
 
χ2 
 
p value 
 
N 
 
HPV16 
 
χ2 
 
p value 
 negative positive negative positive negative positive 
                  
Gender 
   Female 
   Male 
Total 
 
76 
64 
140 
 
60 
56 
116 
 
16 
8 
24 
1.789 
 
 
 
0.181 
 
 
 
 
76 
64 
140 
 
46 
36 
82 
 
30 
28 
58 
0.262 
 
 
 
0.609 
 
 
 
 
76 
64 
140 
 
62 
61 
123 
 
14 
3 
17 
6.142* 
 
 
 
0.013 
 
 
 
 
 
Age group 
   36-64y 
   65-99y 
Total 
 
 
75 
65 
140 
 
 
59 
57 
116 
 
 
16 
8 
24 
 
1.997 
 
 
 
 
0.158 
 
 
 
 
 
75 
65 
140 
 
 
50 
32 
82 
 
 
25 
33 
58 
 
4.363* 
 
 
 
 
0.037 
 
 
 
 
 
75 
65 
140 
 
 
63 
60 
123 
 
 
12 
5 
17 
 
2.253 
 
 
 
 
0.133 
 
 
 
 
 
Disease outcome 
   Alive 
   Dead 
Total 
 
 
81 
59 
140 
 
 
62 
54 
116 
 
 
19 
5 
24 
 
5.394* 
 
0.020 
 
 
81 
59 
140 
 
 
 
50 
32 
82 
 
 
31 
27 
58 
 
0.789 
 
0.374 
 
 
81 
59 
140 
 
 
66 
57 
123 
 
 
15 
2 
17 
 
7.323** 
 
 
 
 
0.007 
 
 
 
 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
129 
11 
140 
 
 
107 
9 
116 
 
 
22 
2 
24 
 
0.009 
 
0.924 
 
 
129 
11 
140 
 
 
78 
4 
82 
 
 
51 
7 
58 
 
2.426 
 
0.119 
 
 
129 
11 
140 
 
 
114 
9 
123 
 
 
15 
2 
17 
 
0.408 
 
 
 
 
0.523 
 
 
 
 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table B: Crosstabs with Chi-square and Cramer’s V tests of p16 status among clinicopathological parameters 
 
Parameters 
 
N 
 
p16 positivity 
 
χ2 
 
p value 
 
N 
 
p16 staining intensity 
 
Cramer’s 
V value 
 
p value 
 negative positive negative 1+ 2+ 3+ 
               
Gender 
   Female 
   Male 
Total 
 
76 
64 
140 
 
25 
8 
33 
 
51 
56 
107 
8.022** 
 
 
 
0.005 
 
 
 
 
76 
64 
140 
 
25 
8 
33 
 
22 
19 
41 
 
25 
30 
55 
 
4 
7 
11 
0.258* 
 
 
 
0.026 
 
 
 
 
 
Age group 
   36-64y 
   65-99y 
Total 
 
 
75 
65 
140 
 
 
25 
8 
33 
 
 
50 
57 
107 
 
8.545** 
 
 
 
 
0.003 
 
 
 
 
 
75 
65 
140 
 
 
25 
8 
33 
 
 
24 
17 
41 
 
 
22 
33 
55 
 
 
4 
7 
11 
 
0.297** 
 
 
 
 
0.006 
 
 
 
 
 
Disease outcome 
   Alive 
   Dead 
Total 
 
 
81 
59 
140 
 
 
29 
4 
33 
 
 
52 
55 
107 
 
15.960** 
 
0.000 
 
 
81 
59 
140 
 
 
 
29 
4 
33 
 
 
26 
15 
41 
 
 
23 
32 
55 
 
 
3 
8 
11 
 
0.403** 
 
0.000 
 
Disease status 
   No Recurrence 
   Recurrence 
Total 
 
 
129 
11 
140 
 
 
32 
1 
33 
 
 
97 
10 
107 
 
1.389 
 
0.238 
 
 
129 
11 
140 
 
 
32 
1 
33 
 
 
38 
3 
41 
 
 
50 
5 
55 
 
 
9 
2 
11 
 
 
0.142 
 
0.421 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table C: Crosstabs with Cramer’s V test of HPV status among clinicopathological parameters 
 
Parameters 
 
N 
 
Overall HPV  
 
Cramer’s 
V value 
 
p value 
 
N 
 
 α-HPV 
 
Cramer’s 
V value 
 
p value 
 negative positive negative Positive 
             
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
Total 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
1 
10 
1 
1 
15 
- 
2 
4 
- 
24 
- 
58 
 
3 
12 
3 
3 
22 
1 
3 
8 
1 
25 
1 
82 
0.191 
 
 
 
0.885 
 
 
 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
1 
11 
1 
1 
19 
- 
2 
5 
1 
27 
1 
69 
 
3 
11 
3 
3 
18 
1 
3 
7 
- 
22 
- 
71 
0.224 0.721 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) 
Total 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
- 
30 
21 
4 
3 
58 
 
 
2 
35 
20 
10 
15 
82 
 
0.225 
 
 
 
 
0.058 
 
 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
1 
33 
24 
7 
4 
69 
 
 
1 
32 
17 
7 
14 
71 
 
0.219 
 
0.150 
 
Regional Lymph Nodes 
   Negative 
   N0 
   N1 
   N2 
Total 
 
 
 
71 
35 
16 
18 
140 
 
 
35 
13 
6 
4 
58 
 
 
36 
22 
10 
14 
82 
 
0.187 
 
0.178 
 
 
71 
35 
16 
18 
140 
 
 
41 
14 
8 
6 
69 
 
 
30 
21 
8 
12 
71 
 
0.190 
 
0.166 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table C: Crosstabs with Cramer’s V test of HPV status among clinicopathological parameters 
 
Parameters 
 
N 
 
HR-HPV  
 
Cramer’s 
V value 
 
p value 
 
N 
 
 LR-HPV 
 
Cramer’s 
V value 
 
p value 
 
N 
 
HPV16 
 
Cramer’s 
V value 
 
p value 
 negative positive negative Positive negative Positive 
                  
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
Total 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
4 
19 
3 
3 
27 
1 
5 
10 
1 
42 
1 
116 
 
- 
3 
1 
1 
10 
- 
- 
2 
- 
7 
- 
24 
0.204 
 
 
 
0.828 
 
 
 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
1 
12 
1 
2 
29 
- 
2 
5 
- 
29 
1 
82 
 
3 
10 
3 
2 
8 
1 
3 
7 
1 
20 
- 
58 
0.334 0.111  
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
4 
21 
3 
4 
27 
1 
5 
10 
1 
46 
1 
123 
 
- 
1 
1 
- 
10 
- 
- 
2 
- 
3 
- 
17 
0.312 
 
0.192 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) 
Total 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
2 
48 
37 
14 
15 
116 
 
 
- 
17 
4 
- 
3 
24 
 
0.248 
 
 
 
 
0.072 
 
 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
1 
43 
27 
7 
4 
82 
 
 
1 
22 
14 
7 
14 
58 
 
0.301* 
 
0.013 
 
 
2 
65 
41 
14 
18 
140 
 
 
2 
51 
39 
14 
17 
123 
 
 
- 
14 
2 
- 
1 
17 
 
0.272* 
 
0.035 
 
Regional Lymph Nodes 
   Negative 
   N0 
   N1 
   N2 
Total 
 
 
 
71 
35 
16 
18 
140 
 
 
59 
28 
13 
16 
116 
 
 
12 
7 
3 
2 
24 
 
0.070 
 
0.875 
 
 
71 
35 
16 
18 
140 
 
 
52 
17 
8 
5 
82 
 
 
19 
18 
8 
13 
58 
 
0.330** 
 
0.002 
 
 
71 
35 
16 
18 
140 
 
 
61 
30 
16 
16 
123 
 
 
10 
5 
- 
2 
17 
 
0.137 
 
0.452 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level 
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Table D: Crosstabs with Cramer’s V test of p16 status among clinicopathological parameters 
 
Parameters 
 
N 
 
p16 positivity 
 
Cramer’s 
V value 
 
p value 
 
N 
 
p16 staining intensity 
 
Cramer’s 
V value 
 
p value 
 negative positive Negative 1+ 2+ 3+ 
               
Anatomic site 
   Buccal mucosa 
   Floor of the mouth 
   Alveolus 
   Gingivae 
   Soft palate 
   Pharynx 
   Lower lip 
   Retromolar pad 
   Supraglottis 
   Tongue 
   Tonsil 
Total 
 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
- 
4 
2 
1 
18 
- 
- 
3 
- 
5 
- 
33 
 
4 
18 
2 
3 
19 
1 
5 
9 
1 
44 
1 
107 
0.409** 
 
 
 
0.009 
 
 
 
 
4 
22 
4 
4 
37 
1 
5 
12 
1 
49 
1 
140 
 
 
- 
4 
2 
1 
18 
- 
- 
3 
- 
5 
- 
33 
 
1 
8 
2 
1 
7 
- 
2 
2 
- 
18 
- 
41 
 
3 
10 
- 
2 
9 
1 
3 
6 
1 
19 
1 
55 
 
- 
- 
- 
- 
3 
- 
- 
1 
- 
7 
- 
11 
0.300 
 
 
 
0.154 
 
 
 
 
 
Tumour size 
   Negative 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) 
Total 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
- 
26 
4 
- 
3 
33 
 
 
2 
39 
37 
14 
15 
107 
 
0.373** 
 
 
 
 
0.001 
 
 
 
 
 
2 
65 
41 
14 
18 
140 
 
 
- 
26 
4 
- 
3 
33 
 
 
1 
21 
13 
- 
6 
41 
 
 
1 
16 
17 
12 
9 
55 
 
 
- 
2 
7 
2 
- 
11 
 
0.309** 
 
 
 
 
0.000 
 
 
 
 
 
Regional Lymph Nodes 
   Negative 
   N0 
   N1 
   N2 
Total 
 
 
 
71 
35 
16 
18 
140 
 
 
20 
8 
2 
3 
33 
 
 
51 
27 
14 
15 
107 
 
0.131 
 
0.492 
 
 
71 
35 
16 
18 
140 
 
 
20 
8 
2 
3 
33 
 
 
16 
11 
6 
8 
41 
 
 
27 
14 
8 
6 
55 
 
 
8 
2 
- 
1 
11 
 
 
 
0.139 
 
0.526 
Note:  * significant at the 0.05 level; ** significant at the 0.01 level
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Parameters 
 
N 
Mean + SDα 
DNA purity  
(A260/A280) 
DNA yield  
(µg/µl) 
 
Gender (N = 183) 
   Female 
   Male 
 
Age groupβ (N = 183)  
   16-57y 
   58-99y 
 
Anatomic site (N = 183) 
   Buccal mucosa 
   Floor of the mouth 
   Gingivae 
   Hard palate 
   Soft palate 
   Upper lip 
   Lower lip 
   Retromolar pad 
   Skin 
   Tongue 
   Tonsil 
 
Pathology (N = 183) 
   Normal    
   Benign 
   Dysplasia 
   Carcinoma 
 
Disease status (N = 183) 
   No recurrence 
   Recurrence 
 
Disease outcome (N = 81) 
   Alive 
   Dead 
 
Tumour size (N = 80) 
   T1 (<2 cm) 
   T2 (2-4 cm) 
   T3 (>4 cm) 
   T4 (>4 cm) and invades  adjacent structures 
 
Regional Lymph Nodes (N = 80) 
   N0 
   N1 
   N2 
 
Histological grade (N = 80) 
   Well differentiated 
   Moderately differentiated 
   Poorly differentiated 
   Basal 
 
 
 
102 
81 
 
 
96 
87 
 
 
46 
23 
10 
3 
39 
2 
9 
5 
1 
44 
1 
 
 
7 
84 
12 
80 
 
 
171 
5 
 
 
45 
35 
 
 
41 
22 
13 
4 
 
 
67 
7 
6 
 
 
9 
58 
11 
2 
 
 
 
1.394 + 0.475 
1.292 + 0.435 
 
 
1.429 + 0.479 
1.261 + 0.422 
 
 
1.202 + 0.416 
1.358 + 0.489 
1.137 + 0.367 
1.149 + 0.412 
1.604 + 0.416 
1.815 + 0.284 
1.143 + 0.350 
1.549 + 0.297ε 
1.784 
1.314 + 0.489 
1.759 
 
 
1.172 + 0.406 
1.317 + 0.470 
1.064 + 0.209 
1.441 + 0.458 
 
 
1.345 + 0.456 
1.491 + 0.593 
 
 
1.232 + 0.432 
1.597 + 0.417 
 
 
1.596 + 0.437 
1.296 + 0.425 
1.124 + 0.210 
1.672 + 0.742 
 
 
1.483 + 0.444 
1.023 + 0.011ε  
1.454 + 0.667 
 
 
1.251 + 0.352 
1.502 + 0.464 
1.171 + 0.348 
2.015 + 0.371 
 
 
 
0.269 + 0.434 
0.291 + 0.427 
 
 
0.167 + 0.309 
0.402 + 0.507 
 
 
0.285 + 0.432 
0.403 + 0.550 
0.704 + 0.547 
0.079 + 0.025 
0.127 + 0.279 
0.110 + 0.027 
0.406 + 0.474 
0.076 + 0.031ε 
0.066 
0.273 + 0.418 
0.143 
 
 
0.183 + 0.113 
0.212 + 0.358 
0.389 + 0.569 
0.341 + 0.484 
 
 
0.278 + 0.430 
0.297 + 0.465 
 
 
0.563 + 0.557 
0.162 + 0.317 
 
 
0.228 + 0.407 
0.402 + 0.523 
0.504 + 0.555 
0.638 + 0.617 
 
 
0.216 + 0.374 
1.112 + 0.399 
0.835 + 0.569 
 
 
0.423 + 0.548 
0.261 + 0.422 
0.739 + 0.605 
0.107 + 0.026 
 
Note: N, number of patients; SD, standard deviation; α - No SD value was calculated for single case; β - Age grouping was 
based on overall median age;  ε - Normal distribution data is assumed 
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